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STELLINGEN 
behorend bij het proefschrift 
Soft tissue sarcomas: 
histopathology and cytogenetics 
in relation to 
diagnosis, treatment and clinical outcome. 
van Boudewijn E. Ch. Plaat 
15 december 1999 

1 .  De tumorrespons van ledemaatperfusie met TNF-n en melphalan bij weke 
delen sarcomen wordt mede veroorzaakt door veranderingen in de celcyclus en 
in apoptose-mechanismen. 
2. Hoewel multidrug resistance eiwitten in weke delen sarcomen frequent worden 
gedetecteerd, blijft de functie en de betekenis hiervan voor de kliniek 
onduidelijk. 
3. Vele klinische kenmerken toegeschreven aan leiomyosarcomen berusten op een 
verkeerde diagnose. 
4. Het gebruik van databases en computers in de analyse van chromosomale 
afwijkingen in solide tumoren, levert gemakkelijker interpreteerbare informatie 
op dan het gebruik van karyotypen alleen. 
5. Het opzetten en gebruik van een database in klinisch gericht medisch 
wetenschappelijk onderzoek is geen randvoorwaarde maar een hoofdzaak. 
6. Wanneer de kosten van het transport van materiaal op droogijs zouden worden 
berekend naar het gewicht van het pakket bij aankomst, zou dit stimulerend 
kunnen werken op de kwaliteit en snelheid van bezorging. 
7. De invoering van de winkelwagentjesgulden heeft het sociale contact tijdens het 
winkelen in de supermarkt sterk bevorderd. 
8. Volgens R. Pirsig is  kwaliteit ondefinieerbaar, maar door het feit dat alle 
mensen het kunnen waarnemen is het gedefinieerd: het is menselijk. 
9. Het steeds frequenter niet aangeven van richting in het verkeer, is een uiting van 
een toenemend gebrek aan identificatie aan de ander en dus een gevaar voor de 
medemens. 
1 0. A little disorder can stimulate creativity enormously (naar: Captain Janeway, 
Star Trek Voyager). 
1 1 . Gokken wordt gezien als een zwakte van de mens, maar in het licht van de 
evolutie is het juist een sterkte. 
12 .  Het gebruik van het woord "ritsen" langs de nederlandse snelwegen heeft 
taalkundig precies de tegenovergestelde betekenis van wat beoogd wordt. 
13. Het toenemend gebruik van het woord "natuurlijk" is niet altijd even natuurlijk. 
1 4. Beter mee verlegen, dan 6m verlegen (dit proefschrift en alles wat er 
uiteindelijk niet in is gekomen). 
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SOFT TISSUE SARCOMAS: 
HISTOPATHOLOGY AND CYTOGENETICS 
IN RELATION TO 
DIAGNOSIS, TREATMENT AND CLINICAL OUTCOME 
Chapter I 
Cancer research has made tremendous progress during the last decades and 
many discoveries in the field of molecular biology have elucidated important 
mechanisms involved in cell biology and oncogenesis 1 •2• The development of new 
laboratory techniques, cancer cell lines and animal models has led to new insights in 
our unde;standing of oncogenesis, tumor progression and treatment effects. A new 
field of cancer research has been grown in which tumor biological parameters are 
translated into a clinical setting: the understanding of tumor biology is now intriguing 
the clinical world of oncologists 3• 
Cancer cells defy normal controls on cell division and the apoptotic pathway. 
The processes leading to the irregular control are not only caused by successive 
mutations of the normal DNA, but subsequent tumor growth is influenced by various 
intracelluli!X and extracellular processes as well. The net result is proliferative 
activity le!ding � tutnor growth. Several authors have raised the question whether 
molecular markers and biological characteristics could predict treatment results and 
clinical outcome 4-7• 
Non-skeletal malignant neoplasms originating from mesenchymal tissue, i.e. 
the soft tissue sarcomas (STS), are a rare group of cancers comprising approximately 
1 %  of all malignancies 8•9• The large proportion of the previous scientific studies that 
have analyzed STS have dealt with broad categories of different histological types or 
heterogeneous patients groups. As a consequence, data concerning single classes of 
STS or specific patients groups are limited. Factors contributing to the oncogenesis 
and the progression of STS and the prognosis of patients with STS are still poorly 
understood and tumor biological factors affecting prognosis of STS patients have not 
been studied widely. 
Diagnosis of soft tissue sarcomas 
Clinical evaluation 
STS may occur anywhere in the body, but are most frequently found in the 
extremities and the retroperitoneum. STS can be found in both children and adults, 
although the distribution of the various histological types is different: (embryonal) 
rhabdomyosarcoma is a typical childhood STS whereas malignant fibrous 
histiocytoma is seldom observed in children. Most patients present with an 
asymptomatic mass as the only symptom. Physical examination, computed 
tomography (CT) or magnetic resonance imaging (MRI) are used to evaluate the 
extent of the local disease. In general, STS preferably metastasize to the lungs. 
Lymph node metastases are rarely found and are mostly associated with epithelioid 
sarcomas, rhabdomyosarcoma, synovial sarcomas and malignant fibrous 
histiocytoma. In the staging of STS, the staging system of the American Joint 
Committee on Cancer (AJCC) is commonly used. This staging system relies on 
histologic grade, tumor size, the presence of lymph node metastases and the presence 
of distant metastases, detected by physical examination, CT or MRI (Table 1 ). 
10  
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For an adequate histopathological diagnosis, tumor tissue should be obtained by 
excisional biopsy (for small lesions) or incisional biopsy for lesions larger than 3 cm 
in diameter. 
Table 1: The AJCC staging s�stem 
Stage grade tumor (0) Lymph node distant 
involvement metastases 
lA I <5cm 
m I �5cm 
IIA II <5cm 
Im II �5cm 
IliA Ill <5cm 
IIIB Ill �5 cm 
IVA I-III any size + 
IVB I-III an� size - or+ + 
Imaging 
Preoperative CT and MRI are important in the staging of STS 10• With CT and 
MRI, not only primary STS, local recurrences and distant metastases can be detected, 
but also the size, the extension (CT), the relation with adjacent structures, can be 
determined. With CT and MRI, STS can be readily distinguished from the 
neurovascular structures without injection of contrast medium 
8•11"14• For the 
assessment of bone destruction or cortical erosian CT is preferred 
8
• CT or MRI can 
further provide additional information regarding the presence of calcification, fat or 
blood within the tumor. However, CT or MRI cannot give an exact, reliable 
diagnosis nor can they reliably distinguish the several histologic types in STS or 
predict tumor grade. CT and MRI are further needed for the determination of a 
precise radiation therapy field. 
Studies using radionuclides try to differentiate between benign and malignant 
soft tissue tumors. Thallium scans have shown not to be helpful for this purpose 
15• 
Imaging techniques such as positron emission tomography (PET) or single photon 
emission computerized tomography (SPECT), both able to visualize biologic 
processes, might be helpful in the assessment of tumor biology in STS and might 
provide an ancillary tool in the assessment of malignancy grade, tumor stage and 
treatment effects in STS 
16•17• Using PET with [
18F]-fluoro-2-deoxyglucose (FDG) it 
is possible to detect local recurrences of STS and to provide an indication of the 





The pathogenesis of STS is not clear, although there might be a relation with 
previous injuries, irradiation, immunosuppression or lymphedema. Genetic factors 
might also contribute to the development of STS, since in up to 5% of the patients 
with neurofibromatosis-!, malignant peripheral nerve sheath tumors will develop 8 
and in the Li-Fraumeni syndrome, a germline mutation of the p53 locus, also familial 
sarcomas have been found 23•24• 
Classification - The heterogeneous group of STS can be classified in several 
histological types, depending on their histological features of differentiation as is 
shown in Table 2. Most common histological types in adult patients are malignant 
fibrous histiocytoma (MFH) ( 1 5%), liposarcoma (LPS) (1 5%), leiomyosarcoma 
(LMS) ( 1 0%), synovial sarcoma ( 1 0%), malignant peripheral nerve sheath tumor 
(MPNST) (1 0%}, rhabdomyosarcoma (RMS) ( 10%), and sarcoma not otherwise 
specified (NOS) (10%). 
Table 2: The primitive mesenchymal stem cell and the classification of soft tissue 
and bone tumors. 
precursor normal benign borderline malignant 
(-oma} (-matosis} (-sarcoma} 
fibroblast fibrous fibroma fibromatosis fibrosarcoma 
tissue 
facultative ? benign fibrous dermatofibrosarcoma malignant fibrous 




lipoblast adipose lipoma {lipoblastomatosis) liposarcoma 
tissue 
rhabdomyoblast skeletal (rhabdomyoma) rhabdomyo-
muscle sarcoma 
leiomyoblast smooth leiomyoma leiomyosarcoma 
muscle 
angioblast blood and (haem )angioma angiomatosis angiosarcoma 
lymph (lymph)angioma 
vessel 
osteoblast bone osteoma osteosarcoma 
chondroblast cartilage chondroma chondrosarcoma 
©According to W.M. Molenaar 
Immunohistochemistry has improved diagnosis of STS and its distinction from other 
tumor types such as carcinomas. For instance, the immunohistological detection of 
keratin is helpful in the differential diagnosis with carcinoma, whereas vimentin is 
predominantly found in malignancies arising from mesenchymal tissue. Although 
diagnosis of STS can be influenced by the subjectivity and experience of the 
individual pathologist, the classification of STS has further improved with the 
detection of differentiation specific antigens, i.e. in MPNSTs neural differentiation is 
associated with the expression of the S 1 00 protein and in RMS muscle differentiation 




STS has changed and, as a consequence, the results of previous studies on STS have 
to be re-evaluated. 
Tumor grade - The assessment of malignancy grade is of clinical and 
prognostic importance. There is discussion about the appropriate grading system for 
STS and several systems exist (Table 3) 25• 
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From: Enzinger FA and W eiss SW 8 
In the commonly applied grading system according to Coindre et al., also used in the 
studies described in this thesis, points are assigned to: differentiation level, necrosis 
and mitotic index (Table 4). 
Table 4: The grading system modified from Coindre et al. 29 
parameter condition score 
differentiation level 
necrosis** 
mitotic count (/ 2 mm2) 
tumor grade 
closely resembling normal tissue 1 





0 - 9  












2 , 3  
4,5 
6' 7 ' 8 
*need for additonal immunohistochemistry 
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Chapter I 
The counting of mitotic figures is one of the hallmarks in the assessment of 
malignancy grade in the various systems. However, the assessment of mitotic rate 
and the identification of mitotic figures can be difficult and has been shown to vary 
between observers 30•32• Mitotic figures are not always easy to detect in 
haematoxylin-eosin stained sections, which are standard in the assessment of 
malignancy grade, and might even resemble apoptotic cells, the other side of the 
equilibrium 33• Furthermore, the mitotic phase is a relatively short period in the cell 
cycle and proliferating cells are not only the cells in mitosis. Therefore, other 
methods have been introduced to examine the proliferative activity in malignant 
tumors. 
Additional parameters: 
Proliferation - One of the techniques to study proliferative activity is the 
detection of nuclei expressing the Ki-67 antigen, which is present in the nucleus of 
cells in all phases of the cell cycle except for the GO and the early G 1 phase. In a 
normal cell cycle, the cell will monitor its environment during the G 1 (Gap 1 )  phase 
and, depending on intracellular and extracellular stimuli and the size of the cell, it 
will start to synthesize new DNA, whereas DNA replication itself happens during the 
S (synthesis) phase. After completion of the S-phase, DNA replication is checked 
during a safety phase or G2 (Gap 2) phase, before the cell will enter the most 
dramatic, but relatively short, phase in the cell cycle: mitosis (M-phase). In STS it 
has been found that high proliferation is associated with high malignancy grade 34•35• 
Apoptosis - DNA damage will lead to cell cycle arrest with or without DNA­
repair, depending on intracellular processes regulated by various genes and proteins 
i.e. p53, p2 1 ,  p l 6, Rb, bcl-2, bcl-x, bax, the various cyclin dependent kinases and 
cyclins. Also extracellular signals can, via fas, fas-ligand and TNF-receptor-1 ,  lead to 
the formation of a so-called death domain which will lead to formation of caspases 
and trigger the signaling cascade leading to apoptosis 36• Apoptosis (so called 
"physiological"programmed cell death) is the final stage of the cell, which has 
activated a control mechanism leading to cleavage of the DNA and finally disposal of 
the cell. Cells Undergoing apoptosis display cell shrinkage, loss of cell-cell contact, 
chromatin condensation and internucleosomal degradation of DNA 37• Apoptosis can 
be visualized in paraffin embedded archival tissue by the TUNEL (Terminal 
deoxynucleotidyl Transferase (TdT) mediated dUTP Nick End Labeling) method. In 
STS it has been found that high malignancy grade is associated with low amounts of 
apoptosis 38, but a relation with histologic type has not been reported. 
DNA-p/oidy- In many malignant tumors an abnormal amount of DNA (DNA­
aneuploid tumors) has been found. In many tumor types, DNA- aneuploid tumors, 
indicating gain or loss of DNA, have been associated with a more aggressive 
biological behavior than tumors with normal DNA content (diploid or euploid 
tumors). Evaluation of DNA-ploidy is a problem itself, since paraffin embedded 
tissue is often not interpretable and is depending on the preparation methods used 39• 
Previous studies in soft tissue tumors have indicated that DNA ploidy is associated 
with malignancy and tumor grade, i.e. benign soft tissue tumors are almost always 
14 
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diploid and sarcomas are either diploid or aneuploid 40 • It has been found that up to 
66% of the STS is DNA aneuploid 41 • Aneuploidy is more common in high grade 
sarcomas than in low- or intermediate grade sarcomas 42• Moreover, a positive 
correlation between DNA aneuploidy and high tumor grade or mitotic activity has 
been observed 3 5•4 1 •43•44• DNA-aneuploidy seems to be associated with specific 
histological types i.e., MFH and RMS are predominantly aneuploid 4 1 •45• The 
assessment of DNA-ploidy can be combined with cytogenetic analysis in order to 
obtain additional and more detailed information regarding abnormalities in 
chromosomal material 42• 
Molecular (cyto)genetics - Cytogenetic analysis has proven to be an important 
tool in the detection of tumor specific alterations in the human genome 46-49• This has 
been achieved by the karyotypic analysis of high numbers of tumors in which 
recurrent chromosomal alterations were found. These cytogenetic changes appeared 
to be related to the activation of an oncogene or the deletion of a functional tumor 
suppressor gene and further studies have finally resulted in the detection of genes 
which either may be characteristic for a tumor type or may be involved in cell 
proliferation in general 50"52• Previous studies on cytogenetic abnormalities in 
sarcomas have focused on the support of the histological diagnosis 8.49•53• Some 
studies have suggested that additional chromosomal changes occur in the process of 
tumor progression 54•5 5• The findings of recurrent cytogenetic abnormalities in the 
various types of STS have lead to the discovery of certain fusion transcripts involved 
in the oncogenetic process of specific types of STS 56" 59• Certain translocations and 
their fusion transcripts are thought to be characteristic for specific STS and can be 
helpful in the diagnosis of STS (Table 5) 52•60•61 • 
Table 5: STS and their characteristic chromosomal translocations and fusion 
transcripts 
Histopathology 
myxoid and round cell liposarcoma 
synovial sarcomas 
alveolar rhabdomyosarcoma 
(extraskeletal) Ewing's sarcoma 
Extraskeletal myxoid chondrosarcoma 
Peripheral primitive neuroectodermal 
turn or 
clear cell sarcoma 
cytogenetics 
t( 12 ; 16)(q13 ;p l l )  
t(X; 18)(p l l ;q l l )  
t(2 ; 1 3)(q35;q14) 
t( l ;  13)(p36;q 14) 
t{l l ;22)(q24;q1 2) 
t(2 1 ;22)( q2 1 ;q 1 2) 
t(9;22) (q22;q1 2) 










t(12;22)(q 13;ql2) EWS-ATFl 
The detection of the fusion transcripts is nowadays a relatively easy and quick 
method 62"69• In this way, it is even possible to discriminate biphasic synovial 
sarcomas from monophasic synovial sarcomas with the detection of SYT-SSXl and 
SYT-SSX2 fusion transcripts 70 • The detection of a t( 1 1 ;22)(q24;q1 2) seemed to be 
characteristic for Ewing's sarcoma 52, but turned out to be involved in other 
15 
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malignant mesenchymal lesions and other neoplasms, indicating a common 
oncogenetic pathway 7 1"74• It has been reported that both EWS-FLI- 1 and EWS-ERG 
fusion proteins may be responsible for the decreased ability of tumor cells to undergo 
apoptosis 75• Furthermore, the same breakpoint 22q l 2  has also been observed in 
extraskeletal myxoid chondrosarcoma, but with other fusion partners 8•76• 
A major problem in cytogenetic studies is the frequently observed complex 
karyotypes, in which non-random chromosomal abnormalities are difficult to detect. 
To discover meaningful chromosomal anomalies, which could be of diagnostic 
importance, karyotypes of relatively large number of tumors are needed as has been 
demonstrated by a recent study of Mertens et al. in various non-STS neoplasms 77• 
Other molecular (cyto)genetic techniques such as comparative genomic 
hybridization (CGH), spectral karyotyping or multicolor fluorescence in situ 
hybridization might reveal additional information, especially in STS with difficulties 
in successful cytogenetic analyses, like MFH. In this way, CGH in MFH revealed 
that the most frequent gains were lp3 1 (33%), and 9q3 1 (29%}, whereas the minimal 
common regions of the most common losses were 1 3q2 1 -22 (2 1% f8• 
Treatment of soft tissue sarcomas 
Radical resection with wide surgical margins is the treatment of choice for 
local disease. In case of irresectable advanced extremity STS, hyperthermic isolated 
limb perfusion with tumor necrosis factor alfa (TNF-a) and melphalan (HILP-TM) 
with or without interferon gamma (IFN- y )is used in several institutions with limb 
salvage in up to 80% of the patients 79-84• Although the biological effects of HILP-TM 
are not completely understood, it is thought that TNF-a and/or IFN-y induce 
apoptosis of vascular endothelial cells, while melphalan induces apoptosis of tumor 
cells 85• 
In case of high grade STS or marginal surgery, postoperative radiotherapy is 
indicated 86• Chemotherapy for primary tumors is applied in childhood RMS and in 
adult patients it should be considered when diffuse distant metastases have 
developed. In case of few solitary lung metastases, depending on the time Jag after 
initial diagnosis, surgical resection can result in a prolonged (disease free) survival 86• 
On a cellular level, both radiotherapy and chemotherapy intend to induce 
apoptosis and necrosis by damaging the DNA. Response to chemotherapy seems to 
be influenced by histological STS type i.e. leiomyosarcomas tend to respond poorly 
and liposarcomas relatively favorably to doxorubicin based chemotherapy 87. 
Furthermore, high grade STS and STS with high S-phase fractions respond better to 
chemotherapy 87'89• However, a study by Daugaard et al 90, in 94 STS treated with 
doxorubicin did not find a relation with either tumor grade or mitotic activity. The 
relation between the amount of apoptosis and responses to specific treatments has not 




Chemotherapeutic regimens do not always lead to tumor regression and tumor 
cells may appear to be resistant to chemotherapy. Overall, the response rates in 
metastatic adult STS patients to various chemotherapeutic regimens are between 20-
40% 87• Drug resistance can be caused by several mechanisms. The observed 
resistance to various structurally unrelated natural chemotherapeutic drugs has been 
called multidrug resistance (MDR). MDR is associated with the elevated expression 
of the MDR1 gene on 7q21 encoding P-glycoprotein (P-gp) and the multidrug 
resistance protein (MRP1), the gene of which is located on 1 6p13 .  They both act as 
ATP dependent transmembrane pumps and are involved in the transport of cytotoxic 
agents towards the extracellular environment 91 • P-gp and MRP 1 have been shown to 
be clinically important in the chemotherapeutic responses in various malignancies 92' 
94• Another protein which is associated with drug resistance in cancer is the lung 
resistance protein (LRP) which has been identified as the human major vault protein. 
The exact function of LRP, the gene of which is located on 1 6p 1 1 ,  is not completely 
understood. It is thought that it functions as a barrel shaped intracytoplasmic 
transporter which mediates nucleocytoplasmic and vesicular transport of cytotoxic 
agents 95• LRP expression is of prognostic value in ovarian cancer and acute myeloid 
leukemia %,97• 
In sarcomas, P-gp expression might be associated with poor response to 
chemotherapy in Ewing's sarcomas 98 as well as with poor prognosis in 
osteosarcomas 99 and adult STS 100•1 01 • P-gp expression in childhood RMS was 
reported to be an extremely useful predictive factor of the response to chemotherapy, 
but the conclusions of this study of Chen et al. 1 02 were weakened by other studies 103• 
Studies evaluating P-gp expression in adult STS vary considerably ( 1 8% to 62%) 
with regard to the amount of P-gp expression, which might be due to the methods 
used and the STS examined 100•1 01 • 1 04•105• P-gp expression in synovial sarcomas seems 
not to be associated with gender, age, location, and proliferative activity of the tumors 
and was not influenced by chemotherapy, neither was response to chemotherapy 
related to P-gp expression 106• The expression of the MDR protein P-gp has been 
associated with. poor survival in a group of high grade STS of which a large number 
of cases received doxorubicin based chemotherapy 101and its prognostic significance 
has been confirmed in other studies 100• It was also found that P-gp expression is 
higher in high grade STS 100• MRP1 has been detected in Ewing's sarcoma 107 and eo­
expression ofMRP1 and P-gp was associated with tumor grade in STS 108• MRP1 has 
not been studied in relation to chemotherapeutic response or clinical outcome in 
sarcoma patients. LRP expression has hardly been studied in sarcomas. 
Imaging of treatment response 
CT and MRI are used in the post-therapy evaluation of treatment responses, 
the presence of local recurrences or distant metastases 8•1 0• 1 09• Other imaging 
techniques using the capacities of tumor biological parameters, have been studied for 
17 
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their ability to detennine responses to various fonn of treatment 
16• It was found that 
Thallium-201 scanning is valuable in the prediction of chemotherapy and 
radiotherapy responses 1 10'11
2• PET using FDG is valuable in the assessment and 
prediction of treatment responses to HILP-TM 113•1 1
4
, but can also be used in the 
assessment of responses to chemotherapy, as has been shown in other malignancies 
19• When comparing FDG-PET with 99mTc-Mffil SPECT with respect to diagnosis 
of recurrent or residual musculoskeletal sarcomas, FOG-PET showed higher 
sensitivity than Mffii-SPECT 1
15• However, FDG-PET in the treatment evaluation 
can be complicated by the detection of a non-tumor specific signal, since a peripheral 
rim of FDG accumulation in the tumor was found in several studies, which correlated 
with the fonnation of a fibrous pseudocapsule or with the presence of inflammatory 
. cells 1 13• 1 16• Shields et al. found that 1 1C Thymidine-PET images show a decline in 
proliferative activity after successful chemotherapy and this technique seems superior 
to FDG-PET 117• 
Clinical outcome of patients with soft tissue sarcomas 
According to Enzinger and W eiss 8, prognosis of patients with STS is closely 
correlated with the histological type: for instance patients with myxoid and well 
differentiated liposarcomas (LPS) have a far better prognosis than patients with 
malignant fibrous histiocytomas (MFH)
8• Various univariate and multivariate 
analyses in clinicopathological studies on different STS types have concluded that 
age of the patient, the histological type, tumor grade, tumor size, tumor location and 
depth, the presence of distant metastases at presentation , and the adequacy of the 
surgical procedure is of important prognostic value 
25•118-140• Some STS, like myxoid 
LPS, are more associated with local recurrences than with distant metastases and 
some authors debate whether it is appropriate to include these tumors in studies 
evaluating prognostic factors 
8• 141• Risk factors for local recurrences are: older age, 
local recurrence at presentation, positive surgical margins, histology of fibrosarcoma 
or malignant peripheral nerVe sheath tumor 
142• Risk factors for distant recurrences 
are high tumor grade, tumor size, tumor depth, leiomyosarcoma and time to local 
recurrence 1
42-144• 
The assessment of tumor grade appears to be the best predictor of prognosis. 
High proliferative activity as reflected by high mitotic counts 145-147and high amount 
of K.i-67 expression 35•101•148-153 can predict poor survival. Furthennore, proliferative 
activity in STS seems to be associated with vascular invasion, metastasis and DNA­
ploidy 3
4• The prognostic significance of amount of apoptosis has not been 
established yet. 
Studies evaluating DNA-ploidy in STS have revealed that non-diploid DNA 
content, alone or in combination with other prognosticators, correlates with poor 
outcomes 35•1
01•127•136•154-1 56• Alvegard et al. found that DNA-aneuploid tumors had a 
worse prognosis than euploid tumors 
1 56• Some studies in heterogeneous groups of 
STS did not find a statistically significant relationship between DNA ploidy and 
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survival126·1S7. The significance of DNA ploidy as a prognostic factor, however, may 
differ among the various histological types of soft tissue sarcomas 126•145·1 S8. For 
example in synovial sarcomas a relationship was found between DNA ploidy and 
survival 159, whereas in liposarcomas DNA ploidy was not of prognostic value 160• 
DNA aneuploidy is associated with higher metastatic risk 161 , although the DNA­
ploidy pattern in the metastatic lesions appears to be similar to that of the primary 
tumors 44• 
The prognostic value of cytogenetics has not been established yet 56• Grade Ill 
pleomorhphic STS have more chromosomal aberrations than grade 11 tumors, but no 
karyotypic pattern has been associated with clinical outcome or distant metastases 162• 
In MFH 19p13 aberrations were related to a higher recurrence rate 163• 164• Other 
molecular cytogenetic techniques such as CGH might unveil prognostic information 
as has been shown in a recent study in with a correlation was found between gain of 
7q32 and worse metastasis-free survival and overall survival of patients with MFH 
78 
In conclusion, tumor biological factors affecting treatment response and 
prognosis of patients with STS have not been studied widely. Studies investigating 
the relation between tumor characteristics and clinical outcome may lead to future 
therapeutic improvements because they will enable us to predict tumor behavior on a 
more individual basis and allow more selective treatment strategies. 
AIM OF THE PRESENT THESIS 
The majority of the previous scientific studies within STS have dealt with 
heterogeneous groups of STS patients. As a consequence, data concerning specific 
patient groups and single classes of sarcomas are very limited. The aim of this thesis 
is to determine the relation of certain tumor biological parameters (i.e. proliferation, 
apoptosis, multidrug resistance, DNA-ploidy and chromosomal aberrations) with the 
histopathologicill diagnosis, treatment response and clinical outcome of patients with 
a STS. 
Proliferation in neoplasms, as assessed by the counting of mitotic figures or 
the estimation of Ki-67 expressing cells detected by the Mffi-1 antibody, has been 
shown to be of high prognostic value. The influence of professional experience with 
these methods could influence the assessment results. In chapter 2, these two 
methods will be compared in STS in a cross over design in which experienced 
observers are compared with less experienced observers. 
Protein synthesis rate can be determined with L-[1-1 1C]tyrosine positron 
emission tomography (TYR-PET). If a relation would exist between high protein 
synthesis measured in vivo and the amount of proliferative activity of STS, this could 
not only be useful in the assessment of malignancy grade in vivo, but also in the 
detection of those tumor regions with the highest proliferative activity. This would be 
helpful in the determination of the optimal localization for tumor biopsy or the 
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assessment of treatment response in vivo. In chapter 3, the relation between 
proliferation and protein synthesis measured with TYR-PET will be determined. 
Since PET needs a complex and expensive infrastructure, the relation between the 
more simple L-3-[Iodine- 123]Iodo-alpha-methyl-tyrosine SPECT {IMT-SPECT) and 
the proliferative activity in STS will be studied for the same reasons (chapter 4). 
Hyperthermic isolated limb perfusion with TNF-a. and melphalan (HILP-TM) 
is used in patients with locally advanced soft tissue sarcomas. In chapter 5, the 
relation of tumor biological parameters (i.e. proliferative and apoptotic activity) with 
treatment response and clinical outcome of the HILP-TM treated patients will be 
established. Response to HILP-TM can be measured clinically by physical 
examination and CT or MRI. PET with either FDG or TYR reflects the metabolic 
properties of the tumor. The decrease in glucose metabolism or protein synthesis rate 
after HILP-TM has clinical importance if the HILP-TM induced changes in FOG­
PET or TYR-PET would reflect changes in tumor proliferation. In chapter 6, the 
relation between proliferative activity before and after HILP-TM will be examined 
and FDG-PET will be compared with TYR-PET. 
Treatment of metastatic or irresectable STS with chemotherapeutic agents is 
often complicated by poor treatment responses. Multi drug resistance (MDR) 
associated proteins like P-gp, MRP1 and LRP could be responsible for the poor 
responses. In chapter 7, the distribution of P-gp, MRP1 and LRP expression in a 
large series of STS will be determined in relation with histological type and tumor 
grade. 
Recent studies indicated that leiomyosarcomas, and especially those with liver 
metastases, have a poor response to chemotherapeutic treatment. However, 
gastrointestinal stromal tumors (GIST) have been considered as LMS of the digestive 
tract for many years. In chapter 8, 29 deep seated LMS will be compared with 26 
malignant GIST with regard to MDR proteins, clinical outcome and the development 
of liver metastases. 
Patients with metastatic or irresectable STS are treated with 
polychemotherapy. In chapter 9, the P-gp, MRP1 and LRP expression will be related 
to treatment response, overall survival and progression free survival in a group of 
patients with metastatic or irresectable STS treated with epirubicin, vindesine and 
ifosfamide. 
Recurrent cytogenetic aberrations are of diagnostic value in STS. A major 
problem in cytogenetic studies is the difficulty of detecting non-random 
chromosomal abnormalities in complex karyotypes. To discover meaningful 
chromosomal anomalies, which could be of diagnostic or clinical importance, 
karyotypes of relatively large numbers of tumors have to be compared with other 
groups of tumors. In chapter 10, a computer assisted method will be introduced for 
the detection of non-random chromosomal aberrations in malignant peripheral nerve 
sheath tumors (MPNST). This method will be used for a direct comparison of 
sporadic vs. neurofibromatosis-!- associated malignant schwannomas. 
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The same method will be used in chapter 1 1  to discover differences between 
mesenchymal gastrointestinal tumors ("GIST"), LMS and MPNST, since GIST have 
features of both smooth muscle or neural differentiation. 
The importance of the t(1 1 ;22) in STS will be illustrated in chapter 12 in which a 
t(1 1 ;22) in an extrarenal malignant rhabdoid tumor was found. 
The 1 6pll breakpoint, present in the t(12 ; 16)(q13,pll) characteristic for 
myxoid liposarcomas, could affect the LRP-gene on 16p l l .2. In chapter 13 the 
expression of LRP in relation to the 16p 1 1  breakpoint in liposarcomas will be 
described. To determine the expression of P-gp, LRP and MRP1 in relation the 
cytogenetically detected breakpoints 7q21 ,  16pll and 16p13 ,  in a more 
heterogeneous group of STS, STS with 7q21 ,  16pll or 16p13  breakpoints will be 
compared with STS with normal chromosomes 7 and 16  in chapter 14. The 
prognostic value of an abnormal karyotype in general with or without an abnormal 
DNA-content, will be examined in chapter 15. 
In chapter 16 a summary of the findings will be presented and conclusions 








OBSERVER RELIABILITY IN ASSESSMENT OF 
MITOTIC ACTIVITY AND MIB-1 DETERMINED 
PROLIFERATION RATE IN PEDIATRIC SARCOMAS 
W.M. Molenaar, B.E.C.Piaat, E.R.Berends, G.J. te Meerman 
Departments of Pathology and Medical Genetics 
University and University Hospital Groningen 




In H&E stained sections of 20 pediatric sarcomas the mitotic index was 
assessed by 4 experienced pathologists and 4 less experienced observers, without 
prior instructions. In adjacent sections immunolabeled for MIB-1, the proliferation 
index was assessed as the estimated percentage of labeled cells in the tumor cell 
population. Analysis of variance revealed that the variation between tumors 
explained 77% of the variation in mitotic indices in the group of experienced 
observers, as compared to 49% in the less experienced group. The variation between 
tumors explained 64% of the variation in proliferation indices in the experienced 
group and 71% in the less experienced group. The proliferation indices showed less 
variation between observers than the mitotic indices. No correlation was found 
between mitotic and proliferation indices. The results suggest that training is an 
important factor in the reliability of mitotic counting. The use of proliferation 
markers has a higher reproducibility, especially in less experienced observers. 
However, for clinical use it has the disadvantage of the more expensive and more 
time-consuming technique; moreover the biological significance of proliferation is as 
yet unestablished and may differ from that of mitotic activity. 
INTRODUCTION 
Microscopic evaluation of mitotic actlVlty is a routine procedure in the 
assessment of the malignancy grade of tumors. This holds also for soft tissue sarcomas, 
in which different grading systems all include mitotic activity as a major parameter, 
which in turn appears to be related to clinical behavior 29.35•138• 165• It is therefore important 
to know the observer related reliability of such evaluations. In the last decade other 
methods to determine proliferative activity have been developed, among which MIB-1 
labeling of proliferating cells is now commonly used. This method might appear more 
objective and easier to interpret than the counting of mitoses, but it is more labor 
intensive and costly. Moreover, it is uncertain whether mitotic activity and proliferation 
have the same biological significance. 
Previous studies have focused on the reproducibility of mitotic counting with 3 1 
or without 30 a strict protocol and training sessions or on the effect of delayed fixation 33• 
In the current study the observer reliability in the counting of mitoses and the estimation 
of proliferation using MIB-1 labeling is assessed in a setting mimicking daily routine 
without previous training sessions. The same test set of 20 pediatric sarcomas was 
assessed by all observers, thus eliminating the effect of tissue procession. The 
correlation between both methods was tested. In addition, the influence of experience 
was evaluated by comparing groups of experienced and less experienced observers. 
26 
Assessment of Mitotic Activity and Proliferation 
METHODS 
Specimens of 20 pediatric sarcomas, i.e. 14 rhabdomyosarcomas, 2 epithelioid 
sarcomas , 2 synovial sarcomas, 1 fibrosarcoma and 1 malignant histiocytic tumor, were 
routinely processed and embedded in paraffm. In each case sections stained with H&E 
were used for mit!)tic counting; consecutive sections were labeled with MIB-1 
(Immunotech S.A., Marseille, France) using alkaline phosphatase as chromogen and 
used for assessment of the proliferative activity. 
From each pair of slides the same area (about 2 cm2) of viable tumor was in­
dicated as target for analysis. For mitotic counting, each observer choose 2 mm2 per 
slide in adjacent high power fields (400x magnification); since observers were using 
different microscopes each calculated the number of fields needed for this surface area. 
The recorded score was formed by adding the scores of each field. This approach was 
chosen to resemble daily practice, but it means that the observers were not necessarily 
scoring identical high power fields. Ten adjacent high power fields were also chosen by 
the observers for MIB analysis. MIB-scores were estimated in percentages of labeled 
tumor cells, an approach that has been found reliable 166• The scores of each field were 
individually recorded, but for better comparison with the mitotic counts the total scores 
of 1 0  fields were added for the evaluation. 
We compared 2 groups of observers, i.e. 4 experienced pathologists and 4 less 
experienced observers (a medical student, a PhD student, a pathology resident in the 
second year of training and a research technician). The unexperienced observers had a 
short introduction by the senior observer in the recognition of mitoses. Twenty 
specimens were scored by two different methods in a factorial experimental design. 
Slides were evaluated in 4 random orders, each order presented forward and backwards 
for counterbalancing reasons. The observers used their personal microscopes for 
evaluation. Scoring was spread over the day and not controlled for better resemblance of 
the evaluation with actual clinical practice. Data were gathered in a period of 14 days. 
Data were entered in a D-base-4 database, exported to ASCII and transformed by 
PASCAL computer programs for entry in SYST AT system files. Data and programs are 
available on demand. 
RESULTS 
The mitotic counts were after a log( l+x) transformation almost normally 
distributed (not shown). The MIB labeling indices were evaluated with the same 
transformation. These variance stabilizing transformations had a clear positive effect 
on the correlations and explained variance due to specimens in the analysis of 
variance. 
Differences in means 
We performed an analysis of variance to separate variance due to differences 
between observers and differences between specimens. In mitotic counting the 
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analysis of variance showed that the results are highly significantly different between 
observers as well as between specimens (table l a). Seven percent of the variance was 
Table 1: Analysis of variance in mitotic count. 
a) (Q[ all QbKOi:Do 
SQUR�E SUM-QE-SQL!ARES DE MEAN-SQUARE E-RATIQ f-Yalue 
Observer 7% 10.340 7 1 .477 4.034 <0.001 
Specimen 59% 84.223 19 4.433 12. 106 <0.001 
ERRQR 34% 48,fi22 133 Q,3QQ 
N: 1 60; multiple r: 0.812; squared multiple r: 0.660. 
lil for �XI!�ritos:e.d Qblii:D!i:[S, 
SQL!R�E SUM-QE-SQL!ARES DF MEAN-SQUARE F-RAIIQ f-vi!]J.!e 
Observer 7% 6.707 3 2.236 8.505 <0.001 
Specimen 76% 7 1 .092 19 3.742 14.234 <0.001 
ERROR l!i0di ]4,284 5:Z Q.2fil 
N:80; multiple r: 0.916; squared multiple r: 0.839. 
!:) f2r l�:ss txp�:ritns:i:d abs�:n::�:rs. 
SQURCE SUM-QE-SQUARES DF MEAN-SQUARE F-RATIQ P-vall.!!: 
Observer 4% 1 .968 3 0.656 1 .635 0.191 
Specimen 50% 23.972 19 1 .262 3. 144 <0.001 
ERRQB. �:z� 22.81.2 �:z Q4QJ 
N: 80; multiple r: 0. 729; squared multiple r: 0.53 1 .  
Dependent variable: log( mitosis+ 1 ) ;  DF: degree o f  freedom (=n-1 ); sum of squares: relative 
proportion in total variance; mean square: relative proportion in variance divided by degrees of 
freedom. 
related to differences between observers, 59 % was related to differences between 
specimens and 34 % was unexplained (random error and interactions). The 
experienced observers counted more mitoses than the less experienced observers, i.e. 
mean values of 16/2mm2 versus 1 1 , respectively (fig. 1) .  Separate analyses of 
variance for the experienced and the less experienced observers (tables lb and l e), 
showed that the experienced observers had highly significant differences in mean 
levels, but the specimens accounted for most of the variance. The less experienced 
observers did not differ significantly in mean levels assigned, but the error variance 
was much higher. 
In the estimation of MIB labeling index the analysis of variance showed that the 
results are highly significantly different between observers and between specimens 
(table 2a). Eleven percent of the variance was related to differences between observers, 
64 % was related to differences between specimens and 25 % was unexplained. The 
experienced and the less experienced observers had comparable scores, i.e. means of 29 
and 30%, respectively (fig.2). The less experienced observers had the same significant 
28 
Assessment of Mitotic Activity and Proliferation 
influence on the results, but they had an even lower error variance ( 18%) than the 
experienced observers (26%) (tables 2b and 2c). 
I I l 4 5 0 I 0 0 11 11 11 ll 11 IS 10 '' 11 10 J0 
A. B. 
Figure 1 
Mitotic index: (A) boxplot for variance in each observer for all sections (experienced: 
gray; less experienced: white) and (B) boxplot for variance per section for all observers 




Proliferation: (A) boxplot for variance in each observer for all sections (experienced: 
gray; less experienced: white) and (B) boxplot for variance per section for all observers 
(experienced: light gray; less experienced: dark gray) 
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Table 2: Analysis of variance in MIB-1 labeling index. 
a) for all observers 
SQURCE SUM-OF-SQUARES DF MEAN-SQUARE 
Observer 1 1% 1 8.553 7 2.650 
Specimen 63% 103.984 19 5.473 
ERROR 25% 40.669 133 0.306 
N: 160; multiple r: 0.866; squared multiple r: 0.75 1 .  
b) for experienced observers. 
SOURCE SUM-OF-SQUARES DF MEAN-SQUARE 
Observer 1 1% 7.166 3 2.389 
Specimen 63% 40. 180 19 2. 1 15 
ERROR 26% 16.905 57 0.297 
N:80;multipler:0.858;squaredmultipler:0.737. 
c)for less experienced observers. 
SOURCE SUM-OF-SQUARES PF MEAN-SQUARE 
Observer 1 1% 1 1 .247 3 3 0.749 
Specimen 71% 69.829 1 9  3 .675 
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Dependent variable: Jog(MIB+l). DF:degree of freedom (=n- 1); sum of squares: relative proportion 
in total variance; mean square: relative proportion in variance divided by degrees of freedom. 
Co"elation analysis 
In order to compare the scores of the individual observers with the mean score of 
all observers, a principal component analysis was performed. With this method a perfect 
coincidence would result in a loading factor of 1 for the principal component. The 
analysis revealed for the mitotic counting that the experienced observers had high factor 
loadings on the first principal component, i.e. 0.9 1 ,  0.80, 0.94 and 0.95, respectively, 
while the less experienced observers had much lower factor loadings of 0.76, 0.76, 0.55 
and 0.67, respectively. The fust principal component accounted for 64% of the total 
variance. 
For the MIB labeling index the results did not differentiate between experienced 
and less experienced observers. The factor loadings for the experienced observers were 
0.95, 0.94, 0.99 and 0.96, respectively, and for the less experienced observers 0.97, 0.91 ,  
0.96 and 0.95, respectively. For the MIB labeling index all observations of  the assessed 
fields per slide were used in a principal components analysis. The fust principal 
component has been computed for each observer on the basis of all measurements. This 
factor explained for the experienced observers 88.9, 8 1 .8, 64.3 and 75.4 %, respectively, 
of the total variance. For the less experienced observers the explained variance for the 
first principal component was 86.6, 72. 1 ,  79.6 and 84.2%, respectively. This implies that 
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the consistency between experienced and less experienced observers does not differ very 
much. The first principal component accounted for 9 1  % of the total variance. 
Correlation between mitotic count and MIB labeling index 
A principal components analysis revealed that there were two important 
orthogonal principal components. The first one was the MIB score (0.9x Mm-0.25x 
mitoses) and the second one was a sum of the mitotic count (for the largest part) and 
the Mm score (0.8x mitoses + 0.25x Mm). The variance accounted for by these two 
components was 48.8% by the first and 30.5% by the second. Finding an important 
second component indicates that the two methods measure different parameters. 
DISCUSSION 
The current study determined the observer reliability in mitotic counting and in 
the estimation of MIB labeling index in a series of pediatric sarcomas. It further studied 
the influence of experience in both assessments and compared the two techniques with 
each other. The study design was such that it resembled daily practice as much as 
possible. In particular, the observers used their own microscopes and archival material 
was used, thus reflecting tissue processed at different time points and different fixation 
periods. The reliability of observations has to be evaluated relative to the variance in the 
observed material: if all specimens have about the same mitotic count, the correlation 
between observers will necessarily be low, if the variance is extreme, the correlation 
between observers will be very high 167• In the current investigation no selection was 
made such that the specimens would represent the full spectrum, which makes it easier 
to evaluate the meaning of differences between observers for actual clinical scoring. In 
the study by Donhuijsen et al. 30 very extreme slides were used, but significant dif­
ferences between observers were found as well. Differences between observers exist as 
a difference in mean, lack of (linear) correlation and in variance. Differences in means 
are analyzed by analysis of variance. The purpose of the principal components analysis 
is to evaluate the correlation between and within observers and methods. The main 
results for both mitotic counting and MIB labeling index estimation are that there are 
highly significant differences between observers in mean levels. The interpretation of 
these differences is difficult. It is conceivable that the experimental setup introduced an 
important source of variation between observers: observers were free to choose their 
high power fields in a designated area. Some may have chosen more variable fields as 
e.g. the observer with the lowest common fust component in the principal components 
analysis, while other observers may have chosen more similar fields. It is impossible to 
evaluate this difference in terms of worse or better, because there is no golden standard. 
It indicates however, that there is a problem, where standardization of procedures, e.g. 
field selection could assist in reducing unwanted variation between observers. Possible 
solutions can be found in systematic training, where observers are trained in consistent 
selection of observation fields, as well as in training to discriminate mitotic cells more 
consistently 33• An improvement in consistency by bringing the 'personal bias' of 
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observers closer together is in principle possible. One approach would be to measure the 
individual bias and to correct for this bias. This can be done by giving percentage scores 
related to results on a standard sample, that indicates for each observer in which 
percentile an observation falls. Such a procedure would also have the same effect as 
taking the log of observations, which gives a score that is better interpretable than the 
raw score, as the variance due to observers decreases and the variance due to specimens 
increases after this transformation. 
Comparison between experienced and less experienced observers revealed 
consistent differences with respect to the evaluation of mitotic counting. Less 
experienced observers had a lower correlation with the average score, as follows from 
the lower factor loadings on the first principal component. This implies that experience 
is evidently required to be able to recognize a mitosis, as previously reported 30• The data 
further indicate that MIB labeling index can be consistently scored by both experienced 
and less experienced observers. This suggests that this technique is simpler to score 
reliably, but since Mm labeling is not (yet) a routinely applied technique the difference 
in experience between the two groups in this respect is smaller than for mitotic counting. 
Mitotic counting and MIB labeling are both supposed to assess cell growth. A 
positive correlation between the two might therefore be expected and was indeed found 
in two earlier studies in soft tissue sarcomas 150•1 68, but not in another 35• In the current 
analysis two relatively independent principle components were established, i.e. the 
MID-I score and the sum of the MID-I score and mitotic count. These differences 
between the various studies may be due to different techniques, e.g. in the study by 
Jensen et al. 168 the comparison was made between the counts of MIB labeled cells and 
classes of mitotic indices, whereas in the current study the Mm labeling index was 
estimated and compared to the full spectrum of mitotic activity. Moreover, our analysis 
was performed after log-transformation of the scores. The absence of a correlation may 
also indicate that mitotic activity and MIB measure different phenomena, e.g. related to 
the variation in fraction of the cell cycle that is taken up by the mitoses or the number of 
proliferating cells that actually goes in mitosis. Finally, these parameters may differ 
between tumor types as demonstrated in a recent study in carcinomas 169• 
In conch.ision, the current study indicates that mitotic counting is reliable when 
done by experienced observers. It further shows that some important aspects of inter­
individual scoring can be analyzed in a simple experimental design. The results suggest 
that there is room for improvement and set at the same time a minimum for the 
magnitude of correlations between observers. The Mm measurement has the advantage 
that it can be scored by relatively inexperienced personnel. However, it is more 
laborsome and costly. Moreover, the clinical relevance of mitotic count and MIB 
labeling index has to be evaluated, because they may measure different aspects of a 
specimen. 
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SUMMARY 
Protein synthesis rate (PSR) can be assessed in vivo using positron emission 
tomography with L-[1-'1C]tyrosine (TYR-PET). Biological activity of soft tissue 
sarcomas (STS) can be measured in vitro by mitotic rate and amount of proliferating 
cells. In STS the grade of malignancy, in which mitotic index plays a major role, is 
considered to be the major standard in predicting biological tumour behaviour. This 
study was designed to test the validity of TYR-PET in relation to different 
histopathological features. In 21 patients with untreated STS, the PSR was measured 
using TYR-PET. The number of mitoses was counted and tumours were graded 
according to the grading system of Coindre et al. (Cancer 1986; 58:306-309). 
Proliferative activity was assessed by immunohistological detection of the Ki-67 
nuclear antigen using MIB-1 monoclonal antibody. To test the association between 
the PSR and these tumour parameters, a correlation analysis was peiformed. A 
significant (p<0. 05) correlation was found between PSR and the Ki-67 proliferation 
index (r=0.54), and between PSR and mitotic rate (r=0.64). There was no 
correlation between PSR and tumour grade. The present study in malignant soft 
tissue tumours connects in vivo tumour metabolism as established with TYR-PET to 
tumour activity measured in vitro and indicates that the non-invasive method ofTYR­
PET can estimate the mitotic and proliferative activity in STS. 
INTRODUCTION 
Soft tissue sarcomas (STS) are a heterogeneous group of malignant tumours arising 
from tissue of mesenchymal origin and account for approximately 1% of all 
malignancies. Patients with STS usually have a poor prognosis. The most significant 
prognostic factor in STS is tumour grade, i.e. a higher tumour grade is associated 
with a worse prognosis 8• 128• 143 • Tumour grade is determined by mitotic activity, 
amount of necrosis and differentiation grade. Also the number of proliferating cells 
has been associated with the grade of malignancy 34• Proliferation can be assessed by 
the detection of Ki-67, which is a nuclear antigen present in all parts of the cell cycle 
except for the G-zero phase of the cell cycle (GO), in which the cells are withdrawn 
from the cell cycle, and the early Gap 1 phase (G 1 ), the phase of the cell cycle before 
the start of DNA synthesis 170• 
Tumour metabolism can be determined in vivo by positron emission tomo­
graphy (PET), in which radiopharmaceuticals labelled with positron-emitting 
nuclides are used to assess metabolic processes. A relation was found between 
glucose consumption as measured with 2-[18F]-fluoro-2-deoxyglucose (FDG)-PET 
and tumour grade in groups of patients with various benign and malignant 
musculoskeletal tumours 2 1• 171 • Because with FDG-PET one cannot discriminate 
between (malignant) viable tumour and inflammatory reaction 1 13, the 
radiopharmaceutical L-[1 -1 1C]tyrosine (TYR) is currently under investigation for its 
use in the detection and therapy evaluation of soft tissue tumours at the Groningen 
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University Hospital. With TYR-PET several types of tumours including STS can be 
visualised and the protein synthesis rate (PSR) can be quantified 1 72"176• The current 
study in malignant soft tissue tumours investigated the correlation between in vivo 
tumour metabolism using TYR-PET and in vitro biological activity as reflected by 
tumour grade, number of mitoses and amount of proliferating cells. 
MATERIALS AND METHODS 
Patients 
TYR-PET was performed in twenty-one patients, 14  males and 7 females, 
with a histological diagnosis of a malignant mesenchymal tumour that measured at 
least 2 cm in diameter and was located in the soft tissues. The tumours were 
originally detected by magnetic resonance imaging or by computed tomography. 
Mean age at the time of diagnosis was 56 (range 24 - 83) years. Eighteen tumours 
were located in the lower limb (85%), one in the upper limb (5%), one in the gluteal 
region (5%) and one in the upper part of the back (5%). 
The TYR-PET study for patients with locally advanced STS was approved of 
by the medical ethics committee of the Groningen University Hospital and all 
patients gave informed consent. 
Methods 
In all patients tumour tissue was obtained by diagnostic incisional biopsy 
within 8 weeks (mean: 1 6  days; range: 1 -55) after PET and the histological diagnosis 
was made on haematoxilin-eosin stained paraffin sections with or without additional 
immunohistological stains. All tumours were classified according to Enzinger and 
Weiss into 10 different histological types 8• The STS were graded according to the 
grading system of Coindre et al. in which points are assigned to differentiation level, 
mitotic index and necrosis 29• This resulted in 6 grade I (29%), 4 grade 11 ( 19%) and 
1 1  grade III (52%) STS (Table 1 ). The number of mitotic figures per 2 mm2 was 
counted in fifteen adjacent fields on haematoxilin-eosin stained paraffin sections. 
Proliferating cells were detected using the monoclonal antibody MIB- 1 
(Immunotech S.A., Marseille, France), which recognises an epitope of the Ki-67 
antigen. Immunohistochemistry was performed on paraffin sections (4 J.tm) according 
to a method modified from Shi et al. 177• 178• In short: after heating on a hot plate, the 
slides were dewaxed in xylene and rehydrated in serial ethanol washes ( 100%, 96% 
and 70%). After two times heating in an autoclave for 10 minutes at 1 10° C in 
cooking solution pH=6.0, the slides were incubated with a 1 :400 dilution of the 
antibody in bovine serum albumin pH=7.4. The primary antibody was detected with 
a biotinylated secondary antibody (multilink) followed by a streptavidine-alkaline 
phosphatase conjugate (Ready-to-Use Link and Label, Biogenex, San Ramon CA, 
USA). Final colour was developed using bromochloroindolyl-phosphate 4-nitroblue­
tetrazoliumchloride (BCIP-NBT; Boehringer, Mannheim, Germany). 
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For measuring the Ki-67 labelling index (LI) we used ocular micrometry on a 
Leica microscope (Rijswijk, the Netherlands) by using an eyepiece grid at x400 
magnification. Fifteen fields were randomly selected throughout histologically viable 
areas. Endothelial cells, inflammatory cells and necrosis were excluded. The number 
of positive nuclei was then divided by the total number of nuclei in each of the 
fifteen fields to calculate an index per field. The Ki-67 LI representing proliferative 
activity was defined as the mean of the indices of the fifteen fields. 
Table 1. Patient characteristics, histology and tumour grade. 
Patient Sex Age Diagnosis Tumour grade 
M 48 fibrosarcoma I 
2 M 49 malignant hemangiopericytoma I 
3 M 58 myxoid liposarcoma I 
4 M 37 myxoid liposarcoma I 
5 M 68 well differentiated liposarcoma I 
6 M 42 sarcoma not otherwise specified I 
7 M 66 malignant fibrous histiocytoma 11 
8 F 69 malignant fibrous histiocytoma 11 
9 M 48 myxoid liposarcoma 11 
10 M 24 synovial sarcoma 11 
1 1  F 69 fibrosarcoma Ill 
12 M 45 leiomyosarcoma Ill 
13 M 66 malignant fibrous histiocytoma Ill 
14 F 67 malignant fibrous histiocytoma Ill 
15  F 83 malignant fibrous histiocytoma Ill 
16 F 32 malignant Schwannoma Ill 
17  M 67 pleiomorphic liposarcoma Ill 
18  M 74 sarcoma not otherwise specified Ill 
19  M 74 sarcoma not otherwise specified Ill 
20 F 69 sarcoma not otherwise specified Ill 
2 1  F 25 synovial sarcoma Ill 
PET experiments. 
Patients fasted for at least eight hours before the study, but could drink water 
and take their usual medication. A venous cannula was placed in the antecubital vein 
of one of the forearms to allow easy injection of TYR. Another cannula was placed 
in the radial artery of the contralateral arm to assess the arterial input function and 
metabolites. The patient was positioned in the PET -scanner (ECA T 95 1 /3 1 , 
Siemens/CTI, Knoxville, TN, USA) with the tumour in the field of view. After a 20 
minute transmission scan to correct for attenuation, 370 MBq TYR was injected via 
the venous access as a 1 minute bolus. Data acquisition started at the time of injection 
(time frames 1 0x30, 3x300, 3x600 seconds). During the study arterial blood samples 
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were taken for the assessment of the plasma tyrosine activity curve and of its 
radiolabelled metabolites e 1C02 and t iC-labelled proteins). The results from these 
measurements were similar as in previous studies m. PET images were displayed in 
transaxial projections on a computer display applying standard ECAT software 
(Siemens/CTI, Knoxville, TN, USA). Tumour definition was done by visual 
inspection based on computed tomography or magnetic resonance images. The 
activity in the selected pixels was averaged and the corresponding time-activity curve 
was calculated. Combining this averaged time-activity data with the plasma input 
data (corrected for t 1C02 and t iC-proteins), the average PSR is calculated in 
nmoVlOOg tumour tissue/minute using a compartmental model describing the 
kinetics of L-[1 -1 1C]tyrosine as described previously m. In brief, it models the 
plasma-tissue transport of tyrosine and its incorporation into protein. In addition, 
tissue metabolites e 1C02) and their transport to plasma are included also. The 
radiochemical and enantiomeric purity were both >99% and the specific radioactivity 
was >18.000 Bq/mmol m. Both the maximal measured PSR (PSRmax) from the ten 
pixels with maximum activity and the average PSR for the whole tumour (PSRavg) 
were calculated. 
Statistical analysis 
Since the distribution of all tumour parameters except for tumour grade was 
normal, a two-tailed Pearson's correlation analysis was performed to quantitate the 
degree of correlation. To determine the relation between PSR and tumour grade a 
Spearman's rank correlation coefficient was calculated. A p-value of < 0.05 was 
considered to be significant. Statistical analysis was performed using Graphpad 
Prism 2.0 (Graphpad Software Inc., San Diego, California, USA). 
RESULTS 
The PSRavg was 1 . 1 8  ± 0.68 nmoVkg tissue/min (mean ± SD) and ranged from 0.33 
to 2.70 nmoVk·g tissue/min, whereas the PSRmax was 2.46 ± 1 .45 (range 0.64 -
5 .66). In the patient with the lowest PSRavg (0.33 nmoVkg tissue/min) it was not 
possible to calculate the PSRmax. A high correlation was observed between PSRavg 
and PSRmax (r=0.95, p<O.OOO l ). 
No correlation was found between tumour grade and either of the PSRs (Table 
2). The PSRavg was 1 .02 ± 0.58 for the 6 grade I STS, 0.89 ± 0.43 for the 4 grade 11 
STS and 1 .37 ± 0.77 for the 1 1  grade Ill STS. The mean PSRmax was 2.40 ± 1 .3 1  
for the 5 grade I STS, 1 .53 ± 1 .0 1  for the 4 grade 11 STS and 2.84 ± 1 .58 for the 1 1  
grade Ill STS. 
A significant correlation was found between the mitotic activity and PSRmax 
as well as PSRavg (Table 2; Fig. lA). Mean mitotic rate was 1 6  ± 1 5  per 2mm2 
(range 0 - 59 /2mm2). 
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The amount of proliferation correlated with PSRmax and PSRavg (Table 2; 
Fig. lB). Mean proliferation was 16  ± 1 1% (range 3 - 44%). Two examples of TYR­
PET images with corresponding MIB-1 stained sections are shown in Fig. 2 .  
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B. 
DISCUSSION 
Mitotic activity and amount of cell proliferation in a tumour are important 
determinants of tumour malignancy and are associated with prognosis i.e. high 
numbers of dividing and proliferating cells are related with a worse prognosis in 
many malignancies 8.34•35•146•150•1 79'183• High proliferative activity in a tumour indicates 
that a high proportion of tumour cells has entered the cell division cycle, whereas a 
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Table 2. Correlation coefficient and two-tailed p-value 
of the studied histological parameters and both PSRavg and PSRmax. 
tumour grade mitoses/2mm2 proliferation 














high mitotic activity implies that a large number of cells is in the final phase of the 
cell cycle. The total protein content of growing cells increases continuously 
throughout the cell cycle 2• Tyrosine is used in the production of various proteins and 
the PSR, as measured by TYR-PET, represents the biological activity of the viable 
parts of a tumour 172• Malignant tumours with high numbers of proliferating cells are 
expected to have a relatively high protein metabolism and can therefore be detected 
by TYR-PET. This study indeed demonstrates the correlation between PSR and both 
mitotic and proliferative activity in malignant soft tissue tumours. The observed link 
between PSR and these indicators of prognosis stress the potential role ofTYR-PET 
in predicting clinical outcome and indicate that the specific parts of STS with 
relatively high mitotic and proliferative activity can be discovered in vivo. It would 
be interesting to know if a stronger correlation could be detected by taking larger 
samples to quantitate the numbers of mitoses or proliferating cells. Moreover, in this 
study the tumour samples were randomly taken and not focused on the areas with the 
highest PET signal. In view of the correlation between the PSR and the markers of 
proliferation, the correlation coefficients are expected to increase when biopsies are 
taken from areas with the highest PET signal. PET directed incisional biopsies may 
also be helpful to avoid large necrotic parts of the tumour and make histological 
diagnosis and assessment of the malignancy grade more accurate. 
In this study tumour grade was not found to correlate with PSR as measured in 
the viable parts of the tumours. This might be due to the fact that the amount of 
necrosis, in which no protein synthesis is present, is part of the used grading system 
of Coindre et al. 29• A large amount of necrosis, indicating a high tumour grade, 
decreases the PSR because the non viable parts of the tumour have no protein 
synthesis and the diffuse small necrotic foci in a tumour cannot be visualised by 
TYR-PET but are incorporated in the microscopic grading. 
Previous studies used FDG-PET in the analysis of soft tissue tumours and a 
relation was found between tumour grade and FDG uptake 2 1 , 1 7 1 , 1 84, 185• However, 
the results of some of these studies cannot be directly translated to STS since the 
authors combined benign and malignant soft tumours to assess the relation between 
tumour grade and FDG-PET or included different types of malignant tumours and 
did not use the appropriate grading system for these tumours. The present study was 





A. TYR-PET image of a sarcoma not otherwise specified with a relatively high PSR and 
B. corresponding MIB-1 stained tissue section (400x) of the tumour showing a high 
amount of proliferating cells. All dark nuclei express Ki-67 and have entered the cell cycle. 
C. TYR-PET image of a malignant Schwannoma with a relatively low PSR and 
D. corresponding MIB-1 stained tissue section (400x) showing a low amount of 
proliferating cells. 
Chemotherapeutic and radiotherapeutic treatment responses are associated 
with reduced mitotic activity and proliferation in various cancers 186"1 88• The observed 
correlation between these tumour parameters and the PSR implies that TYR-PET 
could be used in evaluating treatment responses in vivo. 
In conclusion, this study established the correlation between in vivo tumour 
metabolism and the in vitro biological activity of STS and validates TYR-PET as an 
important tool in the in vivo evaluation of malignant soft tissue tumours. Further 
studies overcoming the limitations of the present study are warranted. They have to 
be performed in a larger group of patients using tumour material obtained after PET 
directed biopsies, with a minimum period between biopsy and PET. If large excision 
specimens could be examined, it is advised to study tumour proliferation and other 
cell cycle parameters as well as amount of cell death in areas of both high and low 
PET signal within the same tumour. 
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The radiolabeled amino acid L-3-[1231]-iodo-alpha-methyl-tyrosine (IMT) is a 
relatively new tumor tracer that accumulates in many tumors and is suitable for 
SPECT imaging. Using IMT SPECT, we studied 32 patients with a soft tissue tumor 
suspect for a soft-tissue sarcoma to determine whether (1) tumors can be visualized, 
(2) benign and malignant lesions can be distinguished and (3) IMT uptake is related 
to tumor grade and proliferation. 
Imaging was performed 15 min after administration of 300 MBq IMT, biopsy 
or resection 1-2 weeks later. IMT uptake was quantified using a region-of-interest 
method resulting in tumor-to-background (TIB) ratios. These were compared with 
tumor grade, mitotic index, tumor cellularity, vascularity and the Ki-67 proliferation 
index. 
Eleven patients had a benign tumor, 21 patients had a soft tissue sarcoma. Six 
benign tumors demonstrated minor IMT uptake, five lipomas had no uptake. All 
malignant tumors had high uptake and were clearly visualized. TIB ratios in 
malignant tumors (3.83±1. 16) were higher (p<0.001) than in benign tumors 
(1.52±0.60). Small (<5 mm) metastases in two patients were not detected. Taking TIB 
ratio 2. 0 as cut-off level, sensitivity for detection of malignancy was 100%, specificity 
88%. IMT uptake correlated with histological grade (r=0.82;p<0.001), mitotic index 
(r=O. 75;p<0.001), tumor ce/lularity (r=O. 73;p<0.01) and with the Ki-67 
proliferation index (r=0. 63;p<0.01). 
IMT SPECT visualized all soft-tissue sarcomas. Uptake in sarcomas was 
clearly higher than in benign lesions, yielding 100% sensitivity for the detection of 
malignancy at a specificity of 88%. Uptake increased with higher tumor grade and 
higher proliferation rate. 
INTRODUCTION 
Soft-tissue sarcomas are a heterogeneous group of malignant tumors that can 
arise from mesenchymal structures at any site of the body. These tumors constitute 
1% of all cancers. A large proportion (60%) is located in an extremity. They often 
reach a large size before a diagnosis is established. They grow locally aggressive, 
frequently invade surrounding tissues and often disseminate to distant sites. 
Treatment planning depends on information regarding the presence or absence of 
metastases, the local situation and histological parameters. Chest CT is commonly 
used to screen for pulmonary metastases and MRl to assess the local situation and 
resectability. The most important prognostic factor is tumor malignancy grade, i.e. a 
higher tumor grade is associated with a worse prognosis 8•86•1 28• 143• 
Considerable interest exists in non-invasive determination of the malignancy 
grade of sarcomas 21 •1 89-192• For this purpose, various nuclear medicine techniques 
such as single photon emission computerized tomography (SPECT) and more 
recently positron emission tomography (PET) employing various tracers have been 
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applied. Radiolabeled amino acids are potentially suitable tracers: due to the 
increased protein metabolism of malignant tumors, uptake in malignancy is increased 
193• Furthermore tumor uptake is less disturbed by uptake in inflammatory tissue than 
the frequently used tracer 1 8F-fluoro-2-deoxy-D-glucose (FDG) 174•1 94' 197• However, 
most carbon- 1 1  labeled amino acids are difficult to synthesize and require the 
infrastructure of PET. 
The radiolabeled amino acid L-3-[123I]iodo-alpha-methyl-tyrosine (IMT) is 
avidly taken up in many tumors 198• 199• The agent has been introduced for imaging of 
brain tumors where tumor uptake was shown to represent amino acid transport 
activity, an important step in protein metabolism 200'203• Since at present IMT is the 
only amino acid tracer suitable for SPECT, imaging with this tracer might combine 
the specificity of amino acids with the wide availability of SPECT. 
The goals of this study were to determine ( 1) whether IMT SPECT can 
visualize soft-tissue sarcomas, (2) whether IMT uptake can discriminate between 
benign and malignant tumors and (3) whether uptake is related to tumor grade and 
the degree of proliferation, using the mitotic index and the Ki-67 proliferation index 
as markers. 
PATIENTS AND METHODS 
Patients 
Patients referred to the University Hospital Groningen between October 1997 
and February 1 999 for management of a suspected soft-tissue sarcoma were asked to 
participate in this study. Suspicion for malignancy was based on rapid growth, size, 
consistency at palpation, location and radiographic appearance of the tumor. 
Selection criteria included age > 1 8  yr and planned histological confirmation within 2 
weeks after the IMT study. 
Thirty-two patients ( 1 6  male, 16  female; median age 45 yr ( 1 8-82) were 
included in the study. Patient and tumor data are presented in Table 1 .  All patients 
were studied t: -2 weeks prior to biopsy or definitive resection. All patients were 
clinically staged with a chest CT, MRI or CT of the soft tissue mass as well as 
ultrasound of the liver and bone scintigraphy. The study was approved by the 
Medical Ethics Committee of the University Hospital Groningen. Written informed 
consent was obtained from all patients. 
Synthesis and Quality Control 
Synthesis of IMT was carried out slightly modified from Krummeich et al. 204• 
Briefly, Iodo-gen ™ iodination with Na1231 (specific activity > 1 85 TBq/mmol (5000 
Ci/mmol), Amersham Cygne, Eindhoven, the Netherlands) of the precursor 1-alpha­
methyl-tyrosine was performed in a borate buffer. IMT was purified by elution with 
saline containing 5% ethanol over a C- 18  SepPak® cartridge (Waters, Milford, Mass. 
USA) preconditioned with l 00% ethanol followed by saline containing 5% ethanol. 
After filtration through a sterile 0.22 Jlm Millex GV filter (Millipore®, S.A., 
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Molsheim, France) a colorless ready-to-inject solution was obtained. Samples were 
demonstrated to be sterile and pyrogen-free. Quality control was performed by HPLC 
on a RP-1 8  column (Multosorb 100 4.6) using H20/ethanoVacetic-acid 87.5/10/2.5 
v/v/v % as eluent. Radiochemical purity was over 99% in all cases. The overall 
synthesis time, including purification and quality control was less than 1 hr. 
Radiochemical yield was 50 - 65%. 
Imaging 
Patiens were injected intravenously with 200-300 MBq IMT after at least a 4 
hr fast. They were given 10  drops of Lugol's solution orally 15  min prior to injection 
to prevent thyroid uptake of possibly formed free 1231. A large-field-of-view double 
headed gamma camera (MUL TISPECT 2, Siemens lnc, Hoffman Estates, Illinois, 
USA) was used with a medium energy all purpose collimator and a 15% window 
centered on the 159 keV photopeak of 1231odine. System resolution was 12  mm 
FWHM at 10  cm distance. 
Fifteen minutes after injection SPECT of the tumor area was performed 
usually followed by a planar spot view. After imaging the tumor area, additional spot 
views were recorded to obtain whole body information in all cases. In 20 patients the 
thorax was imaged using SPECT. 
All SPECT acquisitions included 64 views (2 x 32; 5.6 /step) of 30 seconds 
duration each in a 128 x 128 matrix format with a zoom factor of 1 .23. This 
·corresponds to a pixel dimension of 4. 1 mm. Transaxial tomograms were 
reconstructed without prefiltering using filtered back-projection with a Butterworth 
filter of 6th order and a cutoff frequency of 0.275 Nyquist. Ten minutes spot views 
were recorded in a 128 x 128 matrix. Total imaging time was approximately 1 hr. 
The reported radiation burden of IMT is 0.007 mSv!MBq, yielding an 
effective dose equivalent of 1 .4 - 2. 1 mSv 205• 
Image analysis. 
Without knowledge of the staging and histopathological data, two experienced 
readers analyzed all images visually for tumor uptake and abnormal extratumoral 
uptake. Regions of interest (ROis) were manually placed over SPECT tumor slices 
with maximum visibility and on planar spot views. Reference ROis were placed over 
representative background muscle tissue, usually contralaterally. ROis were drawn at 
80% of the maximal pixel value around the lesion under study, in some cases this 
procedure resulted in more than one ROI per tumor 206• The T/B ratio was calculated 
by dividing tumor ROI intensity (cts/pixel) by background ROI intensity. 
All IMT scintigraphic findings were compared with the results of conventional 
imaging. T/B ratios were compared with tumor grade, mitotic index, tumor 
cellularity and vascularity and the Ki-67 proliferation index. 
Pathological examination 
The histological diagnosis was made on haematoxilin-eosin (HE) stained 
paraffin sections with or without additional immunohistological stains. All tumors 
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were classified according to Enzinger and Weiss into 10  different histological types 8• 
Soft-tissue sarcomas were graded according to the grading system of Coindre et al. in 
which points are assigned to differentiation level, mitotic index and necrosis 29• 
In 27 of the 32 lesions determination of the mitotic index, K.i-67 proliferation 
index, cellularity and vascularity was performed. In five cases (3 benign, 2 
malignant) there was not enough material left for these determinations. The number 
of mitotic figures per 2 mm2 was counted in HE stained paraffin sections. 
Proliferating cells were detected using the monoclonal antibody MIB- 1 (lmmunotech 
S.A., Marseille, France), which recognizes an epitope of the Ki-67 antigen. This is a 
nuclear antigen present in all phases of the cell cycle except for the GO phase, in 
which the cells are withdrawn from the cell cycle, and the early G 1 phase, the phase 
before the start of DNA synthesis 170• Immunohistochemistry was performed on 
paraffin sections according to a method modified from Shi et al. 177• 178• In short: after 
heating on a hot plate, the slides were dewaxed in xylene and rehydrated in serial 
ethanol washes ( 100%, 96% and 70%). After heating twice in an autoclave for 10  
minutes at 1 10 C in  boiling solution pH=6.0, the slides were incubated with a 1 :400 
dilution of the antibody in bovine serum albumin pH=7.4. The primary antibody was 
detected with a biotinylated secondary antibody (multilink) followed by a 
streptavidine-alkaline phosphatase conjugate (Ready-to-Use Link and Label, 
Biogenex, San Ramon CA, USA). Final colour was developed using 
bromochloroindolyl-phosphate 4-nitroblue-tetrazolium-chloride (Boehringer, 
Mannheim, Germany). 
To measure the Ki-67 proliferation index and tumor cellularity we used ocular 
micrometry on a Leica microscope (Rijswijk, the Netherlands) with an eyepiece grid 
at x400 magnification. Fifteen fields were randomly selected throughout 
histologically viable areas. Tumor cellularity (cellular density) was defined as the 
total number of cells excluding endothelial cells, inflammatory cells and necrosis and 
presented as number per 2 mm2• MIB-1 positive nuclei were identified and the 
number of these nuclei was divided by the total number of nuclei in each of the 1 5  
fields to calculate an index per field. The K.i-67 proliferation index (also named Ki-
67 labelling index), representing proliferative activity, was defined as the mean of the 
indices of the 1 5  fields. Vascularity in each tumor was estimated by quantification of 
the total number of small blood vessels or parts of large vessels in HE stained 
paraffin sections. Ten fields were randomly selected and the total number of vessels 
in 10  fields at 400x magnification (corresponding to 2 mm2) was counted. 
Statistics 
To determine the ability to distinguish malignant from benign tumors, a 
Student's t-test was performed on T/B ratios (normally distributed) in both groups. 
Spearman's correlation coefficient was used to correlate T/B ratios with K.i-67 
proliferation index, mitotic index, tumor vascularity and cellularity. Kruskall Wallis 
non-parametric ANOVA with Dunnett's T3 post-hoc multiple comparisons test was 





Eleven patients were found to have a benign lesion, the remaining 2 1  had a 
soft-tissue sarcoma. Three patients had previously been treated for a soft-tissue 
sarcoma (2,3 and 4 yrs earlier) and were now diagnosed to have a local recurrency. 
Eighteen tumors were localized in an extremity (56%), fourteen in the trunk (44%). 
Tumor size was between 2 and 23 cm, median 8.6 cm. There were 4 low grade (grade 
I), 5 intermediate grade (grade II) and 12  high grade sarcomas (grade Ill) (Table 1). 
Benign lesions were assigned grade 0. 
All 21 soft-tissue sarcomas were visualized on the IMT SPECT images. 
Tumors in the extremities and in the chest were well visualized because of high 
tumor uptake and low background uptake, whereas tumors near excretory systems 
(kidneys, bladder, ureters) were more difficult to evaluate. IMT uptake in tumors was 
often inhomogeneous, in accordance with the typical histological appearance of 
sarcomas where areas of necrosis and hemorrhage are interspersed with areas 
containing vital tumor cells. A typical example is presented in Figure 1 .  
Figure 1. 
Coronal SPECT slice 
through the upper legs of 
patient 13 with a high grade 
liposarcoma showing 
intense uptake ofiMT. 
Heterogeneous uptake with 
a central defect is caused by 
necrosis. 
In five of the eleven benign lesions no IMT uptake was found, in four faint 
uptake and in two avid uptake. No uptake was found in all five lipomas, faint uptake 
in two large intramuscular haemangiomas, an aspecific fibrotic lesion and in one 
aggressive fibromatosis lesion. Avid uptake was present in a growing neurofibroma 
and in another agressive fibromatosis lesions (these latter are considered 'borderline 
malignant'). 
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Table 1. Patient characteristics and IMT UEtake. 




1 33 f Liposarcoma (sclerosing) upper leg 1 0  low 2.3 
2 58 m Liposarcoma Retroperitoneal 23 low 2.6 
3 32 f Liposarcoma upper leg 6 low 2.8 
4 45 m Liposarcoma (myxoid) lower leg 13 low 2.9 
5 47 f Liposarcoma (myxoid) knee 6 intermediate 3.8 
6 36 m Malignant fibrous histiocytoma abdominal wall 8 intermediate 3.8 
7 82 m Malignant fibrous histiocytoma lower leg 7 intermediate 5.4 
8 43 m Sarcoma not otherwise specified upper leg 12  intermediate 4.0 
9 35 f Synovial sarcoma upper leg 6 intermediate 3.2 
10 1 8  m Extra skeletal osteosarcoma chest wall 5 high 2.7 
1 1  29 m Extraskeletal mesench�al elbow 2 high 4. 1 
chondrosarcoma 
12  58 m Liposarcoma chest wall 9 high 5.2 
13 46 m Liposarcoma (pleiomorphic) upper leg 20 high 3.6 
14 46 f Malignant fibrous histiocytoma upper leg 8 high 5.1  
15 75 m Malignant fibrous histiocytoma upper leg 10 high 5.8 
16 64 m Malignant fibrous histiocytoma chest wall 6 high 6.1  
17  1 9  m Malignant schwannoma gluteal 7 high 3.2 
18 18 f Sarcoma not otherwise specified gluteal 7 high 2.2 
19  54 f Sarcoma not otherwise specified knee 10 high 3.5 
20 66 m Sarcoma not otherwise specified knee 1 0  high 4.8 
2 1  52 f Synovial sarcoma lower leg 1 0  high 3.4 
BENIGN LESIONS 
22 24 f Fibromatosis - locally invasive neck 5 1 .8 
23 23 f Fibromatosis - locally invasive chest wall 6 2.5 
24 41 m Intramuscular haemangioma back 2 1 .5 
25 42 f Intramuscular haemangioma lower leg 8 1 .8 
26 74 f Lipoma axilla 1 5  1 .0 
27 52 f Lipoma shoulder 6 1 .0 
28 56 m Lipoma upper leg 7 1 .0 
29 53 1 Lipoma upper leg 8 1 .0 
30 42 f Lipoma back 5 1 .0 
3 1  28 m Neurofibroma groin 1 0  2.6 
32 58 f Non s2ecific fibrosis u22er leg 1 0  1 .5 
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The average T/B ratio in benign tumors was 1 .52±0.60 whereas IMT uptake in the 
malignant tumors was much higher: 3.83± 1 . 1 6. (p<O.OO l )(Figure 2). There was 
minimal overlap in individual values, due to avid uptake in the aggressive 
fibromatosis and in the growing neurofibroma (Figure 2). When a T/B ratio of 2.0 
was chosen as cut-off point, sensitivity for the detection of malignancy in a soft­
tissue mass was 100% with a specificity of 88%. Using 2.7 as cut-off point, 
sensitivity was 89% but specificity 100%. 
T/B ratios correlated with histological grades (r=0.82, p<O.OO l) :  IMT uptake 
increased with higher tumor grade. Post hoc analysis revealed that the difference 
between benign tumors vs grade 1 ,2 and 3 tumors caused the significance. Grades 1 
vs 2 and 2 vs 3 could not be distinguished from each other. However, low grade 
tumors could be discriminated from benign tumors in this group (Figure 3). 
Interestingly, IMT uptake correlated with markers of cell proliferation: IMT 
T/B ratio vs the Ki-67 proliferation index gave r=0.75, p<O.OO l (Figure 4A) and vs 
the mitotic index r=0.63, p<O.O l  (Figure 4B). IMT uptake correlated also with tumor 
cellularity (r=0.73 p<O.OO l )(Figure 4C), while no relation with tumor vascularity 
could be established (Figure 40). 
Since whole body images were available in all patients, the ability of IMT 
scintigraphy to detect metastatic disease was also studied. But due to the low number 
of metastasized tumors no reliable assessment of staging could be obtained. Only 2 
patients in this series were found to have metastatic disease: one had small 
pulmonary metastases (2 mm on chest CT) that were negative on the IMT chest 
SPECT study. The other patient had multiple small (<5 mm) intraperitoneal 
metastases, negative on all pre-operative investigations but detected during surgery. 
DISCUSSION 
This study demonstrates high uptake of IMT in soft-tissue sarcomas and low 
uptake in benign processes. All malignant tumors were visualized, leading to 100% 
sensitivity. Tumors in the direct vicinity of bladder or kidneys were somewhat more 
difficult to assess, due to renal excretion of IMT causing high background activity. 
IMT uptake could differentiate benign from malignant tumors with high accuracy. 
Uptake increased· with higher tumor grade, higher Ki-67 proliferation index, mitotic 
activity and tumor cellularity while no correlation with tumor vascularity was found. 
Therefore, this relatively simple non-invasive technique provides information on 
parameters of tumor activity. 
Only limited data were obtained to study whole body staging, since only two 
patients had metastases. In both patients these metastases were not detected. In 
general, lesion detectability depends on the resolution of the gammacamera and the 
amount of tracer uptake in a lesion: in this way a 1 mm lesion with very high tracer 
uptake can theoretically still be detected with a SPECT gammacamera with a 
resolution around 1 5  mm. In practice, however, most known SPECT tracers do not 
detect lesions smaller than 1 .5 - 2 cm. Apparently this also holds true for the new 
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IMT uptake (T/B 
ratios) in benign and 
malignant tumors (open 
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malignant lesions 
uptake is higher than in 
benign lesions: 
3.83±1 .26 VS 1 .52±0.60, 
p<O.OOI .  
Figure 3. 
IMT uptake (T/B ratio) 
versus tumor grade for all 
tumors (open symbols). 
Mean and SD (closed 
symbols). Benign tumors 
are assigned grade 0. 
Spearman correlation 
coefficient r-0.82, 
p<O.OOI .  
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(A) Scatterplots showing IMT uptake (T/B ratio) in correlation with (A) the Ki-67 
proliferation index: r-0.63, p<O.Ol (B) mitotic index: r-0.75, p<O.OOl ,  (C) tumor 
cellularity: r-0.73, p<O.OOl ,  (4) tumor vascularity: no correlation. 
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tracer IMT: In our patient with lung metastases, lesions were probably too small 
and/or IMT uptake not high enough to enable detection. In the case of the patient 
with diffuse peritoneal metastases, both small size and interfering uptake in excretory 
organs (kidneys, ureters, intestine) probably prevented detection. This patient had a 
extra skeletal osteosarcoma of the chest wall. Also CT and MRI of the abdomen 
failed to detect the metastases. Although our experience in staging is very limited, it 
does not seems very likely that this method will contribute to improved staging due 
to above mentioned limitations. 
To understand what processes are visualized by IMT uptake, it is important to 
understand the mechanism of uptake. Using competition experiments in vivo, Langen 
et al. demonstrated that IMT is a substrate for the amino acid transport systems in the 
blood-brain barrier 201 • This has not been demonstrated for tumors outside the brain 
yet. However, in vitro data suggest that also in non glioma tissue, uptake of IMT is 
almost entirely mediated by amino acid transport activity 207• Since in the present 
study no correlation with the amount of tumor vessels was found, tumor perfusion is 
not the dominating factor that governs IMT uptake, as was suggested by Deehan in a 
rat model 208• One could argue that uptake in the two haemangiomas must be related 
to blood flow and diffusion, but these tumors were also very cellular. The presumed 
mechanism of uptake of IMT is the accelerated protein metabolism and the resulting 
increased demand for amino acids. This is further supported by the relation with 
tumor proliferation factors, as found in this study. 
To non-invasively determine the malignancy grade in soft-tissue tumors, 
magnetic resonance spectroscopy 192 and various nuclear medicine techniques and 
tracers have been used such as 201Tl, 99mTc-MIBI, 99mTc-MDP, 67Gallium 1 15•209 and 
more recently FDG and radiolabeled amino acids such as L-[ 1 -1 1C]-tyrosine 
2 1 •1 90•2 10•2 1 1 • Different biochemical processes in tumors are visualized by all these 
tracers: most likely 201Tl uptake is related to cellular Na+K+-ATPase activity, 99mTc­
MIBI to membrane functions and mitochondrial integrity, MDP to 
calcium/phosphate metabolism, 67Ga to transferrine receptors in tumor cells or 
inflammatory cells. In all cases there is more or less effect of tumor vascularization. 
Sensitivity of fumor detection using IMT appears better than other single photon 
tracers in soft-tissue sarcomas, and the presumed uptake mechanism might more 
directly reflect tumor viability than the above mentioned mechanisms, but our results 
need to be confirmed by other studies. 
Many studies have used PET to study sarcomas. FDG generally shows high 
uptake in tumors and has proven to be of value in the visualization and grading of 
soft-tissue sarcomas. In the study by Nieweg et al all 1 8  sarcomas were visualized 
using FDG PET and a correlation was found between the calculated glucose 
consumption and tumor grade 2 1 • Schulte et al found high sensitivity using FDG PET 
for the detection of malignancy in 102 patients, but lower specificity caused by high 
uptake in aggressive benign tumors and a patient with myositis ossificans 191 • Uptake 
of L- l -[1 1C]-tyrosine also showed a correlation with tumor grade, mitotic rate and 
proliferation in soft-tissue sarcoma 190•2 1 1 • Because of lower uptake in inflammatory 
reactions caused by radiotherapy, systemic chemotherapy or regional cytostatic 
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perfusion, it is suggested that radiolabeled amino acids are better suited to monitor 
treatment effects than FDG 190• 194•2 10• The results of the present study using IMT 
SPECT are well in line with these PET studies, with somewhat higher correlation 
factors than reported for L-[ 1 -1 1C]-tyrosine 190•21 1 • 
Almost all studies on soft-tissue tumors have found some uptake in benign 
lesions, regardless of the used tracer 21 •1 15• 190• 19 1 •209• Also using IMT we found minor 
uptake in haemangiomas and more avid uptake in a neurofibroma and in aggressive 
fibromatosis lesions. These latter are actually considered to be 'borderline malignant' 
and therefore presumably have increased amino acid metabolism leading to IMT 
uptake. Similar to our observations Kuwert et al found some IMT uptake in non­
neoplastic brain lesions such as inflammatory lesions and infarctions) 2 12• Recently 
very high uptake was described in a low-grade desmoplatic infantile ganglioglioma, 
another benign neoplasm 2 13• Therefore, it seems most likely to conclude that IMT is 
an aspecific tumor tracer that targets amino acid metabolism in tumors. Difference in 
uptake between malignant and benign disease is based on the degree of accelerated 
protein metabolism. 
In this study we found IMT uptake also to be related with the number of tumor 
cells. Whether this also holds true for other tracers is largely unknown. Since cellular 
density can be high in many tumors the mere fact of many cells per volume (in 
comparison with adjacent tissues) could already cause increased uptake . However, it 
seems unlikely that this effect only would results in T/B ratios between 3 and 6, as 
found in many high grade tumors. Moreover, others have found no relation between 
IMT uptake and cellular density in brain tumors 2 14• 
Although our results appear comparable to those using FDG and L-[ 1-1 1C]­
tyrosine PET, it could be argued that the lower resolution and limited quantification 
possibilities of SPECT make the method inferior to PET. However, in these generally 
large tumors the lower resolution is presumably not a big problem, although partial 
volume effects may decrease tumor heterogeneity. Limited quantification 
possibilities are also controversial, since some authors successfully use T/B also in 
FDG PET studies 19 1 , while others disagree as to what PET uptake parameters gives 
the best results in separation of benign from malignant disease 21 .2 15•217• Furthermore, 
absolute quantification of protein synthesis (as possible in PET) both in tumor tissue 
and in 'background' tissue may be disturbed by systemic influences and vary largely 
from day to day 210• Using ratios might compensate for this effect. 
The good correlation of IMT uptake with parameters of tumor activity may be 
of interest in evaluation of new treatment strategies such as angiogenesis inhibition, 
matrix metalloproteinase inhibition or antisense therapy . These new drugs exert their 
action through new mechanisms and may require new evaluation methods. In these 
methods assessment of metabolic tumor activity may complement the classic 
response parameter, the change in tumor size. In current routine clinical practice, 
however, non-invasive studies of tumor activity or its benign/malignant nature is of 
limited value. Patients and physicians rely on histological evidence, and only in 
exceptional cases these studies will influence diagnostic strategies. 
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In conclusion, IMT scintigraphy clearly visualized all soft-tissue sarcomas in 
this group. Uptake in malignant tumors was higher than in benign lesions, leading to 
a sensitivity for the detection of malignancy of 1 00% at a specificity of 88%. Uptake 
increased with higher tumor grade and higher proliferation rate. Therefore, IMT 
SPECT non-invasively provides information about tumor activity. 
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SUMMARY 
Hyperthermic isolated limb perfusion with tumor necrosis factor-a (TNF-a) 
and melphalan (HILP-TM) with or without interferon-r(IFN-J) is a promising local 
treatment in patients with locally advanced extremity soft tissue sarcomas (STS) with 
response rates of up to 84%. The mechanisms of the treatment response are poorly 
understood. This study determines the HILP-TM induced changes in mitotic activity, 
proliferation and apoptosis in 3 7  STS, the additional effect of IFN-rand the relation 
with treatment response and clinical outcome. 
On archival material, obtained before and 6-8 weeks after HILP-TM with 
TNF-a and melphalan with (n=l 5) or without (n=22) IFN-r. the number of mitoses 
was counted and the proliferation fraction was determined by immunohistologic 
staining for the proliferation associated Ki-67 antigen (MIBJ). Apoptosis was 
visualized by enzymatic detection of DNA fragmentation (TUNEL-method). . Clinical 
and histological response, follow-up status and survival were recorded. 
The number of mitoses dropped 57% and proliferation rate decreased with 
40% after HILP-TM, whereas the amount of apoptosis after HILP-TM more than 
doubled as before HILP-TM. The addition of/FN-rto HILP-TM did not influence the 
changes in tumor parameters and did not affect treatment response. A better clinical 
response to HILP-TM was correlated with high mitotic activity and low amount of 
apoptosis in tumor samples before HILP-TM. Patients with highly proliferative STS 
before and after HILP-TM had a relatively poor prognosis. Furthermore, patients 
who developed distant metastases after HILP-TM had a relatively high number of 
dividing cells in the tumor remnants after treatment. 
INTRODUCTION 
Soft tissue sarcomas (STS) constitute a heterogeneous group of malignant 
tumors which arise from tissue of mesenchymal origin and account for approximately 
1 % of all malignancies. STS predominantly affect the limbs and surgical resection in 
combination with high dose adjuvant external beam radiotherapy, after marginal 
resection, is the treatment of choice8•218•2 19• Because of the size and extent of the 
tumor or the proximity of vital structures, limb saving surgery is not always possible 
and mutilating surgical procedures or amputation are occasionally necessarf 18•220•224• 
One of the currently most promising limb saving procedures is the combination of 
hyperthermic isolated limb perfusion {HILP) with delayed surgical tumor 
excision80•83• The major advantages of HILP are that regional cytostatic 
concentrations can be 1 5  to 20 times as high as after systemic administration and 
that hyperthermia may enhance the cytotoxic effecf25•226• In 1992 Lienard et al. used 
HILP to administer high dose recombinant tumor necrosis factor alfa (TNF-a) in 
combination with melphalan, an alkylating chemotherapeutic agent, resulting in 
encouraging outcomes 8 1 • In HILP with TNF-a and melphalan (HILP-TM) with or 
without interferon-gamma (IFN-y) response rates of up to 84% have been reported in 
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the treatment of STS 79'83• Since the mechanism of the antitumor effects of HILP-TM 
is still poorly understood and studies suggest that chemotherapeutic drugs in general 
inhibit proliferation by generating cell cycle arrest and subsequent apoptosis, it was 
decided to investigate these tumor parameters in HILP-TM 227·234• 
The objective of this study was to investigate whether the treatment response 
and clinical outcome of patients treated with HILP-TM is associated with tumor 
grade, mitotic activity, proliferation and apoptosis in the tumor specimens of STS 
obtained before and after HILP-TM. Furthermore, the influence of HILP-TM on 
these tumor markers and additional effect ofiFN-y was evaluated. 
PATIENTS AND METHODS 
Patients 
The inclusion criteria for the present study were: ( 1) histological diagnosis of 
a malignant mesenchymal tumor, located in the soft tissues; (2) primary irresectable 
tumor of lower or upper limb which was treated with HILP-TM with or without IFN­
y and (3) the availability of paraffin embedded tumor material obtained within 3 
months before HILP-TM with a maximum period between pretreatment and 
posttreatment tumor samples of 5 months. 
Between 1991  and 1997, 37 patients with primary irresectable STS of lower or 
upper limb underwent HILP-TM with TNF-a. and melphalan. HILP-TM with TNF-a. 
and melphalan was combined with IFN-y in 1 5  of the 37 analyzed patients. Mean age 
of the 18  men and 19  women, at the time of diagnosis, was 46 (range: 1 8  - 18 ;  
median: 48; SD: 16.7) years. Four tumors were located in  the upper limb ( 1 1%) and 
33 in the lower limb (89%). At the time of HILP-TM, 6 patients ( 16%) had distant 
metastases and 3 patients (8%) had regional lymph node metastases. The mean time 
between incisional biopsy and perfusion was 22 (range: 0 - 83; median: 17; SD: 17) 
days. In one patient an incisional biopsy of multiple superficial sarcomas was 
performed at �e day of HILP-TM to obtain fresh tumor material. In 35  of the 37 
patients HILP-TM was followed by surgical resection 6-8 weeks later, according to 
the study protocol. In two patients (5%) histological examination after HILP-TM was 
not possible: one patient had progressive lung metastases requiring chemotherapy 
and in the other patient the limb had to be amputated because of vascular occlusion 2 
days after HILP-TM. Local progressive disease or treatment related morbidity were 
reasons to perform the delayed local surgical resection earlier or later than planned in 
the protocol. Specimens to assess histological reaction were obtained after a mean 
period of 61  days following HILP-TM (range: 12 - 103 ;  median: 60; SD: l 6). In three 
patients, in which HILP-TM was performed twice, histological tumor reaction was 
assessed after the first HILP-TM in two patients and after the second HILP-TM in 
one patient, of whom no tumor material was available after the first HILP-TM. The 
mean time between the pre-treatment sample and the post-treatment sample was 83 
days (range: 33 - 138; median: 80; SD: 22). No additional treatment was given 
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between HILP-TM and the delayed resection. Patient characteristics, histology and 
clinical data are presented in Table 1 .  
Histology 
In all cases the histological diagnosis was made on H&E stained paraffin 
sections of incisional biopsies with or without additional immunohistological stains. 
All cases were classified according to Enzinger and W eiss 8 which revealed 16 
different histological types (Table 1). The STS were graded according to the grading 
system of Coindre et al., in which points are assigned to differentiation level, mitotic 
index and necrosis 29• This resulted in 7 grade I ( 19% ), 1 9  grade II (5 1%) and 1 1  
grade III (30%) STS (Table 1 ). In the resection specimens the amount of necrosis 
was estimated on gross examination. For histology at least one section per centimeter 
of the largest tumor diameter was taken. Care was taken to histologically document 
the presence of necrosis, viable tumor or fibrosis. 
Tumor parameters 
The following tumor parameters were studied on adjacent slides of the 
macroscopically and microscopically most viable parts of the tumor before and after 
HILP-TM: mitotic index, proliferation and apoptosis. 
The number of mitoses per 2 mm2 (mitotic index) in adjacent fields was counted 
on H&E stained paraffin sections. 
For proliferation, the monoclonal antibody MIB 1 (lmmunotech S.A., 
Marseille, France) was used. This antibody recognizes an epitope of the Ki-67 
antigen, which is present in the nucleus of cells in all phases of the cell cycle except 
the GO and the early G 1 phase 1 70• Immunohistochemistry was performed on paraffin 
sections (4 J.lm) according to a method modified from Shi et ai. I77. 1 78• Briefly, after 
heating on a hotplate slides were dewaxed in xylene and rehydrated in serial ethanol 
washes ( 100%, 96% and 70%). After two times heating in an autoclave for 10  
minutes at 1 10° C in a 20  mM blocking reagens (Boehringer Mannheim, Mannheim, 
Germany) with pH=6.0, slides were incubated with a 1 :400 dilution of the antibody 
in bovine serum albumin buffer pH=7.4. The primary antibody was detected with a 
biotinylated secondary antibody (multilink) followed by a streptavidine-alkaline 
phosphatase conjugate (Ready-to-Use Link and Label, Biogenex). Final calor was 
developed by the BCIP-NBT method (bromochloroindolyl-phosphate 4-nitroblue­
tetrazoliumchloride; Boehringer Mannheim, Mannheim, Germany). 
Apoptosis was studied in 4 J.lm sections of formaldehyde fixed and paraffin 
embedded tissue using the TUNEL (Terminal deoxynucleotidyl Transferase (TdT) 
mediated dUTP Nick End Labeling)-method. After deparaffination, sections were 
subjected to RNA-se ( 1  mg/ml in 50 mM Tris-HCl and 150 mM NaCl pH 7.5; 
Aldrioch , USA) treatment for 30 minutes at room temperature to prevent non­
specific binding digoxygenin labeled deoxy UTP (DIG-1 1 -dUTP). Slides were 
subsequently incubated with 15  J.ll of a 100 J.ll solution containing Terminal 
deoxynucleotidyl transferase (TdT) buffer (Pharmacia, Uppsala, Sweden) with 5 mM 
cobalt chloride and I% bovine serum albumin (Aldrich, USA) together with 5 nM 
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DIG-1 1-dUTP (Boehringer Mannheim, Mannheim, Germany) for 60 minutes at 37 o 
C. After this reaction, slides were rinsed twice in a 0. 1x  standard sodium citrate 
solution for 1 5  minutes at room temperature. Non-specific background staining was 
prevented by preincubating slides with 5% blocking reagens (Boehringer). Sections 
were incubated overnight at 6 o C with alkaline-phosphatase labeled sheep anti-DIG 
F AB fragments dilu�ed 1 :300 in 2% blocking reagens (Boehringer). After extensive 
washing, alkaline-phophatase was visualized with nitroblue tetrazolium 5-brome-4-
chromo-3-indolyl-phosphatase (Boehringer) for 50 minutes at room temperature. 
Sections were counterstained with haematoxylin and coverslipped with a mounting 
medium soluble in xylene. 
Quantification of Ki-67 and apoptosis 
All sections stained for proliferation and apoptosis were quantified without 
knowing whether this section was before or after HILP-TM. For measuring the Ki-67 
labeling index (LI) and the apoptosis LI we used ocular micrometry on a Leitz 
microscope by using an eyepiece grid at x400 magnification. Fifteen adjacent fields 
in histologically viable areas were quantified. The positive and negative nuclei were 
counted. Endothelial cells, inflammatory cells and necrosis were excluded. The 
number of positive nuclei was then divided by the total number of nuclei in each of 
the fifteen randomly selected fields to calculate an index per field. The Ki-67 LI 
(representing proliferative activity) and the apoptosis LI (representing apoptotic 
activity) were defined as the mean of the indices of the fifteen randomly selected 
fields. 
Drugs and Treatment Schedule 
The technique of HILP with TNF-a. and melphalan with or without IFN-y for 
upper and lower limb was recently extensively described80•83• Briefly, recombinant 
human TNF-a. (0.2 mg per ampule, 4.9 to 5.8 x 107 U/mg per ampule, Boehringer 
Ingelheim, GmbH, Ingelheim/Rhein, Germany) and, in 16  patients, recombinant 
human IFN-y (0.2 mg or 1 .5 x 106 U per ampule, Boehringer lngelheim, GmbH, 
Ingelheim!Rhem, Germany) was used. The cytostatic drug melphalan (Alkeran®) was 
obtained as a sterile powder ( 100 mg) that was dissolved aseptically using solvent 
and diluent as provided by Glaxo Burroughs Wellcome (London, United Kingdom). 
After isolation of the systemic blood circulation under general anaesthesia and with 
heparinization (3 mglkg), the limb was perfused with 3 mg (upper limb) TNF-a. to 4 
mg TNF-a. (lower limb) administered as a bolus and, after 30 minutes, with 13-mg/L 
(upper limb) or 10-mg/L (lower limb) volume of melphalan at 39 to 40° C with or 
without addition of 0.2 mg IFN-y. The HILP treatment with TNF-a. and melphalan 
with or without IFN-y was approved by the local medical ethical committee of the 
Groningen University Hospital. 
59 
Chapter 5 
Assessment of Tumor Response 
Tumor response was assessed as previously described by the European TNF 
perfusion group80•83• To estimate the tumor response, both clinical and histological 
reaction on HILP-TM were validated. Briefly, the clinical response was regularly 
determined by standard physical and radiodiagnostic examination i.e. magnetic 
resonance imaging or computed tomography during the 6-8 weeks period between 
HILP-TM and protocol planned delayed resection. The largest diameter of the tumor 
in centimeters before and after HILP-TM was used as the clinical parameter. Clinical 
complete response (CR) was defined as the disappearance of all measurable disease 
in the limb for longer than 4 weeks; clinical partial response (PR) was defined as a 
regression of the tumor size >50% for longer than 4 weeks. A regression of the tumor 
size <50% or a progression of the tumor size <25% for longer than 4 weeks was 
interpreted as clinical no change (NC), whereas clinical progressive disease (PD) was 
defined as a progression of the tumor size >25% for longer than 4 weeks. 
Histological CR was defined as 100% necrosis after HILP-TM, histological PR as 
�50% and <100% necrosis and histological NC as �0% and <50% necrosis. Overall 
response was determined as the combination of both clinical and histological tumor 
response. A clinical CR was downgraded to overall PR when there was a histological 
PR or NC. Otherwise, a clinical PR could be upgraded to overall CR when a 
histological CR was observed. In addition, a clinical tumor regression of <50 % was 
upgraded to overall PR when a histological PR or CR was present. When a clinical 
PR was observed but the histological examination revealed <50 % necrosis (NC), the 
overall response was considered as a PR. 
Statistics 
A Mann Whitney Test was carried out to analyze the differences in tumor 
parameters before and after HILP-TM of all 37 studied patients. A Wilcoxon 
matched pairs signed rank sum test was used to analyze the differences in tumor 
parameters before and after HILP-TM of the 29 patients with viable tumor both 
before and after HILP-TM. To quantitate the degree of correlation between 
parameters, the· Spearman's rank test was used. A two-tailed p-value of < 0.05 was 
considered to be significant. Statistical analysis was performed using Graphpad 
Prism 2.0 (Graphpad Software Inc., San Diego, California, USA). Actuarial survival 
curves were constructed by the Kaplan-Meier method in order to compare OS and 
DFS for the different patient groups in relation to HILP-TM modality as well as high 
(i.e. above the median value) or low (i.e. smaller or equal to the median value) tumor 
parameters. Survival curves in the different groups were compared by the log-rank 
test using SPSS 8.0 for Windows. 
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Table 1. Patient characteristics, histology, HILP-TM-modality, (clinical, histological and 
overall} treatment resQonse and clinical outcome. 
Pt age sex limb Diagnosis grade Stage +/- Cl in. Hist. Overal LR M eta FU 
IFN ResQ. ResQ. I ResQ. {mth} mth} {mth} 
1 47 F Jower MFH I •• + PR CR CR NED 46 
2 37 M lower Myxoid LPS I IB PR PR PR NED 1 1  
3 44 M lower Myxoid LPS I IB PR PR PR NED 3 1  
4 44 F lower Myxoid LPS I IB + PR PR PR NED 55 
5 48 F lower Well diff. LPS I I8 + NC NC NC NED 48 
6 49 M lower Mal.Hemang. I IB PR PR PR NED 17  
7 42 M lower Clear cell sarc. I IVA PR PR PR 1 0  DOD 23 
8 1 8  M lower Extrask myxoid 11 118 + PR PR PR NED 55 
chondrosarcoma 
9 1 8  F Jower RMS 11 liB + PR CR CR NED 59 
1 0  24 M lower Synovial sarc. 11 118 CR PR PR NED 32 
1 1  37 F upper MPNST 11 118 PR PR PR NED 26 
1 2  43 M lower Synovial sarc. 11 118 + NC NC NC 35 NED 55 
1 3  48 M lower Myxoid LPS 11 118 NC PR PR NED 17  
14 50 F lower Sarcoma NOS 11 118 CR CR CR NED 36 
1 5  53 M Jower MFH 11 118 + PR PR PR 7 DOD 17  
1 6  53 F lower Sarcoma NOS 11 118 PR CR CR NED 27 
1 7  56 F Jower PPNET 11 118 PR CR CR 9 NED 43 
1 8  6 1  F upper MFH 11 liB + PR PR PR NED 64 
19  62 M lower MPNST 11 liB + NC NC NC 5 DOD 16 
20 64 F Jower MPNST 11 118 PR PR PR 4 NED 43 
2 1  66 M Jower MFH 11 118 PR PR PR 6 DOD 28 
22 80 M Jower MFH 11 118 PR NC PR 8 DOD 10  
23 7 1  M lower LPS 11 118 + NC PR PR 13 AWD 59 
24 21  M upper Epith. Sarcoma 11 IVA PR PR PR I 9 AWD 14 
25 22 M lower Epith. Sarcoma 11 IVA + PR NC NC 6 22 DOD 40 
26 33 F lower LMS 11 IV8 PR CR CR 8ef DOD 8 
27 25 F lower Synovial sarc. Ill III8 PR PR PR NED 38 
28 28 M lower Sarcoma NOS Ill III8 + CR NC PR Unc DOD 18  
29 39 F upper Synovial sarc. Ill III8 CR PR PR 23 AWD 23 
30 60 F lower LMS Ill III8 + PR PR PR 15 DOD 38 
3 1  67 F lower MFH Ill III8 PR NC PR 3 DOD 9 
32 69 F lower Fibrosarcoma Ill IIIB PR PR PR NED 28 
33 74 M lower Sarcoma NOS Ill III8 PR PR PR 3 1 1  DOD 1 1  
34 50 F lower Dediff. LPS Ill IV8 + PR PR PR 8ef DOD 9 
35 26 F lower Sarcoma NOS Ill IV8 PR UNK UNK 8ef DOD 7 
36 40 F Jower LMS Ill IVB + PR PR PR 8ef DOD 9 
37 54 M Jower MFH Ill IV8 CR UNK UNK 8ef DOD 3 
HILP-TM: hyperthermic isolated limb perfusion with TNF-a and melphalan, +/- IFN: with or without 
IFN-y, LR: local recurrence, meta: distant metastases, mth: months, FU: follow-up, sarc.: sarcoma, mal.: 
malignant, Hemang.: hemangiopericytoma, LMS: leiomyosarcoma, RMS: rhabdomyosarcoma, 
MPNST: malignant peripheral nerve sheath tumor, MFH: malignant fibrous histiocytoma, pPNET: 
peripheral primitive neuroectodermal tumor, NOS: not otherwise specified, IFN: Interferon gamma, 
CR: complete response, PR: partial response, NC: no change, PD: progressive disease, NED: no 
evidence of disease, A WD: alive with disease, DOD: dead of disease, UNK: unknown, Bef: before, 




HILP-TM with or without IFN-y 
As shown in Table 2, tumor grade, mitotic activity, amount of proliferation 
and apoptosis before and after HILP-TM of the 1 5  STS treated with HILP-TM in 
combination with IFN-y did not differ from the 22 STS treated with HILP-TM alone. 
Furthermore, the changes in these tumor parameters after HILP-TM as compared to 
pre-treatment values did not differ significantly between both groups. Treatment 
responses, clinical outcome and survival did not differ between the IFN-y treated 
patient group and the patients who received HILP-TM without IFN-y. Therefore it 
was decided to perform the statistical analyses on the whole group. 
Table 2. Tumor 2arameters of tumors treated with HILP-TM with or without IFN-y 
HILP-TM HILP-TM p-
with IFN-y without IFN-y value 
(mean ± SD) (mean ± SD) 
n =  1 5  n = 22 
Before HILP-TM: viable tumor (%) 85 (± 23) 86 (± 22) >0.05 
mitotic count (/2 mm2) 1 3  (± 17) 12 (± 1 3) >0.05 
proliferation (%) 16.6 {± 14.5) 1 8.4 {± 1 1 .2) >0.05 
apoptosis (%) 1 .06 {± 1 .022 0.80 {± 0.682 >0.05 
After HILP-TM: viable tumor (%) 45 (± 34) 27 (± 21 )  >0.05 
mitotic count (/2 mm2) 4 {± 5) 8 (± 1 6) >0.05 
proliferation (%) 9.8 {± 9.2) 12.7 (± 1 2.2) >0.05 
apoptosis (%) 2.58 {± 2.402 1 .68 {± 2.562 >0.05 
� viable tumor (%) - 42 (± 35) - 61 (± 28) > 0.05 
11 mitotic count - 8 (± 18) - 6 (± 17) > 0.05 
{12 mm2) 
11 proliferation (%) - 7.6 (± 8 . 1 )  - 6 . 1  (± 10.0) > 0.05 
11 apoEtosis {%} + 1 .57 {+ 2.5 12 + 0.91 {+ 2.672 > 0.05 
overall response complete response 2 ( 13  %) 4 (20 %) 
partial response 9 (60 %) 1 6  (80 %) 
no change 4 {27 %2 0 
mean OS {months} 44 3 1  0.83 
11: absolute change, HILP-TM: hyperthermic isolated limb perfusion, IFN-y: Interferon 
gamma, OS: overall survival 
Treatment response related to tumor parameters before HILP-TM 
A clinically assessed complete response was observed in 5 patients ( 14%), a 
partial response was noticed in 27 patients (73%) and in 5 patients ( 14  %) no 
response could be detected clinically (Table 1 ). After histological evaluation, the 
overall tumor response after HILP-TM was considered to be complete in 6 patients 
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( 1 6%) and partial in 23 patients (62%). In six patients ( 16%) the tumor did not 
respond and in two patients the histological response could not be evaluated. Both 
mitotic rate and the amount of apoptosis before HILP-TM did correlate (p<0.05) with 
the clinical response (r: 0.4 1 and r: -0.33, respectively), i.e. high mitotic index and 
low amount of apoptosis before HILP-TM was associated with a relatively good 
clinical response. However, these parameters did not correlate with the histological 
or overall response. Tumor grade and amount of proliferation before HILP-TM did 
not significantly correlate with clinical, histological or overall response, although a 
nearly significant correlation (r: 0.3 1 ;  p=0.06) between tumor grade and clinical 
response was found i.e. clinical response was relatively good in high grade tumors. 
The clinical, histological or overall response were not associated with the period 
between HILP-TM and the delayed local excision. 
HILP-TM induced changes in tumor parameters 
The changes in tumor parameters in tumors of individual patients could be 
assessed before and after HILP-TM in the 29 patients with viable tumor both before 
and after HILP-TM (Figures la-c). Changes in tumor markers or post-treatment 
values did not correlate with the period between HILP-TM and the collection of the 
post-treatment samples nor between the time between both samples. The mean 
number of mitoses in these patients declined from 14 before HILP-TM to 6 after 
HILP-TM (p<O.O l)  (Table 3). The changes in mitotic index were correlated (r: 0.47; 
p<0.05) with the clinical response, but not with the histological or overall response. 
Furthermore, no correlation with other clinical or tumor markers was found. In 4 out 
of 29 patients the number of mitoses after HILP-TM was elevated as compared to 
before HILP-TM. The two patients with the highest increase developed distant 
metastases after HILP-TM. 
70 60 12 P<001 P<O 0001 P<0.01 1 1  
160 
50 10 
9 s_ so  �40 � 8 Cl) .. c 
Cl) 40 0 Cl) 7 
� 
:;::; iii E ao  % 6 
'0 30  � 0 5 -e c.. .. ... .. 0.. 20 4 � 20 3 :I c 
10 10 2 
0 0 0 A B before HI LP aflerHILP c before HILP afler HILP 
Figure 1 
Paired analysis of the studied tumor parameters (A: mitotic count, B: proliferation, 
C: apoptosis) of the 29 patients with viable tumor both before and after HILP-TM. 
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Table 3: Tumor parameters before and after HILP-TM 





Mitotic count (/2mm2) 
Proliferation 
Apoptosis 
29 14 (± 1 6) 
29 18.2 % (± 13 .6 %) 
29 0.87 % (+ 0.86 %) 
6 (± SD: 12) 
1 1 % (± SD: 10.8 %) 




Mean proliferative activity dropped significantly (p<0.001 )  from 1 8.2 % before 
HILP-TM to 1 1 .0 % after HILP-TM. As shown in Figure 1 b, 23 patients had a 
decrease in proliferation, whereas 6 patients had an increase. The two patients with 
the largest increase in proliferation developed distant metastases and died of disease. 
However, there was no significant correlation between the change in proliferation 
and other tumor or clinical parameters. The mean percentage of apoptotic cells 
increased from 0.87 % before HILP-TM to 2.09 % after HILP-TM (p<O.O 1 ). In seven 
patients (Figure 1 c), a decrease in apoptosis was observed, including two patients 
who had an increase in proliferation after HILP-TM. The increase in apoptosis was 
not correlated with other tumor or clinical parameters. 
Follow-up, metastasis and survival in relation to the studied tumor parameters 
After a mean follow-up period of 29 months (range: 3 - 64; median: 27; SD: 
17. 7) months after HILP-TM, 19 patients were alive without evidence of disease 
(NED), 3 patients were alive with disease (A WD) and 15  patients died of disease 
(DO D) (Table 1 ). In the tumors of the patients who died of disease, a higher amount 
of mitoses and proliferation was observed (p<O.OS) both before and after HILP-TM 
as compared to the patients who were alive (Table 4) . Amount of apoptosis (before 
or after) did not differ between those groups. The change in mitotic, proliferative and 
apoptotic activity after HILP-TM was not related to follow-up status. 
Table 4. 
Tumor parameters bef.gre and af!.er HILP-TM related to follow-up status NED and DOD 
Tumor parameter NED DOD p 
Before number of patients 19  1 5  
HILP: mean mitotic count (/2mm2) 7 (SD: 7) 20 (SD: 1 9) 0.01 
mean proliferation 14.7 % (SD: 13 . 1 )  22.3 % (SD: 1 1 .8 )  0.04 
mean apoptosis 0.92 % (SD: 0.652 0.74 % (SD: 0.622 0.41 
After number of patients 14 12 
HILP: mean mitotic count (/2mm2) 2 ( SD: 3) 13  (SD: 1 7) 0.02 
mean proliferation 8.0 % (SD: 9.6) 1 6.0 % (SD: 1 1 .5 ) 0.02 
mean apoEtosis 2.72 % {SD: 3.27 ! 1 .56 % {SD: 1 .38 ! 0.70 
change: mean .1 mitotic count (/2mm2) -5 (SD: 8) -7 (SD: 25) 0.55 
mean .1 proliferation -7.2 % (SD: 8.8 ) -7.5 % (SD: 9.7 ) 0.69 
mean .1 apoptosis 1 .85 % (SD: 3.29 ) 0.89 % (SD: 1 .53 ) 0.94 
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Table 5. Tumor parameters before and after HILP-TM related to newly developed distant 
metastases after HILP-TM 
Tumor Earameter distant metastases no distant metastases E 
Before number of patients 12 24 
HILP: mean mitotic count (/2mm2) 1 5  (SD: 16) 10  (SD: 9) 0.32 
mean proliferation 20.8 % (SD: 12.5) 1 6.2 % (SD: 12.7 %) 0.22 
mean aEOEtosis 0.92 % {SD: 1 . 12} 0.93 % {SD: 0.68%} 0.56 
After number of patients 12 1 6  
HILP: mean mitotic count (/2mm2) 12 ( SD: 1 7) 2 (SD: 4) 0.05 
mean proliferation 13.6 % (SD: 1 1 .3) 10.1 % (SD: 10.9 %) 0.34 
mean aEOEtosis 1 .26 % (SD: 0.71} 2.79 % (SD: 3.1 7%} 0.53 
change: mean !:. mitotic count -1 (SD: 17) -6 (SD: 8) 0.98 
{12mm2) 
mean !:. proliferation -7.2 % (SD: 6.9) -6.5 % (SD: 10.9 %) 0.50 
mean !:. aEOEtosis 0.32 % (SD: 0.91 )  1 .91  % (SD: 3.26 %) 0.44 
Six patients ( 1 6  %) developed a local recurrence or regional lymph node 
metastasis after a mean disease free survival (DFS) of 4.3 (range: 1 - 9; median: 3.5; 
SD: 2.8) months. Twelve of the 31 patients (39 %) without distant metastases at the 
time of HILP-TM developed distant metastases after a mean DFS of 1 3 .7 (range: 5 -
35  ; median: 1 1 ; SD: 8.9) months. In one patient with a sarcoma not otherwise 
specified, who developed a malignant tumor 1 1  months after HILP, it was uncertain 
whether this was a metastatic lesion or a second malignant primary tumor. Tumor 
grade, mitotic activity, proliferation or apoptosis before HILP-TM were not related to 
the development of metastases. However, in the patients who developed new distant 
metastases after HILP-TM the number of mitoses in the post HILP-TM specimens 
was higher (p<0.05) as compared to that in the patients who did not (Table 5). In 
contrast, proliferation and apoptosis after HILP-TM were not significantly associated 
with development of distant metastases. Development of metastatic disease or clinical 
outcome were neither associated with the time between HILP-TM and the delayed 
local resection nor with the period between the pre-treatment an posttreatment 
samples. 
The 2 years OS for the 37 HILP-TM treated patients was 62 % and 5 years OS 
was 5 1 %. Mean OS of the patients with a clinical CR was 5 1  months (PR: 42 months, 
NC: 42 months). Patients with a complete overall response had a mean OS of 5 1  
months, which differed (p=0.12) from patients who had no response (mean OS: 29 
months). Mean OS of patients with an overall PR was 47 months. As shown in Table 
6, large (i.e. above the median) or small (i.e. below or equal to the median) changes 
in mitotic rate, proliferation or apoptosis after HILP-TM did not influence OS. 
However, the patients with a high amount of proliferation after HILP-TM had a 
shorter (p<0.05) OS than the patients with a low amount of proliferation after HILP­
TM. The amount of mitotic rate or amount of apoptosis did not influence OS. 
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Tumor parameter mean OS of patients mean OS of p 
mean mitotic count (/2mm2) 
mean proliferation 
mean apoptosis 
mean mitotic count (/2mm2) 
mean proliferation 
mean apoptosis 
mean 1::. mitotic count 
(/2mm2) 
mean 1::. proliferation 
mean 1::. apoptosis 
with patients with 
low values high values 
{< or = the median) {> the median) 
50 months 32 months 

























Since it was first described by Creech et al.in 1958, HILP is predominantly 
used in the treatment of melanomas and sarcomas81 •82•235'242• Traditional cytostatic 
agents like melphalan and doxorubicin yielded unsatisfactory response rates after 
HILP for STS243-247• HILP with TNF-a and melphalan with or without interferon­
gamma (IFN-y) has dramaticaiiy improved the local tumor control of primary 
irresectable STS and response rates of up to 84%, resulting in preservation of the 
perfused limb without major dysfunction in over 80 % of the patients, have been 
reported 79-83• This study did correlate tumor markers with treatment response and 
clinical outcome. It was found that a good clinical response was associated with high 
mitotic index, high tumor grade and low amount of apoptotic cells before treatment. 
A relation between tumor grade and treatment response was also suggested by 
Eggermont et al. who noted that high grade tumors grade tend to respond better to 
HILP-TM83• Tumor grade is determined by differentiation level, necrosis and number 
of mitoses. The latter seems to be more associated with clinical response than amount 
of necrosis or degree of differentiation, since also the proportion of the shift in 
mitotic index was correlated with clinical outcome. The pretreatment apoptosis 
values were positively correlated with clinical treatment response and negatively 
correlated with P.retreatment mitotic rates. This might indicate that the response to 
HILP-TM is enhanced in STS with an apparently disturbed balance between cell 
growth and programmed cell death. The absence of a correlation between the studied 
tumor markers before HILP-TM and the histological or overall tumor response can be 
explained by the differences between the clinical and histological assessments. The 
clinical evaluation of tumor regression depends on the estimated size of the perfused 
tumor which is measured several times during the period between HILP-TM and the 
delayed resection by both radiodiagnostic and physical examination. The relatively 
late definitive histological examination 6-8 weeks after HILP-TM is carried out on 
the samples after HILP-TM representing the nonresponding, viable parts of 
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the tumor. Furthermore, the way of assessing histological treatment response could 
also explain the lack of correlation since it is based on the macroscopically and 
microscopically estimated percentage of necrosis after HILP-TM without taking into 
account the amount of necrosis before HILP-TM. Moreover, tumor parameters could 
not be studied in the post HILP-TM samples of 8 patients. 
The additive effect of IFN-y on HILP-TM is subject of debate 83• In this in vivo 
study the changes in proliferation or cell death after HILP-TM did not differ between 
the patients treated with or without IFN-y. Furthermore IFN-y did not influence the 
changes in tumor parameters, nor treatment response or clinical outcome. It can be 
concluded from this study that the addition of IFN-y in HILP-TM for STS does not 
substantially affect treatment response or clinical outcome. 
The biological mechanisms which induce changes in tumor parameters during 
the 6-8 weeks between HILP-TM and resection remain unclear. Several authors 
postulated vascular occlusion as a result of intravascular coagulation after endothelial 
damage by TNF-a. followed by hemorrhagic necrosis 248"251• Since animal models and 
in vitro studies have reported the synergistic effect ofTNF-a. and melphalan resulting 
in cell death and tumor regression, some authors have postulated a more complex 
process in which vascular endothelium of the tumor, adhesion molecules and direct 
cytotoxic effects of melphalan and/or TNF-a. may play a role 252•258• This clinical 
study shows a significant decrease in number of both dividing and proliferating cells 
as well as an increase in apoptosis after HILP-TM. It remains unclear, however, 
whether the observed changes in proliferation and apoptosis are a secondary 
phenomenon occurring 6-8 weeks after HILP-TM induced necrosis, or the remnants 
of a massive chemotherapeutically generated programmed cell death induced by cell 
cycle blockage with or without DNA damage 257• However, the significant increase in 
number of apoptotic cells after HILP-TM indicates a more subtle process of cell 
death induced by TNF-a. and/or melphalan, than hemorrhagic necrosis after vascular 
occlusion alone. 
It is shown that the tumors of the patients who died of disease showed higher 
amounts of proliferative and mitotic activity before and after HILP as compared to 
those patients who were alive without disease. These findings suggest that patients 
with STS treated with HILP with a high proliferation index and high number of 
mitoses still have a worse prognosis, due to a known more aggressive behavior of 
high grade STS 8• The HILP-TM generated changes in these tumor markers did not 
predict clinical outcome. With regard to the development of metastatic disease after 
HILP-TM it should be noted that in the patients with newly developed distant 
metastases, the number of mitotic cells was higher after HILP-TM as compared to the 
patients who did not develop distant metastases. Interestingly, this was not the case 
before HILP-TM, which implies that a high amount of dividing cells detected after 
HILP-TM could indicate patients who are at risk for the development of distant 
metastases. Although not significant, posttreatment proliferation was higher and 
posttreatment apoptosis was lower in the patients who developed new distant 
metastases after HILP-TM as compared to patients who did not. The importance of 
posttreatment proliferation index is also observed in the survival analysis in which a 
67 
Chapter 5 
low proliferative activity after HILP-TM is associated with a significantly better OS. 
Mitotic and apoptotic activity after HILP-TM is not clearly associated with survival. 
In conclusion, the results of this study indicate that a better clinical response in 
HILP-TM is observed in patients with STS displaying high mitotic activity and low 
amounts of apoptosis. The antitumor effects of TNF-a and melphalan seem to result 
in a decrease in both mitotic activity and proliferation as well as an increase in 
apoptosis. Furthermore, patients with a favorable clinical outcome and survival have 
low proliferative STS both before and after HILP-TM, whereas patients who develop 
distant metastases after HILP-TM have relatively high numbers of dividing cells in 
the tumor remnants after treatment. 
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SUMMARY 
The current study was undertaken to investigate the relation of PET using 
FDG or L-l-[1 1C]-tyrosine (TYR) with histopathological findings in soft tissue 
tumors, before and after therapy. Histopathological parameters that were studied 
were tumor grade, mitotic rate, proliferation activity and amount of necrosis. 
PET with either FDG or TYR was performed in 55 patients with a lesion 
suspected to be a malignant soft tissue tumor. In twenty-eight patients a second PET 
study after therapy was performed. Metabolic rate of glucose consumption (MRglc) 
and protein synthesis rate (PSR) were calculated. Histological parameters were 
obtained from a biopsy specimen that was taken just after the first PET study and 
from the tumor remnant that was resected after therapy. 
MRglc correlated with tumor grade (r=O. 71) and mitotic rate (r=0.68), but 
not with proliferation or necrosis. After therapy there was no longer a correlation 
with mitotic rate. PSR correlated with tumor grade (r=0.53), mitotic rate (r=0. 73) 
and proliferation (r=0.66). After therapy, correlation with mitosis and proliferation 
had improved, and a negative correlation was found between PSR and necrosis (r=-
0. 74). 
These results validate the use of both FDG and TYR to give an in vivo 
indication of histological tumor parameters. However, FDG gives a better indication 
of tumor grade, whereas TYR is more accurate in predicting mitotic rate and 
proliferation, especially after therapy. FDG may therefore not be the most suited 
tracer for monitoring therapy. TYR might be more appropriate for that purpose. 
INTRODUCTION 
Although it seems obvious that a higher mitotic rate and proliferation require 
more energy, and that a loss of differentiation results in a less efficient and therefore 
higher metabolism, a clear correlation between metabolic and histologic parameters 
has not yet been demonstrated. With positron emission tomography (PET) the 
metabolism of tumors can be studied in vivo with the use of radiopharmaceuticals. 
The radiopharmaceutical 18F-fluoro-2-deoxy-D-glucose (FDG) is the most widely 
used PET tracer in oncology. With FDG, the metabolic rate of glucose consumption 
(MRglc) can be visualized and quantified 259• High glucose metabolism has been 
demonstrated with FDG-PET in several types of soft tissue tumors (STT) 21 • 17 1 • A 
relation between the glucose consumption and the malignancy grade has been shown, 
but very little is known about the correlation of glucose consumption with other 
histopathological tumor parameters. 
Experimental studies have demonstrated that amino acid transport and protein 
synthesis rate (PSR) are increased in malignant cells 193•260• The majority of the amino 
acid PET studies in oncology have been performed with L-[methyl-1 1C]-methionine 
(MET), which is relatively easy to synthesize. In our institute L- 1 -C 1C]-tyrosine 
(TYR) is used for this purpose, because with TYR-PET the PSR can be quantified, 
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whereas MET-uptake reflects amino acid transport rather than PSR 196•261 • With TYR, 
several types of malignant tumors can be visualized 1 75• The relation of PSR to 
histopathological tumor parameters has not been elucidated yet. The current study 
was undertaken to investigate the relation of both FDG-PET and TYR-PET with 
histopathological findings in STT, before and after therapy. STT comprise 1 %of all 
malignant tumors. Patients with a STT have a poor prognosis (50% 5-year survival). 
The estimation of malignancy of STT depends on mitosis and proliferation. Mitotic 
activity and proliferation have prognostic value 29• Histopathological parameters that 
were studied were tumor grade, amount of necrosis, mitotic rate and proliferation 
activity, as assessed with K.i-67 labeling. 
PATIENTS AND METHODS 
Patients 
The FDG-PET group consisted of 30 patients, thirteen men and seventeen 
women, with a mean age of 50 (range 1 8-84) years (Table 1) .  The TYR-PET group 
consisted of 25 patients, nineteen men and six women, with a mean age of 55 (range 
25-83) years (Table 2). All 55 patients were clinically and radiographically suspected 
of having a malignant SIT, but histological examination after PET revealed 46 
malignant and 9 benign SITs. Conventional imaging consisted of plain radiography, 
bone scintigraphy, computed tomography and/or MRI. All tumors were larger than 2 
cm diameter. A biopsy to obtain a definite diagnosis was performed in all patients 
after the PET study, in order to avoid interference of wound healing on the PET 
signal. The study protocol was approved of by the medical ethics committee of the 
Groningen university hospital and all patients gave informed consent. 
To evaluate treatment response, 28 patients underwent a second PET study ( 17  
FDG-PET and 1 1  TYR-PET) after therapy, which consisted of  hyperthermic isolated 
limb perfusion with tumor necrosis factor- and melphalan (HILP) as described 
previously 83 • 
PET studies 
FDG was routinely produced by a robotic system following the procedure 
described by Hamacher, with a radiochemical purity of more than 98% 262• TYR was 
produced via a modified microwave induced Bticherer-Strecker synthesis 263• The 
radiochemical purity was over 99%. A 95 113 1  ECA T positron scanner (Siemens/CTI, 
Knoxville, USA) was used for data acquisition. The scanner acquires 3 1  contiguous 
tomographic slices simultaneously over a total axial length of 10.8 cm and has a 
spatial resolution of 6 mm at full width half maximum. 
Patients fasted overnight prior to the PET study. Serum glucose levels (and in 
case TYR-PET was performed also tyrosine levels) were measured just before each 
PET session and were all within normal range. A 20 gauge needle was inserted into 
the radial artery under local anesthesia. An intravenous cannula was inserted into the 
contralateral cephalic vein for the injection of the tracer. The patients were positioned 
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supine in the scanner with the tumor in the field of view. A 20 minute transmission 
scan was obtained to correct for attenuation of the photons by the body tissues. Then 
1 85 MBq FDG or 370 MBq TYR was intravenously administered and sequential 
images were acquired at the level of the lesion by obtaining 1 6  frames from the time 
of injection through 50 minutes postinjection. These include ten 30-seconds frames, 
three 5-minute frames, and three 1 0-minute frames. For establishing the input 
function, blood samples were taken simultaneously from the arterial cannula (at 0.25, 
0.5, 0.75, 1, 1 .25, 1 .5, 1 .75, 2.25, 2.75, 3.75, 4.75, 7.5, 12.5, 1 7.5, 25, 35 and 45 
minutes after injection). The same camera protocol was used for both tracers. The 
input function of the TYR-studies was corrected for 1 1C-labeled metabolites. 
PET data analysis 
The MRglc and the PSR of the lesions were calculated as described in detail 
previously 174• For calculating the MRglc or PSR the ten pixels with highest activity 
of the tumor were selected. When the lesion could not be visualized clearly, a region 
of interest was drawn around its location, based on MRI or CT-findings. After 
therapy, the metabolism was calculated over the same volume as before therapy to 
avoid observer-bias. Because it is known from a previous study that MRglc correlates 
better with malignancy grade than standardized uptake values, the latter were not 
calculated 2 1 • 
Histological examination 
Histological parameters that were compared with the PET findings before 
therapy were obtained from a biopsy specimen that was taken after the first PET 
study. Those compared with the PET findings after therapy were obtained from the 
residual tumor that was resected as a whole, approximately eight weeks after HILP. 
Histological diagnosis was made on hematoxylin-eosin stained paraffin sections and 
additional immunohistological stains if necessary. All STT were classified according 
to Enzinger and Weiss 8 and graded according to the system of Coindre et al. 29• 
Benign tumors were assigned tumor grade zero. The amount of necrosis was 
estimated on gross examination and microscopically. At least one section per 
centimeter of the largest tumor diameter was taken. The number of mitoses per 2 
mm2 (mitotic; index) was counted in fifteen adjacent fields on haematoxylin-eosin 
stained paraffin sections. Proliferation activity was assessed by K.i-67 labeling. K.i-67 
is a nuclear antigen that is present during the whole cell cycle except for the GO and 
G 1 phase and is therefore a measure for proliferation. For K.i-67 labeling the 
monoclonal antibody MIB-1 (Immunotech S.A., Marseille, France) was used, which 
recognizes an epitope of the K.i-67 antigen. Ki-67 1abeling was performed on paraffin 
sections (4 11m) according to a method modified from Shi et al. 177. 178• In short: after 
heating on a hot plate, slides were dewaxed in xylene and rehydrated in serial ethanol 
washes ( 100%, 96% and 70%). After heating twice in an autoclave for 10  minutes at 
1 10 oc in 20 mM citrate buffer (pH 6.0), slides were incubated with a 1 :400 dilution 
of the antibody in maleate buffer (pH 7.4). The primary antibody was detected with a 
biotinylated secondary antibody followed by a streptavidine-alkaline phosphatase 
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conjugate (Ready-to-use link and label, Biogenex, San Ramon CA, USA). Final 
color was developed by the bromochlorindolyl-phosphate 4-nitroblue­
tetrazoliumchloride method (Boehringer, Mannheim, Germany). For determining the 
Ki-67 labeling index (Ki-67 LI) we used ocular micrometry on a microscope with an 
eyepiece grid at x400 magnification. In histologically viable areas fifteen fields were 
randomly selected. The positive and negative nuclei were counted. Endothelial cells, 
inflammatory cells and necrosis were excluded. The Ki-67 LI was defined as the 
number of positive nuclei divided by the total number of nuclei in each of the fifteen 
fields. The mean Ki-67 LI of the fifteen fields was calculated. 
Statistical analysis 
To quantify the degree of correlation between the PET findings and the 
histological parameters a Spearman's (non-parametric parameters) or Pearson's 
correlation (parametric parameters) analysis was performed using SPSS statistical 
software. A p-value of <0.05 was considered to be significant. A correction for 
multiple comparisons was made by adjusting the p-level downward. 
Table 1. Characteristics ofQatients that were studied with FDG-PET 
age & sex histology tumor grade 
I 59, F malignant fibrous histiocytoma Ill 
2 54, M malignant fibrous histiocytoma Ill 
3 39, F synovial sarcoma Ill 
4 40, F leiomyosarcoma Ill 
5 84, F sarcoma NOS Ill 
6 28, M sarcoma NOS Ill 
7 53, M malignant fibrous histiocytoma 11 
8 80, M malignant fibrous histiocytoma 11 
9 39, F malignant fibrous histiocytoma 11 
1 0  65, F malignant peripheral nerve sheath tumor 11 
1 1  62, M malignant peripheral nerve sheath tumor 11 
1 2  43, M malignant peripheral nerve sheath tumor 11 
1 3  ,50, F dedifferentiated liposarcoma 11 
14  7 l , M liposarcoma 11 
1 5  1 8, F rhabdomyosarcoma 11 
1 6  56, F primitive peripheral neuroectodermal tumor 11 
1 7  18 , M extraskeletal myxoid chondrosarcoma II 
1 8  49, F sarcoma NOS 11 
1 9  64, M sarcoma NOS 11 
20 47, F myxoid malignant fibrous histiocytoma I 
2 1  39, F myxoid liposarcoma I 
22 44, F myxoid liposarcoma I 
23 48, F well differentiated liposarcoma I 
24 57, M well differentiated liposarcoma I 
25 56, M malignant fibrous histiocytoma 
26 38, M myxoma 0 
27 2 l , M lymphangioma 0 
28 43, F lipoma 0 
29 82, F bursa 0 
30 54, F ganglion 0 




In the FDG-PET group, PET was obtained in 29 patients before therapy (there 
was one technical failure). MRglc ranged from 0.6 to 99. 1 J.Lmol/100 g tissue/minute. 
There were six grade Ill tumors, twelve grade 11, six grade I and five grade 0 (Table 
1 ). One tumor was not graded, because there was too little biopsy material for 
accurate grading. Necrosis ranged from 0 to 70%, mitotic rate from 0 to 25 /2mm2, 
and the K.i-67 LI ranged from 1 .2 to 38.4. After therapy, MRglc (range 7.4-44.4), 
necrosis (range 0-100), mitotic rate (range 0-50), and K.i-67 LI (range 0-37. 1 )  were 
obtained in seventeen patients. 
Table 2. Characteristics of patients that were studied with TYR-PET 
Age & sex histology tumor grade 
I 66, M malignant fibrous histiocytoma Ill 
2 67, F malignant fibrous histiocytoma Ill 
3 83, F malignant fibrous histiocytoma Ill 
4 26, F synovial sarcoma Ill 
5 45, M leiomyosarcoma Ill 
6 7 1 ,  F fibrosarcoma Ill 
7 32, F malignant peripheral nerve sheath tumor Ill 
8 67, M pleiomorphic liposarcoma Ill 
9 75, M sarcoma NOS Ill 
10 69, F sarcoma NOS Ill 
1 1  76, M sarcoma NOS Ill 
12 68, M malignant fibrous histiocytoma II 
13  69, F malignant fibrous histiocytoma 11 
14  25, M synovial sarcoma 11 
1 5  49, M myxoid liposarcoma 11 
16  69, M well differentiated liposarcoma I 
1 7  49, F myxoid liposarcoma I 
1 8  58, M myxoid liposarcoma I 
1 9  48, M fibrosarcoma I 
20 43, M clear cell sarcoma I 
2 1  5 1, M malignant hemangiopericytoma I 
22 54, M lipoma 0 
23 42, M lipoma 0 
24 42, M benign peripheral nerve sheath tumor 0 
25 47 M elastofibroma 0 
NOS: not otherwise specified 
Before therapy, a correlation was found between MRglc and tumor grade 
(r-0.7 1 )  and mitotic rate (r-0.68) (Figure l a  and 2a). There was no correlation 
between the MRglc and K.i-67 LI (Figure 3a) or amount of necrosis neither before 
nor after therapy (Figure 4a). After therapy, the correlation between MRglc and 
mitotic rate disappeared (r-0. 1 8). 
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Figure 1 
Metabolic rate of (a) glucose consumption (MRglc) and (b) protein synthesis rate (PSR) as 
measured with PET versus tumor grade. MRglc correlates better with tumor grade than PSR. 
Correlation-coefficients are 0.71 and 0.58 respectively. 
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Figure 2 
Metabolic rate of (a) glucose consumption (MRglc) and (b) protein synthesis rate (PSR) before 
therapy as measured with PET versus mitotic activity. Correlation-coefficients are 0.68 and 0.73, 
respectively. 
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Figure 3 
Metabolic rate of (a) glucose consumption (MRglc) and (b) protein synthesis rate (PSR) before 
therapy as measured with PET versus proliferation activity. The correlation between MRglc and 




In the TYR-PET group, PET was obtained before therapy in 25 patients. PSR 
ranged from 0. 1 3  to 5.66 nmol/kg tissue/minute. There were eleven grade Ill tumors, 
four grade II, six grade I and four grade 0 (Table 2). Necrosis ranged from 0 to 80%, 
mitotic rate from 0 to 59 /2mm2, and the Ki-67 LI ranged from 0.9 to 43 .8. After 
therapy, PSR (range 0.50-2.79), necrosis (range 0-59), mitotic rate (range 0-40) and 
the Ki-67 LI (range 0-33 .0) were obtained in eleven patients. 
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Figure 4 
Metabolic rate of (a) glucose consumption (MRglc) and (b) protein synthesis rate (PSR) as measured 
with PET versus the amount of necrosis after therapy. There is no significant correlation between 
MRglc and the necrosis percentage, whereas there is a clear negative correlation between PSR and 
necrosis (r= -0.74). 
Before therapy, a correlation was found between PSR and tumor grade 
(r=0.58) (Figure Ib), mitotic rate (r=0.73) (Figure 2b) and the Ki-67 LI (r=0.66) 
(Figure 3b). There was no correlation between the PSR and the amount of necrosis. 
After therapy, the correlation between PSR and mitotic rate (r=0.82), and between 
Ki-67 LI (r=0.87) had improved. There was now also a clear negative correlation 
between PSR and necrosis percentage (r=-0.74) (Figure 4b). 
DISCUSSION 
The current study demonstrates a clear correlation between both FDG-PET 
and TYR-PET on the one hand, and several histopathologic tumor parameters on the 
other. This correlation exists even though the tumor metabolic activity as measured 
with PET is compared to histopathological parameters from a biopsy specimen that 
may not be representative for the whole tumor. 
In several previous PET studies with patients with STT, a relation was found 
between FDG uptake and malignancy grade 21 •1 7 1 • Low grade tumors have lower FOG 
uptake than intermediate and high grade tumors. However, no significant difference 
was found between intermediate and high grade tumors. The present results may 
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elucidate this, because we did find a correlation between MRglc and mitotic rate, but 
not between MRglc and necrosis. Malignancy grade was determined by mitotic rate, 
differentiation and the amount of necrosis 29• These parameters may have opposing 
effects on tumor metabolism as assessed with PET, especially in high grade tumors. 
A high mitotic rate requires more energy and results in a high cell density which in 
itself has been shown to correlate with FOG uptake in other tumor types 264•265• 
Differentiation is based on the resemblance to the normal tissue and poor 
differentiation is associated with more aggressive growth and a tendency to 
metastasize. Necrosis is a clear sign of aggressive and poorly controlled growth and 
will thus be found more in high grade tumors with an increased rate of glucose 
consumption, but necrosis is not metabolically active. Therefore, with an increasing 
amount of necrosis, the average rate of glucose consumption of the tumor will 
decrease. Apparently, the same theory may be valid for TYR-PET. However, the 
influence of necrosis on the tumor PSR appears to be stronger than on MRglc, 
because the correlation coefficient of PSR and tumor grade is lower (r=0.58 versus 
r=0.71)  and after therapy, when necrosis becomes more prominent, a clear negative 
correlation between PSR and necrosis is shown. The latter may be explained by the 
fact that inflammatory cells that are frequently seen in necrotic areas and the reactive 
inflammatory tissue in the tumor rim after therapy also have a high MRglc, but no 
high PSR 194,266-26&. 
FDG uptake was shown to be related to proliferation in patients with 
intracranial tumors, bronchial carcinoma and head-and-neck tumors 269-271 • However, 
we could not confirm this in patients with STT. From the results from Minn and 
Watanabe it was suggested that the increase in glucose utilization in head and neck 
cancers is mainly needed for nucleic acid synthesis 271 •272• However, larger changes in 
proliferation rate result in only moderate changes in FOG uptake 273• In in vitro 
studies only a weak relation of FDG uptake to proliferative activity was established 
264•274• In patients with carcinoma of the hypopharynx, the relation between FDG 
accumulation and the proliferative index was evident (r=0.80), but only when the 
tumors with high and low FOG uptake were separated 275• These data suggest that 
another factor contributes to the uptake of FDG in tumors. This unknown factor 
might be the expression of an oncogene, which enhances glucose transport or density 
of glucose transporter proteins, or a simultaneously occurring inflammatory reaction. 
In studies with patients with lung, breast or head and neck cancer the uptake of 
the amino acid MET correlated well with the proliferative activity of the tumor 276-278• 
In in vitro studies the relation between amino acid uptake and proliferation was better 
than with FOG 274• We now validated these in vitro observations in the clinical 
situation in tumors with different growth characteristics using TYR-PET. In two 
studies of patients with various brain tumors, no correlation was found between PSR 
as measured with TYR-PET and proliferation 176•279 • Although brain tumors and soft 
tissue tumors are two entirely different entities, this suggests that there are also 
confounding factors influencing the PSR of tumors that are worth exploring. 
Both MRglc and PSR correlated with mitotic rate. The disappearance of the 
correlation between MRglc and mitotic rate after therapy might be influenced by the 
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inflammatory reaction that was seen at all tumor sites after HILP. Except for tumor 
grade, TYR correlated better with all histological tumor parameters than FDG, 
especially after therapy. FDG may therefore not be the most suited tracer for 
monitoring therapy. This was also the conclusion in a previous study that studied the 
value ofFDG-PET for monitoring treatment in similar patients 1 13• TYR-PET may be 
more appropriate to monitor therapy. First results of TYR-PET for treatment 
evaluation that were reported recently, indeed confirmed less disturbance of 
inflammatory cells for TYR than for FDG, although neither with TYR a complete 
response could be distinguished from a partial response with 100% accuracy 210• 
Further studies investigating the value of TYR-PET for monitoring therapy are 
therefore required. 
In summary, the current study demonstrates the correlation of tumor grade and 
mitotic rate with MRglc as measured with FDG-PET, whereas there was no 
correlation with the amount of necrosis and proliferation. A correlation was found 
between the PSR as measured with TYR-PET on the one hand and tumor grade, 
mitotic rate and proliferation on the other hand. After therapy there was a clear 
negative correlation between the PSR and the amount of necrosis. FDG may not be 
the most suited tracer for monitoring therapy because of disturbing uptake by 
inflammatory cells. TYR-PET might be more appropriate for that purpose. 
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Responses to chemotherapy va�y between specific types of soft tissue 
sarcomas (STS): poor responses are observed in leiomyosarcomas (LMS), whereas 
favorable responses are found in liposarcomas (LPS). A poor survival after 
chemotherapy for advanced STS is reported especially in malignant fibrous 
histiocytoma (MFH). High grade STS are associated with a favorable response to 
chemotherapy. Cross resistance to a number of functionally and structurally distinct 
natural product drugs is called multidrug resistance (MDR). MDR has been 
associated with the overexpression of P-glycoprotein (P-gp) and the multidrug 
resistance related protein-} (MRPJ. Drug resistance is also associated with the 
expression of the lung resistance protein (LRP). The purpose of this study was to 
evaluate the expression of P-gp, MRP1 and LRP with respect to histological type and 
tumor grade in a series of 115 STS. 
MDR-protein expression was semiquantitatively assessed after 
immunohistochemical detection in paraffin embedded tumor material of 115 
chemotherapy naive STS (23% grade I, 47% grade I! and 30% grade Ill). 
At least one MDR protein was detected in 95% of the STS. eo-expression of 
P-gp and MRP1 was found in 32%, P-gp and LRP in 48% and MRP1 and LRP in 
28% of the analyzed STS. Expression of all 3 MDR proteins was found in 21%. 
Expression of P-gp (71% of the STS) and LRP (70% of the STS) was more observed 
than expression of MRP1 (36% of the STS) (p<O.Ol). P-gp expression was not 
correlated to either MRP1 or LRP and MRP, expression was not correlated to LRP 
expression. P-gp expression was most pronouced in MFH and synovial sarcomas 
and low in LMS. MRP1 was most expressed in malignant peripheral nerve sheath 
tumors and low in rhabdomyosarcomas. LRP was most expressed in MFH and 
sarcoma not otherwise specified and low in LPS. All MFHs expressed at least one 
MDR protein. No correlation was found between tu m or grade and the expresssion of 
P-gp, MRP, or LRP. eo-expression was less frequently observed in grade I STS. 
In conclusion, P-gp, MRP1 and LRP are expressed in the majority of STS, 
whereas eo-expression is frequently found. Expression of P-gp, MRP1 and LRP 
varies between histological types and is not related to tumor grade. eo-expression is 
associated with low grade STS. 
INTRODUCTION 
Soft tissue sarcomas (STS) are a heterogeneous group of malignant tumors 
which arise from tissue of mesenchymal origin and account for approximately I% of 
all malignancies. Approximately 30% of the patients with STS will develop distant 
metastases, predominantly in the lungs 8•9• Chemotherapy is the treatment of choice 
in patients with diffuse distant metastases, but is also applied in advanced inoperable 
sarcomas and childhood rhabdomyosarcomas 86•280• Doxorubicin, alone or in 
combination with other cytostatic drugs such as ifosfamide or etoposide, is the most 
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extensively applied cytotoxic drug in adult STS patients and can be regarded as the 
standard chemotherapeutic agent in STS 86•87•281"284• Response rates in general are 20-
30%, although response rates of up to 57% have been reported, and 2 years overall 
survival is 22% 87• Recent clinical studies indicated that the response to 
chemotherapy is related to histological grade and the histological subtype, e.g. 
leiomyosarcomas have poor responses and liposarcomas have favorable responses 
87• 142•285•286• Patients with metastasized malignant fibrous histiocytomas (MFH) have a 
worse survival time after chemotherapy than other histological types 87• Poor 
responses to chemotherapy may be caused by so called multidrug resistance (MDR). 
MDR can be caused by one or more mechanisms, i.e. 1 )  increased expression 
of energy dependent effiux pumps P-glycoprotein (P-gp) or the multidrug resistance 
related protein-! (MRP 1 ) as well as 2) an increased expression of the lung resistance 
related protein (LRP) and the multidrug resistance related protein-! (MRP1) 96•97•287
-
295. A third possible mechanism of MDR is 3) a reduced expression of topoisomerase 
11. P-gp is localized on the cell membrane, MRP 1 is localized both cytoplasmic and 
on the cell membrane. The spectrum of resistance for cytostatic agents which are 
involved in MDR (such as the anthracyclines, the vinca-alkaloids and 
epipodophyllotoxins) does not differ much between P-gp and MRP1 • LRP, which 
was identified as the human major vault protein is located intracytoplasmic and has 
been considered to play a role in the transport between nucleus and cytoplasm. Until 
now, the role of LRP in MDR is less clear, although some studies in ovarian cancer, 
acute myeloid leukemia and multiple myeloma indicated a possible role in clinical 
drug resistance 96,97,295,296. 
P-gp expression has been detected in STS and might be associated with poor 
response to chemotherapy in childhood rhabdomyosarcomas as well as adult STS 100-
103. MRP 1 has been detected in STS and eo-expression of MRP 1 and P-gp was asso­
ciated with tumor grade in STS 108•297• The combined expression of P-gp, MRP1 and 
LRP in the various histological types of STS is unknown. The purpose of this study 
was to evaluate the expression of P-gp, MRP 1 and LRP with respect to histological 
type, especially LMS, LPS and MFH, and tumor grade in a series of 1 1 5 STS. 
MATERIALS AND METHODS 
Histology 
The criteria for inclusion in the current study were 1 )  an untreated primary 
tumor, 2) a histological diagnosis of a STS and 3) the availability of paraffin 
embedded tumor tissue. All tumors were randomly selected from a STS database. 
However, a relatively high proportion of leiomyosarcomas and liposarcomas was 
selected since these groups were specifically reported in previous clinical studies 
responses 87, 142,285.286. 
The studied group consisted of 1 1 5 STS, obtained from 54 male and 61  
female patients (mean age: 49, median: 48, SD: 1 7.9, range: 1 6-89 years). In all 
cases the histological diagnosis was made on haematoxylin-eosin stained paraffin 
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sections with or without additional immunohistological stains. All cases were 
classified according to Enzinger and Weiss 8 which revealed 26 (23%) 
leiomyosarcomas (LMS), 24 (2 1 %) liposarcomas (LPS), of which were 9 of the 
myxoid subtype, 1 3  ( 1 1 %) malignant fibrous histiocytomas (MFH), 12 ( 10%) 
sarcomas not otherwise specified (NOS), 1 1  ( 10%) rhabdomyosarcomas (RMS), 9 
(8%) synovial sarcomas, 7 (6%) malignant peripheral nerve sheath tumors (MPNST), 
3 (2%) fibrosarcomas and 10 (9%) other STS. The STS were graded according to the 
grading system of Coindre et al. 29, which resulted in 26 grade I (23%), 54 grade 11 
(47%) and 35 grade Ill (30%) STS. 
MDR expression 
For detection of P-gp, the monoclonal antibody C494 (Signet Laboratories, 
Dedham MA, USA) in a concentration of 120 jlg/ml in phosphate-buffered saline 
(PBS) (Merck KgaA, Darmstadt, Germany) plus 1% bovine serum albumin (BSA) 
(Serva Electrophoresis GmbH, Hamburg, Germany) was used. For detection of 
MRP1 the monoclonal antibody MRPrl (provided by Dr. R.J.Scheper, Dept. of 
Pathology, Free University Hospital, Amsterdam) in a concentration of 20 jlg/ml in 
1% BSAIPBS was utilized. For detection of LRP the monoclonal antibody LRP 
(Transduction Laboratories, Los Angeles CA, USA) in a concentration of 250 jlg/ml 
in 1% BSAIPBS was used. As controls for immunohistochemal detection served 
cytospins of the well documented cell lines A2780 and GLC4 and their 
corresponding multi-drug resistant sublines, i.e. overexpressing P-gp (A2780 AD), 
MRP1 (GLC4/ADR) and LRP (GLC4/ADR) 298•299, as well as paraffin embedded 
formalin fixed liver (P-gp ), lung (MRP 1) and colon (LRP) tissue. 
Paraffin sections (3 11m) were placed on positively charged glass slides and 
were air dried. Immunohistochemistry was performed according to a method 
modified from Shi et al. 177• 178 • Briefly, after heating on a hotplate, the slides were 
dewaxed in xylene and rehydrated in serial ethanol washes ( 100%, 96% and 70%). 
After each of the subsequent steps, three 5 minutes washes in PBS were carried out. 
After three times heating in an autoclave for 5 minutes at 1 1 5° C in a 20 mM 
blocking reagens (Boehringer Mannheim, Mannheim, Germany) with pH=6.0, 
endogenous peroxidase activity was blocked by incubation with 1% hydrogen 
peroxide in PBS during 30 minutes. The slides were incubated with the specific 
antibody in 1% BSA/PBS (pH=7.4) for 1 hour at room temperature in a humidified 
chamber. The primary antibody was detected with a rabbit antimouse (DAKO, 
Glostrup, Denmark) (C494 and LRP) or rabbit antirat (DAKO, Glostrup, Denmark) 
(MRPr1) peroxidase labeled secondary antibody diluted in 1 :50 + 1% human serum 
(type AB) followed by incubation with goat antirabbit conjugated peroxidase diluted 
in 1 :50 + 1 %  human serum (type AB). 3.3-diaminobenzidine tetrahydrochloride 
(Sigma, St. Louis, USA) with imidazole (Merck KgaA, Darmstadt, Germany) in PBS 
was used as the chromagen according to the manufacturer's instructions. After 
counterstaining with Mayer's haematoxylin, the slides were dehydrated through 
graded alcohols and mounted with coverslips. 
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The expression of P-gp, MRP 1 and LRP was assessed independently by two 
observers (B.P, H.H.) without knowledge of the histological diagnosis or clinical 
data. The P-gp, MRP., LRP proteins were studied in adjacent slides of the most 
viable parts of the tumor. Amount of P-gp, MRP1 and LRP expression was 
semiquantitatively assessed by estimating the percentage of positive stained tumor 
cells and assessing staining intensity using a scale of 0 -3 (0: no staining, 1 :  very weak 
staining, 2: intermediate staining, 3 :  strong staining). Strong staining intensity was 
comparable to the staining intensity of the simultaneously stained positive control 
tissue. Both staining parameters were also combined into a so called histopath-score 
which is defmed as: the estimated percentage of stained cells (0-1 00%) x the staining 
intensity (0-3) 300• According previous studies, tumor samples were considered 
negative for expression of each of the proteins if $ 5% of the cells were positive 96• 103• 
It was not possible to determine P-gp expression in 3 cases and MRP1 expression in 5 
cases due to insufficient paraffin embedded tumor material. 
Statistics 
A Marm Whitney Test was carried out to analyze the differences in MDR 
parameters. To avoid the problem of multi-comparison in the analyses ofP-gp, MRP1 
and LRP, a Bonferroni correction factor of 3 was introduced and in the comparison 
of the different histological types the Dunn's  multiple comparison test was used. To 
quantitate the degree of correlation between parameters, the Spearman's rank test 
was used. A two-tailed p-value of < 0.05 was considered to be significant. Statistical 
software SPSS 9.0 for Windows (SPSS Inc., Chicago IL, USA) was used for 
statistical analysis. 
RESULTS 
MDR protein expression in STS 
P-gp expression was found in 80 of the 1 12 (7 1 %) analyzed tumors. There 
were 43 MRP1 'positive (36%) and 80 LRP positive (70%) STS. At least one MDR 
protein was detected in 1 0 11107 (94%) of the analyzed STS. As shown in Tables 1 -3, 
P-gp and LRP expression in this series of STS was each significantly higher than the 
MRP1 expression (p<0.01 ). The amount of P-gp expression was not correlated with 
either MRP 1 or LRP expression, whereas the amount of MRP 1 expression was not 
correlated with LRP expression. 
eo-expression of P-gp and MRP1 was found in 34/107 (32%) STS, eo­
expression ofP-gp and LRP in 54/1 12 (48%) and eo-expression ofMRP1 and LRP in 
3 11 1 1 0  (28%) of the analyzed STS. Expression of all three MDR proteins was found 
in 221107 (2 1 %) of the STS (Table 4). Expression ofP-gp and MRP1 was observed in 
both the cytoplasm and on the cell membrane, whereas LRP staining was found 
exclusively in the cytoplasm (Figure 1 ). 
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Table 1. P-gl�col!rotein (P-gp} ex2ression in the various histological sub!i',Ees. 
Diagnosis all FIBR MFH LPS LMS RMS SYNS MPNST S-NOS other 
STS STS 
number of 1 12 3 13 24 25 10  9 7 1 1  1 0  
tumors 
positive 71% 100% 100% 83% 32% 70% 89% 71% 64% 90% 
tumors: 
PQSitiv�:: �:�:lis· 
mean (%): 42 37 65 5 1  13  50 56 43 3 1  59 
median (%): 40 30 70 55 5 55 80 50 30 70 
SD (%): 34.0 1 1 .5 19.8 30.2 23.0 38.0 39.6 34.5 33.8 32.5 
range{%}: 0- 100 30-50 40-90 0-90 0-80 0- 100 0-95 0-90 0-90 0-90 
"histQP!IthS!:Qr!:; 
mean: 74 63 1 12 86 22 1 14 78 76 42 1 17 
median: 60 60 70 75 10  120 80 60 30 80 
SD: 75.6 35.1  9 1 .9 65. 1  38.5 95.8 65.3 93.2 4 1 .9 92.2 
range: 0-300 30-100 40- 0-240 0-160 0-300 0-190 0-270 0- 100 0-270 
270 
STS: soft tissue sarcoma; FIBR: fibrosarcoma, MFH: malignant fibrous histiocytoma; 
LPS: liposarcoma; LMS: leiomyosarcoma; SYNS: synovial sarcoma; MPNST: malignant peripheral 
nerve sheath tumor; S-NOS: sarcoma not otherwise specified 
"histopath score: % positive cells x staining intensity (0-3) 
Table 2. Multidrug resistance 2rotein {MRP1} ex2ression in the various histological sub!i:l!es. 
Diagnosis all FIBR MFH LPS LMS RMS SYNS MPNST S-NOS other 
STS STS 
number of l i O  3 IO  24 24 I I  9 7 I2 10  
tumors 
2ositive tumors: 39% 33% 40% 33% 33% I8% 33% 7I% 42% 70% 
PQSitiv�:: �:�:lis; 
mean (%): I 8  23 19 I5  13  2 22 25 27 32 
median (%): I 0 0 3 0 0 0 20 I 40 
SD (%): . 27.4 40.4 3 1 . 1  27.7 22.9 4.0 34.8 24.3 34.9 26.7 
range(%}: 0-90 0-70 0-80 0-90 0-80 0-1 0  0-90 0-70 0-90 0-80 
"histQpllth S!:Qr!:; 
mean: 74 23 27 32 1 8  5 25 40 63 61 
median: 60 0 0 4 0 0 0 30 I 40 
SD: 75.6 40.4 47.2 68. 1  33.0 10.3 37.1 4 1 .6 89.0 75.4 
range: 0-300 0-70 0-140 0-270 0-140 0-30 0-90 0- 120 0-270 0-240 
STS: soft tissue sarcoma; FIBR: fibrosarcoma, MFH: malignant fibrous histiocytoma; 
LPS: liposarcoma; LMS: leiomyosarcoma; SYNS: synovial sarcoma; MPNST: malignant peripheral 
nerve sheath tumor; S-NOS: sarcoma not otherwise specified 
"histopath score: % positive cells x staining intensity (0-3) 
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Table 3. Lung resistance Erotein (LRP} exEression in the various histological subtypes. 
Diagnosis all FIBR MFH LPS LMS RMS SYNS MPNST S-NOS other 
STS STS 
number of 1 15 3 l 3  24 26 l l  9 7 1 2  10  
tumors 
2ositive tumors: 70% 33% 92% 42% 88% 54% 55% 86% 92% 60% 
J;2!JSitiv�: �;�:lis; 
mean (%): 42 28 59 23 58 32 3 1  2 1  62 43 
median (%): 40 s 60 s 60 10  1 0  20 75 45 
SD (%): 34.3 44.8 1 8.0 32.2 27.3 40.3 38.9 15.4 28.9 39.4 
range{%}: 0-90 0-80 30-90 0-90 0-90 0-90 0-90 S-50 5-90 0-90 
"histQJ:2lltb s�;Qr�:; 
mean: 85 57 125 41 I l l  81  7 1  42 1 1 0 96 
median: 60 10  120 8 90 10  10 20 85 55 
SO: 83.6 89.6 55.6 67.0 73.6 109.7 98.7 50.8 87.0 103.8 
range: 0-270 0-160 60-270 0-240 0-270 0-270 0-270 5-1 50 S-270 0-270 
STS: soft tissue sarcoma; FIBR: fibrosarcoma, MFH: malignant fibrous histiocytoma; 
LPS: liposarcoma; LMS: leiomyosarcoma; SYNS: synovial sarcoma; MPNST: malignant peripheral 
nerve sheath tumor; S-NOS: sarcoma not otherwise specified 
"histopath score: % positive cells x staining intensity (0-3) 
Table 4. Percentage oftumors with eo-expression of the MDR proteins in the analyzed 
histological subtypes. 
Diagnosis all FIBR MFH LPS LMS RMS SYNS MPNST S-NOS other 
evaluable STS 
STS 
no MDR protein 6% 0% 0% 8% 9% 10% 1 1% 0% 0% 0% 
P-gp and MRPI 32% 33% 40% 29% 13% 20% 33% 57% 36% 60% 
P-gp and LRP 48% 33% 92% 33% 32% 40% 56% 57% 55% 50% 
MRP1 and LRP 28% 0% 40% 1 7% 33% 9% 1 1 %  57% 42% 40% 
all 3 MDR 2 1% 0% 40% 1 3% 13% 10% 1 1% 43% 37% 30% 
roteins 
MDR: multdrug resistance; P-gp: P-glycoprotein, MRP1: multidrug resistance protein, LRP: lung resistance 
protein; STS: soft tissue sarcoma; FIBR: fibrosarcoma, MFH: malignant fibrous histiocytoma; 
LPS: liposarcoma; LMS: leiomyosarcoma; SYNS: synovial sarcoma; MPNST: malignant peripheral 
nerve sheath tumor; S-NOS: sarcoma not otherwise specified 
"histopath score: % positive cells x staining intensity (0-3) 
MDR protein expression in relation to histology 
The mean percentages of P-gp, MRP 1 and LRP positive cells for the various 
histological types has been depicted in Figure 2. The combined expression of MDR 
proteins was high in both MFH and sarcomas NOS. P-gp expression was most 
pronouced in MFH and synovial sarcomas, although the staining intensity was not as 
high as in MFH (Table 1 ). P-gp expression was low in LMS. MRP1 expression was 
most pronounced in MPNST, while it was extremely low in RMS and LMS (Table 
2). LRP was most expressed in MFH and sarcoma NOS, while it was low in LPS and 
LMS (Table 3). eo-expression of P-gp and LRP was frequently detected and all 
MFHs expressed at least one MDR protein (Table 4). The expression of P-gp, MRP1 




Figure 1.  
Examples ofMDR-protein expression in STS: ( A )  P-gp expression in an epthelioid 
sarcoma (200x), ( B )  MRP1 expression in a rhabdomyosarcoma (200x) and ( C )  
LRP expression in a malignant hemangiopericytoma (200x) 
P-gp, MRP1 and LRP Expression in STS 
Table 5. Median MDR Erotein exEression in MFH, LPS and LMS. 
Diagnosis MFH MFH well other myxoid LMS LMS LMS 
grade II grade Ill diff LPS LPS grade I grade II grade Ill 
LPS 
number of tumors 7 6 6 9 9 8 1 3  5 
12ositive cells: 
P-gp (%): 70 65 45 80 40 3 5 5 
MRPI (%): 0 10  8 5 0 0 20 0 
LRP {%}: 60 60 15  so 0 65 70 40 
"histo12ath score: 
P-gp: 70 65 60 70 100 4 10  5 
MRPI : 0 20 13  5 0 0 20 0 
LRP: 120 130 20 90 0 1 1 5 90 80 
MDR: multidrug resistance; P-gp: P-glycoprotein, MRP1 :  multidrug resistance protein, 
LRP: lung resistance protein; MFH: malignant fibrous histiocytoma; LPS: liposarcoma; 
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Schematic overview of the mean expression ofP-gp, MRP1 and LRP 
in the various histological types. 
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MDR protein expression in relation to tumor grade 
Expression of the evaluated MDR proteins in relation to tumor grade is shown 
in Table 6. No correlation was found between tumor grade and the expresssion of 
either P-gp, MRP1 or LRP. However, eo-expression of two or all three MDR proteins 
was less frequently observed in grade I (26%) and more in grade Ill (72%) STS 
(p<0.001 ). Higher tumor grade was associated with eo-expression of P-gp and LRP, 
since 4/26 ( 1 5%) grade I, 28/5 1 (55%) grade II and 22/35 (63 %) of the STS eo­
expressed P-gp and LRP (p<0.001). No association existed between tumor grade and 
the eo-expression of either P-gp and MRP1 or MRP1 and LRP. 
Table 6. P-gp, MRPl and LRP expression in relation to turnor grade. 
Number oftumors 
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No MDR protein (%) 6% 4% 6% 6% 
P-gp and MRP1 (%) 32% 23% 35% 34% 
P-gp and LRP (%) 48% 1 5% 55% 60% 
MRP1 and LRP {%) 28% 19% 37% 22% 
a11 3 MDRproteins (%) 2 1%  12% 24% 22% 
MDR: rnu1tidrug resistance; P-gp: P-g1ycoprotein, MRP1: mu1tidrug resistance protein, 
LRP: lung resistance protein 
DISCUSSION 
The present study evaluates the expression ofP-gp, MRP1 and LRP in a group 
of 1 1 5 STS. It was found that (co-)expression is frequently observed in STS, 
although differences exist between the various histological types. eo-expression of 
MDR proteins is associated with higher tumor grade. 
P-gp expression in this study was found in 7 1 %  of the analyzed STS. In 
several previous studies in STS the percentage of P-gp positive STS ranged between 
1 8% and 62% 100• 101 • 104"106•301 •302• However, differences in tissue preparation and 
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storage as well as the use of different techniques and monoclonal antibodies might 
explain the diverse results in relatively small groups of STS 303• Oda et al. 297 found 
that only 47% of the MDRl mRNA positive tumors expressed P-gp as determined by 
immunohistological detection. Furthermore, it appears that not all 
immunistologically detected P-gp expressing tumors have functional P-gp 304• The 
discrepancy between the amount of RT-PCR detected MDRl mRNA, the 
immunohistologically detected P-gp expression and the functional P-gp efflux pump, 
illustrates the problem of interpreting the few studies on P-gp expression in STS. P­
gp expression using the C494 antibody was found both in the cytoplasm and in the 
cell membrane, as has been described earlier 103• Although a correlation between P-gp 
expression and tumor grade was observed in some studies, it could not be confirmed 
in the present study 100•297• Nakanishi et al., reported a relation between tumor grade 
and P-gp expression when intermediate and high grade tumors were compared with 
low grade STS. However, a relatively high proportion of MFH (24/55), most of 
which are intermediate or high grade, were included in their study 100• This is 
confirmed in the present study, since all MFH were P-gp positive and had the highest 
amount of P-gp expressing cells when compared with the other subtypes. Thus the 
reported 100 relation between tumor grade and P-gp expression could also depend on 
the studied histological type. 
Much less is known about MRP1 expression in STS. In our group MRP1 
expression was detected in 36% of the STS and eo-expression with P-gp was 
observed in 32% of the cases. Oda et al. used RT-PCR for the detection of MRP1 
mRNA and found eo-expression with the MDRl mRNA in 38% 108• MRP1 staining 
was found both in the cytoplasm and in the cell membrane as has been observed 
previously 305• The present study showed that MRP 1 expression in STS is less 
pronounced than P-gp and LRP expression. Further studies should determine the 
clinical significance of the low MRP 1 expression and investigate whether the 
expression ofMRP1 is influenced by the high expression of P-gp, LRP or other ATP 
binding cassette proteins involved in MDR such as MRP2 or MRP6• In the earlier 
mentioned study of Oda et al. , a correlation of tumor grade with eo-expression of 
MORI and MRP1 mRNA was found. The relation between tumor grade and P-gp­
MRP 1 eo-expression could not be confirmed in the present study, which might be 
explained by the differences in the utilized techniques. 
No reports, so far, have been published on the expression of LRP in STS. In 
this study it was found that 70% of the STS was LRP positive. LRP expression was 
predominantly found in the cytoplasm, as has been described earlier 96.292• Expression 
of LRP was not correlated with P-gp or MRP 1 • This might indicate that expression 
of LRP is regulated by other factors than the membrane efflux pumps P-gp and 
MRP1• The exact role ofLRP in drug resistance is as yet unclear and it is thought that 
LRP is also involved in the transport of other cytotoxic agents, in particular 
alkalyting agents such as ifosfamide, than the drugs transported by P-gp or MRP1 
289•296•306• However, 48% of the STS were both LRP and P-gp positive and 28% of the 
STS showed eo-expression of MRP1 and LRP. This indicates that chemotherapy in 
STS should contain several compounds to overcome the different resistance 
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mechanisms on tumor level. It is expected that eo-expression is also present on 
cellular level, since many of the analyzed tumors had LRP and P-gp expression in 
more than 50% of their cells. Future studies using double-staining techniques could 
further elucidate the eo-expression on a cellular level. The eo-expression of LRP and 
P-gp or the eo-expression of two or three MDR proteins, regardless which two or 
three proteins were expressed, was associated with higher tumor grade. 
Expression of P-gp, MRP1 and LRP varies between and within the different 
histological types and no clear pattern can be discovered. MFH and sarcomas NOS 
seem to be characterized by high levels of MDR expression, predominantly P-gp and 
LRP in MFH which might explain the reported poor survival after adriamycin based 
chemotherapy 87• LPS, which have favorable responses to doxorubicin based 
chemotherapy, are characterized by relatively low expression of MDR proteins. 
However, when is focussed on the different histological subtypes of LPS it should be 
noticed that myxoid LPS have almost no LRP expression and that MRP 1 expression 
is moderate. This could be explained by the influence of the chromosomal 
aberrations i.e. the t( l 2; 1 6)(ql3 ,p l l )  characteristic for myxoid LPS: the breakpoint 
16p 1 1 .2 might affect expression of the LRP gene on 16p 1 1 .2 and the MRP 1 gene on 
1 6p13 .  The other LPS have higher MDR expression. However, well differentiated 
LPS do not metastasize and are therefore probably not included in the study of V an 
Glabbeke et al., whereas the other non-myxoid LPS are not frequently diagnosed 8•87• 
A high expression of P-gp in MFH, LPS and synovial sarcoma, observed in previous 
studies, was confirmed in our study, but the reported high expression ofP-gp in LMS 
could was not observed in the present study 100• 106•297• The histological diagnosis of 
LMS and their resistance to chemotherapy is the subject of debate during the last 
years. In many previous studies on leiomyosarcomas, a large proportion of the 
tumors was derived from the digestive tract. There is now growing evidence that 
these tumors are derived from the cells of Cajal and are diagnosed as gastrointestinal 
stromal tumors (GIST). They the have to be distinguished from LMS, both 
histopathologically and clinically 307'3 10• A recent study concluded that P-gp and 
MRP 1 expression in LMS is lower than in GIST and the reported drug resistance in 
LMS has to be interpreted with caution 87•3 1 1 • 
RMS had a relative absence of MDR eo-expression when compared with the 
other STS: in 10% ofthe cases no MDR expression was found at all and in only 10% 
of the cases all 3 MDR proteins were expressed. RMS are found in relatively young 
patients and have a better response to vinca-alkaloids containing chemotherapy 312• In 
the current study, the RMS patients (mean age: 26 years) were younger than the other 
STS patients (p<0.0 1). This implies that there might be a relation between the 
expression of MDR, histology and the age of the patient. When the correlation of the 
MDR parameters was analyzed, a weak correlation was found between age and the 
expression of both P-gp (r: -0.2 1 ,  p=0.03) and LRP (r: 0.30; 0=0.00 1). This indicates 
that P-gp expression in STS is more frequently found in younger patients and that 
LRP expression increases with age. Further studies have to investigate the relation 
between patient age, histological type, drug resistance, chemotherapeutic response 
and clinical outcome. 
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STS have a relatively high expression of all three MDR proteins. In breast 
cancer, another doxorubicin treated solid tumor, P-gp expression was observed in 10  
- 50% of the cases, MRP1 in  80% and LRP in  75%313• In  ovarian cancer, P-gp was 
detected in 16-17% of the tumors, MRP 1 in 44-68% and LRP in 7 4-77% 96•3 14• 
In conclusion, 94% of the STS express either P-gp, MRP1 or LRP and eo­
expression of two o.r three MDR proteins is found in 6 1 %, which might explain the 
relative poor responses to polychemotherapy for STS. This studies shows that MDR 
expression varies between and within the histological subtypes and is most 
pronounced in MFH and sarcoma NOS. eo-expression seems to be associated with 
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Several studies have reported clinical behavior and drug resistance in 
leiomyosarcomas, but did not differentiate between soft tissue leiomyosarcomas 
(LMS) and malignant gastrointestinal stromal tumors (GIST). Multidrug resistance 
(MDR) has been associated with the expression of P-gp (P-glycoprotein), MRP1 
(multidrug resistance protein) and LRP (lung resistance protein). The aim of the 
present study was to compare LMS and GIST with respect to clinical outcome and 
MDR parameters. 
Of 29 previously untreated patients with a primary deep seated LMS and 26 
previously untreated patients with a primary malignant GIST, clinical outcome was 
evaluated. Paraffin embedded material, available in 26 LMS and 25 GIST cases, was 
usedfor immunohistochemical detection ofP-gp, MRP1 and LRP. 
The mean OS in patients with a LMS was 72 months and 31 months in patients 
with a GIST (p<0.05). Metastases occurred in 15 (58%) of 26 evaluable LMS 
patients and in 9 (53%) of 1 7  evaluable GIST patients. The lungs were the primary 
affected metastatic site in 13 (87%) of the metastasized LMS and in one of the GIST 
patients (P<0.001), while subsequent liver metastases developed in 4 LMS patients. 
In GIST patients with known metastatic disease during follow-up, liver metastases 
were found in 5 patients and intra-abdominal metastases in 4 patients. P-gp and 
MRP1 expression was significantly more pronounced in GIST than in LMS (p<0.05). 
Mean percentage of P-gp expressing cells in LMS was 13.4%, while it was 38.4% in 
GIST. Mean percentage MRP1 positive cells was 13.3% in LMS and 35.4% in GIST. 
LRP expression did not differ between LMS and GIST. In LMS, OS tended to be 
related to P-gp status: 88 months (P-gp-) versus 33 months (P-gp+), but not to MRP1 
or LRP status. In GIST, OS was not related to MDR status. 
LMS patients have a better survival than GIST patients. LMS predominantly 
metastasize to the lungs, while GIST tend to spread to the liver and the abdominal 
cavity. LMS have a less pronounced drug resistance pattern than GIST. Future 
studies evaluating chemotherapeutic regimens should therefore differentiate between 
LMS and malignant GIST. 
INTRODUCTION 
Leiomyosarcomas (LMS) are a group of malignant tumors which arise from 
tissue of mesenchymal origin and have histologic features consistent with smooth 
muscle differentiation. They account for approximately 10% of all soft tissue 
sarcomas .8•9 However, it appears that the turnors with smooth muscle differentiation 
arising in the digestive tract have to be considered as a distinct turnor entity derived 
from the interstitial cells of Cajal, although the histogenesis of these malignant 
gastrointestinal stromal tumors (GIST) is still subject of debate .307"3 10•3 15"3 19 In several 
studies, metastatic "leiomyosarcomas" are reported to respond poorly to cytostatic 
drugs, but in most of the clinical studies a distinction between LMS and GIST has 
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not been made .87•142•285•286•320 In case of metastatic disease of STS metastases are 
commonly present in the lungs. It has been found that lung metastases only have a 
better response to chemotherapy than metastases elsewhere . 32 1  Whether LMS and 
GIST differ in the development of liver metastases, which are associated with a poor 
prognosis, is at present unknown. 
Multidrug resistance (MDR) i.e. resistance to numerous structurally unrelated natural 
product drugs such as the widely applied anthracyclines, has been associated with the 
overexpression of proteins like the MDR-1 gene product P-glycoprotein (P-gp) 
99•108·288•297•322•326 and the multidrug resistance protein-! (MRP1) in drug resistant cell 
lines and neoplastic tissue . 107• 108•287•289"291 Several studies indicate a possible role in 
clinical drug resistance for another protein: the major vault protein or lung resistance 
protein (LRP).96•97•289•292"295 Expression of the MDR associated proteins P-gp, MRP1 
and LRP has not been studied in LMS and GIST, although this might reveal 
clinically valuable information. 
This study, in a group of 29 LMS and 26 GIST patients, was performed to 
determine whether LMS and GIST are different clinical entities with regard to 
clinical behavior and MDR protein expression. 
PATIENTS AND METHODS 
Clinical data, i.e. patient characteristics, location of the tumor, presence of 
metastatic disease, follow-up status and survival data, were obtained by the analysis 
of the hospital medical records or information of the general practitioners. Between 
1980 and 1998, 29 patients with a deep soft tissue LMS and 26 patients with a LMS 
of the digestive tract or GIST were evaluated in our hospital (Table l a  and b). 
Sixteen (55%) LMS were located in the lower extremity, 6 (2 1 %) in the upper 
extremity, 4 ( 14%) in the retroperitoneum and 3 ( 10%) in other parts of the body. 
Twelve (46%) malignant GISTs were derived from the stomach, 6 (23%) from the 
small intestine, 6 (23%) from the large intestine, one (4%) from the esophagus and in 
one (4%) patient the tumor presented as a large intra-abdominal mass, suspected to 
derive from the stomach. Paraffin embedded tumor material was available of 26 
patients with a LMS of soft tissue and 25 patients with a malignant GIST. Patients 
with superficial LMS i.e. originating from the cutis or subcutis were not included, 
since it is reported that they have a better prognosis than patients with deep soft 
tissue LMS .8 For this study only previously untreated, primary tumors were used. In 
all cases the histological diagnoses were confirmed by central revision of 
haematoxylin-eosin stained paraffin sections with or without additional immuno­
histological stains .8•307 The 29 LMS were graded according to the grading system of 
Coindre et al. 29, which resulted in 8 grade I (28%), 14 grade 11 (48%) and 7 grade Ill 
(24%) LMS. A GIST was considered malignant if there was both mitotic activity and 




Table l a. Patient characteristics, histology and MDR status of the 29 studied LMS 12atients 
diagnosis patient age gender turn or location Follow os P-gp MRP1 LRP 
&rade -UE (months} 
LMS: 
1 44 m right thigh NED 90 + 
2 44 m left lower arm NED 12  + 
3 44 f I right lower arm DOD 26 + + 
4 60 f I retroperitoneum DOD 39 + 
5 64 m I left groin NED 78 + + 
6 73 f I left thigh NED 45 + + 
7 75 f I right ankle NED 97 + 
8 83 f I retroperitoneum DOD 9 + 
9 22 m II right lower leg DOD 40 + ND + 
10  33 f 11 left lower leg DOD 8 + + 
1 1  34 m 11 Tongue DOD 70 + + + 
12  54 f 11 left knee NED 2 1  + 
13  54 f 11 Retroperitoneum AWD 26 + 
14  55  m 11 Retroperitoneum AWD 7 + + + 
1 5  59 m 11 right, AWD 23 + + + 
supraclavicular 
1 6  62 f 11 right lower leg DOD 5 1  + + 
1 7  65 m 11 left lower leg DOD 40 ND 
1 8  69 f II right buttock NED 75 + + 
19  7 1  m 11 right knee DOD 10  + + 
20 72 f 11 right upper leg NED 12  + 
2 1  78 f 11 right buttock DOD 136 ND ND ND 
22 80 f 11 left arm DOD 19  ND + 
23 20 f Ill left thigh NED 12 1  ND ND ND 
24 40 f Ill left groin DOD 22 + + 
25 43 m Ill right upper leg DOC 1 5 1  
26 45 m Ill right arm DOD 4 
27 60 f Ill left lower leg DOD 38 + 
28 70 m Ill right groin DOD 39 ND ND ND 
29 8 1  f Ill right UE�r arm DOD 14 + + 
LMS: soft tissue leiomyosarcoma , P-gp: P-glycoprotein, MRP1: multidrug resistance protein, 
LRP: lung resistance protein; NED: no evidence of disease; A WD: alive with disease; 
DOD: died of disease; DOC: died of other causes; LOF: lost to follow-up; ND: not done 
MDR expression 
For detection of £:!m, the monoclonal antibody C494 (Signet Laboratories, 
Dedham MA) in a concentration of I20 flg/ml in phosphate-buffered saline (PBS) 
(Merck, Darmstadt, Germany) plus I% bovine serum albumin (BSA) (Serva 
Electrophoresis GmbH, Hamburg, Germany) was used. For detection of MRP1 the 
monoclonai antibody MRPri (provided by Dr. R.J.Scheper, Dept. of Pathology, Free 
University Hospital, Amsterdam) in a concentration of 20 11g/ml in I% BSAIPBS 
was utilized. For detection of LRP the monoclonal antibody LRP (Transduction 
Laboratories, Los Angeles CA) in a concentration of 250 flg/ml in 1 %  BSNPBS was 
used. As controls for immunohistochemal detection served cytospins of the well 
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documented cell lines A2780 and GLC4 and their corresponding multi-drug resistant 
sublines i.e. overexpressing P-gp (A2780 AD), MRP1 (GLC4/ADR) and LRP 
(GLC4/ADR) 298•299, as well as paraffin embedded formalin fixed liver (P-gp), lung 
(MRP 1) and colon (LRP) tissue. 
Paraffin sections (3 Jlm) were placed on positively charged glass slides and 
were dried. Immunohistochemistry was performed according to a method modified 
from Shi et al. . 177•1 78 Briefly, after heating on a hotplate, the slides were dewaxed in 
xylene and rehydrated in serial ethanol washes ( 100%, 96% and 70%). After each of 
the subsequent steps, three 5 minutes washes in PBS were carried out. After three 
times heating in an autoclave for 5 minutes at 1 15° C in a 20 mM blocking reagens 
(Boehringer Mannheim, Mannheim, Germany) with pH=6.0, endogenous peroxidase 
activity was blocked by incubation with 1 %  hydrogen peroxide in PBS during 30 
minutes. The slides were incubated with the specific antibody in I% BSA/PBS 
(pH=7.4) for 1 hour at room temperature in a humidified chamber. The primary 
antibody was detected with a rabbit antimouse (DAKO, Glostrup, Denmark) (C494 
and LRP) or rabbit antirat (DAKO, Glostrup, Denmark) (MRPr1 )  peroxidase labeled 
secondary antibody diluted in 1 :50 + 1 %  human serum (type AB) followed by 
incubation with goat antirabbit conjugated peroxidase diluted in 1 :50 + 1 %  human 
serum (type AB). 3.3-diaminobenzidine tetrahydrochloride (Sigma, St. Louis) with 
imidazole (Merck, Darmstadt, Germany) in PBS was used as the chromagen 
according to the manufacturer's instructions. After counterstaining with Mayer's 
haematoxylin, the slides were dehydrated through graded alcohols and mounted with 
coverslips. 
The expression of P-gp, MRP1 and LRP was assessed independently by two 
observers (B.P, H.H.) without knowledge of the histological diagnosis or clinical 
data. The P-gp, MRP1, LRP proteins were studied in adjacent slides of the most 
viable parts of the tumor. Amount of P-gp, MRP1 and LRP expression was 
semiquantitatively assessed by estimating the percentage of positive stained tumor 
cells and assessing staining intensity using a scale of 0 -3 (0: no staining, 1 :  very weak 
staining, 2: intermediate staining, 3 :  strong staining). Strong staining intensity was 
comparable to the staining intensity of the simultaneously stained positive control 
tissue. Both staining parameters were also combined into a so called histopath-score 
which is defined as: the estimated percentage of stained cells (0-100%) x the staining 
intensity (0-3) .300 According to the literature, tumor samples were considered negative 
for expression of each of the proteins if s; 5% of the cells were positive 96 P-gp 
expression in 1 LMS and MRP 1 expression in 2 LMS could not be interpreted. 
Statistics 
A Mann Whitney test was carried out to analyze the differences in MDR 
parameters between LMS and GIST. To avoid the problem of multi-comparison in 
the analyses of P-gp, MRP1 and LRP in relation with response, a Bonferroni 
correction factor of 3 was introduced. A Fisher exact test was used to compare MDR 
status and the frequency of metastases in both groups. To quantitate the degree of 
correlation between parameters, the Spearman 's correlation coefficient was 
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computed. Actuarial survival curves were constructed by the Kaplan-Meier method 
in order to compare OS for the different patient groups in relation to MDR protein 
expression and metastatic disease. OS has been defined as the time between 
diagnosis and the moment of disease related death. Survival curves in the different 
groups were compared by the log-rank test. A two-tailed p-value of < 0.05 was 
considered to be significant. Statistical software SPSS 8.0 for Windows (SPSS Inc., 
Chicago IL) was used for statistical analysis. 
Table lb. Patient characteristics, histology and MDR status of the 26 studied GIST 12atients 
Diagnosis patient age gender location Follow-up os P-gp MRP1 LRP 
(months 
GIST: 
30 1 8  f Stomach LOF + + + 
3 1  35 m Small bowel DOD 14 + + 
32 38 m Small bowel DOD 32 + + + 
33 39 f Small bowel DOD 1 7  
34 46 m Colon DOD 2 + + + 
35 47 m Colon DOD 20 + + 
36 50 m Esophagus NED 14 + + 
37 5 1  m Colon AWD 33 + + 
38 5 1  m Stomach DOD 49 + + 
39 53 m Stomach DOD 28 + + 
40 55 f Stomach DOD 30 + + 
41 59 f Colon DOD 6 + + + 
42 62 f Stomach NED 16  + + 
43 62 f Small bowel NED 13  + + + 
44 63 m Stomach LOF + + + 
45 64 m Stomach NED 1 7  + + + 
46 66 f Stomach DOD 15  + + + 
47 66 m Colon NED 79 
48 67 f Stomach DOD 10  + + + 
49 67 m Stomach DOD 26 + + + 
50 67 f Colon DOC 16  + + 
5 1  70 m Small bowel DOD 28 ND ND ND 
52 73 f Small bowel NED 23 + + 
53 74 f Stomach NED 41  + + + 
54 .78 f intra-abdominal DOD 7 
55 80 f Stomach DOD 8 + + + 
GIST: malignant gastrointestinal stromal tumor, P-gp: P-glycoprotein, MRP1 :  mu1tidrug resistance 
protein, LRP: lung resistance protein; NED: no evidence of disease; A WO: alive with disease; 
DOD: died of disease; DOC: died of other causes; LOF: lost to follow-up; ND: not done 
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RESULTS 
Patient characteristics and clinical outcome: 
As shown in Tables 1 a and 1 b, the LMS group consisted of 12  men and 1 7  
women, with a mean age of 5 7  years (SD: 1 6.2, range: 20-83 years). The GIST group 
consisted of 13  men and 13 women, with a mean age of 58 years (SD: 14.7, range: 
1 8-80 years). Gender and age were equally distributed between both groups. 
Overall survival of the 29 patients with a LMS (mean: 72; median: 40 months) 
was significantly (p<0.05) better than the overall survival of the 26 patients with a 
GIST (mean: 3 1 ;  median: 28 months) (Fig 1). The 2-yrs and 5-yrs OS in the group of 
LMS patients was 69.7% and 35.5%, whereas the 2-yrs and 5-yrs OS was 
significantly lower in the group of GIST patients i.e. 24.5% and 12.2%, respectively. 
In the GIST group, OS was not significantly influenced by the location of the 
primary tumor i.e. patients with malignant GIST located in the stomach had a mean 
OS of 29 months (median: 28 months), whereas these values for small intestine and 
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Due to the long period in which the patients were studied, it was not possible 
to detennine whether there had been distant metastases in 3 LMS cases and 9 GIST 
cases. Of the remaining 26 LMS patients, 1 5  developed metastases: lung metastases 
were found in 13 patients and in skin metastases in two patients (Table 2). None of 
the LMS patients developed liver metastases as the first metastatic site, but four 
patients developed liver metastases subsequent to other distant metastases. Of the 
remaining 17  GIST patients, 9 patients developed distant metastases: liver metastases 
were found in 5 patients, intra-abdominal metastases in 2 patients and regional lymph 
node metastases in one patient. One GIST patient developed intrathoracal metastases, 
presumably per continuitatem with intra-abdominal metastasis. Although the 
frequency of metastases in the evaluable LMS ( 15/26) and GIST (9/ 17) patients was 
comparable, the liver as the first metastatic site was more involved in GIST patients 
(p<0.0 1 ), while the lungs as the first metastatic site were more involved in patients 
with a deep seated LMS (p<O.OO 1 ). 





- lung metastases only 
- lung as primary metastatic site 
liver metastases 
- liver metastases only 
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LMS: soft tissue leiomyosarcoma , GIST: malignant gastrointestinal stromal tumor 
• percentage of patients who were evaluable for the analysis of metastatic disease 
b this patient developed intrathoracal metastases, presumably per continuitatem with intra­
abdominal metastasis 
c 2/4 patients had intra-abdominal metastases as primary metastatic site 
d 2/5 patients had skin metastases as primary metastatic site 
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P-gp, MRP1 and LRP expression in LMS and GIST 
P-gp and MRP1 were significantly more expressed in the GIST than in the 
LMS: P-gp positive LMS were found in 8/26 (3 1 %) cases and P-gp positive GIST 
could be identified in 1 7/25 (68%) cases (p<0.05). MRP1 positive LMS were found 
in 8/26 (3 1 %) cases and MRP1 positive GIST could be identified in 17/25 (68%) 
cases (p<0.05)(Table 3). As shown in Fig 2, the amount of P-gp and MRP1 
expressing tumor cells was significantly higher in GIST than in LMS (both: p<0.05). 
When the percentage positive cells were combined with staining intensity into a 
histopath score, the differences in MRP 1 expression were even more pronounced 
(Table 4). LRP expression did not differ between LMS and GIST, but was more 
often expressed than P-gp and MRP1 (both: p<O.OO l ) .  A minority ofLMS ( 12%) and 
GIST ( 12%) had no MDR expression, while 12% of the LMS and 48% of the GIST 
expressed all three MDR-proteins (p<O.O l ). Numbers of tumors with eo-expression 
ofP-gp, MRP1 or LRP are shown in Table 3 .  
Table 3 .  MDR protein status of the analyzed 26 LMS and 25 GIST. 
LMS GIST 
P-gp + 8 (3 1 %) 1 7 (68%) 
MRP + 8 (3 1%) 1 7  (68%) 
LRP + 23 (88%) 22 (88%) 
P-gp + and MRP + 3 ( 12%) 12 (48%) 
P-gp + and LRP + 8 (3 1 %) 17 (68%) 
MRP + and LRP + 8 (3 1 %) 17 (68%) 
no MDR expression 3 ( 12%) 3 ( 1 2%) 
expression of one MDR protein 10  (38%) 0 (0%) 
eo-expression of two MDR proteins 10  (38%) 10 (40%) 
eo-expression ofall three MDRproteins 3 (12%) 12  (48%) 
LMS: soft tissue leiomyosarcoma , GIST: malignant gastrointestinal stromal tumor, 
P-gp: P-glycoprotein, MRP1 :  multidrug resistance protein, 
LRP: lung resistance protein 
A correlation (r: 0.33;  p<0.05) was found between P-gp and MRP1 expression 
(both percentage positive cells and histopath score) in the whole group of tumors, but 
not in the subgroups of LMS and GIST. LRP expression was not related to P-gp or 
MRP 1 expression. P-gp, MRP 1 and LRP expression was neither correlated with 
tumor grade nor with mitotic activity. 
OS in relation with MDR status in LMS and GIST 
When LMS patients were compared with GIST patients regarding their OS 
and MDR status, it was found that patients with P-gp positive LMS tended to have a 
shorter OS than patients with P-gp negative LMS (Table 5). P-gp expression did not 
influence survival in GIST. No differences in survival in either LMS patients or 




Table 4. Summary of P-gp, MRP1 and LRP expression in the 26 LMS and 25 GIST. 
MDR histology percentage positive cells histopath score* 
protein 
mean SD median range p mean SD median 
P-gp LMS 13 .4% 23.0% 5% 0-80% 0.01 22.5 38.5 10  
GIST 38.4% 33 .9% 30% 0-90% 8 1 .4 92. 1 30 
MRP1 LMS 13.3% 22.9% 0% 0-80% 0.04 17.7 33.0 0 
GIST 35.4% 32. 1% 20% 0-90% 64.6 62.9 40 
LRP LMS 58.5% 27.3% 60% 0-90% 0.59 1 1 1 .2 73.6 90 








*histopath score: percentage positive cells x staining intensity (0-3), LMS: soft tissue 
leiomyosarcoma , GIST: malignant gastrointestinal stromal tumor, 
P-gp: P-glycoprotein, MRP1 :  multidrug resistance protein, LRP: lung resistance protein; 
p: p - values (adjusted for multiple comparison) 
Table 5. MDR status and OS in both LMS and GIST. 
LMS GIST 
OS (months) OS (months) 
median (mean) median (mean) 
all cases 40 (72)* 28 (3 1 )* 
P-gp + 26 (33) 26 (25) 
P-gp - 5 1  (88) 30 ( 40) 
MRPI + 70 (61)  26 (24) 
MRPI - 38 (61)  20 (35) 
LRP + 40 (52) 28 (27) 
LRP - 40 (65) 1 7  (34) 





intestinal stromal tumor, P-gp: P-glycoprotein, MRP1:  multidrug resistance protein, LRP: lung 
resistance protein , *p<0.05 
DISCUSSION 
Immunohistochemical and molecular ( cyto )genetic findings have brought 
evidence that GIST have to be considered as a specific group of neoplasms .307•327 
GIST have been diagnosed as smooth muscle tumors of the digestive tract for many 
years and the studies evaluating clinical outcome and treatment response have 
classified them as "leiomyosarcomas of the digestive tract". A number of studies 
have reported the chemoresistance of the so-called leiomyosarcomas and the poor 
prognosis of patients with an abdominal "leiomyosarcoma", but it is not clear 
whether these non-responding malignant smooth muscle neoplasm are GIST, LMS or 
uterine LMS _87· 142•285•286•320 The results of a recent study by Edmonson et al. 3
28, in 
which malignant GIST and other "leiomyosarcomas" were treated with dacarbazine, 
mitomycine, doxorubicin and cisplatin, indicate that GIST are more chemotherapy 
resistant than other neoplasms with smooth muscle differentiation. 
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Figure 2. 
P-gp, MRP1 and LRP expression in both LMS and malignant GISTs. 
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The present study showed that equal percentages of LMS and GIST develop 
distant metastases. However, the frequency of lung metastases in metastasized LMS 
was 87% and liver metastases 27%, whereas in 1 1% of the metastasized GIST 
patients lung metastases developed and in 56% liver metastases were found. This 
strengthens the idea that most studies reporting the high incidence of hepatic 
metastases in "leiomyosarcomas" 87•329 are in fact evaluating malignant GIST and that 
(metastatic) LMS might be more drug sensitive than has been suggested in earlier 
studies. 
No previous studies were performed in which GIST were compared with LMS 
of deep soft tissue regarding clinical outcome and the presence of drug resistance 
associated proteins. The results of the current study not only indicate that patients 
with a LMS have a better prognosis than patients with malignant GIST, but revealed 
clinically important evidence that malignant GIST express P-gp and MRP1 more 
frequently than LMS. 
The OS was evaluated without information of the adequacy of the primary 
surgical treatment and of additional treatment, since in the accrual of a relatively 
large amount of patient and tumor data of relatively rare neoplasms, a 19  years period 
is involved, making the importance of the additional information of the various 
applied treatment regimens questionable. Although LMS patients have a worse 
prognosis than other STS patients 8, OS in LMS patients is significantly better than in 
GIST patients. It can be concluded that although LMS are aggressive STS, they still 
have a better clinical behavior than malignant GIST. Several studies reported the 5 
yrs survival rate in GIST, ranging from 20% to 78% 3 18, but did not clearly indicate 
whether these GIST were malignant or benign. In our study we combined the 
presence of mitotic activity per 2 mm2 and a tumor size of more than 5 cm in 
diameter, to select the malignant GIST .307 Several studies in large series of GIST 
patients did report a better survival of patients with GIST located in the stomach or 
esophagus than GIST derived from the small or large intestine, but this could not be 
confirmed in our study with a relatively small number of patients .308·3 1 8 It should be 
emphasized that only deep seated LMS were included in this study and that 
(sub)cutaneaous LMS were not examined, since these superficial tumors have a 
better prognosis than the LMS of the deep soft tissues, probably because they are 
small when detected and adequately excised . 8•330•33 1 
The finding that GIST have significantly more expression of P-gp and MRP 1 
than LMS, is not only another indication that GIST is a different tumor, but is also of 
therapeutic importance. In most STS, doxorubicin based regimens are administered 
in metastatic disease, but also in the adjuvant setting .281•282•332-338 Edmonson et al 328 
showed that GIST are more chemotherapy resistant than other malignant smooth 
muscle tumors when doxorubicin based chemotherapy was used. However, 
doxorubicin resistance is related to P-gp and MRP 1 289and the results of our study 
strongly imply that especially in malignant GIST with high expression of both P-gp 
and MRP1o doxorubicin is not indicated and new non-MDR related cytostatic agents 
are awaited. Both P-gp and MRP1 expression is frequently detected in normal tissue 
of the digestive tract 339•340, which could explain their expression in GIST. Since P-gp 
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expression and MRP 1 expression was neither correlated to tumor grade in LMS nor 
to the mitotic activity in both LMS and GIST, it appears that both MDR parameters 
are not related to tumor aggressiveness and are more related to the histological type 
and the tissue they derive from as has been demonstrated in other studies .340-346 
High LRP expression was found in both LMS and malignant GIST and LRP 
expression did not have prognostic value in both groups. The high expression of LRP 
might be due to the fact that LRP is present in the epithelial tissues of digestive tract. 
Although the distribution of LRP expression in normal tissues has not been studied 
extensively, it was found to be present in muscle tissue , but not in muscle tissue with 
high MRP1 expression or in normal smooth muscle .292•347 In the present study, no 
inverse correlation between MRP 1 and LRP expression was found, indicating that 
LRP expression has not been decreased by simultaneous MRP 1 expression in these 
smooth muscle neoplasms. On microscopic examination the LRP staining was most 
cytoplasmic and normal smooth muscle showed no clear staining. The exact function 
of LRP is not yet understood and, although there is evidence that LRP acts as an 
intracytoplasmic transporter of cytotoxic agents. In contrast to acute myeloid 
leukemia and ovarian cancer where LRP expression has been found an independent 
prognostic factor for response to chemotherapy and outcome 96•97•295, not much is 
known about LRP expression in STS and its prognostic role in STS is still unclear. 
Other studies have shown the clinical importance of P-gp and MRP1 (eo-) 
expression in sarcomas in general .98" 103•107• 108 In this study we not only determined the 
percentage of stained cells, but also incorporated the staining intensity in our 
evaluation of the tumors into a histopath score. In this way tumors with high staining 
intensity could be distinguished from moderate stained tumors even if the percentage 
of tumor cells was the same. This way of evaluating immunohistological stained 
sections reveals a broader range of staining results than the estimation of MDR 
positive cells alone. It was found that both the estimation of the amount of positive 
cells as well as the histopath score was highly comparable. The cutoff level of 5% 
was used to assess whether tumors were P-gp, MRP 1 or LRP positive or negative. A 
cutoff level has been introduced earlier 96 since immunohistological assessment 
cannot determine accurately if less than 5% stained cells in a minority of tumor 
specimens are indeed malignant tumor cells or pre-existent normal tissue, blood cells 
or endothelial cells. 
In conclusion, LMS patients have a better survival than GIST patients and 
LMS have a less pronounced drug resistance pattern than GIST. Therefore, studies 
evaluating chemotherapeutic regimens should differentiate between LMS and 
malignant GIST. The observed high expression of P-gp and MRP1 in GIST might 
explain their poor response to standard (anthracycline-based) chemotherapy. 
Although an equal amount of the LMS and the GIST develop distant metastases, 
LMS predominantly metastasize to the lungs, while GIST tend to spread to the liver 
and the abdominal cavity. Further studies are warranted to determine whether new 
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Most adult patients with disseminated (soft tissue) sarcomas (STS) still have a 
poor clinical outcome. Multidrug resistance (MDR) has been associated with the 
expression of P-glycoprotein (P-gp), multidrug resistance protein-] (MRP J and lung 
resistance protein (LRP), but has not been studied intensively in a uniformly treated 
group of adult STS patients. In 28 adult STS patients with metastatic disease or 
irresectable tumor, treated with epirubicin, vindesine and ifosfamide (EVI) we 
evaluated the expression of P-gp, MRP1 and LRP, to determine the relation with 
treatment response and clinical outcome. MDR-protein expression was 
semiquantitatively assessed after immunohistochemical detection in paraffin 
embedded tumor material obtained before start of chemotherapy. 
P-gp positivity was observed in 63%, MRP1 positivity in 57% and LRP 
positivity in 73% of the tumors. In 93% of the tumors at least one analyzed MDR­
protein was present. eo-expression was found in 75% of the tumors and 20% were 
positive for all three MDR proteins. Tumor response was observed in 16 patients (3 
CR, 13 PR) and no response in 11 patients (8 SD, 3 PD). MDR-protein expression 
was not associated with treatment response. Overall survival (OS) (median: 14 
months) and progression free survival (PFS) (median: 8 months) were not associated 
with the expression of P-gp, MRP1 or LRP. However, patients with sarcomas eo­
expressing two or three drug resistance proteins (n = 21) tended to have a worse 
median PFS (7 months) than those without eo-expression (11 months) (p=0.08). In 
conclusion, the majority of adult STS expresses P-gp, MRP1 and/or LRP. In the 
individual patient with a metastasized STS, the assessment of P-gp, MRP1 or LRP 
expression cannot predict response to EVI treatment. There is a tendency that eo­
expression of P-gp, MRP1 and/or LRP is related with a worse PFS. 
INTRODUCTION 
Sarcomas are a heterogeneous group of malignant tumors which arise from 
tissue of mesenchymal origin and account for approximately 2 % of all malignancies. 
They originate in the soft tissues i.e. soft tissue sarcomas (STS) or bone (e.g. Ewing's 
sarcomas and osteosarcomas). STS tend to spread hematogeneously, predominantly 
to the lungs, in up to 30% of the patients 8•142•348• Chemotherapy is the treatment of 
choice in adult STS patients with diffuse distant metastases or advanced inoperable 
tumors 86• Doxorubicin is the most extensively applied cytotoxic drug in STS, alone 
or in combination with other drugs, and can be considered as the standard 
chemotherapeutic agent in STS resulting in response rates of up to 35% 281 •282•332•335• 
The addition of ifosfamide, with single agent response rates of 26%, and etoposide 
has shown to increase response rates to 46% 86•87•283•284•335•349• The efficacy of vinca­
alkaloids has been examined in polychemotherapy schedules in STS 282• Overall, the 
response rates in adult sarcoma patients to various chemotherapeutic regimens are 
around 26% with a median survival time of 5 1  weeks 87• 
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Multidrug resistance (MDR) is cross resistance to a number of functionally 
and structurally distinct drugs such as the anthracyclines (doxorubicin, epirubicin), 
the vinca-alkaloids (vincristine, vindesine) and epipodophyllotoxins (etoposide). 
MDR can be caused by one or more mechanisms i.e. increased expression of energy 
dependent efflux pumps such as P-glypoprotein (P-gp) and the multidrug resistance 
protein- ! (MRP 1 ), or increased expression of the lung resistance related protein 
(LRP) 287•290•292-294•350•35 1 •  P-gp has been found localized on the cell membrane, MRP 1 
has been localized both cytoplasmic and on the cell membrane 1 03.3°5• The spectrum 
of resistance for cytostatic agents relevant in sarcomas does not differ much between 
P-gp and MRP1 • LRP, which was identified as the human major vault protein is 
located intracytoplasmic and has been considered to play a role in the transport 
between nucleus and cytoplasm 289•292'294• Until now, the role of LRP in MDR is less 
clear, although some studies in ovarian cancer, multiple myeloma and leukemia 
indicated a possible role in clinical drug resistance %,97•295•296• 
In sarcomas, P-gp expression was found to be associated with poor response to 
chemotherapy in childhood rhabdomyosarcomas 102•352, although the predictive value 
has been weakened later 103, and Ewing's sarcomas 98 as well as with poor prognosis 
in osteosarcomas 99 and adult STS 100• 101 • MRP1 has been detected in Ewing's  
sarcoma 107 and eo-expression of MRP1 and P-gp was associated with tumor grade in 
STS 108• MRP1 has not been evaluated in relation to chemotherapeutic response or 
clinical outcome in STS patients. LRP expression has not been studied intensively in 
sarcomas. Until now, the combined expression of P-gp, MRP1 and LRP has not been 
studied with respect to clinical outcome in a uniformly chemotherapeutically treated 
group of adult patients with metastatic STS. 
This study was performed to evaluate the expression of P-gp, MRP 1 and LRP 
in adult STS patients and to determine a possible relation with response and survival 
following polychemotherapy (EVI). 
PATIENTS AND METHODS 
Patients 
Between January 1992 and January 1 998, 3 1  adult patients were treated with 
standard chemotherapy consisting of EVI. Patients were eligible for treatment with 
EVI if they had a histologically proven malignant mesenchymal tumor of the soft 
tissues with well documented distant metastases or an irresectable tumor not 
amenable to isolated limb perfusion. Patients had to be between 1 6  years and 75 
years of age, had to have a World Health Organization (WHO) performance status of 
0, 1 or 2 and should not have received prior chemotherapy. 
Since in three patients paraffin embedded tumor material was not available, 
the studied group consisted of 28 patients (mean age 44. 1 ,  median: 44, SD: 14.6 , 
range: 16-67 years). Twenty seven patients were treated for metastatic STS. One 
patient (case 27) received EVI for an irresectable primary STS and this patient was 
not included in the survival analyses. Since in one patient the treatment response 
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could not be assessed, 27 patients were evaluable for analysis of treatment response. 
For this study, tumor material of the last tumor presentation obtained before the start 
of chemotherapy was used: 1 9  primary tumors and 9 distant metastases. The period 
between the last obtained and available pretreatment sample and the start of the EVI 
treatment ranged from 0 - 52 months (median: 4. 1 ,  mean: 9.6, SD: 12.9 months) . 
Patient characteristics, histology and clinical data are presented in Table 1 .  
Table 1 .  Patient characteristics, histology and clinical outcome 
Pat sex age diagnosis tumor treatment os· PFSb 
�de reseonse {monthsl {months· 
1 F 39 leiomyosarcoma Ill PD' 13  0 
2 M 55 synovial sarcoma 11 SD 13 8 
3 M 53 malignant peripheral nerve sheath tumor II NE 20 20 
4 F 58 alveolar soft part sarcoma II PD I 0 
5 F 59 leiomyosarcoma II SD 38 1 1  
6 M 22 synovial sarcoma Ill PR 15  12 
7 F 6 1  leiomyosarcoma Ill PR 14 1 1  
8 M 53 angiosarcoma II PD 7 0 
9 F 60 leiomyosarcoma I PR 39 35 
10 M 62 malignant peripheral nerve sheath tumor II SD 1 1  8 
1 1  F 42 MGCT'" Ill PR 10  6 
12 F 39 rhabdomyosarcoma II PR 1 1  7 
13  F 19  rhabdomyosarcoma I CR 18 16 
14 M 23 sarcoma not otherwise specified 11 SD 6 4 
1 5  F 52 myxoid liposarcoma I PR 34 21 
1 6  F 41  sarcoma not otherwise specified Ill PR 6 5 
17  F 40 uterine leiomyosarcoma SD 20 7 
1 8  F 24 extraskeletal Ewing's sarcoma Ill PR 13 7 
19  M 67 malignant fibrous histiocytoma II CR 20 10  
20 F 16  rhabdomyosarcoma 11 CR 22 1 1  
2 1  F 52 epithelioid sarcoma Ill SD 7 4 
22 F 27 sarcoma not otherwise specified Ill PR 6 5 
23 M 59 leiomyosarcoma 11 SD 16+ 10+ 
24 M 45 rhabdomyosarcoma Ill PR 9 6 
25 F 32 synovial sarcoma 11 PR 12+ 12+ 
26 F 43 myxoid liposarcoma II PR 13+ 13+ 
27 F 41  sarcoma not otherwise specified 11 PR 1 6+ 16+ 
28 M 5 1  maliS!!ant GIST" SD 12+ 12+ 
• OS: overall survival, b PFS: progression free survival, 
<MGCT: malignant giant cell tumor of tendons and aponeuroses/ GIST: gastrointestinal stromal 
tumor, 
• CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, 
NE: not evaluable, + alive with disease or (patient 27) no evidence of disease 
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Histology 
In all cases the histological diagnosis was made on haematoxylin-eosin stained 
paraffin sections with or without additional immunohistological stains. The STS were 
classified according to Enzinger and W eiss 8 and 26 could be graded according to the 
grading system of Coindre et al. 29• This resulted in 3 grade I ( I I %), I4 grade 11 
(54%) and 9 grade Ill (35%) STS (Table 1).  
MDR expression 
For detection of P-gp, the monoclonal antibody C494 (Signet Laboratories, 
Dedham MA) in a concentration of I20 J.lg/ml in phosphate-buffered saline (PBS) 
(Merck, Darmstadt, Germany) plus I% bovine serum albumin (BSA) (Serva 
Electrophoresis GmbH, Hamburg, Germany) was used. For detection of MRP1 the 
monoclonal antibody MRPri (kindly provided by Dr R.J.Scheper, Free University 
Hospital, Amsterdam) in a concentration of 20 J.lg/ml in I %  BSAIPBS was utilized. 
For detection of LRP the monoclonal antibody LRP (Transduction Laboratories, Los 
Angeles CA) in a concentration of 250 J.lg/ml in I% BSAIPBS was used. As controls 
for immunohistochemal detection served cytospins of the well documented cell lines 
A2780 and GLC4 and their corresponding multi-drug resistant sublines i.e. 
overexpressing P-gp (2780 AD), MRP1 (GLC4/ADR) and LRP (GLC4/ADR) 298•299, 
as well as paraffin embedded formalin fixed liver (P-gp), lung (MRP1) and colon 
(LRP) tissue. 
Paraffin sections (3 J.lm) were placed on positively charged glass slides and 
were dried. Immunohistochemistry was performed according to a method modified 
from Shi et al. 177•1 78 • Briefly, after heating on a hotplate, the slides were dewaxed in 
xylene and rehydrated in serial ethanol washes ( 100%, 96% and 70%). After each of 
the subsequent steps, three 5 min washes in PBS were carried out. After three times 
heating in an autoclave for 5 min at 1 I5° C in a 20 mM blocking reagens (Boehringer 
Mannheim, Mannheim, Germany) with pH=6.0, endogenous peroxidase activity was 
blocked by incubation with I% hydrogen peroxide in PBS during 30 min. The slides 
were incubated'with the specific antibody in I %  BSAIPBS (pH=7.4) for I h at room 
temperature in a humidified chamber. The primary antibody was detected with a 
rabbit antimouse (DAKO, Glostrup, Denmark) (C494 and LRP) or rabbit antirat 
(DAKO, Glostrup, Denmark) (MRPri) peroxidase labeled secondary antibody 
diluted in 1 :50 + 1% human serum (type AB) followed by incubation with goat 
antirabbit conjugated peroxidase diluted in 1 :50 +1% human serum (type AB). 3.3-
diaminobenzidine tetrahydrochloride (Sigma, St. Louis) with imidazole (Merck, 
Darmstadt, Germany) in PBS was used as the chromagen according to the 
manufacturer's instructions. After counterstaining with Mayer's haematoxylin, the 
slides were dehydrated through graded alcohols and mounted with coverslips. 
The expression of P-gp, MRP1 and LRP was assessed independently by two 
observers (B.P, H.H.) without knowledge of the EVI treatment response or patient 
survival. The P-gp, MRP1, LRP proteins were studied in adjacent slides of the most 
viable parts of the tumor. Amount of P-gp, MRP1 and LRP expression was 
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semiquantitatively assessed by estimating the percentage of positive stained tumor 
cells and assessing staining intensity using a scale of 0 -3 (0: no staining, 1 :  very weak 
staining, 2: intermediate staining, 3 :  strong staining). Strong staining intensity was 
comparable to the staining intensity of the simultaneously stained positive control 
tissue. Both staining parameters were also combined into a so called histopath-score 
which is defined as: the estimated percentage of stained cells (0-100%) x the staining 
intensity (0-3) 300• According to the literature, tumor samples were considered negative 
for expression of each of the proteins if S 5% of the cells in the tumor section were 
positive 96• Since not enough paraffin embedded tumor material was available, it was 
not possible to determine P-gp expression in one case and LRP expression in two 
cases. 
Chemotherapy treatment 
The treatment protocol consisted of a bolus of 3 mg/m2 vindesine and 120 
mg/m2 epirubicin given intravenously (iv) on day 1 ,  followed by a 1 h infusion of 1 .2 
g/m2/day ifosfamide, combined with mesna, on days 2 to 6. Courses were repeated 
every three weeks. Patients showing a response or stable disease received two 
additional courses until a maximum of 6 courses. Therapy was ended when disease 
progression was documented, unacceptable toxicity occurred or patients refused 
further treatment. 
Assessment of turn or response 
Tumor response was assessed after every two courses. Complete response 
(CR) was defined as the disappearance of all signs of disease for at least 4 weeks. A 
reduction by at least 50% in the sum of the products of the largest perpendicular 
diameters of all measurable lesions was defined as a partial response (PR). Stable 
disease (SD) was defined as a situation with less than 50% decrease or less than 25% 
increase and progressive disease (PD) as more than 25% increase in the sum of the 
aforementioned diameters. Response was scored according to WHO criteria 353 
depending on their tumor localization either by physical examination or 
radiographically. The product of the largest perpendicular diameters of the tumor was 
used as response parameter. Overall survival (OS) was defined as the period between 
the start of the chemotherapy and the patient's death or the last follow-up visit. 
Progression free survival (PFS) was defined as the period between the start of the 
treatment and disease progression. 
Statistics 
A Mann Whitney test was carried out to analyze the differences in MDR 
parameters between poor and good responders. To avoid the problem of multi­
comparison in the analyses of P-gp, MRP 1 and LRP in relation with response, a 
Bonferroni correction factor of 3 was introduced. To quantitate the degree of 
correlation between parameters, the Spearrnan's rank test was used. Actuarial 
survival curves were constructed by the Kaplan-Meier method in order to compare 
OS and PFS for the different patient groups in relation to MDR protein expression 
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and response. Survival curves in the different groups were compared by the log-rank 
test. A two-tailed p-value of < 0.05 was considered to be significant. Statistical 
software SPSS 8.0 for Windows (SPSS Inc., Chicago IL) was used for statistical 
analysis. 
RESULTS 
P-gp expression, i.e. >5% of the cells in the tumor section were positive, was 
found in 1 7/27 (63%) of the EVI treated sarcomas. Median percentage P-gp positive 
cells was 60% and median P-gp histopath score was 60 (Table 2). In 12  of these 
tumors a low diffuse cytoplasmic and membranous staining was observed, while in 2 
cases a moderate and in 3 tumors a strong staining was observed. MRP 1 positive 
sarcomas were found in 1 6/28 (57%) cases. The median percentage of MRP1 
expressing cells was 10% and the median MRP1 histopath score was 15 .  In 9 of these 
tumors a low diffuse cytoplasmic staining was observed, while in 2 cases a moderate 
and in 3 tumors a strong cytoplasmic and membranous staining was observed. LRP 
positive sarcomas were found in 1 9/26 (73%) of the patients. Median percentage 
LRP positive cells was 30%. Median LRP histopath score was 35 .  In 10  of these 
tumors a low diffuse cytoplasmic was observed, while in 8 cases a moderate and in 1 
tumor a strong staining was observed. 
Table 2. Summary of P-gp, MRP1 and LRP exEression in the EVI treated tumors 
n median mean SD range 
122Sitiv!< �!<!Is; 
P-gpb 27 60% 47% 4 1 .9% 0%-100% 
MRPIC 28 1 0% 3 1% 33.9% 0%-90% 
LIW 26 30% 35% 32.5% 0%-90% 
bist2path s�;2�·� 
P-gpb 27 60 74 89.5 0-300 
MRPIC 28 1 5  55 79.2 0-270 
LIW 26 35 59 7 1 .2 0-270 
"histopath score: % positive cells x staining intensity (0-3), bP-gp: P-glycoprotein, 
"MRP 1: multi drug resistance protein, dLRP: lung resistance protein 
Twenty-six of the 28 tumors (93%) did express one or more of the MDR 
proteins. Twenty-one of the 28 tumors (75%) were eo-expressing two or three MDR 
proteins. eo-expression ofP-gp and MRP1 was found in 10/27 cases (37%), P-gp and 
LRP 1 1/25 (44%) cases, MRP1 and LRP in 1 2/26 (46%) cases and expression of all 
three MDR proteins was observed in 5/25 (20%) of the sarcomas. Two sarcomas 
(7%) were negative for all three MDR proteins. The expression of P-gp, as assessed 
by both the percentage of positive cells and the histopath score, did not correlate with 
to the expression (positive cells and histopath score) of either MRP1 or LRP. 
Expression of MRP 1 was not correlated to LRP expression as assessed by both the 
percentage of positive cells and the histopath score. 
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A tumor response was observed in 59% (3 CR, 1 3  PR) of the 27 patients 
evaluable for response. No response was observed in 4 1 %  ( 1 1/27) of the patients (3 
PD, 8 SD). As shown in Table 3,  P-gp, MRP1 or LRP expression did not differ 
between the patients with or without a response on EVI treatment. Although not 
statistically significant, median MRP 1 and LRP expression was lower in the 
responders. No correlation was found between response and P-gp, MRP1 or LRP 
expression as assessed by percentage of positive cells or histopath score (Figure 1).  
Table 3. P-gp, MRP1 and LRP expression in sarcomas of patients with a response (n: 16) 








percentage positive cells 
median mean SD 
80% 60% 38.9% 
5% 33% 4 1 .7% 
0% 26% 34.8% 








93. 1  
8 1 .9 
74.7 
87.6 
response 20% 32% 33 .7% 20 5 1  74.8 
no response 35% 41% 3 1 .3% 50 74 66. 1 
"histopath score: percentage positive cells x staining intensity (0-3), bP-gp: P-glycoprotein, 
'"MRP1 :  multidrug resistance protein, dLRP: lung resistance protein 
Median OS in the EVI treated STS was 14.0 months, whereas median PFS 
was 8.0 months. OS was 14.7 months for responders and 12.7 months for non­
responders (N.S.) (Figure 2). Median PFS was better for responders ( 1 1 .0 months) 
than for non-responders (7.0 months) (p=0.02). Patients with P-gp, MRP1 or LRP 
negative STS did not have a better median OS as compared to patients with P-gp, 
MRP1 or LRP positive tumors: 1 3  (P-gp-), 1 5  (P-gp+), 1 1  (MRP1 -) and 1 8  (MRP1 +), 
1 3  (LRP-) and 14· (LRP+) months. Also median PFS was not associated with MDR: 
8 (P-gp-) and 7 (P-gp+), 8 (MRP1 -) and 8 (MRP1 +), 7 (LRP-) and 10 (LRP+) 
months. However, expression of two or more MDR proteins (i.e. eo-expression) did 
negatively influence OS, but differences in OS were not statistically significant. PFS 
was notably shorter for the patients with tumors eo-expressing two or three MDR 
proteins (p=0.08) (Figure 3). 
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Figure 1 
Tumor reponse (PD: progressive disease, SD: stable disease, PR: partial response, CR: 
complete response) related to (a) P-gp, (b) MRP1 and (c) LRP expression. 
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DISCUSSION 
Although doxorubicin or epirubicin and ifosfamide have shown activity in the 
treatment of STS, it should be envisaged that still the majority of STS patients do not 
respond to chemotherapy 87• This urges not only the need for more active cytostatic 
agents but also for defining tumor biological characteristics with prognostic 
significance. This should lead to more patient or tumor-tailored therapy which might 
be in favor of enhancing response to treatment but also of withholding useless 
therapy with known side-effects. Therefore it was decided to translate the expression 
of P-gp, MRP1 and LRP in chemotherapeutic naive adult STS, obtained from the last 
presentation before the start of EVI treatment, into a clinical setting, i.e. response to 
treatment, OS and PFS. 
In this study it was shown that most of the chemotherapy naive sarcomas 
express P-gp, MRP1 or LRP. Furthermore, eo-expression of two or three MDR 
proteins is present in 75% of the STS and the expression of P-gp, MRP1 and LRP 
did not influence response to EVI. It has to be considered that epirubicin and 
vindesine are typical P-gp related cytostatic agents, whereas ifosfamide is not. So the 
contribution of the individual compounds in this polychemotherapy schedule is 
difficult to establish. In any way, no single parameter seems to overrule the others. 
P-gp expression was common (63%) in STS and was found in both the 
cytoplasm and cell membrane, as described earlier 1 03 •  Levine et al. 101 found 24/50 
(48%) P-gp positive STS using RT-PCR for MDR- 1 mRNA and 5 1% P-gp positive 
STS using immunohistochemistry with the UIC-2 antibody. However, in the latter 
study 7 cases were intermediate malignant desmoid tumors, only 42% of the patients 
received chemotherapeutic treatment with various doxorubicin based regimens and 
only 1 5  patients could be evaluated for treatment response: no conclusion was drawn 
on the predictive value ofP-gp expression on treatment response. Furthermore, the P­
gp expression, evaluated in primary STS specimens, was only an independent 
prognostic indicator when AJCC stages I and IV (with metastatic disease) patients 
were excluded. Their conclusion that P-gp expression is not only associated with 
chemosensitivitY but also reflects aggressive tumor behavior, seems therefore limited 
to AJCC stages 11 and Ill STS. In our study in uniformly treated metastasized STS, 
no clear relation between P-gp expression, OS or PFS could be established. Other 
studies evaluating P-gp expression in STS also did not find a clear relationship with 
clinical outcome and even the reported predictive value in pediatric sarcomas is 
subject of debate 102• 103•1 06• Other immunohistological studies, using different 
monoclonal antibodies, revealed percentage of P-gp positive STS between 1 8% and 
62% 100• 104-106•30 1•302•324, as has been observed in our study in a heterogeneous group of 
malignant mesenchymal tumors. A correlation with tumor grade and tumor type was 
observed in some studies 100•297• No correlation of P-gp with tumor grade or type 
could be found in the present study, which might at least partly be explained by the 
heterogeneity and the relatively small numbers of STS with different tumor grades. 
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Figure 2 
Overall survival (OS) (a) and progression free survival (PFS) (b) of the 27 
sarcoma patients in relation to tumor response. 
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Figure 3 
Overall survival (OS) (a) and progression free survival (PFS) (b) of the 27 sarcoma 
patients with tumors with and without eo-expression of MDR proteins. 
EVI treated STS: P-gp, MRP1 and LRP expression 
Furthermore, in STS it was shown that not all immunohistologically detected P-gp 
expressing tumors have functional P-gp in vitro 304• Further studies evaluating the 
amount of MDR1 mRNA, P-gp expression and P-gp function simultaneously in a 
large series of STS, treated with the same chemotherapeutic regimen, are necessary 
to determine which of the techniques has the highest predictive value. 
Much less is known about expression of the drug efflux pump MRP 1 in STS. 
In our group MRP1 protein expression was detected in 64% of the STS and localized 
in predominantly the cytoplasm, although in the cases with moderate or strong 
staining also membranous staining was observed, as has been reported earlier 305• eo­
expression with P-gp was observed in 36% of the cases, which is highly comparable 
with the study of Oda et al. who detected MRP1 mRNA in 56% of the STS and found 
eo-expression with the MDR1 mRNA in 38% 108• In the latter study a correlation of 
tumor grade with eo-expression of MDR1 and MRP1 mRNA was also found, but we 
could not confirm such a relation, probably because of the heterogeneous small 
group of tumors in our study. Although not statistically significant, it should be noted 
that 9/1 1 (82%) of the cases with no response were MRP1 positive and 9/16  (56%) of 
the responders were MRP 1 negative 
No reports, so far, have been published on the expression of LRP in STS. In 
this study it was observed that 78% of the STS was LRP positive and was localized 
in the cytoplasm, as has been described before 96•292• Expression of LRP was not 
correlated with P-gp or MRPI >  which is important since it has been reported that LRP 
is involved in doxorubicin and vincristine resistance and could therefore have an 
additional function in drug resistance to EVI 289• However, the exact role of LRP in 
drug resistance remains not clear and it is thought that LRP is also involved in the 
transport of other cytotoxic agents than those involved in MDR mediated P-gp or 
MRP I 289.292.296,306. 
The results of this study show that 93% of the STS has expression of one or 
more known drug resistance associated proteins. The assessment of histopath scores 
did not change the results of the various comparisons. This suggest that the 
percentage of MDR expressing tumor cells within a tumor is at least of equal 
importance as the intensity of protein expression within the tumor cells. However, 
when data concerning the studied proteins are limited, histopath scores provide 
valuable information regarding the relation between staining intensity and percentage 
of stained cells. 
STS have a relatively high expression of all three MDR proteins. In other 
doxorubicin treated solid tumors, such as breast cancer, P-gp expression was 
observed in 10 - 50% of the cases, MRP1 in 80% and LRP in 75% and no relation 
with response to chemotherapy was observed 3 13• In ovarian cancer, in which P-gp 
was detected in 16- 1 7% of the tumors, MRP1 in 44-68% and LRP in 74-77%, the 
expression of LRP, but not P-gp or MRPI >  might have prognostic value 96•3 14• In STS, 
the (co-)expression of P-gp, MRP1 or LRP had no predictive value on the treatment 
response. Since there is still a favorable response rate of 59%, indicating that the EVI 
treatment has an encouraging effect on STS, the individual intact detoxifying 
mechanisms in the STS can only be a partial clarification for the 4 1% poor responses. 
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P-gp, MRP1 and LRP was not of prognostic value for OS and PFS. A tumor response 
was associated with a better PFS but not with a better OS as has been observed 
earlier by Van Glabbeke et al in a large series of advanced STS 87• When the eo­
expression of the drug resistance associated proteins was examined, regardless which 
two or three proteins were expressed, PFS was notably, though not significant 
(p=0.08), shorter for the patients with STS with eo-expression as compared to the 
patients with STS without eo-expression, although it did not affect OS. This finding 
might indicate that the expression of more than one MDR protein is more important 
than focusing on just one protein or mechanism, as has also been suggested by 
Izquierdo et al. 289• In this way co-.expression patterns might provide clinically useful 
information. The relevance of MRP2-5 and other drug resistance related proteins 354 
and the possible relation with the apoptotic pathway 355-357 is of more speculation , but 
could be helpful in clarifying the importance of these proteins in clinical drug 
resistance. 
In conclusion, a high percentage of STS is expressing P-gp, MRP1 or LRP, but 
the expression of these drug resistance associated proteins can not predict tumor 
response in the individual patient with a metastasized STS. eo-expression of two or 
more of the drug resistance associated proteins P-gp, MRP1 and/or LRP showed a 
tendency to predict PFS. Therefore, future analyses should not focus on one MDR 
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SUMMARY 
Cytogenetic studies in small groups of patients with malignant peripheral 
nerve sheath tumors (MPNST) revealed complex karyotypes with no consistent 
changes. A computer assisted cytogenetic analysis using a cytogenetic database was 
performed, to determine recurrent cytogenetic alterations in 51 MPNSTs ( 44 from 
the literature and 7 new cases) and to allow direct cytogenetic comparison between 
NF-1 associated and sporadic MPNSTs. Significant (p<0.05) loss was observed in 
the chromosomal regions 9p2, l lpl, llq2 and 18pl. Also, loss in Jp3, 9pl, l lql, 
12q2, 1 7pl, 18ql-q2, 19pl, 22ql, X and Y was detected. Gain of chromosomal 
material was found in chromosome 7, especially 7ql (p<0.05). Most involved 
breakpoints were: 1pl3, lq21, 7p22, 9pll, 1 7pll, 1 7qll, 22qll. Cytogenetic 
differences between NF-1 associated and sporadic MPNSTs included a relative loss 
of chromosomal material in NF-1 associated MPNSTs in lp3, 4p1 and 21p1-q2 and 
a relative gain in 15p1-q1. Differences in breakpoints between the NF-1 associated 
and the sporadic MPNST group were observed in 1p21-22 (28% of NF-1 vs 0% of 
sporadic MPNSTs), 1p32-34 (1 7% vs 0%), Bpll-12 (7% vs 27%) and 1 7q10-12 
(24% vs 7%). This approach, in which the cytogenetic results ofvarious reports are 
combined, shows that losses in 9p2 and gains in 7ql could be of oncogenetic 
importance in MPNSTs. Loss of 1 7q1, on which the NF-1 gene has been located 
(1 7ql1.2), is not a common cytogenetic finding in NF-1 associated MPNSTs. The 
observed differences between NF-1 associated and sporadic MPNSTs might reflect 
different oncogenetic pathways. 
INTRODUCTION 
Cytogenetic analysis is helpful in clarifying oncogenesis of various malignant 
solid tumors and the observation of recurrent chromosome abnormalities led to the 
detection of tumor specific chromosomal alterations which are of diagnostic value 
61 .358'360• Characteristic cytogenetic alterations have been found in several histologic 
types of soft tissue sarcomas {STS) 8•49•53• About 5-10 % of the STS are malignant 
peripheral nerve sheath tumors (MPNSTs). They have also been referred to as 
malignant schwannoma, neurofibrosarcoma and neurogenic sarcoma. MPNSTs are 
highly aggressive neoplasms and half of them arise from neurofibromas in patients 
with neurofibromatosis type 1 (NF-1)  or V on Recklinghausen's disease. About 10 % 
of all NF- 1 patients develop a MPNST at a mean age of 30 years and the 5-year 
overall survival rate is 44 % 8•361 • Previous cytogenetic studies on MPNSTs revealed 
no consistent karyotypic pattern 49•362'374, Since most karyotypes ofMPNSTs are 
highly complex and difficult to interpret, studies focusing on common chromosome 
abnormalities are cumbersome. Studies in relatively small groups of MPNSTs 
reported near triploid or hypodiploid number of chromosomes and many structural 
rearrangements resulting in (partial) loss of chromosomal material of 1 p, 9p, 1 1 , 12p, 
14q, 1 7  q, 22q, X and Y or gain of chromosomes 2 and 7 362•365-370• 373 . 
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The neurofibromatosis- ! gene (NF - 1-gene) is located on 1 7  q 1 1 .2 and is thought to 
act as a tumor suppressor gene encoding for neurofibromin 375•376• Some investigators 
hypothesized that the development of MPNSTs is a multistep process in which NF - 1  
mutations or  loss of  chromosome 1 7q i s  an early event in  the tumorigenesis 366•367• 
To determine meaningful cytogenetic changes observed in MPNSTs and discern 
possible cytogenetic patterns, a computer assisted cytogenetic analysis was 
performed on 46 MPNSTs reported in the literature and 7 new cases with an 
abnormal karyotype. A database was constructed which permits the detection of 
statistically significant non-random chromosomal aberrations and allows direct 
comparison of different karyotypes. This new approach was used to discover non­
random changes in chromosomal material and to detect both frequently involved 
breakpoints in MPNSTs. Furthermore, this approach was used to analyze the 
cytogenetic differences between NF-1 associated MPNSTs and sporadic MPNSTs. 
MATERIALS AND METHODS 
A literature review using Medline® was performed to find reports of 
cytogenetic studies of MPNSTs and 44 cases, including 4 malignant triton tumors, 
with abnormal karyotypes were found 49•362-374• The patients included 20 males and 24 
females ranging in age from 2 to 82 years. Twenty-five patients were reported to 
have a history of neurofibromatosis type- 1 and of nine patients the NF - 1  status was 
unclear. In most cases S l 00 immunohistochemistry was used to support the 
histological diagnosis in the non-NFl MPNSTs (table 1). Fifteen cases had an 
incomplete karyotype according to the ISCN '95 m. 
In our institute tumor material was obtained for cytogenetic analysis from 7 
patients with a MPNST. Diagnosis was made according to the criteria described by 
Enzinger and Weiss including immunohistochemical detection of the S 100 protein 8• 
A cytogenetic analysis of all specimens was carried out according to standard 
procedures and the karyotypes were described according to the ISCN 1 995 Guideli­
nes for Cancer m. A summary of the clinical and histopathological data of these 
cases is presented in table 2. Case 1 is an outside case of which only suspension was 
available and diagnostic criteria could not be identified retropectively. 
The analyzed group thus consisted of 28 NF- 1 associated MPNSTs, 14 
sporadic MPNSTs and 9 MPNSTs with an unknown NF-1 -status and there were 35 
primary tumors (27 with a complete karyotype), 4 metastases (2 with a complete 
karyotype), 1 local recurrence (with a complete karyotype) and 1 1  MPNSTs of which 
the tumor status was unclear (7 with a complete karyotype). If more than one tumor 
per patient was described, it was decided to use the karyotype of one tumor i.e. the 
primary tumor (if possible) to avoid overrepresentation. 
A database was constructed using dBase V Windows and consisted of four 
main parts related to the described karyotype: 1 )  the patient data and histological data 
of the tumor, 2) the gain and loss of chromosomal material, 3) the breakpoints per 
chromosome arm, and 4) the structural rearrangements. After interpretation of the 
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karyotype, the gains and losses of chromosomal material were entered. In short, each 
chromosome was divided according to the ideogram at 400 bands level as described 
by the ISCN, in such a way that net gains and losses in 1 p l l -p 1 3  were summarized 
in 1 p 1 ,  1 p2 1 -22 was summarized in 1 p2, etc . .  In case of (net) loss in these parts of 
one of the chromosomes a - 1  was entered. If the same parts were lost in two 
chromosomes a -2 was entered. Similarly, if (net) gain occurred in one of these 
chromosomal parts a + 1 was entered, etc. . Only changes as compared to the 
constitutional karyotype were evaluated. In this way 86 chromosomal regions per 
karyotype were recorded. All structural rearrangements were categorized per type of 
structural chromosome rearrangement (according to the ISCN). Microsoft Excel 5.0a 
Windows was used to transform the gains and losses of chromosomal material of all 
non-diploid karyotypes to diploid karyotypes. Before this diploidization, the changes 
in the chromosomal material of the X-chromosome of men were multiplied by 2 in 
order to compare male with female karyotypes. 
To analyze the data, Microsoft Excel 5.0a Windows was further used to 
compute: the number of tumors with gains or losses in a particular chromosomal 
region, the mean change in chromosomal material per chromosomal region and the 
mean number of breakpoints per chromosome arm. Mean change in chromosomal 
material in each of the 86 chromosomal regions is expressed as a chromosomal 
change ratio (CCR) which is defined as the absolute change in a specific 
chromosomal region as compared to a normal diploid karyotype e.g. if both 
chromosomes 1 of all analyzed tumors are lost, the mean change in the specific 
chromosomal regions 1 p l , 1p2 , lp3,  1 q l , 1 q2, l q3 and l q4 is: -2.00 in each of the 
regions. Only full abnormal karyotypes were used for the analysis of the over- or 
underrepresentation of chromosomes or chromosomal material. Reports that included 
incomplete karyotypes, which only described the clonal numerical and structural 
rearrangements, were only included in the breakpoint analysis. Graphs were 
constructed to visualize the change in chromosomal material, the amount of 
breakpoints per chromosome arm and the differences between selected groups, i.e. 
the NF- 1  associated MPNSTs versus the sporadic MPNSTs. 
To identify chromosomal regions with significant gains or losses, 95% 
confidence intervals (Cl) were calculated using Microsoft Excel 5.0a Windows. To 
avoid the introduction of significant-appearing associations by chance and to address 
the problem of multiple comparison, the significance level of 0.05 was adjusted 
downwards. The number of tests performed is 86. The tests are however dependent, 
because deletions take place for chromosomal segments in several tests. Therefore a 
Bonferroni correction factor of 86 is conservative. A mean number of breakpoints in 
each chromosome arm > 3 . 1  SO was considered to be significant reflecting a 
probability threshold of 0. 1 .  As an overall test whether the differences in amount of 
chromosomal material for each chromosomal region and the number of breakpoints 
between NF-1 associated and sporadic MPNSTs were statistically significant, an 
analysis of variance was performed where the statistical interaction between the 
chromosomal position x tumor type was calculated. The calculations were made on 
the residuals after adjusting for person differences in amount of chromosomal 
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material. Systat 5 . 1  and 6.0 for Windows was used for the calculation. A p-value 
<0.05 was considered statistically significant. 
Table 1. Diagnostic criteria for the 44 MPNST utilised by the different authors. 
author number of with neuro- S l 00 staining peripheral 
MPNST fibromatosis- I nerve 
{n} {n} association 
Becher et al., 1 984 * 2 l ND uncertain 
Riccardi et al., 1 986 4 4 ND yes 
Decker et al., 1 990 1 l ND uncertain 
Fletcher et al., 1 99 1  * 8 ? ND not reported 
Glover et al., 1 991  1 l ND not reported 
Rey et al., 1 993 l l ND uncertain 
Jhanwar et al., 1 994 10 9 + not reported 
Omdal et al., 1 994 1 1 + not reported 
Travis et al., 1 994 2 0 + not reported 
Mertens et al., 1 995 1 ? + not reported 
Mertens et al., 1 995 7 4 + not reported 
Sciot et al., 1995 1 ? + not reported 
McComb et al., 1 996 2 2 ND yes 
Rao et al., 1 996 3 I + �es 
ND: not done, +: done in (part of) the reported cases, * the karyotypes ofthe MPNST 
reported by Becher et al., 1984 and Fletcher et al., 1 99 1  are described in detail by A.A. 
Sandberg in The chromosomes in human cancer and leukemia,Elsevier, New York ( 1 990). 
RESULTS 
Nearly all cases showed a complex karyotype consisting of many numerical 
and structural rearrangements. The median chromosome number was 58 (range 34 -
270 chromosomes). 
Change in chromosomal material per chromosomal region (Fig. 1): 
Construction of 95% Cl revealed significant loss, expressed as chromosomal 
change ratio (CCR), of chromosomal material in the chromosomal regions 9p2 (-0.64 
CCR), l lp l  (-0.27 CCR), l lq2 (-0.32 CCR) and 1 8p l (-0.34). Although not 
statistically significant, there was also notable loss in l p3,  9pl ,  l lq l ,  1 2q2, 1 3p l ,  
14p 1 ,  1 7p 1 ,  1 8q 1 -q2, 1 9p 1 ,  22q 1 ,  X and Y. A statistically significant gain of 
chromosomal material was observed in the 7q l region (+0.42 CCR) , whereas a 
notable gain was observed in all regions of chromosome 7.  
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Table 2. Summary of clinical and cytogenetic data of the 7 patients with MPNSTs not 
re2orted earlier. 
Case Age/ Location NF-1 Karyotype 
sex 
66/M ? I ?  no 36-43,XY,der( I )t( I ;?;3)(p 13;?;p24),-2,add(3)(p2 1 ),+der( 4)1(2;4)( 
p l l ;ql2),-6,-7,del(7)(ql l ), i(8)(ql0),-9,dic(9; 1 1 )(p l l ;p l l }, 
der(IO)t(I O; 1 7)(q22;ql l },add(l 2)(pl l },·l3,·1 7,-1 7,-1 8,-2 1 ,  
+1-5 mar [cp9] 
2a 41/M sciatic nerve no 36-3 S,X,-Y ,add( I )( q2 1 ),add(3 )( q I 0),-5,-6,add(7)( q36},-8,-8,-
primary tumor 9,der(9)add(9)(pl 2)t(1 ;9) (q23;q22),-1 O,add( l l )(p! O), 
add( l 2)(q22), - 13,- 13,-14,- 15,-1 6,-16,- 1 7,-1 7,-1 8, 
dic( 1 8;?; 1 8) (q2 l ;?;p l l ),- 1 9, -20,-2 1 ,-22,-22,+marl ,+mar2, 
+mar3, +mar4,+mar5,+4-9mar[cp5] I 67-72,idem x2, . 
add(3)(q I O),-mar2,-mar5, +6-17mar[ cp3] 
2b lung no 40,X-Y,add( I )( q2 1 ),add(3)(p22),-6,der(7)t(7 ;?;9)( q32;?;q 1 3  ), 
metastasis add(8)(q24},?add(8)(pl l },-9,-9,-IO, add( l l }(pl5), 
der( l l }t( l l ;?;l2}(pl l ;?;ql 5),-12,-1 3,add( l5)(q22},· 16, 
del(l 6)(p l2), - 1 7,- 1 7,- 1 8,add(l8)(q23),-19,-20,-2 1 ,+22, 
+de1(22)(ql 2),+der(?)t(?;l}(?;q25),+r,+marl ,+mar2, +mar3, 
+mar4[ cp2]/66-79,idemx2,-22,-r,-mar3,-mar4,-mar4[ cp5] 
/143,idemx4,-mar2x4,-mar3x3, mar4x4[ I ]/46,XY[2] 
3 52/F mediastinum yes 42-46,XX,t( I ;  1 7}(q25;q 1 2)[ cp2] 
4 32/F right thigh no 67-73,X,-X,der(X)t(X;?;9)(q 1 1  ;?;q 12),der( I )t( I ;  15)(p 1 3;q 15), 
+der( I )t( I ;  15)(p 13;q 15),+2,-3, add(3)(q25),+der(4;6)(p I O;p I 0), 
de1(6)(p22p24),+5,-6,-6,+ 7 ,+8,+add(8)(p23),-9,-inv(9) (p 1 1  q 13)c, 
der(9)t(9;9)(p2 1 ;ql 3},-10,+ IO,- l l ,- 1 2,der(l 2)t(4; 12)(ql l ;pi ! ), 
dic( l2;22}(pl l ;q I0),-13,-14,- 1 5,-1 5,add(l 5}(pl l },-1 6, 
add(l 6)(q l l ), - 1 7, - 1 8,+1 8,-1 9,der( l 9)t( l 7; 1 9) (ql2;ql3 .4),-20,-
20, +21 ,+22,+der(?)t(?; l4)(?;ql l ),+rl ,+r2,+1 -7mar[cp l0] 
/46,XX,inv(9)(p l l ql3)c[l]  
5 62/F right axilla no 54-6 1 ,X,+ X,Y,+der(l ;S)(q I O;q I O),+der( I ;  14)(p 13;q 1 1  ),+add(2)(q 
l l )x2,+3,+add(3)(ql l },+der(3)t(3; 14)(ql ?2;ql l ), +4, 
+?add( 4 )( q 1 1  ), +5,+5,+add(7)( q36)x2,+add(7)( q36)x2, 
+der(7)de1(7)(p 15p21 )del(7)(q l l . l q2 1  )x2,+add(8)(p 1 1  ), 
+add(8)(p2? I ),der(9)t(9;?; 1 5)(p2 1 ;?;q 1 1  ),der(9)t(9;?; 15) 
(p2 1 ;?;ql l),- 12,- 12,der( l2)t(7; 12)(q?2 1q?l l }x2,- 13, 
dup( l3)(ql2q34)x2,-14,- 14,i(l4)(ql0),- 15,-1 5,der(l 6}t(5; 16) 
(q l5;pl 3)x2,-1 7,-1 7,+psudic(l 8; 1 2)(pl l .3;pl l .2)x2, 
+r( l9)(pl 3;ql 3),+2r, 2-3dmin[cp l0] 
6 53/M interthora- yes 65-70,XY ,-X, add( I )(p22),add( I)( q21 ),-3,-4,-4,-
coscapular 4,add(5)(q l l ),+add(5)(ql l ),der(6)add(6)(p22) idic(6)(ql 4), 
+ 7,+i(7)(p I 0},-8,-8,-9,der(9)t( 4;9)(q 12;p24)x2,-l 0,-1 1 ,- l l ,+ 13, 
- 14, add( l5) (q25),-1 7,-1 8,-19,add(l 9}(p l3},-20, 
der(20)t( I ;20)(q25;q 1 3),-2 1 ,+der(?}t(2;?;8)(p 1 1  ;?;q 13), 
+der(?)t(?;S)(?;q 1 3),+marl ,+mar2x5 [ cp9] 
7 25/F* neck yes 59-72,X,-X,add(X)(q23),-l ,add( I )(p 1 1  ),add( I }(p23), 
del(l )(q2 l ),der( l )t( l ;22)(p 13;ql l }, add(2)(q2 l },add(2)(q3 1 ), 
+del(2)(q 14-q2 1 },+3,-4,-4,-4,+5,der(6)t(6; 1 7)(pl l ;q21), 
+der( 6)t( 6; 1 7)(p 1 1  ;q2 1 ), +add(7)(p22)x2, +add(S)(p 1 1  },+i(8)( q I 0), 
+der(9)t( I ;9)(q 12;p 1 3),-1 O,add( I O)(p 12),+add( I O)(p 1 2),- 1 1 ,  
der(l 2}t( 4; 1 2)(q 13;p 1 2),+der(1 2)t( 4; 1 2)(q 13;p 1 2),+ 1 3,- 14,-14, 
+15, +15,+add( l6)(q23),·1 7,-1 7,+1 8,·19,-20,add(20)(pl2},-2 1 ,  
-2 1 ,-22,-22,-22, +der(?)tF; I )(?;e22),+ l -5mar[ cel l J 
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Figure 1 chromosomal regions 
95% confidence intervals of the change in chromosomal material in the 86 chromosomal regions after computer assisted 
cytogenetic analysis ofall 37 MPNSTs with a complete karyotype 
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Breakpoints: 
Fifty-one percent of the tumors had breakpoints in l p  and in 39% in l q. A 
notable percentage of the MPNSTs had breakpoints in 7p, 9p, 1 7q and 22q (33%, 
39%, 29% and 29%, respectively). The total number of breakpoints per chromosome 
arm varied from 0 to 32 (median: 9). There were no chromosome arms with a 
statistically significant high amount of breakpoints. In 1 p, 1 q, 7p, 9p, 17q and 22q 
the mean number of breakpoints was relatively high (Fig. 2). Most involved 
breakpoints were: 1p13  ( 1 8% of the tumors), 1 q2 1 ( 1 0%), 7p22 ( 1 8%), 9p 1 1  ( 12%), 
1 7q1 1 ( 14%), 22q l l ( 14%). 
NF-1 associated versus sporadic MPNSTs 
When the group ofNF-1 associated MPNSTs (n = 1 7) was compared with the 
sporadic MPNSTs (n = 1 1) a notable (but not statistically significant) difference was 
found in chromosomal regions l p3, 4p 1 ,  15p l -q 1 ,  2 lp l -q2 (Fig. 3). Relative loss of 
chromosomal material in NF- 1 associated MPNSTs as compared to sporadic 
MPNSTs was found in 1p3,  4p l ,  2 lp l -q2. Relative loss of chromosomal material in 
sporadic MPNSTs as compared to NF-1 associated MPNSTs was noticed in 1 5p1-
q 1 .  Shared chromosomal loss was found in chromosomes 9 ,  1 1 , 1 7, 1 8, 19, 20  and Y 
as well as in 14p 1 .  Shared gain was observed in chromosome 7. 
Differences in breakpoints between the NF -1 associated and the sporadic 
MPNSTs were observed in l p, 8p and 1 7q (Fig. 4). Mean number of breakpoints per 
tumor in lp  was 0.82 for NF- 1 associated MPNSTs and 0.43 for sporadic MPNSTs, 
whereas these amounts were 0.07 and 0.43 for 8p and 0.43 and 0.07 for 17q, 
respectively. Breakpoints in lp2 1 -22 were found in 29% (8/28) of the NF-1 
associated tumors and in none (0/14) of the sporadic MPNSTs. Other frequently 
involved breakpoint regions differing between both groups were: l p32-34 (in 1 8% of 
the NF- 1 MPNSTs and in none of the sporadic MPNSTs), 8p l l- 12  (in 7% of the 
NF- 1 MPNSTs and in 29% of the sporadic MPNSTs), 1 7q l 0- 12  (25% of the NF-1 
associated MPNSTs and in 7% of the sporadic MPNSTs). An equal amount of 
breakpoints was observed in l q  (mean number of breakpoints per tumor: 0.54 in the 
NF-1 associated MPNSTs group and 0.50 in the sporadic MPNSTs group), 9p (0.36 
and 0.29, respectively) and 12p (0.29 and 0. 2 1 ,  respectively). 
DISCUSSION 
Cytogenetic analysis has proven to be an important tool in the detection of 
tumor specific alterations in the human genome 4649• This has been achieved by the 
karyotypic analysis of high numbers of tumors in which recurrent chromosomal 
alterations appeared to be related to the formation of an oncogene or the deletion of a 
functional tumor suppressor gene. This resulted in the detection of genes which either 
may be characteristic for a tumor type or may be involved in cell proliferation in 
general so.sl. It is difficult to ascertain whether a recurrent chromosomal anomaly is 
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footprint. Especially complex karyotypes of solid tumors can be difficult to relate to 
the process of oncogenesis because of the amount of chromosomal abnormalities 
which may all be of certain importance. Therefore, the analysis of high numbers of 
tumors is of utmost importance. The next step is to directly compare all the 
chromosomal alterations in different groups of tumors e.g. primary tumors and 
metastases. However, most of the published studies presented karyotypes in such a 
way that even shared chromosomal alterations are difficult to detect. A few studies 
visualized the information of karyotypes in graphics or transformed the cytogenetic 
information in such a way that statistical analysis was possible, although a lot of 
cytogenetic information could not be used in this way or a direct comparison was not 
possible 77•378•379• This problem of interpreting and comparing different tumor groups 
was the reason for the construction of the database which was used in this study. 
Since all karyotypes are interpreted and entered into this database uniformly, this 
computer assisted approach allows the direct comparison of specific tumor groups. 
This direct comparison of cytogenetic data and the visualization in so called 
karyographs makes it easier to interpret the differences between groups of tumors. 
Furthermore, it is possible to select those tumors with a specific structural 
rearrangement or in which specific breakpoints are involved and combine them with 
other databases in which, for instance, treatment response or survival data are logged. 
This way of analysis can not be a replacement of conventional cytogenetic analysis, 
since it is only a tool to combine various cytogenetic and other data into a more 
accessible collection of information after the interpretation of the karyotypes. This 
results in loss of cytogenetically derived information, since all karyotypes are forced 
to be transformed into a uniformly created set of data. Especially, problems arise 
when interpreting and transforming composition karyotypes in which reported 
chromosomal abnormalities can be conflicting i.e. both loss and gain of a 
chromosome l can be described in one composition karyotype. In these exceptional 
cases, it was decided to interpret these abnormalities as no change in chromosomal 
material, since these changes, resulting in gain of chromosomes in one tumor cell or 
clone and a loss in another within the same tumor, are most likely not the hallmarks 
in the oncogenetic process. Furthermore, one has to consider the differences in 
cytogenetic nomenclature which have emerged during the last decades, when 
cytogenetic studies of uncommon solid tumors are interpreted. Although structural 
abnormalities and the number of marker chromosomes are entered into the database, 
the marker chromosomes themselves can not be included in the analysis of over- and 
underrepresentation of chromosomal material. 
This method of computer assisted cytogenetic analysis gives the opportunity 
to expand the understanding of the cytogenetic anomalies of uncommon solid tumors 
by taken together all conventional cytogenetic studies of small numbers of cases and 
extract meaningful shared cytogenetic aberrations. The combination of conventional 
cytogenetic analysis used in this study together with techniques like comparative 
genomic hybridization, spectral karyotyping and multicolor fluorescence in situ 
hybridization, might detect substantial chromosomal alterations of diagnostic, 
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sporadic MPNSTs (e, black line) and 1 7  NF-1 associated MPNSTs <•. grey line) with a complete karyotype. 
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In this study, a series of 51  MPNSTs of both NF-1 patients and non-NF-1 
patients was analyzed using this computer assisted approach. Since the objective of 
this approach was to detect the most common cytogenetic abnormalities in a large 
number ofMPNSTs, it was decided to use karyotypes of primary MPNSTs as well as 
metastatic MPNSTs and tumors of which the tumor status was not clearly described. 
After interpretation of the karyotypes as reported in the literature and our own cases, 
all karyotypes were transformed and entered into the database. In this way the 
changes in chromosomal material in each of 86 previously determined chromosomal 
regions were analyzed. In most tumors the change in chromosomal material was not 
clearly confined to one region: the number of tumors with a normal amount of 
chromosomal material in each of the 86 chromosomal regions was high. If a change 
in chromosomal material was observed, the majority of tumors had loss of 
chromosomal material and this was observed in virtually all the chromosomal 
regions. 
It was found that the loss in 9p, 1 1  and 1 8, as reported in several individual 
reports, was restricted to statistically significant loss in 9p2, 1 1  p 1 ,  1 1  q2 and 1 8p 1 365• 
367•369•380• Since a lot of genes are located on these particular regions, no well 
argumented suggestion of the involved genes can be made. However, recent studies 
have shown that many genes located on 9p2 are involved in cell cycle control and 
proliferation like CDKN2A and CDKN2B encoding for p 1 6  38 1 , whereas on the 
chromosomal regions l lp l  CDKNl C  encoding for p57 is mapped 382• Very recently, 
Lothe et al. (personal communication, 1998) analyzed 1 2  MPNSTs by FISH and 
allelic imbalance studies with 9p2 1-23 markers. They found interstitial deletions that 
supported CDKN2A as a possible target gene that might contribute to the 
development of MPNSTs. The earlier reported loss of sex chromosome material was 
also observed in this study, but was not statistically significant 366•370• The reported 
alterations in 1 2p, 14q, 1 7q and 22q can not be confirmed in this analysis 
362•366•367•370•373• Both gains and losses were found in these chromosomal regions, 
leading to a balanced net result. 
Gain of chromosomal material in chromosome 7 was observed in 1 7  of the 3 7 
MPNSTs. Analyzing the change in chromosomal material of all MPNSTs, mean gain 
of chromosomal material in 7p and 7q varied between +0.42 CCR and +0.47 CCR . 
Several other studies reported gain of chromosome 7 material in MPNSTs 
363•366•370•372• The observed gain of chromosomal material was most manifest in the 7 q 1 
region on which genes like p l 9A, associated with cell cycle regulation, are mapped 
383• Further studies focusing on p l 9A and 7q l may clarify the significance of this 
region in MPNSTs. In a recent study in neurofibromas of NF - 1  patients the authors 
found multiple microsatellite alterations on chromosome 9 and concluded that 
chromosome 9 might have a role in the pathogenesis of neurofibromas 384• An earlier 
study of 10  MPNSTs using comparative genomic hybridization, showed loss of 9p as 
well 380• In our study the MPNSTs of both NF- 1 patients and patients without signs of 
NF - 1  had loss of 9p. These findings suggest that 9p alterations could be early events 
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Breakpoint analysis of  all MPNSTs did not reveal a characteristic breakpoint. 
The most involved breakpoints were lp l3  ( 1 8% of the tumors) and 7p22 ( 1 8% of 
the tumors). On 17q l l .2 the NF-1 gene has been located. Although NF-1 gene 
alterations are present in the majority of NF - 1  patients, cytogenetic loss of 1 7  q 1 1  is 
only present in 14 out of the 37 analyzed MPNSTs in this study. Breakpoints in 
1 7q1 1 were only present in 14% all MPNSTs, whereas 55% of the MPNSTs were 
derived from NF-1  patients. However, differences between the NF-1 associated and 
sporadic MPNSTs were observed in the breakpoint analysis, since breakpoints in 
17q10- 1 2  were found in 25% of the NF- 1  associated MPNSTs and in only 7% of the 
sporadic MPNSTs. Whether the observed differences between the two groups as 
found in the breakpoint analysis are relevant, has to be clarified in further studies. 
When the NF- 1  associated MPNSTs were compared to the sporadic MPNSTs, the 
same pattern of gain in chromosome 7 and loss in chromosome 9p was noticed, 
indicating a common oncogenetic pathway. Loss of chromosomal material in 1p3, 
4p l ,  2 l p l -q2 appeared to be more frequent in NF- 1 associated MPNSTs, whereas 
loss of 1 5p 1 -q I appeared to be more specific for sporadic MPNSTs. Whether the 
differences are correlated with neurofibromatosis or not has to be elucidated. The 
earlier reported gain of 17q2 in NF- 1 associated MPNSTs, detected by comparative 
genomic hybridization, could not be confirmed 380• On 22ql 2.2 the NF-2 gene is 
located and it is suggested that loss of 22 is associated with the development of a 
MPNST, but in this study no significant losses of chromosomal material involving 22 
or 22q 1 were found 362• 
In conclusion , this computer assisted approach has proven to be valuable in 
the analysis of large groups of karyotypes and can automatically detect common 
chromosomal alterations without bias caused by focusing on specific chromosomal 
abnormalities. This study did not unveil specific structural cytogenetic abnormalities, 
which could be of diagnostic importance in MPNSTs. However, the finding of a 
complex karyotype showing loss of 9p2 in combination with gain in 7q I in a tumor 
histologically resembling a MPNST, could be of diagnostic importance. This 
approach revealed indications for cytogenetic differences between NF-1 associated 
and sporadic MPNSTs in chromosomal regions l p3, 4pl ,  2 l p1-q2 and 15p l -q l .  
Additional studies, combining different cytogenetic based techniques, might detect 
differences between NF-1 associated and sporadic MPNSTs which could be helpful 
in clarifying the oncogenesis ofMPNSTs. 
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SUMMARY 
The histogenesis, oncogenesis and clinical behavior of mesenchymal tumors of 
the gastrointestinal tract are the subject of dispute, since these neoplasms may reveal 
either smooth muscle differentiation, resembling leiomyosarcomas of soft tissue 
(LMS), or neural differentiation, resembling malignant peripheral nerve sheath 
tumors (MPNST). Most of them are currently designated gastrointestinal stromal 
tumor (GIST). Previous cytogenetic studies did not clearly differentiate between 
GIST, LMS and MPNST. In this study, a computer assisted method of direct 
cytogenetic comparison was used to discover tumor specific chromosomal patterns in 
16 gastrointestinal mesenchymal tumors ("GIST'') and 14 LMS and 3 7 MPNST of 
soft tissue obtained from the literature and from our own data. In "GIST" a 
statistically significant loss was observed in chromosomal regions 13q2-q3, 14p1-
14q2, 18p1-18q2, 22p1 and 22q1. In LMS the chromosomal changes did not reach 
statistical significance. However, important loss was found in 5p1, 14p1 and of 
chromosome 22, whereas gain was observed of chromosome X In MPNST a 
significant loss of chromosomal material was detected in 9p2, l lp1, l lq2 and 18p1, 
as well as important loss in 22q; a significant gain was noticed in the 7q1 region. 
Breakpoint analysis revealed differences between "GIST" and LMS in 1 p, 7p, 9q and 
14. Differences in breakpoints between the "GIST" and MPNST were observed in 1 q, 
7q, 9 and 12. This cytogenetic me/a-analysis supports the hypothesis that "GIST" is a 
distinct entity which differs from LMS and MPNST and is characterized by losses in 
13q2-q3, 14p1-q2. However, the shared loss of chromosome 22 in "GIST", LMS and 
MPNST, might be indicative for a common oncogenetic pathway, whereas gain of 
7ql and loss of 18pl-q2 seems to be more associated with neural differentiation in 
MPNST and "GIST". 
INTRODUCTION 
Tumors of mesenchymal origin with features of smooth muscle differentiation 
may originate from various anatomic sites, i.e. the soft tissue, the uterus and the 
gastrointestinal tract. Leiomyosarcomas of soft tissue (LMS) account for 
approximately 1 0% of all soft tissue sarcomas and predominantly arise in the 
mesenchymal tissues of the extremities, the skin and the retroperitoneum 8• 
Mesenchymal tumors of the gastrointestinal tract may have ultrastructural and 
immunohistochemical characteristics consistent with smooth muscle differentiation 
and these have in the past been referred to as LMS of the digestive tract. However, 
the histogenesis and oncogenesis of these tumors are the subject of dispute, since 
they may have features not only of smooth muscle differentiation, resembling LMS, 
but also of neural differentiation, resembling malignant peripheral nerve sheath 
tumors (MPNST) 307•385•388• Mesenchymal tumors of the gastrointestinal tract now are 
collectively designated gastrointestinal stromal turnors (GIST) and are assumed to 
arise from interstitial cells of Cajal, to express CD34 and C-kit protein and to have 
1 38  
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mutations in the C-kit gene 307•309•3 15•327•389• Clinical outcome in GIST, LMS and 
MPNST is closely related to the presence of metastatic disease, which may require 
chemotherapeutic treatment. Chemotherapeutic studies report very poor responses in 
LMS, but do not clearly differentiate between metastatic soft tissue LMS or 
metastatic GIST 87, 142,285,286,320. 
Cytogenetic studies have revealed characteristic chromosomal alterations in 
various histologic types of soft tissue sarcomas 49•53• 162•390• However, cytogenetic 
analyses in "smooth muscle" neoplasms have mainly been performed in uterine 
smooth muscle tumors and cytogenetics in "leiomyosarcomas" did not clearly 
discriminate between GIST and soft tissue LMS. Consequently, the findings of 
monosomy 1 ,  9, 1 8  and 22 as well as the chromosomal changes in 1 p l 3  observed in 
groups consisting of both LMS of the soft tissue and of the gastrointestinal tract have 
to be interpreted with caution 391 •392• In cytogenetic studies on mesenchymal tumors 
of the gastrointestinal tract, losses of chromosomes 14, 15 ,  1 8  and 22 were observed 
393•395• Comparative genomic hybridization revealed losses in 14q, 1 5  and 22 as well 
as gains in 3q, 5p, 8q, 1 7q and 19q but could not detect frequently involved 
breakpoints 39&-398• 
In order to compare complex karyotypes of different groups of tumors, we 
recently developed a computer assisted approach, with which the pattern of 
chromosomal change and the presence of frequently involved breakpoints can be 
evaluated 399• In the current study this method was used to compare mesenchymal 
tumors of the gastrointestinal tract with LMS and MPNST of the soft tissue in an 
attempt to discover common and specific chromosomal changes in these groups. 
MATERIALS AND METHODS 
Patients and cytogenetic data 
Twelve cases were diagnosed and cytogenetically analyzed in our institute. A 
histological diagnosis was made according to the criteria described by Enzinger and 
Weiss 8for soft 'tissue tumors and according to Suster 307 for GIST. A cytogenetic 
analysis of all specimens was carried out according to standard procedures. The 
karyotypes were described according to the ISCN 1995 Guidelines for Cancer 377• 
Eight cases ( 1  LMS and 7 MPNST of soft tissue) were previously published 53•399 • A 
summary of the clinical, histopathological and cytogenetic data of the 4 other cases is 
presented in Table 1 .  
Fifty-five cases with abnormal karyotypes were retrieved from the literature 
using Medline®, i.e. 1 5  cases of GIST or LMS of the digestive tract, 1 0  cases of soft 
tissue LMS and 30 of soft tissue MPNST 49,53,363-37 1 ,374,39 1 -393,395,400-405. 
All cases had a complete karyotype description according to the ISCN '95 377. 
The analyzed group thus consisted of 67 cases. Since cases described in the 
older literature as LMS of the gastrointestinal tract presumably include GIST, all 
gastrointestinal mesenchymal tumors were grouped together in a group designated 
"GIST". This consisted of 8 males and 8 females ranging in age from 46 to 83 years 
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(mean: 5 9  years, median: 5 6  years). The soft tissue LMS group consisted of 4 female 
and 10  male patients ranging in age from 29 to 79 years (mean: 54 years; median: 50 
years). One study did not report the age of a male patient with a LMS 392• In the 
MPNST group there were 20 male patients and 17  female patients ranging in age 
from 2 to 82 (mean: 39 years, median: 33 years). There were 38 primary tumors (5 
"GIST", 6 LMS, 27 MPNST), 1 0  local recurrences (6 "GIST", 3 LMS, l MPNST) 
and 3 distant metastases ( 1  LMS, 2 MPNST). In 16  cases (5 "GIST", 4 LMS, 7 
MPNST) the tumor status was unclear. If more than one tumor per patient was 
described, it was decided to use the karyotype of one tumor, preferentially the 
primary tumor, to avoid overrepresentation. 
Computer assisted comparison 
A database was constructed using dBase V Windows and consisted of four 
main parts related to the described karyotype: 1 )  the patient data and histological data 
of the tumor, 2) the gain and loss of chromosomal material, 3) the breakpoints per 
chromosome arm, and 4) the structural rearrangements. After interpretation of the 
karyotype, the gains and losses of chromosomal material were entered. Each 
chromosome was divided according to the ideogram at 400 bands level as described 
by the ISCN, in such a way that net gains and losses in l p l l -p 1 3  were summarized 
in l p l ,  l p2 1 -22 was summarized in lp2, etc. In case of (net) loss in these parts of 
one of the chromosomes a - 1  was entered. If the same parts were lost in two 
chromosomes a -2 was entered. Similarly, if (net) gain occurred in one of these 
chromosomal parts a + 1 was entered, etc. Only changes as compared to the 
constitutional karyotype were evaluated. Uncertain breakpoints, structural 
rearrangements and/or chromosomes were not included in this analysis. If multiple 
clones were described, the changes were combined and averaged to obtain a tumor 
representative karyotype. In this way the changes in 86 chromosomal regions per 
karyotype were recorded. All structural rearrangements were categorized per type of 
structural chromosome rearrangement (according to the ISCN). Microsoft Excel 5 .0a 
Windows was used to transform the gains and losses of chromosomal material of all 
non-diploid kaiyotypes to diploid karyotypes. Before this diploidization, the changes 
in the chromosomal material of the X-chromosome of men were multiplied by 2 in 
order to compare male with female karyotypes. 
The mean change in chromosomal material per chromosomal region as well as 
the total and mean number of breakpoints per chromosome arm were calculated. 
Mean change in chromosomal material in each of the 86 chromosomal regions is 
expressed as a chromosomal change ratio (CCR) which is defined as the absolute 
change in a specific chromosomal region as compared to a normal diploid karyotype, 
e.g. if both chromosomes 1 of all analyzed tumors are lost, the mean change in the 
specific chromosomal regions l p l , l p2, l p3, l q l , l q2, l q3 and l q4 is: -2.00 CCR in 
each of the regions. Only full, abnormal karyotypes were used for the analysis of the 
over- or underrepresentation of chromosomes or chromosomal material. Graphs were 
constructed using Microsoft Excel 5.0a Windows to visualize the change in 
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chromosomal material, the amount of breakpoints per chromosome arm and the 
differences between selected groups, i.e. "GIST" and LMS of soft tissue. 
Table 1. 
Previous}� un2ublished cX!ogenetic data of I GIST and 3 LMS anal�zed at our institute*. 
case Sex I age diagnosis ka!Yotype 
F I 55 GIST - PT, 1 1 7-129,XX,der(X; 19)t(X;?; 1 9)(p22;?;q 13)x3,+der(X; 19)(X; 
stomach ?; 19)(p22;?;q 13),- 1 ,add( 1 )( q42),de1(1 )( q41 ),-2, 
der(2)t(2;?;7)(p25;?;p 13),-3, add(3)(q2?5), add(4)(q 1 ?2)x3, 
+del(4)(p 1 1  or 12)x2,add(5)(q 1 1  ),add(5)(q 1 ? l ), del(5)(p I 0), 
del(5)(p 1 1 or12)x2, +del (5)(p1 O),+i(5)(p1 0)x4, ?6, 
add(6)(q 12), del(6)(q 1 1  )x2,+del(6)(q 1 1 ),add(7)(p22), 
+add(7)(p22),+der(7)add(7)(p22)add(7)( q 1 1 .2), +i(7)(p 1 0),-8, 
del(8)(p 1 1 . 1  ),?del(8)( q21 ),+?del(8)( q21 )x2,del(9)( q21 )x2, 
del(9) (p13 or p21), +?der(9)de1(9)(p2 1 )dic(9; 1 9)(q34;q1 3), 
+dup(9)(q34q 12),+i(9)(q 1 0),- 10,- 1 0,- 10,- 10,-1 0,- 1 1 ,- 1 1 ,-12, 
del(12)(p 1 1 .2)x2, del( 12)(p 1 1 . 1  ),+?del(12)(q 13),- 1 3,-13,-14, 
- 14,- 14,add( 14)(p 1 1  ),-1 5,-1 5,-1 5,-1 6,-16,add( 16)(p 1 3)x3, - 17, 
-1 7,de1(1 7)(p1 1 ),-1 8,? 18), 
der(1 8)(?:: 14q21-+14q32: : 18p 1 1-+18qter), add(1 8)(q23)x2, 
- 19,- 19,-19,+20,+20,+add(20)(q 1 3.3)x2,-2 1 ,-2 1 ,?2 1 ,?21 ,?2 1 ,  
-22,?del(22)(q13)x3, +mar1x2,+mar2x2, +mar3x2, 
+mar4,+mar5,+mar6 [cp6] 
2 M / 59 LMS - PT, left 41-43,XY,add( 1 )(p32),der(1 )t(?X; 1 )(p 1 1  ;p 13),-5, 
trapezius muscle ?add(6)(p2 1 ),-1 O,add( 13)(p 1 1  ),+ 14,dic( 14; 14)(p 13 ;p 13), 
-22[ cp4]/46,XY[9] 
3 F I 40 LMS - local 4 7 ,XX,+ 2[ 4]/9 1-92,add(9)( q2 1 ),add(22)( q 13)x2[ cp5] 
recurrence,left 
knee 
4 F / 62 LMS - meta, 46,X,inv(X)(p 1 1  q27),t( 1 ;3)( q 12;p24 )or( q21  ;p25)[ 4 ]/46,XX, 
thoracic wall inv( 1 )(p36q23),t(2; 1 O)(q 14-2 1 ;p 1 1 .2)[ 4]/47 ,XX,+8[5]/46,XX 
10 
GIST: malignant gastrointestina1 stromal tumor; LMS: leiomyosarcoma of deep soft tissue; PT: primary 
tumor; meta: distant metastasis; *Previously published karyotypes are described in the studies of 
Molenaar et al. ( 1 989) and P1aat et a/.( 1999). 
Statistics 
As an overall test whether the differences in amount of chromosomal material 
for each chromosomal region and the number of breakpoints between "GIST" and 
LMS were statistically significant, an analysis of variance was performed where the 
statistical interaction between the chromosomal position x tumor type was calculated. 
The calculations were made on the residuals after adjusting for person differences in 
amount of chromosomal material. Systat 5 . 1  and 6.0 for Windows were used for 
calculation. A p-value <0.05 was considered statistically significant. To identify 
chromosomal regions with significant gains or losses, 95% confidence intervals (Cl) 
were calculated. To avoid the introduction of significant-appearing associations by 
14 1 
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chance and to address the problem of  multiple comparison, the significance level of 
0.05 was adjusted downwards. The number of tests performed is 86. The tests are 
however statistically dependent, because deletions apply to several chromosomal 
segments. Therefore a Bonferroni correction factor of 86 is conservative. A mean 
number of breakpoints in each chromosome arm > 3 . 1  SD was considered to be 
significant reflecting a probability threshold of 0. 1 .  
RESULTS 
"GIST" : change in chromosomal material per chromosomal region (Fig. 1): 
Construction of 95% Cl revealed significant loss, expressed as chromosomal 
change ratio (CCR), of chromosomal material in the chromosomal regions 1 3q2-q3 (-
0.4 1 ,  -0.48 CCR), 14pl - 14q2 (-0.66, -0.53, -0.55, -0.55 CCR), 1 8p l -q2 (-0.40, -0.40, 
-0.46 CCR), 22p l (-0.76 CCR), 22ql (-0.73 CCR). A statistically significant gain of 
chromosomal material was not observed. Notable gain was observed in 5p 1 and of 
chromosomes 7 and 20. 
LMS: change in chromosomal material per chromosomal region (Fig. 2): 
After construction of 95% Cl, no chromosomal region with significant loss or 
gain could be identified. Although not statistically significant, there was a notable 
loss in 5p l ,  14p l  and chromosome 22. A notable gain was observed in 8ql -q2 (with 
very wide Cl) and chromosome X. 
MPNST: change in chromosomal material per chromosomal region (Fig. 3): 
Construction of 95% Cl showed significant loss of chromosomal material in 
the chromosomal regions 9p2 (-0.64 CCR), l lp l  (-0.27 CCR), l lq2 (-0.32 CCR) 
and 1 8p l (-0.34). Although not statistically significant, there was also notable loss in 
lp3, 9p l ,  l lq l ,  12q2, 1 3p l ,  14p l ,  1 7p l ,  1 8q l -q2, 1 9p 1 ,  22q1 ,  X and Y. A 
statistically significant gain of chromosomal material was observed in the 7 q 1 region 
( +0.42 CCR), whereas a notable gain was observed in all regions of chromosome 7. 
"GIST" compared to LMS and MPNST (Fig. 4): 
Statistically significant differences (P<0.00 1 )  between the three groups were 
observed regarding the variance of the gain or loss of chromosomal material. 
However, it was not possible to confine these differences between the groups to 
specific chromosomal regions. Therefore, the differences between "GIST" (n=16) 
and LMS (n = 14) as found in chromosomal regions 5p l ,  7p, 14q and 15  were 
considered meaningful, but not statistically significant. Relative loss of chromosomal 
material in "GIST" as compared to LMS was found in 8ql -q2, 1 0q l -q2 and 
chromosomes 13 ,  14, 15 ,  1 8, 22 and X. Relative loss of chromosomal material in 
LMS as compared to "GIST" was noticed in Sp 1 and 7p 1 -p 1 .  Shared loss was found 
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Figure 1 
95% confidence intervals of the change in chromosomal material (CCR) in the 86 chromosomal regions after computer assisted 
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When "GIST" (n=1 6) were compared with MPNST (n = 37) notable (but not 
statistically significant) differences, with a relative loss in "GIST", were found in 
chromosomal regions 2p2, 8q1 -q2, 14q1 -q2, 15p1-q2 and 22. A relative gain of 
chromosomal material in "GIST" was observed in 12q 1 -q2, 16q1-q2, 1 7p 1 ,  19  and 
20. In both groups there were losses in 1p 1 -p3, 9p2 (more pronounced in MPNST) 
and 1 3p l .  Furthermore, in both groups there were losses in 14p 1  and 22q1 ,  although 
these were more pronounced in "GIST". Gain of 7p 1 -7q3 was observed in both 
"GIST" and MPNST. 
Breakpoints in "GIST" compared to LMS and MPNST (Fig. 5): 
Differences in number of breakpoints between the "GIST" and LMS were 
observed in 1 p, 7p, 9q and 14p. Mean numbers of breakpoints per tumor are shown 
in Table 2. An equal amount of breakpoints in "GIST" and LMS was observed in 1q, 
Sp and 1 1q. The breakpoints in these chromosome arms were not clustered at a 
specific band. Differences in number of breakpoints between "GIST" and MPNST 
were observed in 1q, 7q, 9p, 9q, 12p, 12q, 14q, 17q and 22q. An equal amount of 
breakpoints was observed in 1p, 7p and 1 1q. The breakpoints in these chromosome 
arms were not clustered at a specific band. 
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"GIST": malignant gastrointestinal stromal tumor; LMS: leiomyosarcoma of deep soft tissue; 
MPNST: malignant peripheral nerve sheath tumor 
As shown in Table 3, 1 p 1 1 - 13  was the most involved breakpoint region in 
both "GIST" (3 1%) and LMS (2 1%). In MPNST, 1p1 1 - 1 3  was affected in 19% ofthe 
cases, whereas 43% of the MPNST had a breakpoint in 9p1 1 -22. The 9p1 1 -22 region 
was involved in one "GIST" and one LMS. Breakpoints in 1 p32-36 were detected in 
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Figure 2 
95% confidence intervals of the change in chromosomal material (CCR) in the 86 chromosomal regions in 14 LMS . 
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Table 3. Percentage oftumors with breakpoints in frequently involved chromosomal regions 
Chromosomal region "GIST" (n=16) LMS (n=14) MPNST (n=37) 
1p1 1- 13  31 % 21 % 19 % 
1p32-36 6 %  14 % 22 % 
1q21-22 6 %  7 %  19 % 
7p22 6 % 0 % 16  % 
9p1 1-22 6 %  7 %  43 % 
1 1q13-21 6 %  7 %  14 % 
17q1 1 0 %  7 %  14 % 
22g 1 1  0 % 0 % 1 1  % 
"GIST": malignant gastrointestinal stromal tumor; LMS: leiomyosarcoma of deep soft tissue; 
MPNST: malignant peripheral nerve sheath tumor 
DISCUSSION 
Previous cytogenetic studies have described chromosomal changes in LMS, 
but did not distinguish between soft tissue, gastrointestinal and uterine tumors 
49,53,391-393,395,400-405. The same holds for clinical studies which reported a 
high level of drug resistance among LMS 87• 142•285•286•320• However, this distinction by 
site may be clinically relevant. Moreover, evidence now accumulates that most, if not 
all, mesenchymal tumors of the gastrointestinal tract are derived from interstitial cells 
of Cajal and are thus histogenetically different from soft tissue LMS which are 
derived from smooth muscle cells 8•3 1 9•327.4°6•407• Histopathologically, mesenchymal 
tumors of the gastrointestinal tract may not only have features of smooth muscle 
cells, but also neural features 307• This leads to the concept that gastrointestinal 
mesenchymal tumors have a common progenitor cell, but nevertheless show 
divergent phenotypic differentiation. The current study aimed at differentiating 
between cytogenetic changes 'characteristic' for gastrointestinal mesenchymal 
tumors, independent of their phenotype, and those that they share with soft tissue 
LMS and MPNST. Therefore, a computer assisted cytogenetic analysis was done, 
comparing cytogenetic changes in mesenchymal tumors of the gastrointestinal tract 
("GIST"), irrespective of their initial histopathologic classification, with those in 
LMS and MPNST of soft tissue, combining own data with data retrieved from the 
literature. 
The use of a cytogenetic database in which all karyotypes and other 
cytogenetic, clinical and histological data are uniformly entered, makes it possible to 
directly compare and statistically analyze different groups of (already cytogenetically 
analyzed) tumors, i.e. "GIST", LMS and MPNST without the bias caused by 
focusing on specific chromosomal abnormalities. Since the objective of this approach 
was to detect the most common cytogenetic abnormalities in "GIST", LMS and 
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tumors as well as metastatic tumors and tumors of which the tumor status was not 
clearly described. However, only one entry per patient was analyzed. 
This computer assisted cytogenetic meta-analysis evaluates only major effects, 
since statistical significance could not be reached in the comparison of the three 
groups due to the relatively small numbers of cases. Nevertheless it has revealed 
further indications that "GIST" and LMS are different entities. This study did not 
only restrict the losses in chromosomes 14, 1 8  and 22 as reported in several 
individual reports on "GIST", to statistically significant loss in 14p 1 -q2, 1 8q2 and 
22p l -q 1 ,  but also revealed significant loss in 13q2-q3 3 17•393-398• The reported loss of 
chromosome 15 was confirmed in this study, although it was not statistically 
significant 395-397• The observed changes in the 1 3p, 14p and 1 5p have to be 
interpreted with caution, since chromosomes 13 ,  14 and 1 5  are acrocentric 
chromosomes. However, this database supported method detects changes in these 
regions. This indicates the involvement of these particular chromosomes in a 
substantial number of structural chromosomal aberrations resulting in a partial loss of 
these chromosomes, including the p-arm. Loss of the entire chromosomes 14 and 22 
might be involved in the oncogenetic processes leading to the development of 
"GIST". Many genes are located on these chromosomes, 
like CDKN3 ( 14q22), a regulator of the cell cycle, and EWSR1 (22q12), associated 
with several malignant mesenchymal tumors, i.e. Ewing's sarcomas and related 
tumors 3 17•383•408• Further investigations like the recent studies of El Rifai et al. have to 
narrow the region of interest in "GIST" 3 17•396•397• Also the loss of genes on 18q2 and 
13q2-q3 might be involved in "GIST" formation. The reported amplifications in 3q2, 
5p, 8q2, 1 7  q2, 19q 1 could only be confirmed in this study for 5p 1 396•398• 
Amplification of 5p 1 mapped genes like TER T, which is correlated with telomerase 
activity in various malignancies, might also be involved in the development of 
"GIST" 409• The expression of the c-kit protein, encoded by the c-kit proto-oncogene 
localized on chromosome 4q12, is highly specific for GIST 389• Although some 
cytogenetically detected loss in the 4q 1 region was observed in "GIST", these 
changes were not statistically significant. Further studies have to analyze the relation 
between c-kit protein expression and ( cyto )genetic alterations in 4q 1 2. Losses in 14 
and 22 were observed in "GIST", LMS and MPNST, but were not statistically 
significant in LMS and MPNST and therefore have no clear diagnostic value. The 
shared losses might eventually indicate a common pathway in the development of 
these tumors. 
Differences between "GIST" and LMS, which might indicate a different 
oncogenesis, were found in the 5p 1 region, i.e.gain in "GIST" and loss in LMS. 
Furthermore, 14q was lost in "GIST", but there was a tendency for gain in LMS and 
the X chromosome material was amplified in LMS, but not in "GIST". Loss of 14q2, 
however, was also observed in uterine LMS and might suggest a closer relation 
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Figure 4 
A schematic overview of the mean change in chromosomal material (CCR) in the 86 chromosomal regions: comparison 
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Although there are no strong indications, it should be noted that chromosomal 
aberrations in 14q have also been described in colorectal cancer suggesting that 14q 
anomalies could also be related to the gastrointestinal localization of these tumors 41 7• 
4 19• Although the gain in 8q1 -q2 was mainly due to one case, as is represented by the 
very wide 95% Cl, amplification of 8q was recently reported in a study assessing 
LMS using comparative genomic hybridization 420• Since no specific breakpoints and 
chromosomal gains or losses could be detected in the LMS, the results of earlier 
studies suggesting involvement of certain chromosomal aberrations specific for LMS 
could not be confirmed 391 •392• The earlier reported involvement of breakpoints in the 
1p l 2- 13 , involving the oncogene N-ras on l p l3 .2, was also detected in this study as 
the most involved breakpoint region in both "GIST" and LMS 392.4°2.42 1 • However, the 
finding that this region was only present in 3 1 %  of the "GIST" and 2 1 %  of the LMS, 
weakens the theory that this cytogenetically detected breakpoint could be 
characteristic for the oncogenetic processes of these tumors. 
In an earlier study in MPNST, we reported losses in 9p2, l lp l ,  l lq2, 14p l ,  
1 8p 1 -q2, 22q 1 ,  X and Y and gain in the 7q1 region 399• Differences between MPNST 
and "GIST", which might have some diagnostic value, were detected in 2p2, 12q1 -
q2, 1 5p 1 -q2, 16q1 -q2, 1 7p l ,  19  and 20. In this study similarities in the chromosomal 
change pattern, indicating a common oncogenetic pathway or neural differentiation 
of "GIST" and MPNST, were observed in 1p1 -p3, 9p2, l 3 p 1 ,  1 8p 1 -q2 (loss) and 
chromosome 7 (gain). No specific differences or similarities in breakpoints could be 
observed in "GIST" and MPNST, although the cytogenetically detected breakpoint 
region 9p 1 1 -22 was involved in 43% of the MPNST and in only 6% of the "GIST". 
Together with the observed loss in 9p2 in MPNST, it can be assumed that genes 
located on 9p2, like CDKN2A and CDKN2B encoding for p 1 6, might be more 
affected in MPNST than in "GIST" 38 1 • 
In conclusion, the results of this study support the hypothesis that "GIST" is a 
distinct entity which differs from LMS and MPNST. In "GIST" a significant loss is 
found in l 3q2-q3, 14p l -q2, 1 8p l -q2 and 22p l -q l ,  whereas gain of chromosome X 
seems to be involved predominantly in LMS. MPNST are characterized by gain of 
chromosome 7 ·and losses in 9p2, l lp l ,  l lq2 and 1 8p l .  However, in "GIST", LMS 
as well as in MPNST losses of chromosomes 22 are observed, indicating a common 
oncogenetic pathway. Gain of 7q l and loss of 1 8q may be more associated with 
neural differentiation in MPNST and "GIST". Further studies, comparing cytogenetic 
changes with phenotype in GIST are warranted, as well as molecular studies further 
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The mean number of breakpoints per tumor in each of the chromosome arms in 16 "GIST" (dark grey bars) compared to 14  LMS 
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SUMMARY 
A case of a two-year-old boy with a palpable mass in the left thigh is presented. 
Incisional biopsy was performed and subsequent histopathological examination 
revealed an infiltrative tumor composed of relatively large cells. The tumor cells 
were immunoreactive for vimentin and keratin, but not for des m in or smooth muscle 
actin. Cytogenetic analysis showed a 46,XY,t(J 1;22)(q24;q1 2) karyotype. The 
translocation (11;22)(q24;q12) is said to be characteristic for the family of Ewing's 
sarcoma and related tumors. As a result of the t(JJ;22)(q24;q12) the EWS gene on 
chromosome 22q12 joins the 3 '  part of FLI-1 gene on chromosome llq24, which 
encodes a member of the ets family of transcriptional regulators. Using RT-PCR a 
corresponding EWS-FLI-1 fusion product was detected. Additional immunohistologi­
cal staining for p30/p32M1c2, which is suggestive, but not specific for Ewing's 
sarcoma, appeared to be weakly positive. In the current case a diagnosis of Ewing's 
sarcoma was considered unlikely, because of the location of the tumor and the 
immunohistological profile. Nevertheless it was decided to treat the patient 
according to a Ewing's sarcoma protocol based on the genotype of the tumor. The 
findings were compared with other extra-osseous pediatric small cell tumors 
showing the t(J 1; 2 2 )(  q 2 4; q 12) described in the literature. 
INTRODUCTION 
The reciprocal translocation ( 1 1 ;22)(q24;q12) is a cytogenetic aberration which 
is found in 83% of the cases diagnosed as Ewing's sarcoma 422•423 but is also often 
described in peripheral primitive neuroectodermal tumors (pPNET's) including 
peripheral neuroepithelioma 424, Askin's tumor 425•426 and esthesioneuroblastoma 427• 
These histogenetically related tumors belong to the highly malignant family of small 
round blue cell tumors which usually involve bone and deeper soft tissue and mainly 
occur in children and young adults. As a consequence of the translocation between 
the long arms of chromosomes 1 1  en 22 the 5' amino- terminal portion of the EWS 
gene on 22q1 2  fuses with the 3 '  carboxy terminal region o f  the FLI-1 gene, 
belonging to the ets family of transcription factors, on chromosome 1 1  q24. As a re­
sult of this fusion the 3' ets DNA binding domain of FLI-1 replaces the 3' RNA­
binding domain of EWS 408•428.429• The hybrid EWS-FLI-1 mRNA transcribed from the 
derivative chromosome 22 encodes a fusion protein with a strong transcription 
activator function which can induce malignant transformation in NIH 3T3 cells 428•430• 
In a few cases of Ewing's sarcoma and pPNET other translocations have been repor­
ted 431 . 
In this case we present an intermuscular small cell tumor in a 2-year-old boy 
showing the t( 1 1 ;22)(q24;q l 2). 
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CASE REPORT 
In August 1 995, a 2-year-old boy was admitted to the Groningen University 
Hospital because of a painless mass at the dorsal site of the left thigh. The mass had 
been slowly increasing in size during the past two months. An incisional biopsy was 
taken and a diagnosis of sarcoma was made; rhabdomyosarcoma could be excluded 
by immunohistology, but otherwise the tumor was difficult to classify (see below). 
Imaging studies did not reveal regional or distant metastases. A complete surgical 
resection was performed. Surgical margins were free of tumor. Cytogenetic analysis 
of the biopsy revealed a t( l 1 ;22)(q24;q1 2) which was further analyzed by reverse 
transcription polymerase chain reaction (RT-PCR). Based on the cytogenetic and 
molecular genetic findings the patient received adjuvant chemotherapy according to a 
protocol for Ewing's sarcoma. A complete tumor re-evaluation after completion of 
chemotherapy in September 1 996 showed no evidence of residual or recurrent 
disease. At the time of this report in January 1998, the patient is still in complete 
remission. 
METHODS 
Tissue of the incisional biopsy was embedded in paraffin for routine 
histological examination. Immunohistological studies were performed on both 
frozen, acetone-fixed sections and paraffin embedded sections using the biotin­
streptavidin-peroxidase method and diaminobenzidine as chromogen. Primary 
antibodies (with their source and optimal working dilutions) were directed against 
vimentin (Boehringer Mannheim, Germany 1 :  1 00), keratin AE 113 (Boehringer 
Mannheim, I :400), actin (Enzo Diagnostics, New York, 1 :  I 0000), desmin (DAKO 
1 : 1 00, Glostrup, Denmark), S-1 00 (DAKO 1 : 1600), keratin CAM5-2 (Bec­
ton/Dickinson 1 :4, San Jose, California), HBA-7 1 anti p30/32Micz (courtesy of Dr. 
Hamilton, Vienna 1 :250 432), neuron specific enolase (Biogenex, San Raman, 1 :  I 00) 
and neurofilaments (Eurodiagnostics, Apeldoorn, 1 :20). 
The DNA ploidy was measured on a tumor cell suspension using a Coulter Epics 
Elite flowcytometer. 
Fresh representative tumor material for chromosomal analysis was cultured for 6-12  
days in  RPMI 1 640 (Gibco BRL Life Technologies, Gaithersburg, MD, USA ), 
supplemented with 13 ,5% fetal calf serum, L-glutamin and penicillin/streptomycin. 
Chromosome preparations were made according to standard cytogenetic techniques. 
Slides were stained with Giemsa after G banding with pancreatin (0. 1 %,Sigma). 
The karyotypes were described according to the ISCN Guidelines for Cancer 
Cytogenetics 377· 
Molecular study was done using Reverse Transciption Polymerase Chain Reaction 
(RT-PCR). 
Total RNA was extracted from short term cultured tumour cells, using RNazol 
(Campro Scientific ). 2,5 Jlg RNA was reverse transcribed into cDNA using random 
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hexamer primers and Ready-to-go You-prime First-strand-beads (Pharmacia). To 
amplify a EWS-FLI-1 junction region, PCR was performed using primers 5'EWS and 
3'FLI-l!ERG 433• As a control for the integrity of the isolated RNA and successful 
reverse transcription a part of c-ABL, which is ubiquitously expressed, was 
amplified. The PCR product was analyzed on a (2)% agarose gel and sequenced 




Histopathological examination of the incision biopsy revealed a solid 
proliferation of large cells with vesicular nuclei and prominent nucleoli (Fig. lA). 
Most cells had amphophilic cytoplasm, but a few cells with strongly eosinophilic 
cytoplasm were observed. There was a high mitotic rate (25/2 mm2), but no necrosis. 
The tumor in the excision specimen measured 2.5x2.5x1 .8cm and was composed of 
several noduli embedded in intermuscular adipose tissue with infiltration in skeletal 
muscle. The microscopic appearance was identical to that in the biopsy. No tumor 
cell rosettes were observed. Immunohistology revealed strong diffuse reactivity for 
keratin AEl/3 (Fig. l B) and for CAM5.2 in virtually all tumor cells as well as for 
vimentin. Immunoreactive globular intracytoplasmic inclusions were not observed 
with any of the antibodies. Weak cytoplasmic immunoreactivity for HBA-71 ,  
recognizing the p30/32M1c2 protein, was seen throughout the tumor and focally for 
neuron specific enolase and neurofilaments. No desmin or actin immunoreactivity 
was present. 
DNA-ploidy and (cyto)genetics 
DNA-ploidy revealed a diploid peak and cytogenetic analysis showed a 46,XY, 
t(1 1 ;22)(q24;q12)[cp9]/46,XY[l ]  karyotype, with a reciprocal t( 1 1 ;22)(q24;q12) 
(Fig.2). In view of the cytogenetic fmdings molecular studies were performed to 
confirm the t( 1 1 ;22) (q24;q12). RT-PCR detected an amplified product of 
approximately 250 basepairs. After sequencing this product appeared to contain a 
junction of exon 7 of EWS to exon 8 of FLI-1. 
DISCUSSION 
The current report describes an intermuscular tumor located at the dorsal site of 
the thigh of a 2 year old boy. Histopathologically the tumor was difficult to classify. 
In view of the morphological aspects, in combination with the widespread dual 
keratin and vimentin immunoreactivity, a diagnosis of extrarenal malignant rhabdoid 
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(A) Light microscopy of the tumor showing large cells with vesicular nuclei and prominent 
nucleoli (hematoxylin-eosin stain; x 400). 
(B) Immunohistologicy using the antibody keratin AEl /3 displaying diffuse strong 
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Figure 2 
Karyotype of the presented case showing a t( 1 1 ;22)(q24;q12). 
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tumor (MRT) was considered. However, immunoreactive globular intracytoplasmic 
inclusions were not observed with any of the antibodies. In view of the cytogenetic 
findings additional immunohistochemistry was performed, in an attempt to find 
support for a diagnosis of Ewing's sarcoma, but these results were inconclusive. 
Weak,cytoplasmic immunoreactivity for HBA-71 recognizing the p30/32mic2 marker 
is seen in many sarcomas other than Ewing's 434.435 (and personal observations), 
immunoreactivity for neuron specific enolase is generally known to be aspecific and 
neurofilaments are present in many sarcomas, including rhabdomyosarcomas and 
malignant rhabdoid tumors of soft tissue (Molenaar et al.: submitted for publication). 
Since the histopathological aspects and intermuscular location are also unusual for 
Ewing's sarcoma this diagnosis was discarded. 
Using RT-PCR a EWS-FLI-1 fusion transcript in which exon 7 of EWS is fused 
to exon 8 of FLI-1 was detected. This seems to be a rare fusion type in Ewing 
tumors, only found in 2 out of 147 cases in a European multicenter study 436• This 
study suggests a possible advantage in relapse-free survival for patients with 
localized disease and a shorter (exon 7 of EWS fused to exon 6, 7 or 8 of FLI-1) 
chimeric product, like in our case. 
Cytogenetic fmding of the t(1 1 ;22)(q24;q12) and molecular detection of the EWS­
FLI-1 fusion transcript have become important diagnostic markers because they were 
supposed to be specific for Ewing's sarcoma and related tumors such as peripheral 
primitive neuroectodermal tumors (pPNET). However, the current case and recent 
reports in the literature suggest that the ( 1 1 ;22)(q24;q12) may occur in a more 
heterogeneous group of tumors, as summarized in Table 1 .  Virtually all tumors 
occurred in the pediatric or young adult age group and most were difficult to classify. 
Immunohistologically, a complex phenotype with expression of neural, myogenic or 
epithelial markers or a combination thereof was often observed (Table 2), leading to 
diagnoses such as "polyphenotypic tumor" 437• The "Ewing's sarcoma and pPNET" 
p30/32mic2 marker was seen in a minority of cases. The biological behaviour is 
difficult to establish in view of the limited number of cases and the relatively short 
follow-up. 
The heterogeneity of pediatric tumors revealing t(1 1 ;22) (q24;q1 2) raises the 
question whether treatment should be based on histological fmdings, clinical 
appearance or cytogenetic and/or molecular analysis. In the case described in this 
report the molecular and cytogenetic findings led to the decision to give adjuvant 
chemotherapy as for Ewing's sarcoma. Currently, there is no evidence of recurrent 






Table 1. Pathological and cytogenetic characteristics of different pedriatic tumors showing the EWS-FLI-1 fusion transcript and their clinical outcome. 
Case No./ Age/ Localization Diagnosis cytogenetics chimeric mRNA follow-up 
cell line a sex t( l 1 ;22) EWS-FLI-1 
I 5/F neck polyphenotypic small cell tumor unsuccessful + NED, 20 months 
2 37mos/M retroperitoneum anaplastic polyphenotypic tumor + + NED, 5 months 
3 20mos/F interscapular mixed embryonal/alveolar RMS unsucessful + DOD, 14 months 
4 44mos/F right parotid area mixed embryonal/alveolar RMS + + NED, 9 months 
5 22mos/F superficial, the posterior malignant sweat gland carcinoma 1/ + + NED, 2 years 
right thigh superficial variant of ES/pPNEr 
6 I I OIF left-upper chest wall at- malignant sweat gland carcinoma 1/ ND + NED, 16 years 
tached to the skin superficial variant of ES/pPNEr 
TC- 1 3 1  
1
1 9/M soft tissue, thigh alveolar RMS - + UNK 
TC-1 74 9/F soft tissue, thigh alveolar RMS + + UNK 




25/M retroperitoneum alveolar RMS + + UNK 
TTC-547 1 3/F retroperitoneum alveolar RMS + + UNK 
current case 2/M intermuscular, thigh malignant rhabdoid tumor + + NED, 23 months 
a References case I-4:(Thomer et al., 1 996) 74; case 5 and 6:(Lee et al., 1995)438; cell lines TC- 1 3 1  :(Whang Peng et al., 1 986; Sorensen et al., 1 995) 426• 437; 
TC-1 74,TC-253,TC-547:(Sorensen et al., 1 995)437; TC-206:(Whang Peng et al., 1 992; Sorensen et al., 1 995) 437•439• 
1: preferential diagnosis and 2: diagnosis later changed in ... 
ND: not done, NED: no evidence of disease, DOD: death of disease, UNK: unknown. 
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Table 2 Immunoreactivity for different antigens in the various tumors with a t( 1 1  ;22)( q24;q 1 2). 1 ;::; 
Case No./ I immunolo cell line gic l!rofile 
vimentin keratin EMA CAMS-2 desmin actin SIOO CDS7 MIC2 NF NSE 
++ - + NO + + + + +I- NO + 
2 ++ ++ - NO ++ - + + - NO + 
3 +++ - - NO +++ +++ - - - NO 
4 ++ - - NO ++ + - - - NO 
5 ++ NO NO - - + - NO +++ NO ++ 
6 ++ NO NO +/- - - - NO +++ NO ++ 
TC- 1 3 1  NO NO NO NO ++ + NO NO NO + NO 
TC- 1 74 NO NO NO NO ++ + NO NO NO + NO 
TC-206 NO NO NO NO ++ ++ NO NO NO + NO 
TC-253 NO NO NO NO + + NO NO NO + NO 
TTC-547 NO NO NO NO ++ ++ NO NO NO + NO 
current case +++ +++ - +++ - - - NO + + + 
NO: immunostaining for this antigen not done; +++:strong positive staining; ++ diffuse positive staining; 
+: focally positive or weak staining; +/- a rare cell positive and - :  negative immunostaining for this antigen 
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Chromosome breakage could influence the expression of genes. This has been 
noticed in specific cases of acute myeloid leukemia, where the 16p13 breakpoint 
affects the expression of the multidrug resistance related protein (MRP). Myxoid 
liposarcomas (LPS) are characterized by the t(J2;16)(q13;pll) which leads to the 
formation of a FUS-CHOP fusion transcript. This study investigates the relationship 
between the cytogenetically detected breakpoint 16p11 in myxoid LPS, the presence 
of the FUS-CHOP fusion transcript in non-myxoid LPS and the expression of the 
lung cancer resistance major vault protein (LRP) gene on 16p11.2. 
Of 16 cases with a diagnosis of a (possible) liposarcoma with an abnormal 
karyotype, fresh frozen tumor material was available for immunohistological 
detection of LRP. Cases without a cytogenetically detected t(J 2; 16)( q 13 ;p 11  ), were 
analyzed for the presence of a FUS-CHOP fusion transcript by RT-PCR. 
In a/1 9 myxoid LPS a t(12;16)(q13;p11) was found and LRP expression was 
absent or low. In none of the remaining 7 cases a FUS-CHOP fusion transcript was 
found and four tumors were LRP positive (p=0.02). LRP expression in myxoid LPS 
(mean: 1.3%) was lower (p=0.07) than in the non-myxoid tumors (mean: 35. 7%). 
These observations indicate a relation between the t(J 2; 16)(q13,p11), leading 
to a FUS-CHOP fusion transcript in myxoid LPS, and the low or absent expression 
of the LRP-gene located on 16pll.2. 
INTRODUCTION 
Soft tissue sarcomas (STS) are malignant tumors of mesenchymal origin. They 
comprise 1 %  of all malignant tumors. About 20% of the STS are liposarcomas (LPS) 
of which approximately 50% is of the myxoid subtype 8• Myxoid LPS are 
histologically characterized by a plexiform network of capillaries and lipoblasts in 
various stages of differentiation. Cytogenetic studies have revealed a 
t(1 2; 1 6)(q 13.3;p l l .2) in about 95% of the myxoid LPS 8•440• This translocation which 
leads to the formation of a FUS-CHOP fusion transcript has also been detected in 
round cell LPS, which is considered to be a poorly differentiated variant of myxoid 
LPS 49•441•442• The remainder LPS consists of well differentiated LPS (WDLPS), 
pleomorphic LPS (PMLPS) and dedifferentiated LPS (DDLPS). Both WDLPS and 
myxoid LPS are low grade STS and have a relatively good prognosis as compared to 
the other LPS, in which distant metastases are frequently observed 8• Myxoid LPS are 
characterized by local recurrences, although they can develop distant metastases 8• 
Doxorubicin- and carbazine-based chemotherapy has shown effectiveness in LPS 
87•443• Nowadays doxorubicin and/or ifosfamide based chemotherapy regimens are 
first-line options in the treatment of STS. A serious clinical insensitivity to various 
chemotherapeutic drugs has been noticed in STS of adult patients 444-446• Multidrug 
resistance (MDR) is a phenomenon frequently observed in STS and other 
malignancies and is associated with the expression of drug efflux pumps like P-
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glycoprotein and the multidrug resistance related protein (MRP), which are 
responsible for the efflux of various natural cytostatic agents among which 
doxorubicin 92•93•96•97• 108•297•322•447449• Another protein thought to play a role in MDR is 
the 1 10 kD major vault protein LRP (lung cancer resistance protein) 96•97•450• LRP 
expression has been shown to be a negative factor concerning prognosis and response 
to chemotherapy in acute myeloid leukemia (AML) and ovarian cancer 96•97• In acute 
myelomonocytic leukemia with abnormal eosinophils (FAB subtype M4eo) an 
inv(16)(p 13q22) has frequently been observed and a relation between the 
chromosome breakage in chromosome 1 6p 13  and the MRP expression has been 
found 97•295•448•450.45 1 • Since the LRP gene is mapped to 16p 1 1 .2, there might be a 
relationship between the breakpoint 1 6p 1 1  in myxoid LPS, the presence of a PUS­
CHOP fusion transcript and the expression ofLRP. 
MATERIAL AND METHODS 
Histology 
The criteria for inclusion in the current study were 1 )  a histological diagnosis 
of liposarcoma or possible liposarcoma, 2) an abnormal karyotype after cytogenetic 
analysis and 3) the availability of fresh frozen tumor tissue. In this way, 1 6  cases 
were selected and in all cases the histological diagnosis was made on H&E stained 
paraffin sections with or without additional immunohistological stains. All sarcomas 
were classified according to Enzinger and Weiss 8 which revealed 9 myxoid LPS, 2 
well differentiated LPS, 3 dedifferentiated LPS and two tumors with preferential 
diagnosis ofnon-myxoid LPS. Two of the myxoid LPS showed transition to round 
cell LPS. 
Cytogenetics 
Fresh representative tumor material for chromosomal analysis was cultured for 
6- 15  days in RPM! 1 640 (Gibco), supplemented with 13 .5% fetal calf serum, L­
glutamin and penicillin/streptomycin. Cultures were harvested and chromosome 
preparations were made according to standard cytogenetic techniques. The metaphases 
were air dried and stained with Giemsa after G banding with either trypsin 1 :250 
(0.25%, Difco) or pancreatin (0. 1 %, Sigma). The karyotypes were described according 
to the ISCN ( 1995) Guidelines for Cancer Cytogenetics 377• Cytogenetic results in 
relation to histology are shown in Table 1 .  
Molecular genetics: TLS-CHOP fusion transcript 
In the 7 cases without a t(12; 1 6)(q1 3;p 1 1), a TLS/FUS CHOP fusion 
transcript analysis was performed. From each tumor ten 5 J.lm frozen sections were 
prepared meticulously obeying Kwok's criteria for avoidance of contaminations 452• 
One slice of each case was mounted and HE-stained for histological control. Total 
RNA was extracted using RNAzolTM B (W AK-Chemie, Bad Homburg, Germany). 
0.5 J.lg to 1 J.lg of total RNA were reverse transcribed to cDNA using MuLV reverse 
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transcriptase (Roche Molecular Systems, Branchburg, NJ, USA), random hexamers 
and RNase inhibitor according to the supplied Roche protocol and 750 f..1moi/L of 
each of the four deoxynucleotide triphosphates. One-fourth of the cDNA-mix was 
used as template for PCR amplification. TLS-CHOP-specific primers, 5 '­
CAGAGCTCCCAA TCGTCTTACGG-3 '  (nucleotide position 3 3 1 -353) and 5'­
TTCCAGCTCCCAGCTGGA CAGTG-3 ' (nucleotide position 992-10 14), each 20 
pmoV50f..ll or HPRT housekeeping gene primers, 5'­
CGAAGTGTTGGATATAAGCC-3 ' (nucleotide position 593-61 2) and 5 '­
CGATGTCAA T AGGACTCCAG-3 ' (nucleotide position 773-792), each 8 
pmoV50f..ll, and 1 .5 U AmpliTaq™ DNA polymerase (Roche Molecular Systems) 
were used for PCR. Each reaction mix was overlaid by one drop of light mineral oil 
(Sigma, Deisenhofen, Germany). Amplification cycles for TLS/CHOP were 94°C for 
5 min, 70°C for 45 s, 72°C for 1 min (first cycle), 94°C for 1 min, 69.5°C 
(temperature decrease 0.5°C/cycle), 72°C l min (for 25 cycles), 94°C for 1 min, 
57.5°C for 45 s, 72°C for 1 min (for 1 3  cycles), and final extension for 1 cycle at 
72°C for 2 min. For HPRT PCR cycles were 94°C for 5 min, 53°C for 1 min, 72°C 
for 45 s (first cycle), and 94°C for 1 min, 53°C for 1 min, 72°C for 45 s (for 35 
cycles) and final extension for 1 cycle at 72°C for 2 min. CDNA synthesis and PCR 
were performed in a TRIO-Thermoblock™ (Biometra, Gottingen, Germany). PCR 
products were analyzed on a 2% agarose gel, and visualized by ethidium bromide 
staining. PCR products indicating a type I (682bp) or type 11 (406bp) amplicon were 
digested with IOU Mbol (MBI Fermentas,Vilnius, Lithuania) according to the 
manufacturers protocol and analysed on an agarose gel. RNA preparation, RT and 
PCR analysis were carried out twice from each tumor. 
Detection of LRP 
Five micron thick frozen tissue sections were airdried, fixed in acetone for 10  
minutes and washed twice with PBS. The slides (except the negative control) were 
incubated for 1 hr with the primary murine monoclonal antibody LRP-56 (diluted 
1 :50, kindly provided by Dr. R.J. Scheper, Department ofPathology, Free University 
Hospital, Amsterdam, The Netherlands). The slides were rinsed three times in PBS 
with calciumchloride-dihydrate for 5 min and blocked for endogenous peroxidase 
activity with 0,03% H202 for 30 min. The sections were rinsed again in PBS with 
calciumchlorid-dihydrate three times for 5 min, followed by two 30-min incubations 
with the HRP-labeled rabbit anti-mouse Ig ( 1 :50, DAKO) and HRP-goat anti-rabbit 
lg ( 1 : 50, DAKO), and subsequent washings in PBS with calciurnhydroxide. 
Peroxidase activity was visualized with 3-amino-9-ethylcarbazole and HP2 for 1 5  
minutes. Nuclear counterstaining was performed with Mayer's Haematoxylin. 
Normal colon tissue and an LRP-positive soft tissue sarcoma was used as a positive 
control. Quantification ofLRP expression was performed by two observers without 
knowledge of the histological diagnosis or the cytogenetic results. The LRP expression 
was analyzed semiquantitatively by estimating the percentage ofLRP-positive cells 
and assessing staining intensity using a scale of 0 -3 (0: no staining, 1 :  very weak 
staining, 2:  intermediate staining, 3 :  strong staining). Strong staining intensity was 
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comparable to the staining intensity of the simultaneously stained positive control 
tissue. Both staining parameters were also combined into a histopath score which was 
defined as: the estimated percentage of stained cells (0-100%) x the staining intensity 
(0-3). According to the literature 96, a tumor was considered LRP-negative if the 
percentage of positive cells was � 5%. 
Statistical analysis 
To test differences between groups, the non-parametric Wilcoxon Rank Sum 
Test and Fisher exact test were used. A p-value of <0.05 was considered statistically 
significant. 
RESULTS 
In all 9 myxoid LPS a t(12; 16)(q13 ;p l l )  was found and LRP expression was 
absent or low (Table 1 ). LRP expression was also absent in areas of dedifferentiation 
towards round cell LPS which were found in two cases. The mean percentage of LRP 
stained cells was 1 .3% (median: 0%, SD: 2 . 1  %). When these values were combined 
with the amount of staining intensity, the mean histopath score was 2.7 (median: 0 ; 
SD: 4.2). In none of the seven other tumors a t(12 ; 16)(q 13 ;p l l )  nor a FUS-CHOP 
fusion transcript could be detected, but careful cytogenetic analysis revealed a 
16p l l . l  in one them (case 1 1 ). LRP expression in these tumors was found in 4/7 
(57%) cases, which was more frequent (p=0.02) than in the myxoid LPS group (0/9). 
The percentage of LRP stained cells (mean: 35 .7%, median: 1 0%, SD: 40.4%) was 
higher (p=0.07) than in the myxoid LPS. The histopath score was also higher 
(p=0.07) than in the myxoid LPS (mean: 39.3, median: 30, SD: 38.3). 
DISCUSSION 
The sites of chromosome breakage could affect genes located in the affected 
chromosomal region as has been found in AML. The specific inv( l 6)(p 13q22) in 
AML is not only of diagnostic importance but also has a prognostic value 45 1 • The 
influence of chromosome breakage in the 1 6p 1 1- 16p 1 3  region on LRP and MRP 
genes has further translated (cyto)genetic findings into a clinical setting 97•295•448•450• 
The finding of a characteristic balanced translocation leading to the TLS/FUS-CHOP 
fusion transcript in myxoid LPS has been of great diagnostic importance. In this 
study it was questioned whether the breakage in 16p 1 1  and the formation of a PUS­
CHOP fusion transcript could alter the transcription of the LRP gene. 
Since all myxoid LPS were LRP-negative, the results of this study support the idea 
that chromosome breakage in 1 6p 1 1  could affect the 1 6p 1 1 .2 region of the LRP gene 
and alter the transcription of LRP. In the only non myxoid LPS with a 
cytogenetically detected 1 6p 1 1  breakpoint and LRP expression (case 1 1  ), the exact 
breakpoint was 1 6p l l . l ,  whereas 1 6pl 1 .2, which is the breakage site involved in the 
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Table la. Cytogenetic and histological data of the myxoid liposarcomas and corresponding 
LRP exEression. 
Case karyotype diagnosis TLS/ LRP LRP LRP LRP 
FUS- stained staining histopath status 
CHOP cells (%2 intensi� score 
47,XY,t(1 ;  10;16;12)(q42;q22;pll; MLPS ND 0 0 
q13), del(5)(q21q3 1),+8[5] 
2 45-47,XY,+8, MLPS ND 0 0 
t(12; 19;16)(q13;q 1 3;p11)[cp9] 
3 45-46,XY,der(7)t(7;8)(q36;q22)x2, MLPS ND 5 ++ 1 0  
add(8)(q21 )  t(12;16)(q13;pll)[cp7] 
4 46,XY, t(3; 1 5)( q21 ;q24), MLPS ND ++ 2 
t(12;16)( q13;p11)[9] 
5 47 ,XX,add(3)(p 12),der(8)t(3;8)(p 14; MLPS ND ++ 2 
p 12),+der(8)t(3;8)(p14;p1 2), 
t(12;16)( q13;pll )[6] 
6 44-45,XX,t(5;22)(q3 1 ;q 1 3), MLPS ND 0 0 
der(1 O)t(1 0; 1 2)(p 13;q 1 3), 
ider( 12)t(12;16)( q13;p11 ),-16[ cp7] 
7 45-46,XY,t(12; 16)( q13;p11 )[ cp7] MLPS ND 5 ++ 1 0  
8 45-47,XX,t(12;16)(q13;p11), MLPS ND 0 0 
+m1 [cp10] 
9 42-4 7 ,XY,t(12; 16)( q13;p11)[ cp4] MLPS ND 0 0 
MLPS: myxoid liposarcoma; LRP: lung resistance protein; ND: not done; -: negative; +: positive 
t( 12; 16)(q13 ;p l l ), is the location of the LRP gene 440• This was confirmed by the 
results of the RT-PCR for TLS/FUS-CHOP. 
The TLS/FUS-CHOP fusion transcript in myxoid LPS has been the subject of 
many studies, but a relation with the LRP gene has not been examined before 
441 •453•454• This study cannot discriminate between the effects of chromosome 
breakage in 16p l l .2 and the effects of the formation ofFUS-CHOP on the expression 
of LRP. The absence of a FUS-CHOP fusion transcript in cases 10- 16  (Table 1 )  
indicates that the 1 6p 1 1 .2 region i s  not affected and therefore LRP could be 
expressed in 4 of them. 
A preferential histological diagnosis of liposarcoma was made in two cases 
(cases 12 and 13). In case 12, a patient with an extensive abdominal mass, a tentative 
diagnosis of RCLPS was made; however, this could not be confirmed by cytogenetics. 
In case 1 3  a preferential diagnosis of PMLPS was made, with a differential diagnosis of 
malignant fibrous histiocytoma. In both cases with an uncertain histological diagnosis, 
no t(12 ; 16)(q13 ;p l l )  nor FUS-CHOP could be detected and LRP expression in these 
tumors was apparently not hampered by the anomalies in the 16p 1 1 .2 region. It 
remains unclear whether transcription of the LRP gene is present or absent in benign 
and the various malignant lipomatous tumors in general or is impossible in the 
myxoid LPS due to the 16p l l .2 breakage site characteristic for LPS. In myxoid LPS, 
the low LRP levels could also be explained by the fact that all myxoid LPS were low 
grade tumors and some studies reported a correlation between tumor grade and MDR 
100•108•455• However, the latter option seems to be contradicted by the absence of LRP 
expression in areas with round cell morphology. 
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Table lb. Cytogenetic and histological data of the other cases and corresponding LRP 
expression. 
Case karyotype diagnosi TLS/ LRP LRP LRP LRP 
s FUS- Stained staining histopath status 
CHOP cells(%) intensity score 
10 46-48,XX,t(9; 15)(p2;ql), WDLPS 0 0 
tas(1 5;22)(p13;p13),+2r[cp7] 
/44-5 1 ,XX,+2r,+l-4,mar[cp7] 
1 1  41 -46,XX,add(1 1 )(p1 1 ), WDLPS 70 + 70 + 
de1{1 l)(q13q24), add (16)(p1 1.1), 
add(20)(ql 1 .2)[cp1 2] 
1 2  43-44,X,-Y,der(1 ;2)(q1 0;q1 0},- RCLPS? 75 + 75 + 
2,i(4)(q1 0),-5,+9,-14, dic(l9;22) 
(ql3 . l ;q l2), +20,+r[cp7] /46,XY[2] 
1 3  20-32(n),X,del(l )(ql 3), PMLPS? 90 + 90 + 
+dic(l ; l 3)(p22;p1 3),- l l ,  
r{l2)(pl2q24), - 13 ,  
der( 14;21 )(  q 1 O;q 1 0), - 16,-1 8,-20, 
-2 1 ,+ 2-6mar[ cp6]/38-55,idernx2 
[ cp5]/80,idernx3 [ 1 ]/85-86,idernx4 
[cp2]/139 
14 35-62,X,-Y,+X,de1( 1 )(q41),add DDLPS 0 0 
(2)(q3 1 ), 
del( 6)( q 1 6), 
de1(7)( q22),add(8)( q24 ),der( 12) 
t(9; 1 2)( q 12;p 13),add( 13)( q22),inc[ cp 
5]/46, XY[lO] 
15 72-76,XXY,add(1 )(q4), DDLPS 1 0  +++ 30 + 
der(1 ;3}(p 1 O;p 1 0), 
+dic(3;4)(q2l ;pl 5),+2, add(3) 
( q25), ?add(3)( q 1 ),add(5)( q35), 
+add( 5)( q 1 ), add( 6)(p22prp23 ), 
+ 7dic(8;?; 12)(p 1 ;?;p 1 1 .2),+?dic(8;?; 
8)(p 1 ;?;p 1 ),+dic(8;?; 15)(p 1 1  ;?;p 1 1  ), 
+i(8)(q10),+9,- 1 1 ,- 1 1 ,  
add( 1 1 )(p1 1), der(12; 1 5)(q10;q10), 
- 13,add( l 5)(p1 1),+ 17, +18,- 19, -20, 
-21 ,i(2 1 )  (q1 0),+22,+r,+1 -8mar[cp5] 
16 clonal aberrations: ±3n,add(5)(p15), DDLPS 5 ++ 10  
add(1 1 )(p1?4) or 
dic(7;?; 1 1  )(p22;?;p 1 ?4), 
add(1 1 )(p 1 ?4), add(1 8)(q21), 
add(22)(q 13),mar[5] 
WDLPS: well differentiated LPS; RCLPS: round cell liposarcoma; PMLPS: pleomorphic 
liposarcoma; DDLPS: dedifferentiated LPS; LRP: lung cancer resistance protein; 
ND: not done; -: negative; +: positive 
Although LRP has shown to be associated with clinical drug resistance in ovarian 
carcinoma and AML, LRP has also been detected in many normal cell types and is 
thought to act as an intracellular transporter protein not only carrying MDR cytotoxic 
substances towards the extracellular environment 95-97•292•294 Therefore, this 
observation of a correlation between chromosome breakage and diminished 
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expression of  LRP in  solid tumors i s  not only of  oncologic importance, but might be 
meaningful for the pathophysiological mechanisms in which major vaults are 
involved. 
In summary, in this small group of LPS it was found that expression of the 
LRP gene on 16p 1 1 .2 is absent or very low in myxoid LPS and might be related to 
the 1 6p l l breakpoint characteristic for myxoid LPS. These findings might be of 
pathophysiological, tumor biological and clinical importance. Further studies have to 
analyze the significance of the MDR protein expression in relation to detected 
chromosomal breakpoints in LPS. Moreover, studies in larger groups of various 
benign and malignant lipomatous tumors have to clarify whether LRP expression in 
lipomatous tumors is low or absent in general. 
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Multidrug resistance (MDR) has been associated with the expression of the P­
gp (P-glycoprotein), LRP (lung resistance protein) and MRP1 (multidrug resistance 
related protein) genes on chromosomes 7q21, 16pll and 16p13, respectively. 
Chromosome breakage in 16p13 can influence the expression of MRPb as has been 
shown in specific cases of acute myeloid leukemia. In soft tissue sarcomas (STS), 
cytogenetic analyses revealed characteristic cytogenetic alterations in several 
histologic types. This study in 39 STS was performed to evaluate whether 
cytogenetically detected alterations in 7q21, 16pll and 16p13 could influence the 
expression of P-gp, MRP1 and LRP. 
From a cytogenetic database, 24 STS cases were selected with abnormalities, 
i.e. breakpoints, loss or gain of chromosomal material in 7q21, 16p11 and/or 16p13. 
Eight of the 16 cases with 16p11 breakpoints were myxoid liposarcomas. As a 
control group served 15 STS with an abnormal karyotype, but with cytogenetically 
normal chromosomes 7 and 16. P-gp, MRP1 and LRP expression was 
semiquantitatively assessed by immunohistochemical evaluation. 
P-gp and MRP1 expression did not differ between STS with breakpoints in or 
loss of the 7q21 or 16p13 regions as compared to STS with normal chromosomes 7 
and 16. However, in STS with 16p11 breakpoints or loss, the median percentage of 
LRP expressing cells was 3% and in STS with normal 16p11 regions the median 
percentage of LRP expressing cells was 40% (p<0.01). LRP expression, but not 
MRP1 or P-gp expression, correlated with the amount of cytogenetically intact 
chromosomal material (p<0.01). LRP expression in liposarcomas did not differ from 
that in STS other than liposarcomas, whereas myxoid liposarcomas had lower LRP 
expression than other liposarcomas (p<0.01). 
In conclusion, the present study shows that breakpoints in or loss of 16p11 
might affect LRP expression in STS. LRP expression correlates with amount of 
chromosome 16p11 material. In STS, P-gp and MRP1 expression seems not to be 
affected by breakpoints in or loss of7q21 and 16p13, respectively. 
INTRODUCTION 
Soft tissue sarcomas (STS) are malignant tumors of mesenchymal origin and 
comprise 1% of all malignant tumors. They tend to spread hematogeneously, 
predominantly to the lungs, in up to 30% of the patients 8•9• Metastasized STS are 
treated with doxorubicin based chemotherapy and response rates are in general 20-
30% 86•87•28 1 •284• Poor response to various functionally and structurally distinct natural 
cytostatic agents has been called multidrug resistance (MDR) 288•350• MDR has been 
associated with the overexpression of proteins like P-glycoprotein (P-gp), the product 
of the MDRl gene located on 7q2 1 ,  288•325•326•350 and the multidrug resistance related 
protein- 1 (MRP 1) gene, located on 1 6p 1 3  287•289'291•35 1 • Some studies reported a 
prognostic value of P-gp and MRP1 in STS 100'103• 108•297•324• In addition, a possible role 
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in clinical drug resistance of another gene on 1 6p 1 1 .2 encoding the major vault 
protein or lung resistance protein (LRP) has been reported 96•97•289•292•295• In acute 
myeloid leukemia (AML) with abnormal eosinophils (FAB subtype M4eo) with an 
inv(1 6)(p1 3q22) it was found that breakage in chromosome 1 6p 1 3  affects MRP1 
expression, which was shown to be of prognostic significance 450•451 • Previous studies 
on cytogenetic abnormalities in STS have focussed on the significance for histolo­
gical classification and tumor progression 42•49•53•54•456458• In myxoid liposarcomas 
(LPS) a t(1 2; 1 6)(q 13 .3 ;p l l .2) is found in about 95% of the cases, which involves 
the chromosomal region 16p l l .2 on which the LRP gene has been located 8•440• Since 
clinical drug resistance in STS has been frequently observed, it was decided to 
evaluate in 39  STS the relation between chromosome breakage and/or loss or gain of 
7q2 1 ,  1 6p l l and 1 6p 1 3  with the expression of P-gp, MRP1 and LRP, respectively. 
MATERIALS AND METHODS 
Patients and study design 
The criteria for inclusion in the current study were 1) a histological diagnosis 
of a STS, 2) an abnormal karyotype with abnormalities of chromosomal regions 
7q2 1 ,  1 6pl l and/or 1 6p 1 3  and 3) the availability of paraffin embedded tumor tissue. 
In this way a study group was selected of a) 20 cases with breakpoints in or loss of 
the chromosomal regions 7q2 1 ,  16p 1 1  and/or 1 6p 1 3  and b) 5 cases with gain of 
7q2 1 ,  1 6p 1 1  and/or 1 6p 13 .  As a control group served 14 STS with an abnormal 
karyotype, but with cytogenetically normal chromosomes 7 and 1 6. For the 
assessment of the relation between chromosomal damage and the P-gp expression in 
STS, the cases with breakpoints in or loss of the specific region i.e. 7q2 1 were 
compared with all STS with cytogenetically normal 7q21 regions, thus excluding the 
cases with gain of chromosomal material. The same holds for the 1 6p 1 1  and the 
16p 1 3  region for the analysis of LRP and MRP 1 expression. Thus, breakpoints were 
considered as loss of chromosomal material in the specific chromosomal region. The 
relation between gain of 7q2 1 ,  1 6p l l and/or 16p 1 3  and expression of the P-gp, 
MRP 1 and LRP was evaluated in a correlation analysis. 
In all cases the histological diagnosis was made on haematoxylin-eosin stained 
paraffin sections with or without additional immunohistological stains. All STS were 
classified according to Enzinger and Weiss 8 (Table 1 ). The primary STS were 
graded according to the grading system of Coindre et al. 29• Tumor material of three 
primary tumors was obtained after hyperthermic isolated limb perfusion with tumor 
necrosis factor alfa and melphalan 80•84• The karyotypes of these three STS showed no 
alteration in chromosomes 7 or 1 6. 
Cytogenetics 
For the cytogenetic analyses, fresh representative tumor material for 
chromosomal analysis was cultured for 6-1 5  days in RPMI 1640 (Gibco, Paisley, 
Scotland), supplemented with 13 .5% fetal calf serum, L-glutamin and 
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penicillin/streptomycin. Cultures were harvested and chromosome preparations were 
made according to standard cytogenetic techniques. The metaphases were air dried and 
stained with Giemsa after G banding with either trypsin 1 :250 (0.25%, Difco, Detroit 
IL, USA) or pancreatin (0. 1 %, Sigma, St. Louis, USA). The karyotypes were described 
according to the ISCN ( 1995) Guidelines for Cancer Cytogenetics 377• 
MDR expression 
For detection of P-gp, the monoclonal antibody C494 (Signet Laboratories, 
Dedham MA, USA) in a concentration of 120 J.lg/ml in phosphate-buffered saline 
(PBS) (Merck, Darmstadt, Germany) plus 1% bovine serum albumin (BSA) (Serva 
Electrophoresis GmbH, Hamburg, Germany) was used. For detection of MRP1 the 
monoclonal antibody MRPrl (provided by Dr. R.J.Scheper, Dept. of Pathology, Free 
University Hospital, Amsterdam) in a concentration of 20 J.lg/ml in 1% BSA/PBS 
was utilized. For detection of LRP the monoclonal antibody LRP (Transduction 
Laboratories, Los Angeles CA, USA) in a concentration of 250 J.lg/ml in 1% 
BSA/PBS was used. As  controls for immunohistochemal detection served cytospins 
of the well documented cell lines A2780 and GLC4 and their corresponding multi­
drug resistant sublines i.e. overexpressing P-gp (A2780 AD), MRP1 (GLC4/ADR) 
and LRP (GLC4/ADR) 298•299, as well as paraffin embedded formalin fixed liver (P­
gp), lung (MRP1) and colon (LRP) tissue. 
Paraffin sections (3 J.lm) were placed on positively charged glass slides and 
were dried. Immunohistochemistry was performed according to a method modified 
from Shi et al. 177.l78 • Briefly, after heating on a hotplate, the slides were dewaxed in 
xylene and rehydrated in serial ethanol washes ( lOO%, 96% and 70%). After each of 
the subsequent steps, three 5 minutes washes in PBS were carried out. After three 
times heating in an autoclave for 5 minutes at 1 15° C in a 20 mM blocking reagens 
(Boehringer Mannheim, Mannheim, Germany) with pH=6.0, endogenous peroxidase 
activity was blocked by incubation with 1% hydrogen peroxide in PBS during 30 
minutes. The slides were incubated with the specific antibody in 1% BSA/PBS 
(pH=7.4) for 1 hour at room temperature in a humidified chamber. The primary 
antibody was detected with a rabbit antimouse (DAKO, Glostrup, Denmark) (C494 
and LRP) or rabbit antirat (DAKO, Glostrup, Denmark) (MRPrl )  peroxidase labeled 
secondary antibody diluted in 1 :50 + 1 %  human serum (type AB) followed by 
incubation with goat antirabbit conjugated peroxidase diluted in 1 :50 + 1% human 
serum (type AB). 3 .3-diaminobenzidine tetrahydrochloride (Sigma, St. Louis, USA) 
with imidazole (Merck KgaA, Darmstadt, Germany) in PBS was used as the 
chromagen according to the manufacturer's instructions. After counterstaining with 
Mayer's haematoxylin, the slides were dehydrated through graded alcohols and 
mounted with coverslips. 
The expression of P-gp, MRP 1 and LRP was assessed independently by two 
observers (B.P, H.H.) without knowledge of the histological diagnosis or cytogenetic 
data. The P-gp, MRP t> LRP proteins were studied in adjacent slides of the most 
viable parts ofthe tumor. Amount ofP-gp, MRP1 and LRP expression was 
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Table 1. Patient characteristics, histolog:t and c:t!ogenetic data of the 39 STS. 
case sex age diagnosis tumor case/control 7q21 amount of 1 6p l l amount of 1 6 p l 3  amount of P-gp LRP MRP1 
grade breakEoint 7g2 1 breakEoint 1 6EI I breakEoint 1 6EI 3 
I f 24 Rhabdomyosarcoma 11 7q21 -2/3 -1 1/3 -1 1/3 50 80 70 
2 f 5 1  fibrosarcoma Ill 7q21 • + I  3 0  5 70 
3 f 3 4  liposarcoma 7q21 -1 20 80 70 
4 m 62 sarcoma NOS Ill 7q2 1 , 1 6p l 3  • • -2 0 20 I 
5 m 52 Myxoid liposarcoma 7q2 1 , 1 6p 1 3 ,  gain 1 6p l l -1 + 1 /2 • -1 90 60 5 
6 f 52 liposarcoma 11 gain 7q21 +2 5 80 30 
7 m 67 liposarcoma Ill gain 7q21 +2/3 40 0 0 
8 m 54 MPNST 11 gain 7q21 +2/3 30 5 20 
9 f 69 sarcoma NOS Ill gain 7q2 1 ,  1 6p l l ,  1 6 p l 3  +2/3 +2/3 +2/3 0 40 0 
1 0  f 25 MPNST 11 gain 7q2 1 ,  1 6p l l ,  1 6p l 3  + I  113 +2/3 +2/3 60 1 0  5 
1 1  f 5 1  Myxoid liposarcoma I 1 6p l l • -1 90 0 0 
1 2  m 82 Myxoid liposarcoma 1 6p l l • -1 0 5 5 
1 3  m 7 1  Myxoid liposarcoma 1 6p l l • -1 5 0 0 g 1 4  m 35 Myxoid liposarcoma I 1 6p l l • -1 60 0 0 
15 m 26 Myxoid liposarcoma I 1 6p l l • -1 50 0 70 c:l 
1 6  m 49 Myxoid liposarcoma 1 1  1 6p l l • -1 0 5 0 � c 
1 7  m 37 Myxoid liposarcoma I 1 6p l l • -1 80 0 0 "" 
1 8  f 5 1  Myxoid liposarcoma • Ill 1 6p l l • -1 20 0 20 c � 
1 9  f 37 Myxoid liposarcoma I 1 6p l l • -1 -1 80 5 0 l:l 
20 f 47 Liposarcoma I 1 6p l l ,  1 6p l 3  • -1 -1 80 40 50 -� 
21 f 32 MPNST 11 1 6p l l , l 6p l 3 +213 -2/3 -2/3 0 1 0  0 <:::-
22 m 42 MPNST Ill 1 6p l l ,  1 6 p l 3  -2 -2 90 20 70 (I) 
� 23 m 1 6  Synovial sarcoma Ill 1 6p l l ,  1 6p l 3  + I  - 1  - 1  80 0 5 l:l 
24 f I Rhabdomyosarcoma 1 1  1 6p l l , l 6p l 3  -I  -I  5 30 I --· 
25 m 68 I i posarcoma Ill 1 6p 1 3  • -1 40 80 90 c ;::: 
26 f 70 liposarcoma I control 0 0 0 "" 
27 f 43 liposarcoma 1 1  control 70 50 5 l:l ;::: 
28 m 4 8  liposarcoma 1 1  control 60 90 5 � 
29 m 69 I i posarcoma 11 control 60 40 5 � 30 f 84 sarcoma NOS 11 control 60 90 1 0  "t:::i 
3 1  f 5 9  sarcoma NOS 1 1  control 0 30 1 0  � 
32 f 26 Synovial sarcoma Ill control 1 0  90 0 � 
33 m 43 Synovial sarcoma control 40 0 0 c;· 
34 f 28 Mal. Hacmangiopericytoma 1 1  control 40 40 40 ;::: 
35 m 5 0  Mal. Haemangiopericytoma control 0 0 0 � 
36 m 22 Epithelioid sarcoma control 20 70 70 
� 37 f 27 angiosarcoma I control 60 90 40 
38 m 60 Leiomyosarcoma 1 1  control 80 90 40 � 
39 m 89 Mal. Fibrous histioc�oma Ill control 40 50 1 0  � 
P-gp: P-glycoprotein, MRP1: multidrug resistance protein, LRP: lung resistance protein,m: male, f: female, abnorm.: abnormalities, Mal.: malignant, c:l 
*myxoid liposarcoma with round cell component NOS: not otherwise specified, MPNST: malignant peripheral nerve sheath tumor; •: breakpoint � ..... ;;· -..I ""' "" 
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semiquantitatively assessed by estimating the percentage of  positive stained tumor 
cells and assessing staining intensity using a scale of 0 -3 (0: no staining, 1 :  very weak 
staining, 2: intermediate staining, 3 :  strong staining). Strong staining intensity was 
comparable to the staining intensity of the simultaneously stained positive control 
tissue. Both staining parameters were also combined into a so called histopath-score 
which is defmed as: the estimated percentage of stained cells (0-100%) x the staining 
intensity (0-3) 300• According to the literature, tumor samples were considered negative 
for expression of each of the proteins if� 5% of the cells were positive 96• 1 03 • 
Statistics 
A Fisher exact test was used to analyze the distribution of the examined cases 
within the groups. A Mann Whitney Test was carried out to analyze the differences 
in MDR parameters between the tumors with and without abnormal chromosomal 
regions i.e. 7q2 1 ,  1 6p l l ,  1 6p l 3 .  To avoid the problem of multi-comparison in the 
analyses of P-gp, MRP 1 and LRP expression, a Bonferroni correction factor of 3 was 
introduced. To quantitate the degree of correlation between MDR protein expression 
and the amount of chromosomal gain or loss, the Spearman's rank test was used. A 
two-tailed p-value of < 0.05 was considered to be significant. Statistical software 
SPSS 9.0 for Windows (SPSS Inc., Chicago IL, USA) was used for statistical 
analysis. 
RESULTS 
One out of 1 1  (9%) f:il2 negative STS and 4/28 ( 14%) P-gp positive STS had 
breakpoints or loss of 7q2 1 (N.S.). As shown in Table 2 and Figure I ,  P-gp 
expression in the 5 STS with breakpoints in or loss of 7q21 was not different from 
the P-gp expression in the 27 STS with normal chromosomes 7, as assessed by both 
the percentage of positive cells and the histopath score (Figure l a). When the P-gp 
expression was related to chromosomal gain or loss in 7q21 ,  no correlation was 
observed with either percentage of positive cells (Figure 1b) or histopath score. 
Ten out of 1 6  (63%) LB.£ negative STS and 5/23 (22%) LRP positive STS had 
breakpoints or loss of 1 6p 1 1 (p=0.02). As has been depicted in Figure 2, the 
expression of LRP, as assessed by the percentage of positive cells and histopath 
score, in the 1 5  STS with a breakpoint in or loss of 1 6p 1 1  was significantly lower 
than in the 2 1  STS with normal chromosomes 16  (p=0.03)(Table 2). In the 39 STS, a 
significant correlation was observed between the amount of cytogenetically intact 
chromosomal material in 1 6p 1 1  and the LRP expression (Figure 2c). 
Six out of 22 (27%) MB£1 negative STS and 4/17  (24%) MRP1 positive STS 
had breakpoints or loss of 16p 1 3  (N.S.). No differences in MRP1 expression, as 
assessed by either the percentage of positive cells or histopath-score, were observed 
between the 1 0  STS with breakpoints in or loss of 16p l 3  and the 27 STS with normal 
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Table 2. 
















3 1 .9 
0-90 






in 1 6pl l in 1 6pl3 














mean: 79 52 1 13• 20• 30 48 
median: 60 40 120• 10• 1 0  5 
SD: 77.3 42. 1  96.0 40.7 48.4 83.5 
range: 0-270 0- 100 0-270 0- 160 0-2 10  0-270 
P-gp: P-glycoprotein, MRP1 :  multidrug resistance protein, LRP: lung resistance protein; 
"histopath score: % positive cells x staining intensity (0-3), •p=0.03 
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chromosomes 1 6  (Table 2; Figure 3a). MRP1 expression did not correlate with the 
amount of intact chromosomal material in 16p 13  (Figure 3b). 
Ten (26%) of the 39 studied STS were myxoid LPS and in nine of them a 
t{ l2 ; 16)(q 13 ;p l l )  was found. No differences in P-gp and MRP1 expression were 
observed between the myxoid LPS group and the other LPS or the other STS, but 
LRP expression in the myxoid LPS was lower (p=0.03). P-gp, MRP1 or LRP 
expression in the non-myxoid LPS was comparable with the expression in the STS 
other than liposarcomas (Table 3). P-gp expression, as determined by the amount of 
positive cells and the histopath score, did not correlate with LRP or MRP 1 
expression. However, MRP 1 expression did correlate with LRP expression with 
respect to both the percentage positive cells (r: 0.49; p=O.OOS) and histopath score (r: 
0.52; p=0.002) and the correlation was still present when the myxoid LPS were 
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Table 3. 
The expression ofP-gp, LRP and MRP1 in myxoid LPS, other LPS and non-lipomatous 
STS. 
P-gp LRP MRPI 
myxoid other other myxoid other Other Myxoid other other 
LPS LPS STS LPS LPS STS LPS LPS STS 
tumors {n}: 1 0  9 20 10  9 20 10  9 20 
P2Sitiv�: �;�:lis; 
mean (%): 48 42 35 8•• 5 1 *  39H 1 0  28 23 
median (%): 55 40 35 o•• 50* 30. 0 5 10  
SD (%): 38.0 28.5 30. 1 1 8.6 34.4 34.5 22.0 34.0 27.6 
range{%}: 0-90 0-80 0-90 0-60 0-90 0-90 0-70 0-90 0-70 
"hifitQpiltb fi!;Q�; 
mean: 88 64 57 16·· 107* 87" 20 52 32 
median: 75 60 35 o•• 1 00* 30" 0 5 15  
SD: 83.2 5 1 .7 69.8 37.2 84.3 95. 1  44. 1 86.6 48.7 
range: 0-240 0-160 0-270 0-1 20 0-240 0-270 0-140 0-270 0-2 10 
P-gp: P-glycoprotein, MRP 1 :  multidrug resistance protein, LRP: lung resistance protein; 
"histopath score: % positive cells x staining intensity (0-3), * difference between myxoid 




Cytogenetic analysis led to the detection of tumor specific chromosomal 
alterations which are of diagnostic value and has been helpful in clarifying 
oncogenesis of various malignant solid tumors 6 1•358"360• The sites of chromosome 
breakage could affect genes located in the affected chromosomal regions. In AML, 
the inv( 1 6)(p 13q22) is not only of diagnostic importance, but also has a prognostic 
value 45 1 • Chromosome breakage in the 16p 1 1- 16p 13  region could affect the 
expression of the genes for LRP and MRP 1 genes which might be of clinical 
importance 97•295•448•450• In a recent study of Van der Kolk et al. (personal 
communication) the activity of MRP1 in AML patient samples was shown to 
correlate with the presence of the number of fluorescence in situ hybridization 
(FISH) signals, suggesting that there is a relation between number of altered 
chromosomes and the functional activity ofMRP1 • 
The current study, using conventional cytogenetics, examined whether chromosome 
alterations in 7q21 ,  16p 1 1 and 1 6p13  could affect the expression of P-gp, MRP1 and 
LRP in STS. 
It was observed that P-gp expression is not modified by breakpoints in or loss 
of 7q2 1 .  However, only 5 STS could be detected from our database with breakpoints 
in or loss of 7 q2 1 whereas eight cases had gain of 7 q2 1 .  In combination with the 
frequent expression of P-gp STS (chapter 7 of this thesis) 100. 103• 108•297•324, this suggests 
that deletion of P-gp gene on 7q21 is infrequent. No evidence was found that gain of 
chromosomal material of 7q2 1 leads to more expression ofP-gp. 
MRP 1 expression seems not to be influenced by chromosome breakage or loss 
in STS, although MRP1 expression in the 27 STS with normal chromosomes 16 was 
also low. Another recent study of immunohistochemically detected MRP1 in STS, 
indicates that MRP 1 expression in STS is low as compared to P-gp and LRP 
expression (chapter 7 of this thesis). This means that the influence of chromosome 
breakage on immunohistochemically detected MRP 1 expression has to be examined 
in larger groups of specific histological types with relatively high MRP 1 expression. 
LRP expression was low or absent in most of the tumors with breakpoints in 
or loss of 16p 1 1 ,  but abundant in the other STS with normal chromosomes 1 6. This 
indicates that, unlike P-gp and MRPh damage or loss of the 1 6p 1 1 region of one 
chromosome could dramatically alter the expression of LRP. Furthermore, when the 
amount of intact chromosome 16p 1 1  material was correlated with LRP expression, 
the LRP expression was more prominent in the tumors with normal chromosomes 16  
or  gain of  16p 1 1 .  Van der Kolk et al. (personal communication) have observed a 
similar correlation between the biological activity of MRP 1 and the number of intact 
MRP 1 genes in AML. Since LRP expression is prominent in STS in general (chapter 
7 of this thesis), a non-functioning LRP gene can be recognized easily. In myxoid 
LPS, LRP expression was lower than in other LPS, indicating that low LRP 
expression is not related to lipogenic differentiation. The importance of the 
chromosomal aberrations in 1 6p 1 1  on the expression of LRP is further strenghtened 
by the finding of a t( 12 ; 16)(q 13 ;p 1 1 )  in 9 of the myxoid LPS. In parallel to studies 
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reporting a correlation between tumor grade and P-gp and MRP1 expression, low 
LRP levels might also be explained by the fact that all myxoid LPS were low grade 
tumors 100• 108•455• However, in a previous study (chapter 7 of this thesis) no relation 
between LRP expression and tumor grade was found and also in the present study the 
expression of LRP did not correlate with tumor grade. Although LRP has been 
shown to be associated with clinical drug resistance in ovarian carcinoma, AML and 
multiple myeloma, LRP has also been detected in many normal cell types and is 
thought to act as an intracellular transporter protein not only carrying MDR cytotoxic 
substances towards the extracellular environment 95'97•292•294•296• LRP seems to be 
correlated with MRP1 expression in this group of STS which were selected for the 
presence of 16p l 1 - 1 3  abnormalities. Twelve out of 16  (75%) LRP negative tumors 
were also MRP 1 negative, which indicates that chromosome breakage in or loss of 
1 6p l l could also affect the expression of the MRP1 gene. However, of the 27 STS 
with normal 16p 1 3  regions 14 cases were MRP1 negative and 6 of 2 1  cases with a 
cytogenetically normal 1 6p 1 1  had no expression of LRP. This indicates that, 
although a cytogenetically normal gene is present it is not necessarily transcribed. 
Future studies in STS, should examine the expression of and interaction between 
other A TP binding cassette membrane efflux pumps such as MRP 2 or MRP 6 , which 
are of clinical importance in other malignancies, or the ARA (anthracycline resistance 
associated) gene, located immediately beside the MRP1 gene 354•459• 
Since the present study was performed with conventional cytogenetics, non­
identified chromosomal material, e.g. marker chromosomes, could contain the P-gp 
or MRP 1 gene. Furthermore, DNA mutations or small deletions can not be recognized 
with cytogenetic analysis. Therefore, future studies should use FISH or spectral 
karyotyping to identify "hidden" 7q2 1 or 16p13  regions with intact P-gp or MRP1 
genes. 
In conclusion, the expression of LRP in STS seems to be influenced by 
chromosome breakage, loss or gain, while P-gp and MRP 1 expression are not. Future 
FISH studies might confirm the relation between 16p 1 1  aberrations, the expression 
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SUMMARY 
The most important prognostic factor in soft tissue sarcomas (STS) is tumor 
grade. Since most grading methods are subject to the interpretation of the individual 
pathologist, there is a need for more objective criteria like DNA ploidy and 
karyotype, which are of prognostic value in several malignancies. The current study 
analyses the relationship between tumor grade, DNA ploidy, cytogenetic 
abnormalities and the clinical outcome of 44 previously untreated patients with 12 
different histological types of primary STS. The tumors were graded according to 
the method described by Coindre which resulted in 9 grade I (20%), 18 grade If 
(41%) and 1 7  grade Ill (39%) STS. DNA flow cytometry and chromosomal analysis 
were performed using standard techniques. After a median follow-up time of 39 
(range: 2 to 124) months, Kaplan-Meier survival analysis was performed. Significant 
differences in 5-years overall survival were found between patients with grade I or If 
and grade Ill STS (p<0.05). Seventeen STS were aneuploid and twenty-six were 
euploid. In 21 out of 3 9 successfully cultured STS an abnormal karyotype was found. 
There were no significant differences in survival in relation to DNA ploidy or the 
presence of chromosomal abnormalities. These results demonstrate that grading is of 
more prognostic value than DNA ploidy or the presence of cytogenetic abnormalities 
in this heterogeneous group of STS. Further studies on the different histological 
types of STS and including more patients are needed to definitely asses the 
prognostic value of these adjuvant techniques. 
INTRODUCTION 
In soft tissue sarcomas (STS) tumor grade is the most significant prognostic 
factor 8• A higher tumor grade is associated with a worse prognosis. However, 
different grading systems are being used 29 which consider mitotic activity and 
necrosis as most important factors. The significance of other criteria, such as tumor 
type and differentiation level, cellularity, nuclear atypia, cellular pleomorphism, a­
mount of fibrous stroma and extent of myxoid areas is debated. Because these factors 
are subject to the interpretation of the pathologist, more objective criteria are needed 
29• One such criterion could be DNA ploidy, which has been shown to be of 
prognostic value in different types of epithelial tumors as well as in sarcomas of bone 
and cartilage 40• Previous studies in soft tissue tumors have indicated that DNA 
ploidy is associated with malignancy and tumor grade, i.e. benign soft tissue tumors 
are almost always diploid and sarcomas are either diploid or aneuploid 40• 
Aneuploidy is more common in high grade sarcomas than in low- or intermediate 
grade sarcomas 42• The significance of DNA ploidy as a prognostic factor, however, 
may differ among the various histological types of soft tissue sarcomas 156• 159• 160• 
Previous studies on cytogenetic abnormalities in sarcomas have focused on 
the significance for histological classification 49•53•457• In addition, some studies have 
suggested that chromosomal changes occur in the process of tumor progression 42•457• 
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In hematologic malignancies and in brain tumors cytogenetic abnormalities have 
been shown to be of prognostic value 358• In STS few attempts have been made to 
establish a relationship between chromosomal abnormalities and prognosis. Recent 
studies showed a higher risk for relapse in patients with a malignant fibrous 
histiocytoma expressing 19p+ 1 63• 
In a previous study we compared the relation between cytogenetic abnor­
malities and DNA ploidy of benign, borderline malignant and different grades of 
malignant soft tissue tumors 
42
• The current study analyses the relationship between 
tumor grade, DNA ploidy, cytogenetic abnormalities and the clinical outcome of 44 
previously untreated patients with different malignant soft tissue tumors. 
MATERIALS AND METHODS 
Selection of material 
During the period 1984 - 1993 an attempt was made to obtain karyotypes from 
all sarcoma specimens submitted for pathological examination. The criteria for 
inclusion in the current study were 1 )  a histological diagnosis of a primary, malignant 
mesenchymal tumor, located in the soft tissues, which was previously untreated, 2) 
the availability of fresh, viable tissue submitted for chromosomal analysis and 3) the 
availability of clinical follow-up of the patients who were diagnosed at least 2 years 
before analysis. Mesenchymal proliferations of parenchyma! organs were excluded. 
Cases with a doubtful histological diagnosis in regard to the mesenchymal character 
of the tumor were excluded, but malignant tumors with a definite mesenchymal 
histogenesis, but uncertain classification were included. 
Patients 
Between 1984 and 1 993, 44 patients fulfilled the selection criteria and were 
studied. The patient group consisted of 1 8  male and 26 female patients. Age of the 
patient, histological diagnosis and tumor grade of all 44 cases are presented in Table 
I. The age of the patients at the time of diagnosis ranged from 1 0  to 84 years. The 
median age was 54 years. Four tumors were located in the head-neck region (9%), 
two in the thoracic region (5%), two in the abdomen (5%), three in the 
retroperitoneum (7% ), five in the upper limb ( 1 1%) and twenty-eight in the lower 
limb (63%). 
Disease free survival (DFS) time (i.e. the time between the treatment of the 
primary tumor and the time of local recurrence or distant metastasis) and overall 
survival (OS) time were recorded. All patient and treatment data were documented. 
Patients with marginal resections received adjuvant external beam radiotherapy. 
Patients with wide local resections or radical resections e.g. amputations received no 
adjuvant radiotherapy. These treatments were considered adequate. Patients with 
intralesional resections or contaminated surgical resections received adjuvant high 
dose radiotherapy, and their treatment was considered inadequate. Patients with 
adequate local treatment with distant metastasis at the time of diagnosis were 
183 
Chapter 15 
analyzed in the group of inadequately treated patients, since there was no curative 
treatment option. 
Tumor parameters 
The tumor parameters grade, DNA ploidy and karyotype were studied. 
Because other studies reported the artefact of normal karyotypes most likely due to 
overgrowing fibroblasts in culture 42, the results of DNA flowcytometry and 
chromosomal analysis were also combined by subdividing the STS in four groups: I )  
DNA-euploid with a normal karyotype, 2 )  DNA-euploid with an abnormal 
karyotype, 3) DNA-aneuploid with an abnormal karyotype, 4) DNA- aneuploid with 
a normal or unsuccessful karyotype. 
Histology and grading 
In all cases the histological diagnosis was made on H&E stained paraffin 
sections with or without additional immunohistological stains on paraffin and/or 
frozen sections. All cases were classified according to Enzinger and W eiss 8 which 
revealed 1 3  different histological types (table I ). The STS were graded according to 
the system described by Coindre et al. 29, in which points are assigned to differentiati­
on level ( 1 :  closely resembling normal tissue; 2: certain histogenetic classification; 3 :  
undifferentiated), mitotic index per 2 mm2 ( 1 : 0-9; 2:  I 0- 1 9; 3 :  2 0  or more) and 
necrosis (0: none; I :  less than 50%; 2: more than 50%). Tumors with a total score of 
2 or 3 were graded as grade I, those with a total score of 4 or 5 as grade 11 and those 
with a total score of 6-8 as grade Ill. This resulted in 9 grade I (20%), 1 8  grade 11 
(4I %) and 1 7  grade Ill (39%) STS. 
DNA flow cytometry 
DNA flow cytometry was primarily performed on single cell suspensions 
obtained from frozen material adjacent to the material submitted for tissue culture 
and chromosome analysis. If this did not yield an interpretable result, samples prepa­
red from paraffin blocks of the same operation specimen were used. Samples from 
frozen material were prepared according to the method described by Vindelov 460• 
Nuclear suspensions from paraffin embedded tissue were made according to method 
described by Hedley 461 •  H&E-stained histologic slides were used to select 
representative parts of the tumor. To determine the DNA ploidy, isolated nuclei from 
the tumor were stained with propidium iodide and the intensity of the fluorescent signal 
was measured using a FACS 440-, FACStar- (Becton Dickinson) or ICP22- (Ortho) 
flow cytometer. In each sample at least I 0.000 nuclei were analyzed. 
The DNA profile was considered euploid when a single stem line was present 
in the diploid or in the tetraploid range; all others were considered aneuploid. 
Tissue culture and chromosome analysis 
Fresh representative tumor material for chromosomal analysis was cultured for 
6-I5  days in RPMI I 640 (Gibco), supplemented with 13 .5% fetal calf serum, L­
glutamin and penicillin/streptomycin. Cultures were harvested and chromosome 
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preparations were made according to standard cytogenetic techniques. The metaphases 
were air dried and stained with Giemsa after G banding with either trypsin 1 :250 
(0.25%, Difco) or pancreatin (0. 1 %, Sigma). The karyotypes were described according 
to the ISCN ( 1995) Guidelines for Cancer Cytogenetics 377• 
Statistical analysis 
In order to compare overall survival (OS) and disease free survival (DFS) for 
the different patient groups in relation to grade, DNA ploidy, karyotype and the 
combination of DNA ploidy and karyotype, actuarial survival curves were 
constructed by the Kaplan-Meier method. Survival curves in the different groups 
were compared by the log-rank test. A Chi squared test or Chi squared test for trend 
was used to estimate the differences in tumor characteristics (tumor grade, DNA 
ploidy and karyotype). A p-value of <0.05 was considered statistically significant. 
RESULTS 
Tumor grade in relation to DNA ploidy and karyotype 
Histology: The two most frequent histological diagnoses were malignant 
fibrous histiocytoma (MFH; 12  cases) and myxoid liposarcoma (8 cases) (Table I). 
Nine tumors were grade I (20%), 1 8  grade 11 (4 1%) and 1 7  grade Ill (39%). 
DNA ploidy: All grade I tumors except one (an extraosseous myxoid chondro­
sarcoma), appeared to be DNA-euploid. In contrast, 8 of the 1 8  grade 11 and 8 of the 
1 7  grade Ill tumors were ON A-aneuploid (Table 11). The suspension of one grade Ill 
MFH yielded no interpretable results. The difference in distribution of the euploid 
and aneuploid tumors among the three tumor grade groups was not quite statistically 
significant (p= 0.08). There were significantly more aneuploid MFHs than aneuploid 
liposarcomas or synovial sarcomas: 2 out of 1 3  liposarcomas and 1 out of 6 synovial 
sarcomas were aneuploid, whereas 9 out of 13  MFHs were aneuploid (p<O.OS). 
Karyotype: Abnormal karyotypes were found in 4 out of 9 grade I (44%), 10  
out of  1 8  grade 11 (56%) and 7 of  1 7  grade Ill (41%) tumors (Table 11). In 8 
liposarcomas, 4 synovial sarcomas and in 4 out of 1 2  MFHs an abnormal karyotype 
was found The differences among these groups were not statistically significant. 
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Table 1. Patients, tumor grade, histology and median age 
tumor grade histologic diagnosis n age (years) 
grade I (n=9) 
grade 11 (n=l8) 
grade Ill (n=17) 
myxoid liposarcoma 
synovial sarcoma 
clear cell sarcoma 
MFH1 






























2 1  
56 
58 
1MFH: malignant fibrous histiocytoma; 2pPNET: peripheral primitive neuroectodermal 
tu m or 
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Combination of karyotype and DNA ploidy: There were 9 euploid tumors 
with a normal karyotype, 14 euploid tumors with an abnormal karyotype, 7 aneuploid 
tumors with an abnormal karyotype. The remaining group of 1 4  STS consisted of 
aneuploid tumors with either a normal or unsuccessful karyotype or in which 
assessment of DNA ploidy or karyotyping was unsuccessful. Euploid STS with an 
abnormal karyotype can be explained by either minor numerical or structural 
chromosomal aberrations as discussed before 
42•462• 
Treatment 
Of the 44 patients 33 were treated for cure. Nine other patients were treated 
for local cure but had distant metastases at the time of diagnosis. In the remaining 
two other patients adequate treatment was not conceivable since surgery or adjuvant 
radiotherapy was not possible because of the location of the tumor ( 1  patient) or 
adjuvant radiotherapy was not desirable because of poor wound healing (1 patient). 
Overall survival and disease free survival 
The median follow-up period was 39 months and ranged from 2 months in a 
woman who died from a grade Ill malignant rhabdoid tumor, to 1 24 months, a man 
with a grade II leiomyosarcoma. Survival status in relation to tumor grade, DNA 
ploidy and karyotype is presented in Table Ill. At the end of the follow-up period 1 8  
patients were alive with no evidence of disease (NED), 2 patients were alive with 
disease (A WD) and 1 9  patients died of their disease (DOD). Two patients died of 
another cause after 84 and 1 1  months follow-up. Three patients were lost to follow­
up. Five patients had an isolated local recurrence, 9 patients developed isolated 
distant metastases and 4 patients developed a local recurrence with distant 
metastases. Fifteen out of 1 9  patients developed a local recurrence or metastasis 
within 2 years after treatment. In the patients with distant metastases DNA 
flowcytometry of their primary tumor revealed 8 euploid and 5 aneuploid patterns. 
Table 3. Survival status in relation to tumor grade, DNA ploidy and karyotype 
Survival number Grade DNA-ploidy Karyotype 
status of 
atients 
NED 1 8  
AWD 2 




I 11 Ill 
4 lO  4 
1 1 0 
3 5 1 1  
0 0 2 
1 2 0 
9 1 8  1 7  
EuQI. Aneu21. Unsucc. Normal Abnormal 
10  8 0 5 1 1  
2 0 0 1 1 
1 2  6 1 9 7 
1 1 0 1 1 
1 2 0 0 1 








NED: alive, no evidence of disease; A WD: alive with disease; DOD: died of disease; 
DOC: died of other causes; LOFU: Lost to follow-up; Eupl. :  euploid, 
Aneupl.: aneuploid; Unsucc.: unsuccessful 
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OS and DFS of STS-patients were determined in relation to tumor grade, 
DNA ploidy, karyotype and the four groups in which karyotype and DNA ploidy 
were combined. In view of the limited number of patients, a 2-years DFS analysis 
was performed. Table IV shows the mean and median OS and DFS time as well as 
the 5-years OS and 2-years DFS percentages. 
OS curves according to the different tumor grades are shown in Figure 1 .  
Significant differences in OS time were found between patients with grade I and 
grade Ill STS (p = 0.02) as well as between patients with grade 11 and grade Ill STS 
(p = 0.005). OS analysis revealed neither significant differences between patients 
with DNA-euploid versus -aneuploid STS (Fig. 2) nor between patients with STS 
with a normal versus abnormal karyotype (Fig. 3) . Furthermore, no significant 
differences in OS were observed among the four patient groups in which the results 
of DNA flowcytometry and chromosomal analysis were combined (Fig. 4). The 
differences in 2-years DFS of the analyzed patient groups were not statistically 
significant. 
After stratification for adequate and inadequate treatment or for the three 
major histological types (MFH, liposarcoma, synovial sarcoma), no significant 
differences in OS and DFS were found in relation to DNA ploidy and karyotype. A 
significant difference (p<O.OOO l )  in OS was found between the patients who were 
adequately treated (mean OS time: 56 months) and those who were not (mean OS 
time: 20 months). The 5-years OS of patients which were adequately treated was 
75%, while the 5-years OS of patients who could not be adequately treated was 9%. 
Table 4. 
Overall and disease free survival according to tumor grade, DNA ploidy and karyotype 
parameter number OS DFS 5-yrs 2-yrs 









euploid + normal karyotype 
euploid + abnormal karyotype 
aneuploid + abnormal karyotype 
aneuploid + normal or 
unsuccessful karyotype 
patients mean/median mean/median 
8 93 I I l l  7 1  I 50 
16 93 1 108 78 1 -
17  42 1 16 *  54 1 21 
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Overall survival for patients with STS expressing a normal ( +) or abnormal (e) 
karyotype or in which karyotyping was unsuccessful <•). 
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Figure 4 
Overall survival for the four STS-patient groups with euploid and cytogenetically normal 
STS ( + ), euploid and cytogenetically abnormal STS (e), aneuploid and cytogenetically 
abnormal STS <•) and the remaining STS expressing either an aneuploid STS with a 
normal karyotype or in which assessment of DNA ploidy or karyotyping was 
unsuccessful (T). 
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DISCUSSION 
The prognosis of patients with STS is determined by three major factors: the 
patient, the tumor (histology and stage) and the treatment. In order to adjust therapy 
to improve survival of a patient, the pathologist has to estimate the degree of 
malignancy by assessing the biological properties of the tumor. Therefore several 
systems of classification and grading have been established for STS. Because these 
systems are subject to controversies 2
9
, there is a need for more objective criteria 
which are directly related to the individual tumor and have a high prognostic value. 
The prognostic value of two such possible criteria (DNA ploidy and karyotype) was 
assessed in relation to the established grading system as described by Coindre 2
9 
on 
44 patients with histotypically different STS. To reduce the possibility of therapy 
induced alterations in DNA content or chromosomal aberrations, only previously 
untreated patients were entered in this study. 
Tumor grade, DNA ploidy and karyotype 
The majority of the liposarcomas and synovial sarcomas were euploid and 
had a structural or minor numerical chromosomal aberration. In contrast, the majority 
ofMFHs were aneuploid, but had a normal karyotype. Half of the grade Ill STS were 
aneuploid, while in grade I STS only I out of 9 was aneuploid. Half of all grade Ill 
STS revealed a normal karyotype, while only 4 out 1 8  grade 11 STS and 3 out of 9 
grade I STS did. This relative high percentage of normal karyotypes in grade Ill STS 
and MFH together with a tendency towards DNA-aneuploidy when tumor grade is 




Overall survival and disease free survival 
By determining OS and DFS of STS-patients with different tumor grades, we 
showed that our patient group was representative. In concordance with reports in the 
literature, we found a significant relationship between tumor grade and survival 
8• 
No statistically significant relationship was found between DNA ploidy and 
survival which is in agreement with recent studies of heterogeneous groups of STS 
126•157• In contrast, in other studies a relationship was found between DNA ploidy and 
prognosis, i.e. DNA-aneuploid tumors had a worse prognosis than euploid tumors 156• 
However, studies of specific histological types of STS revealed different outcomes 
1 56• 1 59•160• For example in synovial sarcomas a relationship was found between DNA 
ploidy and survival 1 5
9
, whereas in liposarcomas DNA ploidy was not of prognostic 
value 160• The lack of a correlation between DNA ploidy and survival in our group 
could be explained by the fact that our group of STS included relatively many 
liposarcomas. 
Karyotyping has been shown to be an adjunct in histological diagnosis. 
Whether it is of prognostic significance has to be determined. In this respect, we 
believe that the finding of an abnormal karyotype (e.g. t( 12 ; 16)(q 13 ;p l l )  in myxoid 
or round cell liposarcoma) in a primary untreated STS is of more diagnostic value 
1 9 1  
Chapter 15 
than it  is  of prognostic value. Additional chromosomal abnormalities could be of 
more prognostic value than the finding of a type characteristic cytogenetic anomaly 
55•463• Comparing the cytogenetic results with survival, no statistically significant 
differences were found between patients with cytogenetically normal or abnormal 
STS. This could be due to the previous described difficulties in culturing highly 
malignant STS 42• Even by the formation of 4 groups combining DNA ploidy and 
karyotype in order to solve this problem of the overgrowing fibroblasts, no 
significant differences in OS and DFS were found between those groups. Recent 
studies 163 showed that chromosomal alterations involving 19p 13  are associated with 
a high recurrence rate in MFH. This was not confirmed in our study, in which one 
MFH showing an alteration in 19p 1 3  was found in a patient who is without evidence 
of disease 105 months after treatment. 
This study shows that for this heterogeneous group of previously untreated 
patients with STS, the histological grade of the primary tumor is of more prognostic 
value than DNA ploidy and the karyotypic findings. Further studies in larger groups 
of untreated patients, focusing on separate histological types of STS are mandatory. 
In this way the prognostic value of these techniques can further be assessed. 
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SUMMARY, GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
Chapter 16 
The heterogeneous group of STS is  characterized by their unknown 
tumorigenesis and the absence of clear tumor biological prognostic markers. 
Traditional prognostic factors such as tumor grade and size still have the best 
predictive value. Research has been performed on tumor biological characteristics 
which could be helpful in the adequate diagnosis of STS, tumor tailored therapy and 
the prediction of treatment results and clinical outcome. Although the knowledge of 
oncogenesis and treatment induced biological changes in STS is increasing, many 
questions have still to be answered. 
In this thesis, histopathological and cytogenetic methods in STS were used to 
assess their value in diagnosis, treatment and the prediction of clinical outcome. 
HISTOPATHOLOGY 
A reliable recognition of mitotic figures needs training. 
Tumor grade is one of the most important prognostic factors in STS. An 
inaccurate assessment of tumor grade may also have clinical consequences. In most 
of the commonly used grading systems, the mitotic activity plays a central role. It is 
known that there is interobserver variability in the assessment of mitotic figures and 
that the number of mitoses also depends on the fixation protocol. Another method to 
assess proliferative activity is the MIB-1 labeling of proliferating cells. MIB- 1 is an 
antibody directed against the nuclear antigen Ki-67. Those two methods were 
compared in chapter 2. It was demonstrated that experience in the assessment of 
mitotic figures decreases the "unexplained" variance in the mitotic counts. The 
assessment of MIB- 1 detected proliferation is less influenced by experience and the 
"unexplained" variance is lower than in the mitotic counts. However, staining costs 
are relatively high as compared to the simple and quick haematoxylin-eosin staining 
used in the counting of mitotic figures. MIB-1 detected proliferation and mitotic 
indices were not correlated, indicating that proliferating cells are not the same as 
dividing cells: Ki-67 precedes the actual cell division and remains present in the 
nucleus even when the cell cycle is interrupted. 
This study suggests that the assessment of mitotic figures is a learning process 
which can be trained. Modem image software and multimedia devices, could be used 
for this purpose in the training of pathologists. This will be helpful in the 
differentiation from, for instance, apoptotic cells. It will further improve the internal 
personal and laboratory standard for the recognition of mitotic figures and will lead 
to a more uniform assessment of malignancy grade. 
TYR-PET is a suitable way to assess proliferative activity in STS. 
As has been demonstrated in chapter 3, the proliferative activity in STS can 
also be detected in vivo by the assessment of protein synthesis rate (PSR) using 
positron emission tomography with L-[1 -1 1C]tyrosine {TYR-PET). A correlation was 
found between PSR and the Ki-67 proliferation index, and between PSR and mitotic 
rate. 
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These findings indicate that the non-invasive method of TYR-PET can 
estimate the mitotic and proliferative activity in STS and might provide additional 
information in the assessment of malignancy grade. It can be used in the detection of 
those tumor regions that have the highest proliferative activity. This would be helpful 
in the determination of the optimal localization for tumor biopsy. In addition it might 
be worthwhile to use TYR-PET in the evaluation of treatment responses in vivo, 
which could be more reliable that the traditional assessment with physical 
examination and radiographical screening. 
IMT-SPECT can also be used to assess proliferative activity in STS. 
Another method to visualize PSR and amino acid transport in tumors is the use 
of single photon emission computerized tomography (SPECT) with 123I-labeled 
amino acid L-3-[123I] iodo-alpha-methyl tyrosine (IMT). Proliferative and mitotic 
activity is a measure of malignancy grade and can be assessed in vitro. Cellularity 
has also been used in grading systems and could affect the tumor related PSR. 
Furthermore, the amount of blood vessels and capillaries in a tumor could also affect 
the PSR specific IMT -SPECT signal. In chapter 4 of this thesis, it was found that in 
benign and malignant soft tissue tumors IMT -SPECT correlates with cellularity, 
proliferative and mitotic activity , but not with vascularity. 
This means that IMT -SPECT is indeed a measure for malignancy in vivo and 
could be used to detect proliferative activity in tumors. These results indicate that 
IMT-SPECT could be used for detection of high proliferative regions before 
diagnostic surgery or could be helpful in the assessment of treatment response. 
Unlike TYR-PET, IMT-SPECT does not require a complex infrastructure. However, 
in future studies IMT-SPECT should be validated and compared with TYR-PET in a 
group of solely malignant soft tissue tumors. 
Response to HILP with TNF-a and melphalan is better in STS with high mitotic 
activity and is associated with an increase in apoptotic cells. 
Hyperthermic isolated limb perfusion with tumor necrosis factor-a (TNF-a) 
and melphalan (HILP-TM) with or without interferon-y (IFN-y) is a breakthrough in 
the local treatment of patients with primary irresectable locally advanced extremity 
STS with response rates of up to 84%. The mechanisms of the treatment response are 
poorly understood. Chapter 5 of this thesis demonstrates that proliferative activity 
dropped after HILP-TM, whereas the amount of apoptosis was increased. The 
addition ofiFN-y to HILP-TM did not influence the changes in tumor parameters and 
did not affect treatment response. A better clinical response to HILP-TM was 
correlated with high mitotic activity and low amount of apoptosis in tumor samples 
before HILP-TM. Patients with highly proliferative STS before and after HILP-TM 
had a relatively poor prognosis. Furthermore, patients who developed distant 
metastases after HILP-TM had a relatively high number of dividing cells in the 
residual tumor after treatment. 
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These results indicate that HILP-TM directly affects tumor cells and that 
tumor biological processes involved in apoptosis are related with the response rate in 
HILP-TM treated patients with locally advanced STS. The value of other proteins 
involved in the apoptotic pathway for the prediction of treatment response has to be 
evaluated in future studies. 
Proliferative activity after HILP with TNF-a and melphalan can be measured with 
TYR-PET. 
In the experimental treatment with HILP-TM a period of 6-8 weeks is used 
before delayed local excision of the perfused residual tumor will take place. In 
chapter 6 it has been demonstrated that the proliferative and mitotic activity before 
HILP-TM can be measured with both 1 8F-fluoro-deoxy-D-glucose (FDG)-PET, a 
method to visualize glucose consumption, and TYR-PET. However, after HILP-TM, 
the correlation between FDG-PET and proliferative activity disappeared, whereas 
correlation between proliferative activity and TYR-PET improved. 
This means that TYR-PET is the most suitable tracer to assess responses to 
HILP-TM. This is important since with TYR-PET the turning point in proliferative 
activity in the perfused tumor can be visualized and the optimal time point for 
delayed tumor resection can be chosen. 
Expression of P-gp, MRP1 and LRP varies between the histological types of STS. 
In case of diffuse distant metastases, chemotherapy is used in STS. Poor 
responses to chemotherapy are observed in specific types of STS, especially 
leiomyosarcoma (LMS) and malignant fibrous histiocytoma (MFH). Liposarcomas 
(LPS) have a favorable response to chemotherapy. Cross resistance to a number of 
functionally and structurally distinct natural product drugs is called multidrug 
resistance (MDR). Several mechanisms have been found to be responsible for MDR. 
In this study we have focussed on expression ofP-glycoprotein (P-gp), the multidrug 
resistance related protein- 1 (MRP1) and the lung resistance protein (LRP). In chapter 
7 of this thesis, a series of 1 1 5 chemotherapy naive STS was studied for the 
expression of P�gp, MRP 1 and LRP with respect to histological type and tumor grade. 
Seventy-one percent of the STS expressed P-gp, 36% MRP1 and 70% LRP. At least 
one MDR protein was detected in 95% of the STS. No correlation was found 
between tumor grade and the expression of P-gp, MRP1 or LRP. However, eo­
expression was less frequently observed in low grade STS. These results demonstrate 
that P-gp, MRP1 and LRP are expressed in the majority of STS, which could explain 
their poor responses to chemotherapy. Expression of P-gp, MRP1 and LRP varies 
between histological types and is not related to tumor grade. LPS, known for their 
relatively good response to chemotherapy, did show remarkably low LRP levels, 
which might be due to the high proportion of myxoid LPS with a 16p 1 1  breakpoint 
(chapter 13). The in the literature reported poor responses in leiomyosarcomas were 
not reflected by abundant P-gp, MRP1 or LRP expression in the examined soft tissue 
LMS. 
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Further studies have to evaluate the prognostic value of the ( co )-expression of 
these parameters in relation with various treatment regimens in each of the 
histological types. 
LMS and GIST differ in clinical outcome, metastatic pattern and MDR. 
Several studies have reported clinical behavior and drug resistance in 
leiomyosarcomas, but did not differentiate between soft tissue LMS and malignant 
gastrointestinal stromal tumors (GIST). Multidrug resistance (MDR) has been 
associated with the expression of P-gp (P-glycoprotein), MRP 1 (multidrug resistance 
protein) and LRP (lung resistance protein). In chapter 8, the differences between 
LMS and GIST with respect to clinical outcome and MDR parameters were studied. 
The mean overall survival in patients with a LMS was 72 months and 3 1  months in 
patients with a GIST (p<0.05). Metastases occurred in 53% of the GIST patients and 
in 58% of the LMS patients. In GIST patients with known metastatic disease during 
follow-up, liver metastases were found in 5 patients and intra-abdominal metastases 
in 3 patients. The lungs were the primary affected metastatic site in 1 3  (87%) of the 
metastasized LMS and in none of the GIST patients (P<O.OOI ), whereas subsequent 
liver metastases developed in 4 LMS patients. P-gp and MRP 1 expression was 
significantly (p<0.05) more pronounced in GIST than in LMS, i.e. 3 1 %  of the LMS 
and 68% of the GIST were P-gp positive and 3 1 %  of the LMS and 68% of the GIST 
were MRP 1 positive. These findings demonstrate that LMS patients have a better 
survival than GIST patients. Although the frequency of distant metastases in LMS 
and GIST are comparable, LMS predominantly metastasize to the lungs, while GIST 
tend to spread to the liver and the abdominal cavity. 
LMS have a less pronounced drug resistance pattern than GIST. Future studies 
should therefore differentiate between LMS of soft tissue and GIST. These findings 
indicate that previously studied clinical and histopathological variables 
"leiomyosarcomas" have to be re-evaluated. Studies reporting a high number of 
gastro-intestinal leiomyosarcomas, without differentiation, have to be interpreted 
with extreme caution. Therefore, studies are needed to establish the clinical, 
histopathological and (onco)genetic differences between LMS and GIST, especially 
in relation with their metastastatic behavior and their response to chemotherapy. 
P-gp, MRP1 and LRP expression cannot predict responses to EVI polychemo­
therapy in STS. 
A large proportion of adult patients with disseminated STS do not respond to 
chemotherapy which might be due to multidrug resistance (MDR) protein 
expression. MDR has been associated with the expression of P-gp, MRP1 and LRP. 
Whereas P-gp and MRP1 are involved in the efflux of anthracyclines (doxorubicin, 
epirubicin), the exact role of LRP in the efflux of cytostatic agents is less known. In 
chapter 9 of this thesis, we studied 28 adult STS patients with metastatic disease or 
irresectable tumor, treated with epirubicin, vindesine and ifosfamide (EVI) for 
treatment response and evaluated the expression of P-gp, MRP1 and LRP with 
respect to treatment response and clinical outcome. Fifty-eight percent of the STS 
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were P-gp positive, 6 1% were MRP1 positive and 68% were LRP positive. In  93% 
of the STS at least one analyzed MDR-protein was present. eo-expression was found 
in 75% of the tumors. MDR-protein expression was not associated with treatment 
response. Overall and progression free survival (OS and PFS) were not associated 
with the expression of P-gp, MRP 1 or LRP. However, patients with sarcomas eo­
expressing two or three drug resistance proteins had a worse median PFS (7 months) 
than those without eo-expression ( 1 1 months). These results indicate that, although 
the majority of adult STS expresses P-gp, MRP1 and/or LRP, the assessment of P-gp, 
MRP 1 or LRP expression in the individual patient with a metastasized STS cannot 
predict response to EVI treatment. However, eo-expression of P-gp, MRP1 and/or 
LRP tends to be associated with poor PFS. 
These findings indicate that expression of single MDR proteins in STS alone 
can not predict responses to chemotherapy and implies that additional tumor 
biological parameters have to be evaluated. Furthermore, multi-center studies in 
larger, uniformly treated, patient groups are needed to validate the results of this 
study. 
(CYTO)GENETICS 
(Cyto )genetic analysis is helpful in clarifying oncogenesis of various 
malignant solid tumors and the observation of recurrent chromosome abnormalities 
led to the detection of tumor specific chromosomal alterations which are of 
diagnostic value. Characteristic cytogenetic alterations have been found in several 
histologic types of STS. However, most of the published studies in small groups of 
tumors presented karyotypes in such a way that even shared chromosomal alterations 
are difficult to detect and a lot of cytogenetic information could not be used in this 
way for a direct comparison of specific tumors. This problem of interpreting and 
comparing different tumor groups was the reason for the construction of the database 
which was used in chapters I 0 and 1 1  of this thesis. This direct comparison of 
cytogenetic data and the visualization in so called karyographs makes it easier to 
interpret the differences between groups of tumors e.g. malignant peripheral nerve 
sheath tumors (MPNST), leiomyosarcomas (LMS) or gastrointestinal stromal tumors 
(GIST). This method of computer assisted conventional cytogenetics gives the 
opportunity to expand the understanding of the cytogenetic anomalies of uncommon 
solid tumors by taking together all cytogenetic studies of small numbers of cases and 
extract meaningful shared cytogenetic aberrations. 
Signijica11t loss of 9p2 a11d gai11 of 7ql in MPNST might be of oncogenetic 
importance. 
Cytogenetic studies in small groups of patients with malignant peripheral 
nerve sheath tumors (MPNST) revealed complex karyotypes without consistent 
changes. In chapter 10, a computer assisted cytogenetic analysis using a cytogenetic 
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database was performed, to determine recurrent cytogenetic alterations in 5 1  
MPNSTs and to assess differences between sporadic MPNST and neurofibromatosis­
} associated MPNST. Significant (p<O.OS) loss was observed in the chromosomal 
regions 9p2, l lp l ,  l lq2 and 1 8p l .  Gain of chromosomal material was found in 
chromosome 7, especially 7q l (p<O.OS). Cytogenetic differences between NF-1 
associated and sporadic MPNSTs included a relative loss of chromosomal material in 
NF-1 associated MPNSTs in l p3,  4p l and 2 1 p l -q2 and a relative gain in 15p l-ql .  
This approach, in which the cytogenetic results of various reports are combined, 
shows that losses in 9p2 and gains in 7ql could be of oncogenetic importance in 
MPNSTs. Loss of 1 7q l ,  on which the NF- 1  gene has been located ( 17q l l .2), is not a 
common cytogenetic finding in NF- 1 associated MPNSTs. The observed differences 
between NF-1 associated and sporadic MPNSTs might reflect different oncogenetic 
pathways. 
Further studies in MPNST should focus on the genes located on the 
chromosomal regions with significant gains or losses. The expression of for instance 
the p 1 6  protein is expected to be low as compared to STS without loss of 9p2. The 
use of so called computer assisted cytogenetic analysis is not a substitution of 
conventional cytogenetics. It is merely a tool to obtain more information from 
already cytogenetically analyzed tumors. In this way karyotypes can be interpreted 
more easily and a comparison between specific patient or tumor groups can be made. 
In the next future, this method can be used to compare metastases and their primary 
tumors and might contribute to the detection of those tumors with high metastatic 
potential. 
Cytogenetic comparison of GIST, LMS and MPNST. 
The histogenesis, oncogenesis and clinical behavior of malignant 
gastrointestinal stromal tumors (GIST) are the subject of dispute, since these 
neoplasms may reveal either neural differentiation, resembling malignant peripheral 
nerve sheath tumors (MPNST), or smooth muscle differentiation, resembling 
leiomyosarcomas of deep soft tissue (LMS). Previous cytogenetic studies did not 
clearly differentiate between GIST, LMS and MPNST. In chapter 11, the earlier 
mentioned computer assisted method of direct cytogenetic comparison was used to 
discover tumor specific chromosomal patterns in 1 6  malignant mesenchymal tumors 
("GIST") of the digestive tract, 14 soft tissue LMS and 37 MPNST. In "GIST" a 
statistically significant loss was observed in chromosomal regions 13q2-q3, 14p l -
14q2, 1 8p 1 - 1 8q2, 22p 1 and 22q 1 .  In LMS the chromosomal changes did not reach 
statistical significance. However, important loss was found in 5p 1 ,  14p 1  and of 
chromosome 22, whereas gain was observed of chromosome X. In MPNST a 
significant loss of chromosomal material was detected in 9p2, 1 1  p 1 ,  1 1  q2 and 18p 1 ,  
as well as important loss in  22q; a significant gain was noticed in  the 7q1  region. 
This cytogenetic meta-analysis supports the hypothesis that malignant mesenchymal 
tumors arising in the digestive tract or "GIST" are a distinct entity which differs from 
LMS and MPNST and is characterized by losses in 13q2-q3, 14p l -q2, 1 8p l -q2 and 
22p l-ql .  However, the shared loss of chromosome 22 in "GIST", LMS and MPNST, 
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might be indicative for a shared oncogenetic pathway, whereas gain of 7q 1 and loss 
of 18p 1 �q2 seems to be more associated with neural differentiation. 
This study did not succeed to discover chromosomal aberrations which could 
be of highly diagnostic importance. However, differences in these small groups of 
already cytogenetically analyzed tumors make further evaluations worthwhile. These 
studies should use a combination of CGH for detection of more specific 
chromosomal alteration, molecular genetics for detection of c�kit mutations and 
immunohistochemistry to detect more significant differences. 
(Cyto)genetic analyses in STS can have clinical consequences. 
In chapter 12, a case is described of a boy with a small cell tumor with a 
cytogenetically discovered t( 1 1 ;22). Molecular genetic analysis revealed also a EWS� 
FLI� l fusion transcript, which has also been observed in Ewing's sarcoma. After 
excisional biopsy, the boy was treated with Ewing's sarcoma based chemotherapy 
and is still without evidence of disease three years after treatment. This case is an 
example that additional (cyto)genetic data might have clinical consequences. 
The detection of fusion transcripts and their future immunohistological 
assessment, are of utmost diagnostic and clinical importance. 
The 16p11.2 breakpoint in myxoid liposarcomas might affect the expression of the 
LRP gene on 16pl1.2. 
Myxoid liposarcomas (LPS) are characterized by the t( l 2; 1 6)(q13 ;p l l ) which 
leads to the formation of a FUS�CHOP fusion transcript. In chapter 13 of this thesis, 
we examined the relationship between the cytogenetically detected breakpoint 16p 1 1  
in myxoid LPS, the presence of the FUS�CHOP fusion transcript in non�myxoid LPS 
and the expression of the lung resistance major vault protein (LRP) gene on 16p 1 1 .2. 
In all 9 myxoid LPS a t( l 2; 1 6)(ql 3 ;p l l )  was found and LRP expression was absent 
or low. In none of the remaining 7 cases of a with a preferential diagnosis of 
liposarcoma a FUS�CHOP fusion transcript was found and four tumors were LRP 
positive (p=0.02). 
These observations indicate a relation between the t( 12; 16)(q l 3;p l l ), leading 
to a FUS�CHOP fusion transcript in myxoid LPS, and the low or absent expression 
of the LRP�gene located on 16p 1 1 .2. Further studies have to examine whether LRP 
expression is related to the breakpoint 16p l l characteristic for myxoid LPS. It would 
be interesting to investigate if myxoid LPS have better response to drugs which are 
normally affected by LRP, e.g. melphalan in HILP�TM. The relation between 
chromosomal aberrations and the expression of MDR proteins was further 
investigated in chapter 14. 
Chromosomal aberrations in 1 6pll might affect LRP expression in STS. 
Multi drug resistance (MDR) has been associated with the expression of the P� 
gp (P�glycoprotein), LRP (lung resistance protein) and MRP1 (multidrug resistance 
related protein) genes on chromosomes 7q2 1 ,  1 6p l l and 1 6pl3 .  Chromosome 
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breakage in 1 6p 1 3  could influence the expression of MRP h as has been shown in 
specific cases of acute myeloid leukemia. In soft tissue sarcomas (STS), cytogenetic 
analyses revealed characteristic cytogenetic alterations in several histologic types. 
The influence of chromosomal aberrations on protein expression has not been studied 
before in STS. In chapter 14 of this thesis, it was found that P-gp and MRP1 
expression did not differ when STS with breakpoint in or loss of the 7 q2 1 or 1 6p 1 3  
region were compared to STS with normal 7q21 or 1 6p 1 3  regions. However, i n  STS 
with breakpoints in or loss of 1 6p 1 1 , the median percentage of LRP expressing cells 
was 3% and in STS with cytogenetically intact 1 6p1 1 regions the median expression 
was 40% (p<0.0 1 ). LRP expression, but not MRP1 or P-gp expression, correlated 
with the amount of cytogenetically intact chromosomal material. LRP expression in 
liposarcomas did not differ from STS other than liposarcomas, whereas myxoid 
liposarcomas had lower LRP expression than other liposarcomas (p<0.0 1 ), indicating 
that low LRP expression is not associated with the lipomatous character but with the 
1 6p 1 1  breakpoint (as observed in chapter 1 3). We conclude that cytogenetically 
detected loss or breakpoints in 16p 1 1 might affect LRP expression, whereas P-gp and 
MRP 1 expression are not clearly affected by loss of or breakpoints in the 
chromosomal regions 7q2 1 and 16p 13,  respectively. 
This study indicates that in STS the MDR associated protein LRP plays a 
prominent role: it is abundantly expressed in STS, but is low in STS with damage of 
16p 1 1  material. The possible association between the reported favorable response 
rates in advanced (myxoid) LPS, the 1 6p 1 1  breakpoint, LRP expression and the 
various forms of chemotherapy or HILP with TNF-a and melphalan have to be 
investigated. 
Abnormal karyotypes and DNA-aneuploidy are not of prognostic value in STS. 
DNA ploidy and karyotype could of prognostic value in STS. In chapter 15, 
we examined the relationship between tumor grade, DNA ploidy, cytogenetic 
abnormalities and the clinical outcome of 44 previously untreated patients with 12 
different histological types of primary STS. Significant differences in 5-years overall 
survival were found between patients with grade I or II and grade Ill STS (p<0.05). 
Seventeen STS were aneuploid and twenty-six were euploid. In 21 out of 39 
successfully cultured STS an abnormal karyotype was found. There were no 
significant differences in survival in relation to DNA ploidy or the presence of 
chromosomal abnormalities. 
These results demonstrate that grading is of more prognostic value than DNA 
ploidy or the presence of an abnormal karyotype. The use of other (cytogenetic) 
methods such as CGH or computer assisted cytogenetic analyses have to compare 
different homogeneous groups, e.g. MFH and LMS or patient groups with a 
favorable and poor clinical outcome. In this way more specific chromosomal regions 




General conclusions and future perspectives: 
The work described in this thesis is focussed on the relation of certain tumor 
biological parameters (i.e. proliferation, apoptosis, multidrug resistance, DNA-ploidy 
and chromosomal aberrations) with the histopathological diagnosis, treatment 
response and clinical outcome of patients with a STS. 
The diagnosis of STS can be difficult and tumor grading is influenced by the 
experience of the individual pathologist. New imaging techniques such as TYR-PET 
and IMT -SPECT can support the diagnosis and the assessment of the tumor grade, 
but further studies on tumor biology related radionuclides are needed. The additional 
diagnostic value of conventional cytogenetics has reached its limits and other 
cytogenetic methods such as computer assisted cytogenetics or CGH will provide 
useful diagnostic information. The results of the described computer assisted 
cytogenetic studies in MPNST and GIST revealed chromosomal changes with could 
be of additional diagnostic value. Other histological types should be compared with 
the same method to discover "hidden" chromosomal differences within the various 
STS. It is expected that especially molecular genetic techniques in combination with 
histopathological examination, i.e. the immunohistological detection of fusion 
transcripts such as the FUS-CHOP or the EWS-FLI-1 protein, will have additional 
diagnostic value. 
One of the objectives of this thesis was to determine the influence of 
proliferative activity or apoptosis on the response to HILP-TM in locally advanced 
primary STS. We found that proliferative activity and apoptosis of tumor cells might 
influence the spectacular responses to HILP-TM, whereas HILP-TM appears to alter 
the proliferative and apoptotic activity in the tumors. Future studies on the expression 
of recently detected cell cycle and apoptosis related genes/proteins in combination 
with examination of the endothelial changes after HILP-TH might reveal tumor 
related predictive factors. With the improvement of culturing techniques, in vitro 
studies on tumor cells and the vasculature in short term cultures of STS could clarify 
the biological ·mechanism of HILP-TM. Tumor biological examination of the 
residual tumor after HILP-TM could elucidate the biological resistance to HILP-TM. 
When tumor markers are studied in relation to treatment response, the assessment of 
those responses have to be highly reliable. Tumor biology related imaging techniques 
such as TYR-PET or IMT-SPECT turned out to provide tumor proliferation related 
information which might be more specific than physical examination and traditional 
radiographic screening according to 20-years old WHO standards. It was shown that 
chemotherapeutic treatment of advanced/metastasized STS with epirubicin, vindesine 
and ifosfamide results in a promising response rate of 59%. The expression of the 
single MDR proteins P-gp, MRP 1 and LRP can not predict treatment response or 
clinical outcome. However, the expression of these MDR-proteins and their 
distribution within the various histological types is now better understood. The 
relation between ( cyto )genetics and histopathology has been emphasized with the 
observed relation between 16p 1 1  aberrations and decreased LRP expression. Future 
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studies in LPS have to examine the clinical relation: do myxoid LPS or other STS 
with 1 6p 1 1  aberrations respond better to alkalyting agents contammg 
chemotherapeutic regimens? This thesis weakens the conclusions of many clinical 
studies that LMS are characterized by liver metastases, drug resistance and poor 
survival. We demonstrate that previous studies in "leiomyosarcomas" examined the 
biological behavior of both LMS and GIST. LMS do not frequently metastasize to 
the liver and have low P-gp and MRP1 levels as compared to GIST. Survival in 
patients with GIST is relatively poor, but not associated with MDR expression. 
In the examined specific patient groups, only tumor grade, mitotic activity and 
proliferation had some prognostic value . Other parameters such as the presence of an 
abnormal karyotype, DNA-aneuploidy, expression of single MDR proteins and 
amount of apoptosis, could not be identified as prognostic markers. Taken together, 
treatment response and clinical outcome are influenced by many biological 
parameters. It would be narrow minded to assume that only one or two biological 
variables would affect the metastatic potential or clinical outcome of an individual 
STS. The combination of predictive markers, rather than single parameters, might 
provide useful prognostic information. In the next future, studies in large 
homogeneous groups of STS have to validate recently discovered tumor biological 
parameters. New techniques such as DNA-chip technology could be helpful: in this 
way a pattern of risk factors for each individual STS can be developed, which might 
reveal clinically important information such as the prediction of treatment response 
or the occurrence of distant metastases. Because of the rarity of the whole group of 
STS, this can only be done in large collaborative studies. Furthermore, future studies 
in STS should concentrate on distant metastases. It should be determined whether 
expression of proteins involved in tumor proliferation, apoptosis, and angiogenesis or 
the expression of adhesion molecules could predict development of metastases. 
Conventional (computer assisted) cytogenetics and comparative genomic 
hybridization might reveal which chromosomal parts are involved in the metastatic 
process This might lead to early detection of STS with high metastatic potential. To 
predict the MDR pattern of the distant metastases by examination of the primary 
tumor, evaluation of the changes in expression of MDR-proteins between primary 
tumors and their distant metastases is necessary. Further studies in uniformly treated 
patients should investigate the (eo-)expression of other drug resistance related 
proteins and genes/proteins involved in the processes leading to apoptosis. 
With the progress of new insights in tumor biology, it is a challenge for the 
next future to search for new diagnostic and prognostic factors which can be helpful 
in histopathological diagnosis of STS and will lead to more tumor adjusted therapies 
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NEDERLANDSE SAMENV ATTING 
Weke delen sarcomen (WDS) zijn kwaadaardige (maligne) tumoren die 
ontstaan uit de mesenchymale cellen die o.a. het bindweefsel, vetweefsel en 
spierweefsel vormen. Het zijn zeldzame tumoren die slechts 1 %  van alle 
maligniteiten vormen. Afhankelijk van hun uitrijpingskenmerken (differentiatie) 
wordt deze heterogene groep tumoren onderverdeeld in o.a. liposarcomen (LPS), 
leiomyosarcomen (LMS), rhabdomyosarcomen, maligne fibreus histiocytomen 
(MFH), maligne perifere zenuwschede tumoren (of MPNST) en synoviosarcomen. 
De onstaanswijze van WDS is onduidelijk. De reactie op verschillende vormen van 
behandeling, zoals bijvoorbeeld chemotherapie of geYsoleerde ledemaat perfusie met 
TNF-a en melphalan (HILP-TM), is niet goed te voorspellen. We! is uit eerder 
onderzoek gebleken dat een hoge mate van kwaadaardige kenmerken (hoge 
maligniteitsgraad) en een grote tumor het klinisch beloop (de overleving) negatief 
belnvloeden. 
De laatste jaren is steeds meer bekend geworden over de invloed van bepaalde 
biologische mechanismen in tumorcellen op verschillende behandelingen en op het 
ziekte beloop. Binnen de groep van WDS is echter in het verleden relatief weinig 
onderzoek verricht naar tumorcel gerelateerde biologische eigenschappen, die 
behulpzaam zouden kunnen zijn bij het stellen van een adequate diagnose of het 
voorspellen van de behandelingsresultaten en het ziektebeloop. 
In het onderzoek dat beschreven wordt in dit proefschrift, wordt onderzocht of 
bepaalde histopathologische en cytogenetische parameters kunnen bijdragen aan het 
stellen van de diagnose, de behandelingsresultaten kunnen belnvloeden en het 
klinisch beloop van bepaalde patientengroepen kunnen voorspellen. 
Hiervoor zijn verschillende methoden gebruikt en is gekeken naar een aantal 
eigenschappen van een kwaadaardige tumor. 
Wanneer een tumor veel kenmerken heeft van een kwaadaardige tumor, zoals 
veel celdelingen (mitosen), veel necrose en een slechte differentiatie, wordt 
gesproken van een hoge maligniteitsgraad of tumorgraad. Niet alleen het aantal 
delende cellen, maar ook de hoeveelheid cellen die zich klaarmaken zijn om te gaan 
delen (prolifereren) kan informatie geven over de agressiviteit van een tumor. Deze 
prolifererende cellen werden in dit onderzoek aangetoond met behulp van een 
zogenaamde immuunhistochernische kleuring waarbij een bepaald antilichaam (MIB-
1 )  het Ki-67 eiwit in de kern herkent. Ki-67 is een eiwit wat alleen voorkomt in de 
kemen van cellen die aan het prolifereren zijn. Wanneer een "gezonde" eel door 
beschadiging van het erfelijke materiaal (het DNA) een tumorcel dreigt te worden zal 
deze zichzelf vemietigen. Dit proces van zelfvemietiging heet geprogrammeerde 
celdood of "apoptose". Cellen die zichzelf vemietigen hebben bepaalde aan apoptose 
gerelateerde kenmerken die o.a. kunnen worden aangetoond met behulp van een 
speciale kleuringstechniek, de TUNEL- methode. Bepaalde behandelingen zoals het 
geven van cytostatica of bestraling hebben juist het doe! om nog meer DNA-schade 
te veroorzaken zodat tumorcellen uiteindelijk toch in apoptose zullen gaan en de 
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tumor dus dood gaat. Wanneer een tumor niet dood gaat na het geven van 
chemotherapie, kan dit ook veroorzaakt warden doordat een tumor als het ware 
resistent is tegen de verschillende cytostatica. Nu is de laatste jaren duidelijk 
geworden dat hierbij een aantal eiwitten een rol spelen die het effect van 
chemotherapie tegenwerken, wat "multidrug resistance" (MDR) wordt genoemd. In 
de celmembraan zitten o.a. twee soorten pompen die de cytostatica de tumorcel uit 
kunnen pompen: het P-glycoprotein (P-gp) en het multidrug resistance protein- ! 
(MRP1). P-gp en MRP1 zijn betrokken bij o.a. het uitpompen van anthracyclines 
(doxorubicine, epirubicine), cytostatica die veelvuldig gebruikt warden bij de 
behandeling van WDS.  Een ander eiwit wat zich met name in het cytoplasma bevindt 
en schadelijke, alkylerende stoffen de eel uit lijkt te transporteren wordt het lung 
resistance protein (LRP) genoemd. De exacte rol van LRP in de efflux van 
cytostatica is niet goed bekend. Deze drie eiwitten werden in dit onderzoek 
aangetoond met behulp van immunhistochemische kleuringen. 
In de meeste maligne tumoren zijn  allerlei afwijkingen in het DNA ontstaan: 
er ontbreken stukken DNA of er is extra DNA gemaakt. De hoeveelheid DNA (DNA­
ploidie) in een eel kan gemeten worden met behulp van DNA-flowcytometrie. 
Hierbij wordt het DNA gekleurd met een fluorescerende stof, waama men de cellen 
door een dun buisje laat stromen en ze worden beschenen met een laser-straal. De 
hoeveelheid gereflecteerd licht wordt gemeten en is dan een maat voor de 
hoeveelheid DNA. 
Een andere manier om naar veranderingen in het DNA te kijken is door 
chromosomen te bestuderen (cytogenetica). Vlak voor een eel gaat delen zal het 
DNA samentrekken tot 23 paar chromosomen, waarbij een vrouw twee X 
chromosomen heeft en een man een X chromosoom en een Y chromosoom in de 
lichaamscellen heeft. Chromosomen kunnen zichtbaar gemaakt worden op 
microscopisch niveau ( I OOOx vergroot) tijdens bepaalde stadia van de celdeling. Ze 
hebben een korte en een lange arm (p en q arm) gescheiden door een centromeer in 
het midden van het chromosoom. Met behulp van speciale kleuringstechnieken 
vertoont elk chromosoom een uniek patroon van bandjes, waaraan de individuele 
chromosomen kunnen worden herkend. De verschillende chromosoombanden zijn 
genummerd volgens intemationaal geldende regels. Op grand van deze kenmerken 
kunnen afwijkingen van het normale patroon herkend en beschreven worden. Het is 
bekend dat bij veel WDS karakteristieke chromosomale afwijkingen voorkomen die 
gebruikt kunnen worden bij het stellen van de juiste diagnose. In veel WDS zijn er 




Voor eetz betrouwbare lzerkenning van mitosen is ervaring nodig. 
Tumorgraad is een van de belangrijkste prognostische factoren in WDS. Een 
verkeerde beoordeling van de tumorgraad kan klinische consequenties hebben. Bij de 
meeste graderingsmethoden speelt het tellen van het aantal celdelingsfiguren 
(mitosen) een centrale rol, waarbij een zekere subjectiviteit van de beoordelende 
patholoog een rol kan spelen. In hoofdstuk 2 werden twee methoden gebruikt die 
beide te maken hebben met celdeling: het beoordelen van het aantal mitosen en de 
hoeveelheid prolifererende cellen. Er werd aangetoond dat ervaring in het beoordelen 
van mitosen de "onverklaarde" statistische spreiding verlaagt. Hoewel de 
beoordeling van MIB - 1  gedetecteerde proliferatie minder werd bei·nvloed door het 
verschil in ervaring, zijn de kosten van deze methode veel hoger en is een correlatie 
tussen MIB - 1  detectie en mitose frequentie niet altijd aanwezig. Daarom wordt 
geadviseerd om de ervaring in het herkennen van mitosefiguren, en het onderscheid 
met bijvoorbeeld apoptose, te vergroten door middel van training. Hiervoor zouden 
modeme interactieve multimedia-technieken gebruikt kunnen warden binnen de 
opleiding tot patholoog, waardoor de interne persoonlijke standaard en de 
laboratoriumstandaard zouden kunnen verbeteren en maligniteitsgraad op een 
uniformere manier kan warden bepaald. 
TYR-PET is een bruikbare manier om proliferatie in WDS te meten. 
De eiwitsynthese van tumoren, wat een maat is voor de biologische activiteit, 
kan warden bepaald door middel van positron emissie tomografie met L-[ 1 -
1 1C]tyrosine (TYR-PET). L-[ 1 - 1 1C]tyrosine is een radioactief gemaakt aminozuur 
wat in eiwitten wordt ingebouwd. De hoeveelheid gemeten radioactiviteit is dan een 
maat voor de eiwitsynthese. In hoofdstuk 3 werd een relatie gevonden tussen de 
eiwitsynthese gemeten met TYR-PET en zowel de mitosefrequentie als de Ki-67 
proliferatie index. Dit impliceert dat TYR-PET niet alleen kan bijdragen aan de 
beoordeling van de maligniteitsgraad, maar oak een rol kan spelen bij het bepalen 
van die tumor regia' s met de hoogste proliferatie. Dit zou van belang kunnen zijn in 
het bepalen van de optimale biopsieplaats. Verder zou TYR-PET gebruikt kunnen 
warden in de evaluatie van behandelingsresponsen in vivo, hetgeen misschien 
bruikbaarder zou kunnen zijn dan de huidige beoordeling door middel van 
lichamelijk onderzoek en radiologische screening. 
IMT-SPECT kan ook warden gebruikt om proliferatie in WDS te beoordelen. 
Een andere methode om eiwitsynthese in tumoren te beoordelen is single 
photon emission computerized tomography (SPECT) met radioactief ( 1 23I-gelabeled) 
aminozuur L-3-[ 1231] iodo-alpha-methyl tyrosine (IMT). In hoofdstuk 4 wordt 
beschreven dat in een groep van zowel goedaardige als kwaadaardige weke delen 
tumoren de mate van het IMT -SPECT signaal correleert met zowel de celdichtheid in 
een tumorbiopt als met de mate van proliferatie en mitosefrequentie. Dit betekent dat 
met behulp van IMT -SPECT maligniteit in vivo kan warden beoordeeld en dat deze 
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methode de mate van proliferatie zou kunnen bepalen. In tegenstelling tot TYR-PET, 
is voor de IMT-SPECT methode niet een complexe infrastructuur nodig. Echter, in 
toekomstige studies zal IMT-SPECT moeten warden vergeleken met TYR-PET in 
een groep die bestaat uit alleen maligne weke delen tumoren (WDS). 
Response op HILP met TNF-a en melphalan is gerelateerd aan de 
mitosefrequentie en gaat gepaard met een toename van apoptotische cellen. 
Hyperthermische ge'isoleerde ledemaat perfusie met tumor necrose factor-a. 
(TNF-a.) en melphalan (HILP-TM) met of zonder interferon-y (IFN-y) kan warden 
beschouwd als een doorbraak in de behandeling van patienten met niet chirurgisch 
verwijderbare grate WDS van de extrerniteiten. Het mechanisme achter de 
behandelingsrespons is nog steeds onduidelijk, hoewel gedacht wordt dat TNF-a. en 
melphalan o.a. een beschadiging geeft van de bloedvaten die de tumor van bloed 
voorzien, waama uiteindelijk door stolselvorming de bloedvaten verstoppen en de 
tumor dood gaat. Hoofdstuk 5 van dit proefschrift laat zien dat de mate van 
proliferatie afneemt na HILP-TM, terwijl de hoeveelheid apoptotische cellen 
toeneemt. De toevoeging van IFN-y aan HILP-TM be'invloedde de veranderingen in 
de onderzochte tumorparameters overigens niet en had ook geen effect op de 
behandelingsrespons. Wel leek een betere klinische response na HILP-TM 
gecorreleerd aan hoge rnitose activiteit en !age hoeveelheid apoptose in de tumoren, 
zoals beoordeeld voor HILP-TM. Patienten met sterk prolifererende WDS, zowel 
voor als na HILP-TM, had den een relatief slechte prognose. Patienten die metastasen 
ontwikkelden na HILP-TM hadden een relatief hoge delingsactiviteit in de 
overgebleven tumor resten na HILP-TM. Deze resultaten wijzen erop dat HILP-TM 
oak op een direct wijze de tumorcellen be'invloedt en dat biologische processen 
binnen het apoptose mechanisme betrokken zouden kunnen zijn bij de respons op 
HILP-TM. 
Proliferatie na HILP met TNF-a en melphalan kan wordetr gemeten met TYR­
PET. 
In de experimentele behandeling van WDS met HILP-TM is het gebruikelijk  
om na  een periode van 6-8 weken de tumorresten alsnog chirurgisch te verwijderen. 
In hoofdstuk 6 wordt in twee groepen patienten aangetoond dat proliferatie- en 
rnitose-activiteit voor het starten van HILP-TM kan warden gemeten met behulp van 
zowel 1 8F-fluoro-deoxy-D-glucose (FDG)-PET, een methode om glucose consumptie 
wat een maat is voor de biologische activiteit (suikerstofwisseling), als TYR-PET. 
Echter, na HILP-TM verdween in de ene groep de correlatie tussen FDG-PET en 
proliferatie, terwij l  in de andere groep de correlatie tussen tumorcelproliferatie en 
TYR-PET verbeterde. Dit duidt erop dat TYR-PET de best bruikbare PET-methode 
is om responsen op HILP-TM te beoordelen. Dit is belangrijk omdat nu met TYR­
PET de response van de geperfundeerde tumor kan warden beoordeeld en op 
indicatie het moment voor verwijderen van de tumorresten kan warden bepaald. 
245 
Nederlandse samenvatting 
Expressie van P-gp, MRP1 en LRP varieert tussen de histologische typen van 
WDS. 
In het geval van (diffuse) uitzaaiingen (metastasen) is chemotherapie 
ge"indiceerd. Hoewel in het algemeen slechts 20-40% van de WDS reageert op 
cytostatica, lijken vooral leiomyosarcomen (LMS) en maligne fibreus histiocytomen 
(MFH) slecht te reageren. Liposarcomen (LPS) hebben daarentegen een relatief 
goede reactie op chemotherapie. De studie beschreven in hoofdstuk 7 werd 1 1 5 
WDS, die niet eerder behandeld waren met chemotherapie, de expressie van P-gp, 
MRP1 en LRP bestudeerd in relatie tot het histologische type en de tumor graad. De 
resultaten laten zien deze MDR-eiwitten tot expressie worden gebracht in het 
merendeel van de WDS, wat mogelijk  de in het algemeen slechte respons op 
chemotherapie kan verklaren. De expressie van P-gp, MRP1 en LRP varieert tussen 
histologische types en is niet duidelijk  gerelateerd aan tumorgraad. LPS, die goed 
reageren op chemotherapie, hadden opmerkelijk weinig LRP expressie, hetgeen 
mogelijk  verklaard zou kunnen worden door het relatief hoge aandeel myxoid LPS 
met hun karakteristiek breukpunt in chromosoom 1 6p 1 1  (hoofdstuk 1 3  ). Opvallend 
was dat LMS, waarvan in de literatuur de relatief slechte respons op chemotherapie 
wordt benadrukt, een relatief !age expressie hadden van P-gp en MRP1 •  Verder 
onderzoek is noodzakelijk om prognostische waarde van (co)-expressie van MDR 
eiwitten te evalueren en een relatie te leggen met de verschillende combinaties van 
cytostatica voor elk van de histologische types. 
LMS ell GIST verschillell in klinisch beloop, metastaserings patrooll ell MDR. 
In verscheidene klinische studies werd met name een hoge mate van 
chemotherapieresistentie in leiomyosarcomen beschreven. Echter, de meeste 
onderzoeken maakten geen onderscheid tussen "echte" weke delen LMS en 
gastrointestinale stroma tumoren (GIST), die in het verleden oak we! 
leiomyosarcomen van het maag-darm kanaal werden genoemd. In hoofdstuk 8, 
werden de verschillen tussen LMS en GIST ten aanzien van het klinisch beloop en 
expressie van MDR eiwitten onderzocht. Er werd aangetoond dat LMS patienten een 
betere prognose hebben dan GIST patienten. Hoewel de frequentie van 
afstandsmetastasen in LMS en GIST vergelijkbaar is, metastaseren LMS 
voomamelijk naar de longen, terwij l GIST lijken uit te zaaien naar de lever en de 
buikholte. Expressie van P-gp en MRP1 was minder uitgesproken in LMS dan in 
GIST. Toekomstige studies moeten daarom een duidelijk onderscheid maken tussen 
weke delen LMS en GIST. Dit alles wijst erop dat de conclusies van eerdere 
klinische en histopathologische studies in "leiomyosarcomen" opnieuw moeten 
worden geevalueerd. In de toekomst zijn studies nodig die zich richten op de 
klinische, histopathologische en (onco)genetische verschillen tussen LMS en GIST, 
met name in relatie met hun metastaseringsgedrag en de reactie op chemotherapie. 
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De expressie van P-gp, MRP1 en LRP kan de reactie op EVI polyc/zemotherapie in 
STS niet voorspel/en. 
Een aanzienlijk deel van de volwassen patienten met een uitgezaaid WDS 
reageert onvoldoende op chemotherapie wat mogelijk wordt veroorzaakt door 
expressie van P-gp, MRP1 en LRP. In hoofdstuk 9 van dit proefschrift, werden 28 
volwassen WDS patienten, met afstandsmetastasen of niet chirurgisch te verwijderen 
tumor, behandeld met epirubicine, vindesine en ifosfamide (EVI) en werd de relatie 
tussen de expressie van P-gp, MRP1 en LRP bestudeerd in relatie met de 
behandelingrespons en het klinisch beloop. Hoewel het merendeel van de WDS 
MDR-eiwitten tot expressie brengt, de beoordeling hiervan in het geval van de 
individuele patient met een gemetastaseerd WDS de respons op behandeling met EYI 
niet kan voorspellen. Echter, co-expressie van P-gp, MRP1 en/of LRP lijkt mogelijk 
te zijn gerelateerd aan een slechtere progressie vrije overleving. Deze resultaten 
impliceren dat het beoordelen van alleen de expressie van MDR eiwitten in WDS 
niet voldoende is om respons op chemotherapie te voorspellen en dat additionele 
tumor biologische parameters moeten worden onderzocht. Yerder dient onderzocht te 
worden of de expressie van de verschillende MDR-eiwitten verband houdt met het 
biologisch gedrag van de WDS. 
(CYTO)GENETICA 
In de meeste gepubliceerde cytogenetische studies van relatief kleine groepen 
tumoren werden de karyotypen op zodanige wijze gepresenteerd dat bepaalde 
overeenkomstige chromosomale afwijkingen moeilijk te detecteren waren en een 
relatief grote hoeveelheid aan waardevolle cytogenetische informatie niet kon 
worden gebruikt in de vergelijking tussen verschillende groepen tumoren. Dit 
probleem van interpretatie en vergelijking van tumor groepen was de reden voor het 
construeren van een cytogenetische database die werd gebruikt in de hoofdstukken 
l O  en 1 1 . 
Significallt verlies vall 9p2 ell willst vall 7ql in MPNST kall belangrijk zijn in de 
ollcogellese. 
Cytogenetische studies in kleine groepen patienten met een maligne 
zenuwschede tumor of "malignant peripheral nerve sheath tumor" (MPNST) 
leverden complexe karyotypen op zonder aanwijzingen voor consistente 
chromosomale veranderingen. In hoofdstuk 10, werd een zogenaamde "computer 
assisted cytogenetic analysis" uitgevoerd waarbij een cytogenetische database werd 
gebruikt om steeds terugkerende cytogenetisch veranderingen op te sporen in 5 1  
MPNSTs en om te beoordelen of er verschillen waren tussen sporadische MPNST en 
neurofibromatose- 1 gerelateerde MPNST. Deze benadering, waarin de 
cytogenetische bevindingen van verscheidene studies zijn gecombineerd, laat zien 
dat verlies in 9p2 en winst in 7q 1 mogelijk  belangrijk zou kunnen zijn  in de 
oncogenese van MPNSTs. Verlies van 17q I ,  waarop het NF- 1 gen is gelokaliseerd 
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( 1 7q 1 1 .2), wordt niet vaak gevonden in NF- 1 gerelateerde MPNSTs. De gevonden 
verschillen, hoewel niet statistisch significant, zouden kunnen wijzen op verschillen 
in oncogenese tussen NF- 1 gerelateerde en sporadische MPNSTs. Vervolgstudies in 
MPNST zouden zich moeten richten op de genen gelokaliseerd op die chromosomale 
regia' s met significant winst of verlies. Het is bijvoorbeeld te verwachten dat de 
expressie van p l 6, een eiwit wat de processen die leiden tot een celdeling remt, 
relatief Iaag is vergeleken met andere WDS zonder ver1ies van 9p2. Het gebruik van 
deze zogenoemde "computer assisted cytogenetic analysis" is geen substitutie van de 
conventionele cytogenetische analyses, maar een hulpmiddel om meer informatie te 
verkrijgen uit al bestaande karyotypen. 
Cytogenetische vergelijking van GIST, LMS en MPNST. 
De histogenese, de oncogenese en het klinisch gedrag van maligne 
gastrointestinale stroma tumoren (GIST) is onvoldoende opgehelderd, omdat deze 
neoplasmata zowel kenmerken vertonen van neurale differentiatie, wat hen doet 
gelijken op maligne zenuwschede tumoren (malignant peripheral nerve sheath 
tumors) (MPNST), als van differentiatie in de richting van glad spierweefsel, wat hen 
doet gelijken op leiomyosarcomen van de weke delen (LMS). Eerdere cytogenetische 
studies hebben geen duidelijk onderscheid gemaakt tussen GIST, LMS en MPNST. 
In hoofdstuk 11, wordt de eerder genoemde "computer assisted" methode gebruikt 
om eventueel specifieke verschillen in chromosomale patronen te ontdekken bij 1 6  
malignant mesenchymale tumoren van het maag-darm kanaal ("GIST"), 1 4  weke 
delen LMS en 37 MPNST. Deze cytogenetische meta-analyse lijkt de hypothese te 
bevestigen dat de maligne mesenchymale tumor van het maag-darm kanaal (of we! 
"GIST") een aparte entiteit is die verschilt van LMS en MPNST en wordt 
gekarakteriseerd door verlies van 1 3q2-q3, l 4p 1 -q2, 1 8p 1 -q2 en 22p 1 -q 1 .  Echter, 
het gezamenlijke verlies van chromosoom 22 in zowel "GIST", LMS en MPNST zou 
kunnen wijzen op een samenhang in de oncogenese, terwijl winst van 7q l en verlies 
van 1 8p 1 -q2 mogelijk gere1ateerd lijkt te zijn aan een neura1e differentiatie. In deze 
studie is het niet gelukt om chromosomale afwijkingen te ontdekken die van duidelijk 
diagnostische betekenis kunnen zijn. Echter, de gevonden verschillen in deze kleine 
groepen zouden kunnen dienen als basis voor vervolgstudies. Om in deze studies 
meer verschillen tussen de drie tumorgroepen op te kunnen sporen zou bijvoorbeeld 
"comparative genomic hybridization" (CGH) voor de detectie van specifieke kleinere 
chromosomale afwijkingen gecombineerd kunnen worden met zowe1 moleculaire 
genetica, voor de detectie van c-kit mutaties, als immunohistochemie. 
(Cyto)genetische analyses in WDS kwmell klinische consequenties hebben. 
In hoofdstuk 12 wordt een casus beschreven van een jongen met een 
kleincellige tumor waarin bij cytogenetisch onderzoek een t( 1 1  ;22) werd gevonden. 
Moleculair genetisch onderzoek liet verder een EWS-FLI- 1 fusie transcript zien, 
zoals ook wordt gevonden in Ewing's sarcoom. Na excisie, werd de jongen 
behandeld met chemotherapie zoa1s voor Ewing's sarcoom en is drie jaar na diagnose 
nog steeds ziektevrij . 
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De detectie van fusietranscripten en toekomstige hierop gebaseerde 
immunohistologische technieken zijn van diagnostisch en klinisch belang in de 
toekomst. 
Het 16p11.2 breukpullt ill myxoide liposarcomen zou de expressie van lzet LRP gen 
op 16pl1.2 kumzell beiizvloeden. 
Myxoide liposarcomen (LPS) worden gekarakteriseerd door de 
t( l 2; l 6)(q l 3 ;p l l )  die leidt tot de vorming van het FUS-CHOP fusie transcript. In 
hoofdstuk 13 van dit proefschrift, hebben we de relatie onderzocht tussen het 
cytogenetisch gedetecteerde breukpunt l 6p l l in myxoide LPS, de aanwezigheid van 
het FUS-CHOP fusie transcript in niet-myxoide LPS en de expressie van het LRP 
gen op 16p l l .2. In alle 9 myxoide LPS werd een t( 12 ; 1 6)(q 13 ;pl l )  gevonden en de 
LRP expressie was afwezig of zeer laag. In geen van de overige 7 gevallen met een 
(voorkeurs)diagnose van liposarcoom werd een FUS-CHOP fusie transcript 
aangetroffen en 4 van de 7 tumoren waren LRP positief. Deze waamerningen wijzen 
op een mogelijke relatie tussen de t( l 2; 1 6)(q 1 3 ;p l 1 ), die leidt tot het FUS-CHOP 
fusie transcript in myxoide LPS, en de !age of afwezige expressie van het LRP-gen 
op 1 6p l l .2. Toekomstige studies zouden moeten onderzoeken of de expressie van 
LRP is gerelateerd aan het breukpunt 1 6p 1 1 . Het zou interessant zijn om te 
onderzoeken of myxoide LPS een betere respons hebben op alkylerende cytostatica 
waarvan de effectiviteit door de aanwezigheid van LRP mogelijk wordt be"invloed. 
De relatie tussen chromosomale afwijkingen en de expressie van de MDR eiwitten 
wordt verder onderzocht in hoofdstuk 1 4. 
Clzromosomale afwijkillgen ill 16pll kall de LRP expressie ill WDS beiizvloeden. 
Multidrug resistance (MDR) is gerelateerd aan de expressie van P-gp (P­
glycoprotein), LRP (lung resistance protein) en MRP1  (multidrug resistance protein) 
genen op chromosomen 7q2 l ,  1 6p l l en 1 6p l 3 . Een breuk van het chromosoom in 
1 6p l 3  kan de expressie van MRP1 bei·nvloeden zoals ook is gevonden in bepaalde 
gevallen van acute myeloide leukernie. Het effect van chromosomale afwijkingen op 
eiwit expressie is nog niet eerder onderzocht in WDS. In hoofdstuk 14 van dit 
proefschrift, werd gevonden dat P-gp en MRP1 expressie niet verschilde tussen WDS 
met een breukpunt in of verlies van de 7q2 1 of de 1 6p 1 3  regio wanneer zij werden 
vergeleken met WDS met normale 7q2 1 of 1 6p l 3  regio's. Echter, in WDS met 
breukpunten in of verlies van 1 6p 1 1 , was het mediane percentage cell en wat LRP tot 
expressie bracht 3% terwijl dit in STS met cytogenetisch intacte 1 6p l l regio's 40% 
was (p<O.O I ). Wij concluderen dat het cytogenetisch gevonden verlies van of 
breukpunten in l 6p l l mogelijk effect heeft op de expressie van LRP, terwijl P-gp en 
MRP1 expressie niet duidelijk worden be·invloed door verlies van of breukpunten in 
respectievelijk de chromosomale regio's 7q2 1 en 1 6p l 3 .  Toekomstige studies zullen 
met moleculair genetische technieken deze resultaten moeten bevestigen. 
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Een abnormaal karyotype en DNA-aneuploidie zijn niet van prognostische waarde 
WDS. 
DNA-ploidie en de aanwezigheid van chromosomale afwijkingen in 
tumorcellen zouden van prognostische waarde kunnen zijn in WDS. In hoofdstuk 
15, hebben we de relatie onderzocht tussen tumor graad, DNA-ploidie, 
cytogenetische afwijkingen en het klinisch beloop van 44, eerder onbehandelde, 
patienten met 1 2  verschillende typen van primaire WDS. De resultaten Iieten zien dat 
de tumorgraad meer prognostische waarde heeft dan de DNA-ploidie of het aanwezig 
zijn van chromosomale afwijkingen. Het gebruik van andere (cyto)genetische 
methoden zoals CGH of "computer assisted cytogenetic analysis" in het vergelijken 
van specifieke patientengroepen met bijvoorbeeld een goede of slechte prognose of 
goede of slechte respons op chemotherapie, zou specifiekere chromosomale regia's 
kunnen detecteren die van belang kunnen zijn in het voorspellen van het klinisch 
beloop of de reactie op verschillende therapievormen. 
Algemene conclusies en vooruitblik 
Het werk dat wordt beschreven in dit proefschrift richt zich met name op de 
relatie tussen bepaalde tumorbiologische parameters (zoals proliferatie, apoptose, 
MDR, DNA-ploidie en chromosomale afwijkingen) en de histopathologische 
diagnose, behandelingsrespons en het klinisch beloop van patienten met een WDS. 
Het is bekend dat de diagnose van een WDS moeilijk kan zijn en het blijkt dat 
gradering van een WDS kan worden be"invloed door het ervaringsniveau van de 
individuele patholoog. Nieuwe beeldvormende technieken zoals TYR-PET en IMT­
SPECT kunnen behulpzaam zijn bij de diagnose en de beoordeling van de 
tumorgraad, maar vervolgonderzoek naar het gebruik van tumorbiologisch 
gerelateerde radionucliden is nodig. De diagnostische waarde van conventionele 
cytogenetica lijkt zijn grenzen bereikt te hebben en andere (cyto)genetische 
technieken zoals "computer assisted cytogenetics" of CGH zullen mogelijk meer 
bruikbare informatie opleveren. Naast de beschreven resultaten in LMS, MPNST en 
GIST kunnen in de toekomst ook andere histologische typen op deze manier worden 
vergeleken waardoor ''verborgen" chromosomale verschillen worden ontdekt tussen 
de verscheidene WDS typen. Verder ligt het in de lijn der verwachting dat met name 
moleculair genetische technieken, zoals het aantonen van fusietranscripten, eventueel 
in combinatie met hierop gebaseerde irnmunohistochernische methoden hun waarde 
zullen bewijzen in de diagnostiek van WDS. 
Een van de doelen van dit proefschrift was om een relatie aan te tonen tussen 
de hoeveelheid proliferatie of apoptose in een WDS en de reactie van de tumor op 
HILP-TM. Wij vonden dat tumorcelproliferatie en -apoptose de reactie op HILP-TM 
lijkt te be"invloeden en HILP-TM zelf ook effect l ijkt te hebben op mechanismen in 
de tumorcel die betrokken zijn bij proliferatie en apoptose. B innen het onderzoek 
naar deze behandeling zullen in de toekomst studies zich moeten richten op de 
verschillende eiwitten die betrokken zijn bij apoptose en proliferatie. Wanneer 
tumormerkers worden bestudeerd in relatie tot de behandelingsrespons, dan moeten 
de methoden van beoordeling van deze respons betrouwbaar zijn.  Tumorbiologie 
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gerelateerde beeldvormende technieken zoals TYR-PET of IMT-SPECT, die 
informatie over tumorproliferatie blijken te geven, zouden misschien beter de 
behandelingsrespons kunnen weergeven dan de combinatie van lichamelijk 
onderzoek en radiologische screening die gebaseerd is op 20 jaar oude WHO 
standaards. In dit proefschrift werd aangetoond dat cytostatische behandeling van 
WDS met epirubicine, vindesine en ifosfamide resulteerde in een veelbelovende 
respons van 59%. De expressie van de afzonderlijke MDR eiwitten P-gp, MRP1 en 
LRP kan echter de behandelingsrespons of het klinisch beloop niet voorspellen in de 
onderzochte groep patienten. De expressie van deze MDR-eiwitten en de verdeling 
over de verschillende histologische typen is door dit onderzoek nu we! beter 
beschreven. De relatie tussen (cyto)genetische afwijkingen en histopathologie werd 
benadrukt met de aangetoonde relatie tussen de afwijkingen in 1 6p 1 1  en de 
verminderde expressie van LRP. In de toekomst zullen studies in liposarcomen de 
relatie met de kliniek moeten onderzoeken: hebben myxoide LPS of andere WDS 
met een 1 6p l l afwijking een betere respons op de door LRP bei"nvloede alkylerende 
cytostatica? Dit proefschrift zwakt de conclusies af van vele klinische studies die ten 
onrechte beweren dat leiomyosarcomen warden gekarakteriseerd door het veelvuldig 
optreden van levermetastasen, het aanwezig zijn van "drugresistentie" en een 
extreem slechte prognose. Hieruit blijkt dat eerdere studies in groepen patienten met 
"leiomyosarcomen" hoogstwaarschijnlijk het klinisch en biologisch gedrag hebben 
onderzocht van zowel LMS als gastrointestinale stroma tumoren (GIST), die vroeger 
leiomyosarcomen van het maag-darm kanaal werden genoemd. 
In de onderzochte specifiek patientengroepen waren alleen tumorgraad, mitose 
activiteit en proliferatie van prognostische waarde. Andere parameters zoals het 
aanwezig zijn van een abnormaal karyotype, DNA-aneuploidie, de expressie van de 
afzonderlijke MDR eiwitten en de mate van apoptose, konden niet warden 
ge"identificeerd als prognostische factoren. Samenvattend lijkt het erop dat 
behandelingsrespons en het klinisch beloop warden bei·nvloed door veel 
verschillende biologische variabelen. Het zou getuigen van een tekort aan inzicht als 
we aan zouden nemen dat slechts een of twee biologische variabelen bijvoorbeeld het 
metastaseringsgedrag van een WDS of het klinisch beloop van een individuele 
patient zouden be"invloeden. Nieuwe technieken zoals DNA-chip technologie kunnen 
behulpzaam zijn  bij het vinden van een patroon van "risicofactoren" voor elke 
individuele tumor, zoals het aanwezig zijn van genmutaties of het tot expressie 
komen van oncogenen. Dit zou kunnen leiden tot klinisch relevante informatie zoals 
het voorspellen van behandelingsresultaten en metastaserings-potentie van de 
primaire tumor. Vanwege het feit dat WDS zeldzaam zijn, kan dit alleen warden 
bereikt binnen samenwerkingsverbanden. 
Met het voortschrijden van het inzicht in de tumorbiologie is het een uitdaging om 
met behulp van modeme technieken nieuwe tumorbiologische variabelen te 
implementeren in de diagnostiek en in de keuze van de op de individuele patient 
toegesneden behandeling. Hierdoor zal het uiteindelijk mogelijk  zijn de prognose van 
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Dag en Nacht 
M.C. Escher ( 1 898- 1 972) - februari 1 938, houtsnede 
" Ik probeer in rnijn prenten ervan te getuigen dat we !even in een schone, geordende 
wereld, en niet in een nameloze chaos zoals het soms lijkt." 
De prenten van Escher dienen " . . .  om een bepaalde gedachtengang duidelijk te 
maken. De ideeen die eraan ten grondslag liggen getuigen veelal van rnijn 
verwondering over en rnijn bewondering van wetmatigheden die de ruimte om ons 
been bevat. Wie zich verwondert geeft zich rekenschap van een wonder. Door 
zintuigelijk open te staan voor raadsels die ons omringen en door rnijn 
gewaarwordingen te overdenken en te analyseren, kom ik in de buurt van het domein 
van de wiskunde . . .  ". 
M.C. Escher 
Uit: "Leven en werk van M.C. Escher", Meulenhoff Amsterdam 1 98 1 
Tumor l ijkt chaos, maar we gaan ervan uit dat deze zich vo1gens, nog niet 
geheel bekende, regels gedraagt. Zo probeert het onderzoek beschreven in dit 
proefschrift, deze regels te ontdekken door het bekijken van afgeleide bee1den. Maar 
hoe interpreteren we wat we zintuigelijk waamemen en wanneer mogen we iets 
"waarschijnlijk" noemen? De ene onderzochte figuur bei'nvloedt namelijk de andere. 
Op welk moment wordt het duidelijk dat velden veranderen in vogels? 
Pas als het de som der delen bekend is, wordt de geordende wereld, waar we naar op 
zoek zijn, duidelijk. Het ontdekken van de ordening. Daar houdt wetenschappelijk 
onderzoek zich mee bezig. 
Vaak worden variabelen onderzocht die elkaars uitersten blijken te zijn. Het 
tussenliggende dynarnische en grijze gebied is niet duidelijk te herkennen, maar wel 
af te leiden uit een analyse van die schijnbare chaos. Ondanks het voortschrijden van 
onze inzichten, blijven we nog steeds in het grijze rnidden. Pas wanneer het exacte 
verband tussen de bepaalde vormen duidelijk wordt en daardoor het contrast grater 
wordt, zal een compleet beeld ontstaan. 
B .E.Ch. Plaat 
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